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FSP Section 11,000
Checklists and Illustrative Financial 
Statements for Health Care Organizations
Description
.01 Health care organizations may be classified by sponsorship or legal structure within the following 
broad categories:
Not-for-profit business-oriented: These are essentially self-sustaining from fees charged for goods and 
services. The fees charged by such organizations generally are intended to help the organization main­
tain its self-sustaining status rather than to maximize profits for the owner's benefit. Such organizations 
often are exempt from federal income taxes and may receive contributions of relatively small amounts 
from resource providers that do not expect commensurate or proportionate pecuniary returns.
Not-for-profit nonbusiness-oriented: These are voluntary health and welfare organizations as defined in 
Financial Accounting Standards Board Statement of Financial Accounting Standards (SFAS) No. 117, 
Financial Statements of Not-for-Profit Organizations. Such organizations are within the scope of AICPA 
Audit and Accounting Guide Not-for-Profit Organizations, rather than that of Audit and Accounting 
Guide Health Care Organizations.
Governmental: Often called public health care entities, the entities are owned and operated by federal, 
state, city, or county governments or other political subdivisions.
Investor- (or operator-) owned: These organizations operate as stock corporations, partnerships, or sole 
proprietorships.
.02 Health care organizations include, but are not limited to, the following:
• Clinics, medical group practices, individual practitioners and practice associations, and other ambu­
latory care organizations
• Continuing care retirement communities
• Health maintenance organizations and similar prepaid health care plans
• Home health agencies
• Hospitals
• Nursing homes that provide skilled, intermediate, and less intensive levels of health care
• Parent companies, holding companies, and other organizations that primarily plan, organize, and 
oversee health care services
Applicability of These Checklists
.03 These checklists, and the illustrative financial statements included herein, follow the guidance con­
tained in the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of 
May 1, 2008), referred to as the guide. These checklists and illustrative financial statements should be used for 
not-for-profit business-oriented and investor-owned health care organizations. These checklists do not apply to 
not-for-profit nonbusiness-oriented health care organizations. For these types of organizations, follow the guid­
ance in the AICPA Audit and Accounting Guide Not-for-Profit Organizations and the AICPA's disclosure 
checklist titled Not-for-Profit Organizations.
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.04 Not-for-profit health care providers that receive federal financial assistance may be required to have 
an audit conducted in accordance with Office of Management and Budget (OMB) Circular A-133 Audits of 
States, Local Governments, and Non-Profit Organizations. FSP section 11,400 includes guidance for auditors' 
reports for audits performed under OMB Circular A-133.
.05 Although the guide also applies to state and local government-owned health care providers, these 
checklists do not include disclosures or sample financial statements of government-owned providers. Chapter 1 
of the guide discusses the application of generally accepted accounting principles (GAAP) to governmental 
health care providers.
Legislation and Regulation
.06 Significant aspects of health care organization operations are affected by government legislation and 
regulation with many states adopting laws governing the granting of licenses, as well as scope of services to 
be rendered. In addition, many independent organizations and governmental agencies, including Medicare 
and Medicaid, evaluate programs and services of health care organizations to determine compliance with set 
standards.
Basic Financial Statements
.07 The financial reporting for not-for-profit business-oriented organizations and investor-owned health 
care enterprises generally is consistent except for transactions that clearly are not applicable. For example, 
not-for-profit business-oriented organizations, by their nature, do not have shareholders' equity. On the other 
hand, investor-owned health care enterprises typically do not receive contributions.
.08 The basic financial statements of health care providers generally consist of a statement of financial 
position or balance sheet, a statement of activities or income statement or statement of operations, a statement 
of changes in net assets (equity), a statement of cash flows, and notes to the financial statements. The titles of 
the financial statements will depend upon the business form of the provider (that is, not-for-profit and 
investor-owned). See the following chart.
Basic Financial Statements
Not-for-Profit
Business-Oriented Organization Investor-Owned Organization
Balance Sheet/Statement of Financial Position Balance Sheet
Statement of Operations/Statement of Activities Statement of Operations/Income Statement
Statement of Changes in Net Assets Statement of Changes in Equity
Statement of Cash Flows Statement of Cash Flows
Note: This publication was extracted from sections 11,000 through 11,500 of the AICPA Financial Statement 
Preparation Manual (FSP).
FSP §11,000.04
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FSP Section 11,100 
Instructions
General
.01 This publication includes the following information:
• Financial Statements and Notes Checklist (FSP section 11,200)—For use by preparers of financial 
statements and by practitioners who audit, review, or compile them as they evaluate the adequacy of 
disclosures.
• Auditors' Reports Checklist (FSP section 11,300)—For use by auditors in reporting on audited finan­
cial statements.
• Auditors' Reports Checklist for Audits Performed in Accordance With Government Auditing Stan­
dards and OMB Circular A-133 (FSP section 11,400).
• Illustrative Financial Statements (FSP section 11,500)—Illustrating full sets of financial statements 
for both not-for-profit business-oriented and investor-owned healthcare organizations.
.02 These checklists and illustrative financial statements have been developed by the AICPA Accounting 
and Auditing Publications staff to serve as nonauthoritative technical practice aids to be used by preparers 
and auditors of healthcare organization financial statements prepared in conformity with generally accepted 
accounting principles (GAAP). They have not been reviewed, approved, disapproved, or otherwise acted on 
by any senior technical committee of the AICPA and do not represent official positions or pronouncements of 
the AICPA.
.03 Users of the financial statements and notes checklist are reminded that it is a disclosure checklist only 
and not a comprehensive GAAP application or measurement checklist. Accordingly, application and meas­
urement issues related to preparing financial statements in conformity with GAAP are not included in the 
checklist. Users of the auditors' reports checklist are reminded that it addresses those requirements most 
likely to be encountered when reporting on a healthcare organization's financial statements prepared in 
conformity with GAAP. It does not include reporting requirements relating to other matters such as internal 
control or agreed-upon procedures.
.04 These checklists and illustrative financial statements should be used by, or under the supervision of, 
persons having adequate technical training and proficiency in the application of GAAP, generally accepted 
auditing standards, and other relevant technical guidance.
These checklists have been updated to include relevant reporting and disclosure guidance is­
sued through September 30, 2008, including the following:
• Financial Accounting Standards Board (FASB) Statement of Financial Accounting Stan­
dards (SFAS) No. 163, Accounting for Financial Guarantee Insurance Contracts—an interpre­
tation of FASB Statement No. 60
• Revised FASB statements issued through September 30, 2008, including FASB Statement 
No. 141 (revised 2007), Business Combinations
• FASB Interpretation No. (FIN) 48, Accounting for Uncertainty in Income Taxes—an interpre­
tation of FASB Statement No. 109
(continued)
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• FASB Technical Bulletin (FTB) No. 01-1, Effective Date for Certain Financial Institutions of 
Certain Provisions of Statement 140 Related to the Isolation of Transferred Financial Assets
• FASB Staff Positions (FSPs) issued through September 30, 2008
• FASB Emerging Issues Task Force (EITF) consensus positions adopted at meetings of the 
EITF held through September 2008
• AICPA Statement of Position (SOP) 07-1, Clarification of the Scope of the Audit and Account­
ing Guide Investment Companies and Accounting by Parent Companies and Equity Method 
Investors for Investments in Investment Companies (AICPA, Technical Practice Aids, ACC sec. 
10,930)
• AICPA Practice Bulletin No. 15, Accounting by the Issuer of Surplus Notes (AICPA, Technical 
Practice Aids, vol. 1, PB sec. 12,150)
• AICPA Statement on Auditing Standards No. 114, The Auditor's Communication With Those 
Charged With Governance (AICPA, Professional Standards, vol. 1, AU sec. 380)
• Interpretation No. 3, "Financial Statement Audited in Accordance With International 
Standards on Auditing," of AU section 534, Reporting on Financial Statements Prepared for 
Use in Other Countries (AICPA, Professional Standards, vol. 1, AU sec. 9534 par. .09-.11)
• SOP 07-2, Attestation Engagements That Address Specified Compliance Control Objectives and 
Related Controls at Entities That Provide Services to Investment Companies, Investment Advi­
sers, or Other Service Providers (AICPA, Technical Practice Aids, AUD sec. 14,430)
• AICPA Statement on Standards for Attestation Engagements No. 14, SSAE Hierarchy 
(AICPA, Professional Standards, AT sec. 50)
• Interpretation No. 6, "Reporting on Attestation Engagements Performed in Accordance 
With Government Auditing Standards," of AT section 101, Attest Engagements (AICPA, 
Professional Standards, vol. 1, AT sec. 9191 par. .56-.58)
• Public Company Accounting Oversight Board Auditing Standard No. 6, Evaluating Con­
sistency of Financial Statements (AICPA, PCAOB Standards and Related Rules, Rules of the 
Board, "Standards")
These checklists and illustrative financial statements should be modified, as appropriate, for 
subsequent pronouncements. In determining the applicability of a pronouncement, its effective 
date should also be considered.
Instructions
.05 These checklists consist of a number of questions or statements accompanied by references to the 
applicable authoritative pronouncements, and provide for checking off or initialing each question or point to 
show that it has been considered. Carefully review the questions and statements listed and consider whether 
they represent potential disclosure items for the reporting entity for which you are preparing or auditing 
financial statements. Users should check or initial:
• "Yes" if the disclosure has been appropriately made.
• "No" if the disclosure has not been made.
• "N/A" if the disclosure is not applicable to the organization.
It is important that the effect of any "No" response be considered on the auditor's report. For audited 
financial statements, a "No" response that is material to the financial statements may warrant a depar­
ture from an unqualified opinion as discussed in paragraphs .20-.64 of AU section 508, Reports on Audited 
Financial Statements (AICPA, Professional Standards, vol. 1).
FSP §11,100.05
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.06 Users may find it helpful to use the right margin for certain other remarks and comments as appro­
priate, including the following:
a. For each disclosure for which a "Yes" is indicated, a notation as to where the disclosure is located in 
the financial statements and a cross-reference to the applicable workpapers where the support to a 
disclosure may be found.
b. For items marked as "N/A", the reasons for which they do not apply in the circumstances of the 
particular report.
c. For each disclosure for which a "No" response is indicated, a notation as to why the disclosure was 
not made (for example, because the item was not considered to be material to the financial state­
ments).
.07 These checklists are applicable to not-for-profit business-oriented and investor-owned health care organi­
zations. While financial reporting for these types of organizations is generally consistent, there are require­
ments that apply to only not-for-profit business-oriented organizations and those that apply to only investor- 
owned enterprises. Symbols have been used to indicate the applicability of presentation and disclosure 
requirements to these types of organizations. Not-for-profit business-oriented organizations should complete 
all disclosure items denoted with a star (★). Investor-owned organizations should complete all disclosure 
items denoted with a diamond (♦).
.08 The use of these checklists, or any other checklist, requires the exercise of individual professional 
judgment and is not a substitute for the authoritative pronouncement. Users of these checklists and illustrative 
financial statements are urged to refer directly to applicable authoritative pronouncements when appropriate. 
The checklists and illustrative financial statements do not include all disclosures and presentation items 
promulgated nor do they represent minimum requirements. Additionally, users of these checklists and illus­
trative materials are encouraged to tailor them as necessary to meet the specific circumstances of each partic­
ular engagement.
.09 If you have further questions, call the AICPA Technical Hotline at (877) 242-7212.
FSP §11,100.09
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FSP Section 11,200
Financial Statements and 
Notes Checklist
.01 The checklists and illustrative financial statements do not include all disclosures and presentation 
items required by generally accepted accounting principles (GAAP); as a result, pronouncements deemed 
unlikely to be encountered in financial statements of health care providers are not included. Symbols have 
been used to indicate the applicability of presentation and disclosure requirements as follows:
1. Not-for-profit business-oriented organizations should complete all disclosure items denoted with a 
star (★).
2. Investor-owned organizations should complete all disclosure items denoted with a diamond (♦).
.02 Explanation of References:
AAG = AICPA Audit and Accounting Guide Health Care Organizations (with conform­
ing changes as of May 1, 2008)
AAG-NPO = AICPA Audit and Accounting Guide Not-for-Profit Organizations (with conform­
ing changes as of March 1, 2008)
AAG-SLA = AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits 
(with conforming changes as of August 1, 2008)
ACC = Reference to a section number in AICPA Technical Practice Aids, Statements of 
Position—Accounting
APB = Accounting Principles Board Opinion
ARB = Accounting Research Bulletin
AU = Reference to section number in AICPA Professional Standards (vol. 1) for U.S. 
Auditing Standards, which are applicable to nonissuers
AUD = Reference to a section number in AICPA Technical Practice Aids, Statements of 
Position—Auditing and Attestation
EITF = FASB Emerging Issues Task Force consensus
FIN = FASB Interpretation No.
FSP = FASB Staff Position
PCAOB AU= Reference to a section number in AICPA Professional Standards for interim au­
diting standards, as amended, of the PCAOB, which are applicable to issuers
SFAS = FASB Statement of Financial Accounting Standards
SOP = AICPA Statement of Position
TB = Technical Bulletin issued by the staff of FASB
TIS = Reference to section number in AICPA Technical Practice Aids Technical Ques­
tions and Answers
FSP §11,200.02
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.03 Checklist Questionnaire:
Place by
Sections Not Applicable
• General
A. Titles and References ---------------
B. Comparative Financial Statements ---------------
C. Consolidated Financial Statements ---------------
• Statement of Financial Position/Balance Sheet
A. General __________
B. Cash and Cash Equivalents __________
C. Investments __________
D. Receivable and Loans __________
E. Beneficial Interests in Assets Held by Others __________
F. Property and Equipment, and Supplies __________
G. Deferred Income Tax Assets and Liabilities __________
H. Intangible Assets and Goodwill __________
I. Current Liabilities __________
J. Notes Payable and Other Debt __________
K. Other Liabilities and Deferred Credits __________
L. Net Assets/Shareholders' Equity __________
M. Restricted Resources __________
• Statement of Activities/Income Statement/Statement of 
Operations/Statement of Changes in Net Assets
A. General __________
B. Revenue __________
C. Income Taxes __________
D. Extraordinary Items __________
F. Unusual or Infrequent Items __________
F. Advertising Costs __________
G. Donated or Contributed Services __________
H. Donated Materials and Facilities __________
I. Fund Raising __________
J. Contributions/Pledges __________
K. Expenses __________
L. Wills __________
M. Endowments __________
N. Earnings Per Share __________
O. Comparative Income __________
• Statement of Cash Flows
• Other Financial Statement Disclosures
A. Accounting Changes and Error Corrections __________
B. Accounting Policies __________
C. Business Combinations __________
D. Commitments and Contingencies __________
E. Exit or Disposal Activities __________
F. Derivative Instruments and Hedging Activities __________
G. Financial Instruments __________
G1. Financial Instruments of Enterprises Subject to SFAS 161 __________
H. Nonmonetary Transactions __________
FSP §11,200.03
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Place by
Sections Not Applicable
I. Employers' Disclosures for Defined Benefit Pension and Other Pos­
tretirement Plans for Investor-Owned Organizations Only
J. Related Organizations and Economic Dependency
K. Risks and Uncertainties
L. Segment Information
M. Subsequent Events
N. Stock-Based Compensation/Share-Based Payment
O. Accounting for Servicing of Financial Assets
P. Long-Lived Assets and Disposal Groups to Be Disposed Of
Q. Asset Retirement Obligations
R. Impaired Loans
S. Impairment of Long-Lived Assets to Be Held and Used
T. Lessor Leases
U. Lessee Leases
V. Fair Value Measurements
• Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
B. Fees Refundable to Residents Only From Reoccupancy Proceeds of 
a Contract Holder's Unit
C. Nonrefundable Advance Fees
D. Obligation to Provide Future Services and Use of Facilities to Cur­
rent Residents
E. Costs of Acquiring Initial Continuing-Care Contracts
F. Other
Yes No N/A
I. General
A. Titles and References
★ ♦ 1. Are the financial statements suitably titled? ------- ------- ------
[AU 623.07; AAG 1.05 fn 3]
★ ♦ 2. Does each statement include a general reference that the notes are an
integral part of the financial statement presentation? ------- ------- ------
[Generally Accepted]
★ ♦ 3. Do the basic financial statements of the health care organization include:
a. Statement of financial position (balance sheet)? ------- ------- ------
b. Statement of activities (statement of operations/income statement)? ------- ------- ------
c. Statement of cash flows? ------- ------- ------
d. Statement of changes in net assets (equity)? (Note: This statement
may be combined with the statement of activities.) ------- ------- ------
e. Notes to the financial statements? ------- ------- ------
[SFAS 117 par. 1-2 and 6; AAG 1.05]
B. Comparative Financial Statements
★ ♦1. Has presentation of comparative statements been considered? ------- ------- ------
[SFAS 117 par. 69; ARB 43 ch. 2A par. 1-2]
FSP §11,200.03
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★ ♦ 2. If comparative statements are presented, are the notes and other disclo­
sures included in the financial statements of the preceding year(s) re­
peated, or at least referred to, to the extent that they continue to be of 
significance?
[ARB 43 ch. 2A par. 2]
★ ♦ 3. If changes occurred in the manner of or basis for presenting correspond­
ing items for two or more periods, are appropriate explanations of the 
changes disclosed?
[ARB 43 ch. 2A par. 3]
C. Consolidated Financial Statements
Notes: EITF 97-2, "Application of FASB Statement No. 94 and APB Opinion 
No. 16 to Physician Practice Management Entities and Certain Other Entities 
with Contractual Management Arrangements," provides guidance to assist 
physician practice management companies (PPMs) in applying SFAS 94, 
Consolidation of All Majority-owned Subsidiaries—an amendment of ARB No. 51, 
with related amendments of APB Opinion No. 18 and ARB No. 43, Chapter 12, 
when PPMs acquire a physician practice.
In March 2008, FASB issued SFAS 160, Noncontrolling Interests in Consolidated 
Financial Statements—an amendment of ARB No. 51, to establish accounting 
and reporting standards for the noncontrolling interests in a subsidiary and 
for the deconsolidation of a subsidiary, areas for which limited guidance 
previously existed. SFAS 160 clarifies that a noncontrolling interest in a 
subsidiary is an ownership interest in the consolidated entity that should be 
reported as equity in the consolidated financial statements. This statement 
amends authoritative accounting literature to change the term minority 
interest to noncontrolling interest. SFAS. 160 does not change the require­
ments in FIN 46 (revised December 2003), Consolidation of Variable Interest 
Entities—an interpretation of ARB No. 51.
This statement changes the way the consolidated income statement is pre­
sented. It requires consolidated net income to be reported at amounts that 
include the amounts attributable to both the parent and the noncontrolling 
interest. It also requires disclosure, on the face of the consolidated statement 
of income, of the amounts of consolidated net income attributable to the 
parent and to the noncontrolling interest.
SFAS 160 establishes a single method of accounting for changes in a parent's 
ownership interest in a subsidiary that do not result in deconsolidation and 
clarifies that all of those transactions are equity transactions if the parent 
retains its controlling financial interest in the subsidiary.
This statement requires expanded disclosures in the consolidated financial 
statements that clearly identify and distinguish between the interests of the 
parent's owners and the interests of the noncontrolling owners of a subsid­
iary. Those expanded disclosures include a reconciliation of the beginning 
and ending balances of the equity attributable to the parent and the noncon­
trolling owners and a schedule showing the effects of changes in a parent's 
ownership interest in a subsidiary on the equity attributable to the parent.
(continued)
FSP §11,200.03
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Financial Statements and Notes Checklist 11
Yes No N/A
SFAS 160 is effective for fiscal years, and interim periods within those fiscal 
years, beginning on or after December 15, 2008 (that is, January 1, 2009, for 
entities with calendar year-ends). Earlier adoption is prohibited. As such, 
this checklist has not been updated to include the presentation and disclo­
sure requirements of SFAS. 160. Readers can refer to the full text of the 
statement on the FASB Web site at www.fasb.org.
Practice Tip
Paragraph 1 of ARB No. 51, Consolidated Financial Statements, notes the presumption in GAAP that consoli­
dated financial statements are more meaningful than parent company-only financial statements, but para­
graph 24 of ARB No. 51 acknowledges that parent company financial statements may be needed in addition 
to consolidated financial statements. However, it does not suggest that parent company financial statements 
may be prepared in place of consolidated financial statements. TIS section 1400.32, "Parent-Only Financial 
Statements and Relationship to GAAP" (AICPA, Technical Practice Aids), clarifies that, even if a legal or 
regulatory agreement requires an entity to submit restricted or special use parent-only financial statements 
without related consolidated financial statements, the restricted or special use parent-only financial state­
ments are not in accordance with GAAP.
★ ♦ 1. If the provider and another entity are related and they meet the criteria
for consolidation, are consolidated financial statements presented? 
[AAG 11.10-.11; ARB 51, as amended; SFAS 94]
★ ♦ 2. If consolidated statements are presented:
a. Is the consolidation policy disclosed?
[ARB 51 par. 5; APB 22 par. 13]
b. When the financial reporting periods of consolidated entities dif­
fer, is recognition given, by disclosure or otherwise, to the effect of 
intervening events that materially affect financial position or re­
sults of operations?
[ARB 51 par. 4]
Note: EITF 06-9, "Reporting a Change in (or the Elimination of) a Previously 
Existing Difference between the Fiscal Year-End of a Parent Company and 
That of a Consolidated Entity or between the Reporting Period of an Inves­
tor and That of an Equity Method Investee," clarifies that a parent company 
should report a change to (or the elimination of) a previously existing dif­
ference between the parent's reporting period and the reporting period of 
a consolidated entity in the parent's consolidated financial statements as a 
change in accounting principle in accordance with the provisions of SFAS 
154, Accounting Changes and Error Corrections—a replacement of APB Opinion 
No. 20 and FASB Statement No. 3. This issue applies to all types of health 
care organizations. This issue does not apply in situations in which a parent 
company or an investor changes its fiscal year-end. This issue is effective 
for changes occurring in interim or annual reporting periods beginning 
after board ratification (November 29, 2006). Readers can refer to the full 
text of EITF 06-9 on the FASB Web site at www.fasb.org.
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★ ♦ 3. If a parent company reports a change to (or the elimination of) a pre­
viously existing difference between the parent's reporting period and 
the reporting period of a consolidated entity in the parent's consoli­
dated financial statements as described in EITF 06-9, has the change 
been reported as a change in accounting principle in accordance with 
the provisions of SFAS 154, excluding retrospective application if it is
impracticable to do so? _____
[EITF 06-9 par. 4]
★ ♦ 4. If the provisions of EITF 06-9 are applicable to the financial statements
of a parent company, are the disclosures required by SFAS 154 made? _____
[EITF 06-9 par. 5]
★ ♦ 5. Are material intercompany transactions and accounts, and any income
or losses on assets that are eliminated, disclosed? _____
[ARB 51 par. 6]
★ ♦ 6. For limited partnerships or similar entities in the scope of EITF 04-5,
"Determining Whether a General Partner, or the General Partners as a 
Group, Controls a Limited Partnership or Similar Entity When the 
Limited Partners Have Certain Rights," and if the guidance in EITF 
04-5 is in effect or is applied:
a. If Transition Method A is used, (1) are prior year financial state­
ments presented as previously reported; (2) is any cumulative ef­
fect of adoption on retained earnings (or other appropriate com­
ponents of equity or net assets) at the beginning of the period that 
the guidance is first applied, included in the opening balance of 
retained earnings (or other appropriate components of equity or 
net assets) in the period of change; (3) if early adoption in an in­
terim period is elected, are the provisions of SFAS 3, Reporting 
Accounting Changes in Interim Financial Statements—an amendment 
of APB Opinion No. 28, applied, except a cumulative-effect-type 
adjustment is recognized in beginning retained earnings (or other 
appropriate component of equity or net assets); and (4) is the effect 
of adoption on the opening balance sheet or statement, or both, of 
financial position disclosed in the year of adoption? _____
b. If Transition Method B is used, is the guidance applied by retro­
spective application and are the disclosures required by paragraph
17 of SFAS 154 presented? _____
[EITF 04-5 par. 22-26]
★ ♦7. If the organization is the parent company of, or an equity method
investor in, a for-profit entity that early adopted SOP 07-1, Clarification 
of the Scope of the Audit and Accounting Guide Investment Companies and 
Accounting by Parent Companies and Equity Method Investors for Invest­
ments in Investment Companies (AICPA, Technical Practice Aids, ACC sec.
10,930), prior to fiscal years beginning on or after December 15, 2007, 
and the subsidiary has not elected to rescind its early adoption of SOP 
07-1 as permitted by paragraph 11 of FSP SOP 07-1-1, Effective Date of 
AICPA Statement of Position 07-1, do the financial statements include 
the disclosures required by paragraphs .50-.53 of SOP 07-1 if invest­
ment company accounting is retained in the consolidated financial
statements? _____
[SOP 07-1 par. D-2 (ACC 10,930.D2)]
FSP §11,200.03
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Financial Statements and Notes Checklist 13
Yes No N/A
Consolidation of Variable Interest Entities
Notes: FIN 46(R) clarifies the application of ARB No. 51 and replaces the 
original FIN 46 issued in January 2003. This interpretation provides guid­
ance for identifying entities for which analysis of voting interests, and the 
holdings of those voting interests, is not effective in determining whether a 
controlling financial interest exists because the entity does not have ade­
quate equity capital or the equity instruments do not have the normal char­
acteristics of equity that provide its holders with a potential controlling 
financial interest. Those entities are called variable interest entities.
This interpretation also provides guidance for determining whether an en­
terprise shall consolidate a variable interest entity. An enterprise that con­
solidates a variable interest entity is called the primary beneficiary of that 
variable interest entity. The guidance in this interpretation identifies the 
primary beneficiary as a holder of variable interests in a variable interest 
entity that absorb or receive a majority of the entity's expected losses or 
expected residual returns. FIN 46(R) contains scope exceptions that should 
be considered in determining whether its provisions apply to a particular 
entity. Additionally, FSP FIN 46(R)-7, Application of FASB Interpretation No. 
46(R) to Investment Companies, amends FIN 46(R) by clarifying that invest­
ments accounted for at fair value in accordance with the specialized ac­
counting guidance in the AICPA Audit and Accounting Guide Investment 
Companies are not subject to consolidation according to the requirements of 
that interpretation. Readers can refer to the full text of FIN 46(R) on the 
FASB Web site at www.fasb.org.
♦ 8. Does the primary beneficiary of a variable interest entity disclose the
following (unless the primary beneficiary also holds a majority voting 
interest):
a. The nature, purpose, size, and activities of the variable interest 
entity?
b. The carrying amount and classification of consolidated assets that 
are collateral for the variable interest entity's obligations?
c. Lack of recourse if creditors (or beneficial interest holders) of a 
consolidated variable interest entity have no recourse to the gen­
eral credit of the primary beneficiary?
[FIN 46(R) par. 23]
♦ 9. Does an enterprise that holds a significant variable interest in a variable
interest entity but is not the primary beneficiary disclose:
a. The nature of its involvement with the variable interest entity and 
when that involvement began?
b. The nature, purpose, size, and activities of the variable interest 
entity?
c. The enterprise's maximum exposure to loss as a result of its in­
volvement with the variable interest entity?
[FIN 46(R) par. 24]
FSP §11,200.03
14 Health Care Organizations
♦ 10. Are the disclosures in paragraph 24 of FIN 46(R) provided if a report­
ing enterprise is not the primary beneficiary but holds a significant 
implicit variable interest in a variable interest entity?
[FSP FIN 46(R)-5 par. 6]
♦ 11. Are disclosures required by SFAS140, Accounting for Transfers and Serv­
icing of Financial Assets and Extinguishments of Liabilities—a replacement 
of FASB Statement No. 125, about a variable interest entity included in 
the same note to the financial statements as the information required 
by FIN 46(R)?
[FIN 46(R) par. 25]
♦ 12. If an entity does not apply FIN 46(R) to one or more variable interest
entities or potential variable interest entities because of the condition 
described in paragraph 4(g) of FIN 46, is the following information 
disclosed:
a. The number of entities to which that interpretation is not being 
applied and the reason why the information required to apply that 
interpretation is not available?
b. The nature, purpose, size (if available), and activities of the en- 
tity(ies) and the nature of the enterprise's involvement with the 
entity(ies)?
c. The reporting enterprise's maximum exposure to loss because of 
its involvement with the entity(ies)?
d. The amount of income, expense, purchases, sales, or other measure 
of activity between the reporting enterprise and the entity(ies) for 
all periods presented? (However, if it is not practicable to present 
that information for prior periods that are presented in the first set 
of financial statements for which this requirement applies, the in­
formation for those prior periods is not required.)
[FIN 46(R) par. 26]
♦ 13. If it is reasonably possible that an enterprise will initially consolidate
or disclose information about a variable interest entity when FIN 46(R) 
becomes effective, does the enterprise disclose the following informa­
tion in all financial statements initially issued after December 31, 2003, 
regardless of the date on which the variable interest entity was created:
a. The nature, purpose, size, and activities of the variable interest 
entity?
b. The enterprise's maximum exposure to loss as a result of its in­
volvement with the variable interest entity?
[FIN 46(R) par. 27]
♦ 14. Is the effect of applying FIN 46(R) to an entity to which FIN 46(R) had
previously been applied reported as the cumulative effect of an ac­
counting change?
[FIN 46(R) par. 39]
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♦ 15. Is the excess, if any, of (a) the fair value of the newly consolidated assets
and (b) the reported amount of assets transferred by the primary ben­
eficiary to the variable interest entity over the sum of (1) the fair value 
of the consideration paid, (2) the reported amount of any previously 
held interests, and (3) the fair value of the newly consolidated liabilities 
and noncontrolling interests allocated and reported as a pro rata ad­
justment of the amounts that would have been assigned to all of the 
newly consolidated assets as specified in paragraphs 44-45 of SFAS 
141, Business Combinations, as if the initial consolidation had resulted
from a business combination? _____ _____ ____
[FIN 46(R) par. 21]
♦ 16. Is the excess, if any, of the sum of (a) the fair value of the consideration
paid, (b) the reported amount of any previously held interests, and (c) 
the fair value of the newly consolidated liabilities and noncontrolling 
interests over (1) the fair value of the newly consolidated identifiable 
assets and (2) the reported amount of identifiable assets transferred by 
the primary beneficiary to the variable interest entity reported in the 
period in which the enterprise becomes the primary beneficiary as:
a. Goodwill, if the variable interest entity is a business? _____ _____ ____
b. An extraordinary loss, if the variable interest entity is not a busi­
ness? _____ _____ ____
[FIN 46(R) par. 21]
Statement of Financial Position/Balance Sheet
A. General
★ ♦ 1. For classified statements of financial position/balance sheets, are assets
and liabilities segregated into current and noncurrent classifications,
with totals presented for current assets and current liabilities? _____ _____ ____
[ARB 43 ch. 3A par. 2-8; SFAS 78 par. 5 and 13; SFAS 6 par. 15; FIN 8 
par. 3; TB 79-3 par. 2; SFAS 117 par. 12]
★ ♦2. Are assets not expected to be realized during the current operating
cycle classified as noncurrent? _____ _____ ____
[ARB 43 ch. 3A par. 5-6]
★3. Does the statement of financial position/balance sheet report total as­
sets, liabilities, and net assets as well as separate amounts for each of 
three classes of net assets with captions used to describe their meaning 
as explained in SFAS 117, Financial Statements of Not-for-Profit Organi­
zations? _____ _____ ____
[SFAS 117 par. 10,13, and 100]
★4. Does the entity provide information about liquidity by one or more of 
the following presentations:
a. Sequencing assets according to their nearness of conversion to cash
and sequencing liabilities according to the nearness of their matur­
ity and resulting use of cash? _____ _____ ____
b. Classifying assets and liabilities as current and noncurrent? _____ _____ ____
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c. Disclosing in notes to financial statements relevant information 
about the liquidity or maturity of assets and liabilities, including
restrictions on the use of particular assets? ------
[SFAS 117 par. 12]
★ ♦5. Are valuation allowances for assets shown as deductions from their
related assets with appropriate disclosure? ------
[APB 12 par. 3]
★ ♦ 6. Is the need for disclosure of the impact of a new FASB statement, is­
sued but not yet effective where restatement of prior periods is re­
quired, considered? ------
[AU 9410.13-18]
B. Cash and Cash Equivalents
★ ♦ 1. Is restricted cash appropriately segregated from cash available for cur­
rent operations? ------
[ARB 43 ch. 3A par. 6; AAG 3.01]
★ ♦ 2. Are restrictions on cash (such as for plant acquisition, debt reduction
or working capital maintenance) appropriately disclosed? ____
[SFAS 5 par. 18-19]
★ ♦ 3. Are personal funds of patients, residents and others under an agency
arrangement reported as unrestricted assets and corresponding liabili­
ties in the balance sheet/statement of financial position? ____
[AAG par. 3.02]
★ ♦4. If a concentration of credit risk arises from deposits in excess of feder­
ally insured limits, is it disclosed? ____
[SFAS 107, as amended by SFAS 133 par. 531; AAG 3.26]
★ ♦ 5. If the organization has material bank overdrafts or a material balance
of undelivered checks as of the statement-of-financial-position/bal­
ance-sheet date, are:
a. Bank overdrafts presented as a separate caption within current
liabilities? ____
b. Undelivered checks classified as accounts payable? ____
[Generally Accepted]
★ ♦6. Are internally designated funds reported separately from externally
designated funds? ____
[AAG par. 3.01]
C. Investments
Note: In February 2007, FASB issued SFAS 159, The Fair Value Option for 
Financial Assets and Financial Liabilities—Including an amendment of FASB 
Statement No. 115, which is effective as of the beginning of an entity's first 
fiscal year that begins after November 15,  2007. Early adoption is permitted 
as of the beginning of a fiscal year that begins on or before November 15, 
2007, provided the organization also elects to apply the provisions of SFAS 
157, Fair Value Measurements. The choice to adopt early should be made 
after issuance of this statement but within 120 days of the beginning of the 
fiscal year of adoption, provided the entity has not yet issued financial
(continued)
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statements, including required notes to those financial statements, for any 
interim period of the fiscal year of adoption.
This statement applies to all entities, including not-for-profit organizations. 
Most of the provisions of this statement apply only to entities that elect the 
fair value option. However, the amendment to SFAS 115, Accounting for 
Certain Investments in Debt and Equity Securities, applies to all entities with 
available-for-sale and trading securities. Some requirements apply differ­
ently to entities that do not report net income. This checklist has been up­
dated to include the presentation and disclosure requirements of SFAS 159. 
Readers can refer to the full text of the statement on the FASB Web site at 
www.fasb.org.
See section V, "Fair Value Measurements," for more information. If SFAS 
159 is applicable to the financial statements, begin with question 1. Other­
wise, begin with question 3.
♦ 1. Does the entity report its investments in available-for-sale securities
and trading securities separately from similar assets that are subse­
quently measured using another measurement attribute on the face of 
the balance sheet and, in doing so, does the entity either:
a. Present the aggregate of those fair value and non-fair-value 
amounts in the same line item and parenthetically disclose the 
amount of fair value included in the aggregate amount? or
b. Present two separate line items to display the fair value and non- 
fair-value carrying amounts?
[SFAS 115 par. 17]
♦ 2. If an entity elects the fair value option for a held-to-maturity or avail­
able-for-sale security in conjunction with the adoption of SFAS 159, is 
the security then reported as a trading security under SFAS 115 but not 
subjected to the accounting rules normally associated with transfers to 
the trading category?
[SFAS 159 par. 29]
★ ♦ 3. Are investments reported as current or noncurrent assets in conformity
with GAAP?
[AAG 4.25]
★ ♦4. Are the appropriate disclosures made for investments in common
stock accounted for by the equity method?
[APB 18 par. 20]
★ ♦ 5. Are other investments (such as real estate) reported at amortized cost,
(subject to impairment considerations consistent with SFAS 144, Ac­
counting for the Impairment or Disposal of Long-Lived Assets)?
[AAG 4.02]
♦ 6. Are debt and equity securities classified as (a) held-to-maturity, (b)
available-for-sale, or (c) trading?
[SFAS 115 par. 6]
♦ 7. For securities classified as available-for-sale, has the reporting entity
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
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a. Aggregate fair value?
b. Total gains for securities with net gains in accumulated other com­
prehensive income?
c. Total losses for securities with net losses in accumulated other 
comprehensive income?
[SFAS 115 par. 19]
♦ 8. For securities classified as held-to-maturity, has the reporting entity
made the following disclosures by major-security type as of each date 
for which a statement of financial position is presented:
a. Aggregate fair value?
b. Gross unrecognized holding gains or losses?
c. Net carrying amount?
d. Gross gains and losses in accumulated other comprehensive in­
come for any derivatives that hedged the forecasted acquisition of 
the held-to-maturity securities?
[SFAS 115 par. 19]
♦ 9. For investments in debt securities classified as available-for-sale and
separately for securities classified as held-to-maturity:
a. Is disclosure made about their contractual maturities as of the date 
of the latest balance sheet presented (maturity information may be 
combined in appropriate groupings)?
b. If securities not due at a single date (such as mortgage-backed 
securities) are allocated over several maturity groupings, is the 
basis for allocation disclosed?
[SFAS 115 par. 20]
♦ 10. For each period for which an income statement is presented, are the
following disclosed:
a. The proceeds from sales of available-for-sale securities and gross 
realized gains and losses that have been included in earnings as a 
result of those sales?
b. The basis on which the cost of a security sold or the amount reclas­
sified out of accumulated other comprehensive income into earn­
ings was determined (that is, specified identification, average cost, 
or other method used)?
c. The gross gains and losses included in earnings from transfers of 
securities from the available-for-sale category to the trading cate­
gory?
d. The amount of the net unrealized holding gain or loss on available- 
for-sale securities for the period that has been included in accu­
mulated other comprehensive income and the amount of gains and 
losses reclassified out of accumulated other comprehensive income 
into earnings for the period?
e. The portion of trading gains and losses for the period that relates 
to trading securities still held at the reporting date?
[SFAS 115 par. 21]
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♦ 11. For any sales of or transfers from securities classified as held-to-matur-
ity, are the following disclosed for each period for which an earnings 
statement is presented:
a. Net carrying amount of the sold or transferred security? _____ _____ ____
b. The net gain or loss in accumulated other comprehensive income 
for any derivative that hedged the forecasted acquisition of the
held-to-maturity security? _____ _____ ____
c. Related realized or unrealized gain or loss? _____ _____ ____
d. The circumstances leading to the decision to sell or transfer the
security? _____ _____ ____
[SFAS 115 par. 22]
♦ 12. If an option that is not a derivative subject to SFAS 133, Accounting for
Derivative Instruments and Hedging Activities (to purchase securities that 
will be accounted for under SFAS 115) is classified as held-to-maturity 
or available-for-sale, is the accounting policy for the premium paid to
acquire the option disclosed? _____ _____ ____
[EITF 96-11]
★ ♦ 13. For financial instruments, are significant concentrations of credit risk 
arising from concentrations of securities of a particular issuer dis­
closed? _____ _____ ____
[SFAS 107, as amended by SFAS 133 par. 531]
★14. Are realized gains and losses; unrealized gains and losses; dividend, 
interest, and other similar investment income; and other than tempo­
rary impairment losses reported in the statement of activities as in­
creases or decreases in unrestricted net assets or in temporarily re­
stricted net assets or in permanently restricted net assets, depending
on the existence of or lack of donor restrictions or law? _____ _____ ____
[SFAS 124 par. 8-9; AAG 4.07-.08]
★15. Are realized gains and losses; dividend, interest and other similar in­
vestment income; and other than temporary impairment losses in­
cluded in the performance indicator within the statement of activities? _____ _____ ____
[SFAS 124 par. 49; AAG 4.07]
★16. Are unrealized gains and losses on trading securities (as defined in 
SFAS 115) included in the performance indicator within the statement
of activities? _____ _____ ____
[SFAS 124 par. 49; AAG 4.07]
★17. Are unrealized gains and losses on other than trading securities ex­
cluded from the performance indicator within the statement of activi­
ties? _____ _____ ____
[SFAS 124 par. 49; AAG 4.07]
★18. If a provider reports gains and investment income that are limited to 
specific uses by donor-imposed restrictions as increases in unrestricted 
net assets because the restrictions are met in the same reporting period 
as the gains and income are recognized, does the provider:
a. Have a similar policy for reporting contributions received? _____ _____ ____
b. Report consistently from period to period? _____ _____ ____
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c. Disclose its accounting policy?
[SFAS 124 par. 10; AAG 4.09]
★19. For each period that a statement of activities is presented, are the fol­
lowing disclosures made on the face of the financial statements or in 
the notes thereto:
a. The composition of investment return including, at a minimum, 
investment income, net realized gains or losses on investments 
reported at other than fair value, and net gains or losses on invest­
ments reported at fair value?
b. A reconciliation of investment return to amounts reported in the 
statement of activities, if investment return is separated into oper­
ating and nonoperating amounts?
c. A description of the policy used to determine the amount of in­
vestment return included in the measure of operations, if invest­
ment return is separated into operating and nonoperating 
amounts?
d. A discussion of circumstances leading to a change, if any, in the 
policy referred to in question 19c?
[SFAS 124 par. 14; AAG 4.11]
★20. For each period for which a statement of financial position is presented, 
are the following disclosures made on the face of the financial state­
ments or in the notes thereto:
a. The aggregate carrying amount of investments by major types (for 
example, equity securities, corporate debt securities, and so on)?
b. The basis for determining the carrying amount for investments 
other than equity securities with readily determinable fair values 
and all debt securities?
c. The methods and assumptions used to estimate the fair values of 
investments other than financial instruments, if those other invest­
ments are reported at fair value?
d. The aggregate amount of the deficiencies for all donor-restricted 
endowment funds, for which the fair value of the assets at the 
reporting date is less than the level required by donor stipulations 
or law?
[SFAS 124 par. 15; AAG 4.11]
★21. For the most recent period for which a statement of financial position 
is presented, does the provider disclose the nature of and carrying 
amount for every individual investment or group of investments that 
represents a significant concentration of market risk (market risk may 
result from the nature of the investments, a lack of diversity of indus­
try, currency, or geographic location)?
[SFAS 124 par. 16 and 86; AAG 4.11]
★ ♦ 22. Are significant net realized and net unrealized gains and losses that 
arose after the latest statement of financial position date, but before 
issuance of the financial statements, disclosed?
[AU 560.05 and .07]
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Note: EITF 03-1, "The Meaning of Other-Than-Temporary Impairment and 
Its Application to Certain Investments," requires certain disclosures about 
unrealized losses that have not been recognized as other-than-temporary 
impairments. EITF 03-1 applies to debt and equity securities within the 
scope of SFAS 115 and SFAS 124, Accounting for Certain Investments Held by 
Not-for-Profit Organizations (applicable to investments held by a not-for- 
profit health care organization in the scope of AAG). See EITF 03-1 for 
further information regarding investments within the scope of this Issue.
★ ♦ 23. For all investments in an unrealized loss position for which other-than-
temporary impairments have not been recognized, do the annual fi­
nancial statements disclose:
a. Quantitative information as of each date for which a statement of 
financial position presented aggregated by each category of invest­
ment that the investor discloses in accordance with SFAS 115 and 
SFAS 124 and cost method investments, in tabular form:
(1) The aggregate amount of unrealized losses (that is, the amount 
by which cost or amortized cost exceeds fair value), segregated 
by those investments that have been in a continuous unreali­
zed loss position for less than 12 months and those that have 
been in a continuous unrealized loss position for 12 months or 
longer?
(2) The aggregate related fair value of investments with unreali­
zed losses, segregated by those investments that have been in 
a continuous unrealized loss position for less than 12 months 
and those that have been in a continuous unrealized loss posi­
tion for 12 months or longer?
b. Additional information in narrative form, as of the date of the most 
recent statement of financial position, that provides sufficient in­
formation to allow financial statement users to understand the 
quantitative disclosures and the information that the investor con­
sidered in reaching the conclusion that the impairments were not 
other than temporary?
[EITF 03-1 par. 21]
★ ♦ 24. For cost method investments, is the following additional information
disclosed in annual financial statements, if applicable, as of each date 
for which a statement of financial position is presented:
a. The aggregate carrying amount of all cost method investments?
b. The aggregate carrying amount of cost method investments that 
the investor did not evaluate for impairment?
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c. The fact that the fair value of a cost method investment is not 
estimated if there are no identified events or changes in circum­
stances that may have a significant adverse effect on the fair value 
of the investment and (1) the investor determined, in accordance 
with paragraphs 14-15 of SFAS 107, Disclosures about Fair Value of 
Financial Instruments, that it is not practicable to estimate the fair 
value of the investment, or (2) the investor is exempt from estimat­
ing fair value under SFAS 126, Exemption from Certain Required Dis­
closures about Financial Instruments for Certain Nonpublic Entities—an 
amendment to FASB Statement No. 107?
[EITF 03-1 par. 22]
Notes: FSP FAS 115-1 and FAS 124-1, The Meaning of Other-Than-Temporary 
Impairment and Its Application to Certain investments, includes a tabular ex­
ample of the quantitative disclosures (see appendix A of the FSP) referred 
to in question 23a of this section.
If SFAS 157 has been adopted, refer to section V, "Fair Value Measure­
ments," within the section of this checklist titled, "Other Financial State­
ment Disclosures," for additional disclosure requirements.
★ ♦ 25. If the organization has investments that would have been accounted
for under the equity method if the organization had not chosen to 
apply the fair value option in SFAS 159 or in paragraph 16 of SFAS 133, 
has it disclosed for each period for which a statement of financial po­
sition is presented the information required by paragraph 20 of APB 
18, The Equity Method of Accounting for Investments in Common Stock, 
excluding the disclosures in paragraphs 20(a)(3), 20(b), and 20(e) of 
that APB?
[SFAS 159 par. 18f]
D. Receivables and Loans
★ ♦ 1. Are charity care revenue and receivables excluded from the financial
statements?
[AAG 5.03]
★ ♦ 2. Are differences between the estimates originally reported and subse­
quent revisions, including final settlements:
a. Included in the statement of activities/income statement in the 
period the revisions are made and disclosed, if material?
b. Reported in the current period unless they meet the criteria for 
prior-period adjustments?
[AAG 5.08; SFAS 16]
★ ♦ 3. Are amounts due from third-party payors for retroactive adjustments
of items (such as final settlements or appeals) reported separately in 
the financial statements?
[AAG 5.21]
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★4. When displaying total assets and total liabilities, are interfund assets
and liabilities eliminated?1 _____ _____ ____
[AAG 5.28]
Note: Accounting for contributions is an issue primarily for not-for-profit 
organizations because contributions are a significant source of revenues for 
many of those organizations. However, SFAS 116, Accounting for Contribu­
tions Received and Contributions Made, applies to all entities (not-for-profit 
and business enterprises) that receive or make contributions. [SFAS 116 
par. 1]
★5. Do entities that receive unconditional promises to give disclose the 
following:
a. The amounts of promises receivable in less than one year, in one 
to five years, and in more than five years?
b. The amount of any allowance for uncollectible promises receiva­
ble?
[SFAS 116 par. 24]
★6. Do entities that receive conditional promises to give disclose the fol­
lowing:
a. The total of the amounts promised?
b. A description and amount for each group of promises having sim­
ilar characteristics (such as amount of promises conditioned on 
establishing new programs, completing a new building, and rais­
ing matching gifts by a specified date)?
[SFAS 116 par. 25]
★ ♦ 7. Are all receivables reported net of any related allowance for uncollec­
tible amounts, with appropriate disclosure?
[AAG 5.21; APB 12 par. 3]
★ ♦ 8. Are accounts and notes receivable from officers, employees, and affili­
ated organizations shown separately with appropriate disclosures? 
[ARB 43 ch. 1A par. 5]
★ ♦ 9. For financial instruments, are significant concentrations of credit risk
arising from receivables disclosed?
[SFAS 107, as amended by SFAS 133 par. 531]
★ ♦ 10. Are unearned discounts (other than cash or quantity discounts and the
like), finance charges, and interest included in the face amounts of 
receivables shown as a deduction from the related receivables?
[APB 6 par. 14]
★ ♦11. Does the summary of significant accounting policies include the fol­
lowing disclosures:
a. The basis of accounting for loans, trade receivables, and lease fi­
nancings, including those classified as held for sale?
1 The display of interfund items in a statement of financial position is not prohibited by SFAS 117, Financial Statements of Not-for-Profit
Organizations. However, because interfund items are not organizational assets or liabilities, those interfund items must be clearly labeled
and arranged in the statement of financial position to eliminate their amounts when total assets and liabilities are displayed. [SFAS 117
par. 85 fn 8]
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b. The method of determining the lower of cost or fair value of non­
mortgage loans held for sale (that is, aggregate or individual asset
basis)? -------
c. The classification and method of accounting for loans and other
receivables that can be contractually prepaid or otherwise settled 
in a way that the holder would not recover substantially all of its 
recorded investment (applies to instruments within the scope of 
paragraph 14 of SFAS 140)? -------
d. The method for recognizing interest income on loan and trade re­
ceivables, including a statement about the entity's policy for treat­
ment of related fees and costs, including the method of amortizing
net deferred fees or costs? _____
e. A description of the accounting policies and methodology the en­
tity used to estimate its allowance for loan losses, allowance for 
doubtful accounts, and any liability for off-balance sheet credit 
losses and related charges for loan, trade receivable or other credit 
losses, including a description of the factors that influenced man­
agement's judgment? _____
f. The policy for placing loans (and trade receivables if applicable)
on nonaccrual status (or discontinuing accrual of interest) and re­
cording payments received on nonaccrual loans (and trade receiv­
ables if applicable), and the policy for resuming accrual of interest? _____
g. The policy for charging off uncollectible loans and trade receiva­
bles? _____
h. The policy for determining past due or delinquency status (that is, 
whether past due status is based on how recently payments have
been received or contractual terms? _____
[SOP 01-6 par. .13a-c (ACC 10,850.13a-c)]
★ ♦ 12. Is the aggregate amount of gains or losses on sales of loans or trade
receivables presented separately in the financial statements or dis­
closed in the notes? _____
[SOP 01-6 par. .13d (ACC 10,850.13d)]
★ ♦ 13. Are loans and trade receivables held for sale presented as a separate
balance sheet or statement of financial position category, or both? _____
[SOP 01-6 par. .13e (ACC 10,850.13e)]
★ ♦ 14. Are major categories of loans and trade receivables presented sepa­
rately in the balance sheet or statement of financial position, or both,
or in the notes to the financial statements? _____
[SOP 01-6 par. .13e (ACC 10,850.13e)]
★ ♦ 15. Are the allowances for credit losses and doubtful accounts disclosed? _____
[SOP 01-6 par. .13e (ACC 10,850.13e)]
★ ♦ 16. Is the recorded investment in loans (and trade receivables, if applica­
ble), on nonaccrual status as of each balance-sheet date disclosed in the 
notes to the financial statements? (The recorded investment in loans, 
and if applicable, trade receivables, past due ninety days or more and
still accruing should also be disclosed.) _____
[SOP 01-6 par. .13g (ACC 10,850.13g)]
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★ ♦17. Is the carrying amount of loans and trade receivables that serve as 
collateral for borrowings disclosed pursuant to paragraphs 18-19 of
SFAS 5, Accounting for Contingencies? _____ _____ ____
[SOP 01-6 par. .13j (ACC 10,850.13j)]
Notes: SOP 03-3, Accounting for Certain Loans or Debt Securities Acquired in a 
Transfer (AICPA, Technical Practice Aids, ACC sec. 10,880), addresses ac­
counting for differences between contractual cash flows and cash flows 
expected to be collected from an investor's initial investment in loans or 
debt securities (loans) acquired in a transfer if those differences are attrib­
utable, at least in part, to credit quality. This SOP applies to all nongovern­
mental entities, including not-for-profit organizations, that acquire loans.
Readers may also refer to AICPA Technical Practice Aids TIS section 
2130.09-.37 for additional nonauthoritative guidance pertaining to various 
topics on the application of SOP 03-3.
★ ♦ 18. Is a description of the accounting policies and methodology used to
estimate the allowance for doubtful accounts, allowance for loan losses 
and any liability for off-balance-sheet credit losses and related charges 
for loan, trade receivable or other credit losses included in the notes to 
the financial statements? (Note: Such description should identify the 
factors that influenced management's judgment.)
[SOP 01-6 par. .13(b) (ACC 10,850.13b)]
★ ♦ 19. Do the notes to the financial statements describe how prepayments are
considered in the determination of contractual cash flows and cash 
flows expected to be collected?
[SOP 03-3 par. .14 (ACC 10,880.14)]
★ ♦ 20. Is information about loans meeting the scope criteria of paragraph 3 of
SOP 03-3 included in the disclosures required by paragraphs 20(a) and 
20(b) of SFAS 114, Accounting by Creditors for Impairment of a Loan—an 
amendment of FASB Statements No. 5 and 15, if the condition in para­
graph 16 of SFAS 115 or paragraph 8(a) of SFAS 5 is met?
[SOP 03-3 par. .15 (ACC 10,880.15)]
★ ♦ 21. In addition to disclosures required by other GAAP principles, for each
balance sheet or statement of financial position, or both, presented, is 
the following information disclosed by an investor about loans within 
the scope of SOP 03-3:
a. Separately for both those loans that are accounted for as debt se­
curities and those loans that are not accounted for as debt securi­
ties:
(1) The outstanding balance and the related carrying amount at 
the beginning and end of the period?
(2) The amount of accretable yield at the beginning and end of the 
period, reconciled for additions, accretion, disposal of loans, 
and reclassifications to or from nonaccretable difference dur­
ing the period?
(3) For loans acquired during the period, the contractually re­
quired payments receivable, cash flows expected to be col­
lected, and fair value at the acquisition date?
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(4) For those loans within the scope of SOP 03-3 for which the 
income recognition model in SOP 03-3 is not applied in accor­
dance with paragraph .06 of that SOP, the carrying amount at 
the acquisition date for loans acquired during the period and 
the carrying amount of all loans at the end of the period?
b. Further, for those loans that are not accounted for as debt securi­
ties, does an investor disclose:
(1) The amount of (a) any expense recognized pursuant to para­
graph .08a of SOP 03-3 and (b) any reductions of the allowance 
recognized pursuant to paragraph .08(b)(1) of SOP 03-3 for 
each period for which an income statement/statement of op­
erations is presented?
(2) The amount of the allowance for uncollectible accounts at the 
beginning and end of the period?
[SOP 03-3 par. .16 (ACC 10,880.16)]
Notes: SFAS 159 permits an organization to irrevocably elect fair value as 
the initial and subsequent measurement attribute for certain financial assets 
and financial liabilities on a contract-by-contract basis, with changes in fair 
value recognized in the statement of activities/income statement as those 
changes occur. SFAS 159 is effective as of the beginning of an organization's 
first fiscal year that begins after November 15, 2007. Early adoption is per­
mitted as of the beginning of a fiscal year that begins on or before Novem­
ber 15, 2007, provided the organization also elects to apply the provisions 
of SFAS 157.
See section V, "Fair Value Measurements," for more information. If SFAS 
159 is applicable to the financial statements (and related notes) of the entity, 
questions 22-23 should be answered.
★ ♦ 22. As of each date for which a statement of financial position is presented, 
has the organization disclosed the following information for assets for 
which the fair value option under SFAS 155, Accounting for Certain 
Hybrid Financial Instruments—an amendment of FASB Statements No. 133 
and 140, or SFAS 159 has been elected:
a. The difference between the aggregate fair value and the aggregate 
unpaid principal balance of loans and long-term receivables (other 
than securities subject to SFAS 124, Accounting for Certain Invest­
ments Held by Not-for-Profit Organizations) that have contractual 
principal amounts?
b. The aggregate fair value of loans that are 90 days or more past 
due?
c. The aggregate fair value of loans in nonaccrual status, if the orga­
nization's policy is to recognize interest income separately from 
other changes in fair value?
d. The difference between the aggregate fair value and the aggregate 
unpaid principal balance for loans that are 90 days or more past 
due, in nonaccrual status, or both?
[SFAS 159 par. 18]
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★ ♦ 23. As of each date for which a statement of activities or income statement,
or both, is presented, has the organization disclosed the following in­
formation for loans and long-term receivables for which the fair value 
option under SFAS 155 or SFAS 159 has been elected:
a. The estimated amount of gains or losses included in the change in 
each of the net asset classes (unrestricted, temporarily restricted, 
and permanently restricted) during the period, and in an interme­
diate measure of operations if one is presented, that is attributable
to changes in instrument-specific credit risk? _____ _____ ____
b. How the gains or losses attributable to changes in instrument-spe­
cific credit risk were determined? _____ _____ ____
[SFAS 159 par. 19]
E. Beneficial Interests in Assets Held by Others
★1. If the organization transferred assets to another entity and specified 
itself or its affiliate as the beneficiary, has it disclosed the following for 
each period in which a statement of financial position is presented:
a. The identity of the recipient organization to which the transfer was
made? _____ _____ ____
b. Whether variance power was granted to the recipient organization
and, if so, a description of the terms of the variance power? _____ _____ ____
c. The terms under which amounts will be distributed to the organi­
zation or its affiliate? _____ _____ ____
d. The aggregate amount recognized in the statement of financial po­
sition for those transfers and whether that amount is recorded as 
an interest in the net assets of the recipient organization or as an­
other asset (such as a beneficial interest in assets held by others or
as a refundable advance)? _____ _____ ____
[SFAS 136 par. 19]
F. Property and Equipment, and Supplies
★ ♦ 1. Are donor or legal restrictions on the proceeds from the disposition of
donated property and equipment (or of property and equipment pur­
chased with cash restricted for acquisition of long-lived assets) dis­
closed? _____ _____ ____
[AAG 6.09]
★ ♦ 2. For depreciable assets, do the financial statements or notes disclose:
a. Depreciation expense for each period? _____ _____ ____
b. Balances of major classes of depreciable assets by nature or func­
tion? _____ _____ ____
c. Accumulated depreciation, either by major classes of assets or in
total? _____ _____ ____
d. The method or methods used in computing depreciation with re­
spect to major classes of depreciable assets? _____ _____ ____
[APB 12 par. 5]
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★ ♦ 3. Is the amount of interest cost incurred and charged to expense during
the period disclosed for an accounting period in which no interest cost
is capitalized? -------
[SFAS 34 par. 21a]
★ ♦4. Is the amount of interest cost incurred during the period and the
amount that has been capitalized disclosed for an accounting period in
which some interest cost is capitalized? -------
[SFAS 34 par. 21b]
★ ♦ 5. Are material commitments for property expenditures disclosed? -------
[SFAS 5 par. 18-19]
★ ♦ 6. For an existing property with an asbestos problem, are the costs in­
curred to treat the problem, if charged to expense, not classified as an
extraordinary item? -------
[EITF 89-13]
★ ♦ 7. Is the method of determining inventory cost disclosed? _____
[ARB 43 ch. 3A par. 9]
★ ♦ 8. Are the disclosures required by paragraph 19(c) of APB 20, Accounting
Changes, made if there are significant changes to an entity's inventory 
accounting as a result of adopting SFAS 151, Inventory Costs—an amend­
ment of ARB No. 43, Chapter 41 _____
[SFAS 151 par. 4]
G. Deferred Income Tax Assets and Liabilities
♦ 1. In a classified balance sheet:
a. Are deferred tax assets and deferred tax liabilities classified as cur­
rent or noncurrent based on the classification of the related asset
or liability for financial reporting? _____
[SFAS 109 par. 41]
h. Are deferred tax assets or liabilities not related to an asset or liabil­
ity for financial reporting (including those related to carryfor­
wards) classified according to the expected reversal date of the 
temporary difference pursuant to SFAS 37, Balance Sheet Classifica­
tion of Deferred Income Taxes—an amendment of APB Opinion No. 11? _____
[SFAS 109 par. 41]
c. Is the valuation allowance for a particular tax jurisdiction allocated 
between current and noncurrent deferred tax assets for that tax
jurisdiction on a pro rata basis? _____
[SFAS 109 par. 41]
d. Are the following items offset and presented as a single amount 
for a particular taxpaying component and within a particular tax- 
paying jurisdiction:
(1) All current deferred tax liabilities and assets? _____
(2) All noncurrent deferred tax liabilities and assets? _____
[SFAS 109 par. 42]
♦ 2. Are the components of the net deferred tax liability or asset recognized
in the balance sheet disclosed as follows:
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a. The total of all deferred tax liabilities (measured as described in
paragraph 17b of SFAS 109, Accounting for Income Taxes)? _____ _____ ____
b. The total of all deferred tax assets (measured as described in para­
graph 17c and 17d of SFAS 109)? _____ _____ ____
c. The total valuation allowance recognized for deferred tax assets
(determined as described in paragraph 17e of SFAS 109)? _____ _____ ____
[SFAS 109 par. 43]
♦ 3. Is the net change during the year in the total valuation allowance dis­
closed? _____ _____ ____
[SFAS 109 par. 43]
♦ 4. If the reporting entity is a public enterprise, is the approximate tax
effect of each type of temporary difference and carryforward that gives 
rise to a significant portion of deferred tax liabilities and deferred tax
assets (before valuation allowances) disclosed? _____ _____ ____
[SFAS 109 par. 43]
♦ 5. If the reporting entity is a nonpublic enterprise, are the types of signif­
icant temporary differences and carryforwards disclosed? _____ _____ ____
[SFAS 109 par. 43]
Practice Tip
SFAS 109 requires that deferred taxes be determined separately for each taxpaying component in each tax 
jurisdiction (for example, federal, state or local). A component may be an individual entity or a group of 
entities that is consolidated for tax purposes.
H. Intangible Assets and Goodwill
Notes: Questions 1-16 apply if the provisions of SFAS 142, Goodwill and 
Other Intangible Assets, are applied to the financial statements. The provi­
sions of SFAS 142 are required to be applied starting with fiscal years begin­
ning after December 15, 2001. SFAS 142 is required to be applied at the 
beginning of an entity's fiscal year and to be applied to all goodwill and 
other intangible assets recognized in its financial statements at that date. 
The provisions of SFAS 142 should not be applied to goodwill and intangi­
ble assets acquired in a combination between not-for-profit organizations 
or arising from the acquisition of a for-profit business entity by a not-for- 
profit organization until the FASB completes its project on those types of 
combinations. (Refer to paragraphs 48-61 of SFAS 142 for effective date and 
transition guidance.) If the provisions of APB 16, Business Combinations, and 
APB 17, Intangible Assets, are applied, see questions 13-14.
In April 2008, FASB issued FSP FAS 142-3, Determination of the Useful Life of 
Intangible Assets, to improve the consistency between the useful life of a 
recognized intangible asset under SFAS 142 and the period of expected cash 
flows used to measure the fair value of the asset under SFAS 141 and other 
U.S. GAAP. This FSP applies to recognized intangible assets that are ac­
counted for pursuant to SFAS 142 and applies regardless of the nature of 
the transaction that resulted in the recognition of the intangible asset, that 
is, whether acquired in a business combination or otherwise.
(continued)
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Among other significant provisions, FSP FAS 142-3 provides that, in deter­
mining the useful life of the intangible asset for amortization purposes, an 
entity shall consider the period of expected cash flows used to measure the 
fair value of the recognized intangible asset, adjusted for the entity-specific 
factors in paragraph 11 of SFAS 142. This FSP contains several disclosures 
requirements in addition to the required disclosures in paragraphs 44-45 of 
SFAS 142, including information that enables users of financial statements 
to assess the extent to which the expected future cash flows associated with 
the intangible asset are affected by the entity's intent or ability to renew or 
extend the arrangement.
FSP FAS 142-3 is effective for financial statements issued for fiscal years 
beginning after December 15, 2008, and interim periods within those fiscal 
years. Early adoption is prohibited. As such, this checklist has not been 
updated to include the disclosure requirements of this FSP. Readers can 
refer to the full text of FSP FAS 142-3 on the FASB Web site at 
www.fasb.org.
★ ♦1. At a minimum, are all intangible assets aggregated and presented as a
separate line item in the statement of financial position? (This require­
ment does not preclude presentation of individual intangible assets or 
classes of intangible assets as separate line items.)
[SFAS 142 par. 42]
★ ♦ 2. Are amortization expense and impairment losses for intangible assets
presented in income statement or statement of activities, or both, line 
items within continuing operations as deemed appropriate for each 
entity?
[SFAS 142 par. 42]
♦ 3. Is the aggregate amount of goodwill presented as a separate line item
in the statement of financial position?
[SFAS 142 par. 43]
♦ 4. Is the aggregate amount of goodwill impairment losses presented as a
separate line item in the income statement before the subtotal income 
from continuing operations (or similar caption) unless a goodwill impair­
ment loss is associated with a discontinued operation?
[SFAS 142 par. 43]
♦ 5. Is a goodwill impairment loss associated with a discontinued operation
included (on a net-of-tax basis) within the results of discontinued op­
erations?
[SFAS 142 par. 43]
★ ♦ 6. For intangible assets acquired either individually or with a group of
assets, is the following information disclosed in the notes to the finan­
cial statements in the period of acquisition:
a. For intangible assets subject to amortization:
(1) The total amount assigned and the amount assigned to any 
major intangible asset class?
(2) The amount of any significant residual value, in total and by 
major intangible asset class?
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(3) The weighted-average amortization period, in total and by
major intangible asset class? _____ ____
b. For intangible assets not subject to amortization, the total amount 
assigned and the amount assigned to any major intangible asset
class? _____ ____
c. The amount of research and development assets acquired and 
written off in the period and the line item in the income statement 
or statement of activities, or both, in which the amounts written off
are aggregated? _____ ____
[SFAS 142 par. 44]
7. Has the following information been disclosed in the financial state­
ments or the notes to the financial statements for each period for which 
a statement of financial position is presented:
★ ♦ a. For intangible assets subject to amortization:
(1) The gross carrying amount and accumulated amortization, in
total and by major intangible asset class? _____ ____
(2) The aggregate amortization expense for the period? _____ ____
(3) The estimated aggregate amortization expense for each of the
five succeeding fiscal years? _____ ____
★ ♦ b. For intangible assets not subject to amortization, the total carrying
amount and the carrying amount for each major intangible asset
class? _____ ____
♦ c. The changes in the carrying amount of goodwill during the period 
including:
(1) The aggregate amount of goodwill acquired? _____ ____
(2) The aggregate amount of impairment losses recognized? _____ ____
(3) The amount of goodwill included in the gain or loss on dis­
posal of all or a portion of a reporting unit? _____ ____
[SFAS 142 par. 44]
♦ 8. If the entity reports segment information in accordance with SFAS 131,
Disclosures about Segments of an Enterprise and Related Information, is the 
preceding information about goodwill provided in total and for each 
reportable segment and are any significant changes in the allocation of
goodwill by reportable segment disclosed? _____ ____
[SFAS 142 par. 45]
♦ 9. If any portion of goodwill has not yet been allocated to a reporting unit
at the date the financial statements are issued, is that unallocated
amount and the reasons for not allocating that amount disclosed? _____ ____
[SFAS 142 par. 45]
★ ♦ 10. For each impairment loss recognized related to an intangible asset, is 
the following information disclosed in the notes to the financial state­
ments that include the period in which the impairment loss is recog­
nized:
a. A description of the impaired intangible asset and the facts and
circumstances leading to the impairment? _____ ____
FSP §11,200.03
32 Health Care Organizations
b. The amount of the impairment loss and the method for determin­
ing fair value? -------
c. The caption in the income statement or statement of activities, or
both, in which the impairment loss is aggregated? -------
d. If applicable, the segment in which the impaired intangible asset is
reported under SFAS 131? -------
[SFAS 142 par. 46]
♦ 11. For each goodwill impairment loss recognized, is the following infor­
mation disclosed in the notes to the financial statements that include 
the period in which the impairment loss is recognized:
a. A description of the facts and circumstances leading to the impair­
ment? —
b. The amount of the impairment loss and the method of determining 
the fair value of the associated reporting unit (whether based on 
quoted market prices, prices of comparable businesses, a present
value or other valuation technique, or a combination thereof)? _____
c. If a recognized impairment loss is an estimate that has not yet been
finalized (refer to SFAS 142 par. 22), that fact and the reasons there­
fore and, in subsequent periods, the nature and amount of any 
significant adjustments made to the initial estimate of the impair­
ment loss? _____
[SFAS 142 par. 47]
♦ 12. Are effects on a goodwill impairment charge resulting from the appli­
cation of EITF 04-1, "Accounting for Preexisting Relationships between
the Parties to a Business Combination," reported in operating income? _____
[EITF 04-1 par. 9]
★ ♦13. Do disclosures relating to intangible assets include the method and
period of amortization? _____
[APB 16 par. 95e; APB 17 par. 30; APB 22 par. 13]
★14. Do disclosures relating to intangible assets include the reason for any 
unusual reduction of the value and future benefits of intangible assets
recognized during the period? _____
[APB 17 par. 31]
Note: If SFAS 157 has been adopted, refer to section V, "Fair Value Meas­
urements," within the section of this checklist titled, "Other Financial State­
ment Disclosures" for additional disclosure requirements.
I. Current Liabilities
★ ♦ 1. For classified balance sheets and classified statements of financial po­
sition, do current liabilities include:
a. Obligations for items that entered the operating cycle?
b. Collections received in advance of the performance of services?
c. Debts that arise from operations directly related to the operating 
cycle?
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d. Other liabilities whose regular and ordinary liquidation is likely to
occur within a relatively short time period? _____ _____ ____
e. Obligations that, by their terms, are due on demand or will be due 
within one year (or operating cycle, if longer) from the balance- 
sheet date, even though liquidation may not be expected within
that period? _____ _____ ____
[ARB 43 ch. 3A par. 7-8; SFAS 78 par. 5]
★ ♦2. Do current liabilities exclude short-term obligations that the provider
intends to refinance on a long-term basis, provided the provider has
demonstrated the ability to consummate the long-term financing? _____ _____ ____
[SFAS 6 par. 8-14; FIN 8 par. 2-4]
★ ♦ 3. In classified statements of financial position and in classified balance
sheets, are current portions of debt obligations presented as current
liabilities? _____ _____ ____
[ARB43ch.3A par.7-8]
Notes: Current liabilities may include notes payable to banks; the current 
portion of long-term debt; accounts payable; advances from and amounts 
payable to third-party payors for estimated and final reimbursement settle­
ments; refunds to and deposits from patients and others; deferred revenue; 
accrued salaries and payroll taxes; and other accruals.
[AAG 7.01]
SFAS 158, Employers' Accounting for Defined Benefit Pension and Other Postre­
tirement Plans—an amendment of FASB Statements No. 87, 88, 106, and 132(R), 
requires employers to recognize the overfunded or underfunded positions 
of defined benefit postretirement plans, including pension plans, in their 
statement of financial position as of the end of the fiscal year ending after 
June 15, 2007. For additional information, refer to Other Financial Statement 
Disclosures section I., "Pension and Other Postretirement Benefit Plans for 
Investor-Owned Organizations Only."
★ ♦ 4. In classified statements of financial position, is the current liability for
defined benefit postretirement plans, including pensions, determined 
on a plan-by-plan basis as the amount by which the actuarial present 
value of benefits included in the benefit obligation payable in the next 
12 months (or operating cycle if longer) exceeds the fair value of plan 
assets?
[SFAS 87 par. 36, as amended by SFAS 158 par C2(k); SFAS 106 par. 
44A-B, as amended by SFAS 158, par D2(d)]
J. Notes Payable and Other Debt
★ ♦1. Is there adequate disclosure of interest rates, maturities, and other
terms and conditions provided in loan agreements and bond inden­
tures (such as assets pledged as collateral, and covenants to reduce 
debt, and maintain working capital)?
[SFAS 5 par. 18]
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★ ♦ 2. Are the combined aggregate amounts of maturities and sinking fund
requirements for all long-term borrowings disclosed for each of the 
five years following the date of the latest balance sheet or statement of
financial position, or both, presented? ____
[SFAS 47 par. 10b]
★ ♦ 3. For unconditional purchase obligations that have been recorded in ac­
cordance with SFAS 47, Disclosure of Long-Term Obligations, paragraph 
6, is the amount of payments due in the aggregate and for every year 
during the five years following the date of the latest statement of finan­
cial position/balance sheet presented disclosed? ____
[SFAS 47 par. 10a]
★ ♦4. If a note is noninterest-bearing or has an inappropriate stated interest
rate:
a. Is the discount or premium presented as a deduction from or ad­
dition to the face amount of the note? ____
b. Does the disclosure include the effective interest rate and face
amount of the note? ____
c. Is amortization of the discount or premium reported as interest? ____
d. Are issue costs reported in the balance sheet/statement of financial
position as deferred charges? ____
[APB 21 par. 16]
★ ♦ 5. Are debt conversion features (such as rates and pertinent dates) dis­
closed? ____
[APB 14]
★ ♦ 6. If a short-term obligation is to be excluded from current liabilities in a
classified balance sheet/statement of financial position, do disclosures 
include:
a. General description of the financing agreement? ____
b. Terms of any new obligation incurred or expected to be incurred, 
or equity securities issued or expected to be issued as a result of
the refinancing? ____
[SFAS 6 par. 15]
★ ♦ 7. For a troubled debt restructuring occurring during the current period,
do disclosures include:
a. Description of the principle changes in terms or the major features
of settlement, or both? ____
b. Aggregate gain on restructuring of payables? ____
c. Aggregate net gain or loss on transfers of assets recognized during
the period? ____
d. Per-share amount, if applicable, of the aggregate gain on restruc­
turing of payables? ____
[SFAS 15 par. 25, as amended by SFAS 145]
★ ♦ 8. For periods after a troubled debt restructuring, do disclosures include:
a. Extent to which amounts contingently payable are included in the
carrying amount of restructured payables? ____
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b. Total amounts contingently payable, if applicable, and conditions
under which those amounts would become payable or forgiven? _____ _____ ____
[SFAS 15 par. 26]
★ ♦ 9. If debt was considered to be extinguished under the provisions of SFAS
76, Extinguishment of Debt—an amendment of APB Opinion No. 26, prior 
to the effective date of SFAS 125, Accounting for Transfers and Servicing 
of Financial Assets and Extinguishments of Liabilities, do disclosures in­
clude:
a. A general description of the transaction? _____ _____ ____
b. The amount of debt that is considered extinguished at the end of
the period as long as the debt remains outstanding? _____ _____ ____
[SFAS 140 par. 17b]
★ ♦10. If assets are set aside after the effective date of SFAS 125 solely for
satisfying scheduled payments of a specific obligation, is disclosure
made describing the nature of restrictions placed on those assets? _____ _____ ____
[SFAS 140 par. 17c]
Note: SOP 02-2, Accounting for Derivative Instruments and Hedging Activities 
by Not-for-Profit Health Care Organizations, and Clarification of the Performance 
Indicator (AICPA, Technical Practice Aids, ACC sec. 10,860), addresses the 
reporting by not-for-profit health care organizations of gains or losses on 
hedging derivative instruments under SFAS 133, as amended, and requires 
that not-for-profit health care organizations apply the provisions of SFAS 
133, including the provisions pertaining to cash flow hedge accounting, in 
the same manner as for-profit enterprises. The provisions of SOP 02-2 are 
effective for fiscal years beginning after June 15, 2003. Earlier application is 
encouraged but permitted only as of the beginning of any fiscal quarter that 
begins after issuance of SOP 02-2. See paragraphs .10-11 of SOP 02-2 for 
additional effect date and transition information.
♦ 11. If the reclassification to earnings of the amount in accumulated com­
prehensive income resulting from a cash flow hedge of debt is required 
under SFAS 133 when the debt is extinguished, is the reclassified 
amount not classified as extraordinary?
[EITF 00-9]
★ ♦ 12. Are long-term obligations that are or will be callable by the creditor, 
either because the debtor's violation of the debt agreement at the bal­
ance-sheet/statement-of-financial-position date makes the obligation 
callable, or because the violation (if not cured within a specified grace 
period) will make the obligation callable, classified as current unless 
one of the following conditions is met:
a. The creditor waives or subsequently loses the right to demand 
repayment for more than one year (or operating cycle, if longer) 
from the balance-sheet date?
b. The obligation contains a grace period within which the debtor 
may cure the violation and it is probable that the violation will be 
cured within that period, thus preventing the violation from be­
coming callable?
[SFAS 78 par. 5]
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★ ♦ 13. If an obligation under question 12b of the preceding is included in long­
term liabilities (or in the case of an unclassified balance sheet is in­
cluded as a long-term liability in the disclosure of debt maturities), are
the circumstances disclosed? ____
[SFAS 78 par. 5; see also EITF 86-30]
★14. Does the not-for-profit provider report tax-exempt obligations that 
were issued for its benefit as liabilities if the provider is responsible for
repayment? ____
[AAG par. 7.19]
★ ♦15. Are disclosures appropriate regarding the provider's tax-exempt
status and any other significant tax matters? ____
[AAG par. 7.14]
Notes: SFAS 159 permits an organization to irrevocably elect fair value as 
the initial and subsequent measurement attribute for certain financial assets 
and financial liabilities on a contract-by-contract basis, with changes in fair 
value recognized in the statement of activities or income statement, or both, 
as those changes occur. SFAS 159 is effective as of the beginning of an 
organization's first fiscal year that begins after November 15, 2007.
See section V, "Fair Value Measurements," for more information. If SFAS 
159 is applicable to the financial statements (and related notes) of the entity, 
questions 16-17 should be answered.
★ ♦ 16. If the organization measures certain long-term debt instruments at fair
value under the option in SFAS 159 or the option in paragraph 16 of 
SFAS 133, did it disclose the difference between the aggregate fair 
value and the aggregate unpaid principal balance of long-term debt 
instruments that have contractual principal amounts and for which the 
fair value option has been elected?
[SFAS 159 par. 18d]
★ ♦ 17. As of each date for which a statement of activities or income statement,
or both, is presented, has the organization disclosed the following in­
formation about liabilities that are measured at fair value under the 
option in SFAS 159 or the option in paragraph 16 of SFAS 133 for which 
fair values have been significantly affected during the reporting period 
by changes in the instrument-specific credit risk:
a. The estimated amount of gains and losses from fair value changes 
included in change in each of the net asset classes (unrestricted, 
temporarily restricted, and permanently restricted), and in the in­
termediate measure of operations, if one is presented, that are at­
tributable to changes in the instrument-specific credit risk?
b. Qualitative information about the reasons for those changes?
c. How the gains and losses attributable to changes in instrument- 
specific credit risk were determined?
[SFAS 159 par. 19d]
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K. Other Liabilities and Deferred Credits
★ ♦ 1. If the reporting entity has not accrued compensated absences (SFAS
43, Accounting for Compensated Absences), including sabbatical leaves 
described in EITF 06-2, "Accounting for Sabbatical Leave and Other 
Similar Benefits Pursuant to FASB Statement No. 43," because the
amount cannot be reasonably estimated, is that fact disclosed? ------- ------
[SFAS 43 par. 6; EITF 06-2 par. 5]
★ ♦2. If an obligation for postemployment benefits is not accrued in accor­
dance with SFAS 5 or SFAS 43 only because the amount cannot be 
reasonably estimated, is the fact that the benefits have not been accrued
disclosed in the financial statements? ------- ------
[SFAS 112 par. 7]
★ ♦3. If the organization has defined benefit pension plans for which the
projected benefit obligation exceeds the fair value of plan assets:
a. Is the aggregate amount of all unfunded projected benefit obliga­
tions reported as a liability? ------- ------
b. If the organization presents a classified statement of financial po­
sition, is the entire liability classified as a noncurrent unless there 
is a current portion? (Refer to "Restricted Resources" part M ques­
tion 4.) ------- ------
[SFAS 87 par. 35-36, as amended by SFAS 158 par. C2(j)-(k)]
★ ♦ 4. If the organization has defined benefit postretirement plans other than
pensions for which accumulated postretirement benefit obligation ex­
ceeds the fair value of plan assets:
a. Is the aggregate amount of all underfunded plans reported as a
liability? ------- ------
b. If the organization presents a classified statement of financial po­
sition, is the entire liability classified as a noncurrent unless there 
is a current portion? (Refer to "Restricted Resources" part M ques­
tion 4.) ------- -----
[SFAS 106 par. 44A-B as amended by SFAS 158 par. D2(d)]
L. Net Assets/Shareholder's Equity
♦ 1. Are the equity accounts of investor-owned providers presented in a
similar fashion as other investor-owned businesses? ------- -----
[AAG9.01]
★ ♦ 2. Is the nature of restrictions on donor-restricted resources disclosed? ------- -----
[AAG par. 9.06]
★3. Are limits on the use of unrestricted net assets (such as loan covenants 
and board-designated endowments) and information about the nature 
and amounts of different types of permanent and temporary restric­
tions disclosed? ------- -----
[SFAS 117 par. 16; AAG 9.03-.04]
★4. Are net assets released from restriction, such as those related to the 
fulfillment of time or purpose restrictions, reported separately in the
financial statements or disclosed in the notes? ------- -----
[AAG 10.08]
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Yes
♦ 5. Shareholders' equity (corporations):
a. For each class of stock, do disclosures include the number of shares 
authorized, issued and outstanding, and par or stated value per
share and changes therein? ____
[Generally Accepted]
b. Are classes of capital stock presented in order of priority in liqui­
dation? ____
[Generally Accepted]
c. Do the financial statements include a description, in summary 
form, sufficient to explain the pertinent rights and privileges of the 
various securities outstanding, (for example, dividend and liqui­
dation preferences, participation rights, call prices and dates, con­
version or exercise prices or rates and pertinent dates, sinking fund 
requirements, unusual voting rights, significant terms of contracts
to issue additional shares)? ____
[SFAS 129 par. 4]
d. Do disclosures include the number of shares issued upon conver­
sion, exercise, or satisfaction of required conditions during at least 
the most recent annual fiscal period and any subsequent interim
period presented? ____
[SFAS 129 par. 5]
e. Are the following disclosed on the face of the statement of financial 
position or in the notes:
(1) The aggregate or per-share amounts at which preferred stock
may be called or is subject to redemption through sinking-fund 
operations or otherwise? ____
(2) The aggregate and per-share amounts of arrearages in cumu­
lative preferred dividends? ____
[SFAS 129 par. 7]
f. For preferred stock that has a preference in involuntary liquidation 
considerably in excess of par or stated value of the shares, is the 
liquidation preference disclosed? (Note: Disclosure shall be made 
in the equity section of the statement of financial position in the 
aggregate, either parenthetically or "in short," rather than on a per-
share basis or through disclosure in the notes.) ____
[SFAS 129 par. 6]
g. For redeemable stock, do disclosures include the amount of re­
demption requirements, separately by issue or combined, for all 
issues of capital stock that are redeemable at fixed or determinable 
prices on fixed or determinable dates in each of the five years fol­
lowing the date of the latest statement of financial position pre­
sented? ____
[SFAS 129 par. 8]
h. Are significant terms of the conversion features of contingently 
convertible securities disclosed to enable users of financial state­
ments to understand the circumstances of the contingency and the
potential impact of conversion? ____
[FSPFAS 129-1 par. 3]
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i. Do disclosures indicate whether the shares that would be issued if 
the contingently convertible securities were converted are in­
cluded in the calculation of diluted earnings per share, and the
reasons why or why not? ------- ------
[FSP FAS 129-1 par. 4]
Note: Disclosures of information about derivative transactions entered into 
in connection with the issuance of the contingently convertible securities 
may be useful in terms of fully explaining the potential impact of the con­
tingently convertible securities.
[FSP FAS 129-1 par. 5]
j. Are applicable disclosures required by SFAS 129, Disclosure of In­
formation about Capital Structure, made for instruments within the 
scope of EITF 05-2, "Meaning of 'Conventional Convertible Debt 
Instrument' in Issue No. 00-19"?
[EITF 05-2 par. 10]
k. Are any appropriations of retained earnings for loss contingencies 
clearly identified and included in stockholders' equity?
[SFAS 5 par. 15]
l. Are restrictions on payment of dividends disclosed?
[SFAS 5 par. 18-19]
m. Are receivables for stock issued or subscribed appropriately iden­
tified and presented as a deduction from capital or, if presented as 
an asset, stated separately, clearly labeled, and their status clearly 
described to distinguish them from any other type of assets?
n. Are the carrying basis, the cost and the number of shares disclosed 
for treasury stock?
[Generally Accepted]
o. After completion of a quasi-reorganization, is a new retained earn­
ings account established and dated with the date being disclosed 
in subsequent financial statements until it is no longer deemed 
significant?
[ARB 43 ch. 7A par. 10; ARB 46 par. 2]
p. If state laws relating to acquisition of stock restrict the availability 
of retained earnings for payment of dividends or other significant 
effects, is appropriate disclosure made?
[APB 6 par. 13]
♦ 6. If interim financial reports contain an adjustment related to prior in­
terim periods of the current fiscal year, do disclosures include:
a. The effect on income from continuing operations, net income, and 
related per share amounts for each prior interim period of the cur­
rent fiscal year?
b. Income from continuing operations, net income, and related per 
share amounts for each prior interim period restated?
[SFAS 16 par. 15]
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♦ 7. If the reporting entity is a publicly traded company and if interim 
financial data and disclosures are not separately reported for the fourth 
quarter, are accounting changes made during the fourth quarter, dis­
posals of components of an entity, extraordinary, unusual or infre­
quently occurring items recognized in the fourth quarter, and the ag­
gregate effect of year-end adjustments that are material to the results 
of the quarter disclosed in a note to the annual financial statements? 
[APB 28 par. 31]
M. Restricted Resources
★1. Are cash or other assets received with a donor-imposed restriction that 
limits their use to long-term purposes reported separately from assets 
that are unrestricted and available for current use?
[SFAS 117 par. 11]
★2. Does the entity provide information about the nature and amounts of 
different types of permanent restrictions and temporary restrictions by 
reporting their amounts on the face of the statement of financial posi­
tion or by including relevant details in notes to financial statements? 
[SFAS 117 par. 14]
★3. Is property and equipment that is donor-restricted reported as tempo­
rarily or permanently restricted assets?
[SFAS 116 par. 14]
Statement of Activities/Income Statement/Statement of
Operations/Statement of Changes in Net Assets
A. General
★1. Does the statement of activities/operations or statement of changes in 
net assets report the amount of change in net assets for the period for 
the provider as a whole (using a descriptive term such as change in net 
assets or change in equity), and does that amount articulate to the net 
assets reported in the statement of financial position?
[SFAS 117 par. 18]
★2. Does the statement of activities/operations or the statement of changes 
in net assets report the amount of change in permanently restricted net 
assets, temporarily restricted net assets, and unrestricted net assets for 
the period?
[SFAS 117 par. 19]
★3. Does the statement of activities/operations report the following:
a. Revenues as increases in unrestricted net assets unless the use of 
the assets received is limited by donor-imposed restrictions?
b. Expenses as decreases in unrestricted net assets?
c. Events that simultaneously increase one class of net assets and 
decrease another (reclassifications), including expiration of donor- 
imposed restrictions, separately from revenues, expenses, gains, 
and losses?
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d. Gains and losses as increases or decreases in unrestricted net assets 
unless a donor or law temporarily or permanently restrict their
use? _____ ____
[SFAS 117 par. 19-20 and 22; SFAS 116 par. 17]
★4. Are revenues and expenses (arising from ongoing activities associated
with health care services) displayed as gross amounts? _____ ____
[SFAS 117 par. 24]
★5. If the provider elects to report investment revenues net of related ex­
penses, does the provider disclose the amount of expenses, either on 
the face of the statement of activities or in the notes to the financial
statements? _____ ____
[SFAS 117 par. 24]
★6. If the entity reports an intermediate measure of operations (for exam­
ple, excess or deficit of operating revenues over expenses), is this inter­
mediate measure reported only in a financial statement that, at a mini­
mum, reports the change in unrestricted net assets for the period? _____ ____
[SFAS 117 par. 23]
★7. If the entity's use of the term operations is not apparent from the details 
provided on the face of the statement of activities, does a note to finan­
cial statements describe the nature of the reported measure of opera­
tions or the items excluded from operations? _____ ____
[SFAS 117 par. 23]
★8. If the entity reports net gains and losses on its statement of activities/ 
operations, do these net amounts result from peripheral or incidental 
transactions or from events largely beyond the control of the entity and
its management? _____ ____
[SFAS 117 par. 25 and 138]
★ ♦ 9. Is management's policy for providing charity care, as well as the level
of charity care provided, disclosed? _____ ____
[AAG 10.28]
★10. Does the statement of activities/operations include a performance in­
dicator that reports results of operations and that is clearly labeled with 
a descriptive term such as revenues over expenses, revenues and gains over
expenses and losses, earned income, or performance earnings? _____ ____
[AAG 10.20]
★11. Do the notes to the financial statements include a description of the
nature and composition of the performance indicator? _____ ____
[AAG 10.20]
★12. Does the not-for-profit provider report the performance indicator in a 
statement that also presents the total changes in unrestricted net assets?
(Note: Other changes in net assets may be presented separately or in
the same statement.) _____ ____
[AAG 10.20]
★13. Does the organization report the following items separately from the 
performance indicator:
a. Transactions with owners acting in that capacity? _____ ____
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b. Equity transfers involving other entities that control the reporting 
entity, are controlled by the reporting entity, or are under common 
control with the reporting entity?
c. Receipt of restricted contributions, including temporary restric­
tions (such as time or purpose) or permanent restrictions?
d. Contributions of (and assets released from donor restrictions re­
lated to) long-lived assets?
e. Items that are required to be reported in or reclassified from other 
comprehensive income, such as minimum pension liabilities in ac­
cordance with paragraph 37 of SFAS 87, Employers' Accounting for 
Pensions; foreign currency translation adjustments and the effective 
portion of the gain or loss on derivative instruments designated 
and qualifying as cash flow hedging instruments?
f. Items that are required to be reported separately under specialized 
not-for-profit standards. These include extraordinary items, the ef­
fect of discontinued operations, and the cumulative effect of ac­
counting changes pursuant to the provisions of SFAS 117; and un­
realized gains and losses on investments not restricted by donors 
or by law (except for those investments classified as trading secu­
rities) and investment returns restricted by donors or by law, as 
required by paragraphs 4.07-.10 of the AAG?
[SOP 02-2 (ACC 10,860); AAG 10.21]
★ ♦ 14. For investments in common stock accounted for by the equity method,
is the investor's share of earnings shown as a single amount except for 
investee extraordinary items and prior-period adjustments that are 
material to the investor?
[APB 18 par. 19c-d]
★ ♦15. Are total research and development costs charged to expenses dis­
closed for each period for which a statement of activities/income state­
ment is presented?
[SFAS 2 par. 12-13; FIN 4 par. 5; FIN 6 par. 8; SFAS 86 par. 3]
★ ♦ 16. If the provider accounts for its obligation under a research and devel­
opment arrangement as a contract to perform research and develop­
ment for others, is there disclosure of:
a. The terms of significant agreements under the research and devel­
opment arrangement as of the date of each balance sheet or state­
ment of financial position, or both, presented?
b. The amount of compensation earned or costs incurred under such 
contracts for each period for which a statement of revenues and 
expenses (statement of operations) is presented?
[SFAS 68 par. 14]
♦ 17. Are the following excluded from the determination of net income or 
results of operations under all circumstances:
a. Adjustments or charges or credits resulting from transactions in 
the provider's own capital stock?
b. Transfers to and from accounts properly designated as appropri­
ated retained earnings?
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Yes No N/A
c. Adjustments made pursuant to a quasi-reorganization? ------- ------- ------
[APB 9 par. 28]
★18. Are net assets released from restriction, such as those related to the 
fulfillment of time or purpose restrictions, reported separately in the
financial statements or disclosed in the notes? ------- ------- ------
[AAG 10.08]
B. Revenue
★ ♦1. Is revenue classified based on the type of service (such as patient or
resident) rendered or contracted to be rendered? ------- ------- ------
[AAG 10.04]
★ ♦2. Are gains, losses, and interest earned properly classified and reported? _____ _____ ____
[AAG 10.08]
★ ♦ 3. Is patient service revenue reported net of provisions for contractual
and other adjustments? _____ _____ ____
[AAG 10.26]
★ ♦ 4. Do disclosures include methods of revenue recognition? _____ _____ ____
[AAG 10.26]
★ ♦5. With regard to contractual adjustments and third-party settlements,
does the provider identify and explain the estimated amounts payable
or receivable? _____ _____ ____
[AAG 10.26]
★ ♦ 6. Is significant revenue earned under capitation arrangements reported
separately? _____ _____ ____
[AAG 10.26]
C. Income Taxes
♦ 1. Are the following significant components of income tax expense attrib­
utable to continuing operations for each year presented disclosed in 
the financial statements or notes thereto:
a. Current tax expense or benefit? _____ _____ ____
b. Deferred tax expense or benefit (exclusive of the effects of other
components listed in the following)? _____ _____ ____
c. Investment tax credits? _____ _____ ____
d. Government grants (to the extent recognized as a reduction of in­
come tax expense)? _____ _____ ____
e. The benefits of operating loss carryforwards? _____ _____ ____
f. Tax expense that results from allocating certain benefits, either di­
rectly to contributed capital or to reduce goodwill or other noncur­
rent intangible assets of an acquired entity? _____ _____ ____
g. Adjustments of a deferred tax liability or asset for enacted changes
in tax laws or rates or a change in the tax status of the provider? _____ _____ ____
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h. Adjustments of the beginning-of-the-year balance of a valuation 
allowance because of a change in circumstances that causes a 
change in judgment about the realizability of the related deferred
tax asset in future years? ____
[SFAS 109 par. 45]
♦ 2. Is the amount of income tax expense or benefit allocated to continuing
operations and the amounts separately allocated to other items dis­
closed for each year for which those items are presented? ____
[SFAS 109 par. 35-39 and 46]
♦ 3. If the reporting entity is a public enterprise, is a reconciliation in both
percentages and dollars of the reported amount of income tax expense 
attributable to continuing operations for the year to the amount of 
income tax expense that would result from applying domestic federal
statutory rates to pretax income from continuing operations? ____
[SFAS 109 par. 47]
♦ 4. If the reporting entity is a nonpublic enterprise, is there disclosure of
the nature of significant items required to reconcile the reported 
amount of income tax expense attributable to continuing operations 
for the year to the amount of income tax expense that would result 
from applying domestic federal statutory tax rates to pretax income
from continuing operations? ____
[SFAS 109 par. 47]
♦ 5. Are the amounts and expiration dates of operating loss and tax credit
carryforwards for tax purposes disclosed? ____
[SFAS 109 par. 48]
♦ 6. Is the amount of any portion of the valuation allowance for deferred
tax assets for which subsequently recognized tax benefits will be allo­
cated to reduce goodwill or other noncurrent intangible assets of an
acquired entity or directly to contributed capital disclosed? ____
[SFAS 109 par. 48]
♦ 7. If the provider is a member of a group that files a consolidated tax
return, are the following items disclosed in its separately-issued finan­
cial statements:
a. The aggregate amount of current and deferred tax expense for each 
statement of earnings presented, and the amount of any tax-related 
balances due to or from affiliates as of the date of each balance
sheet presented? ____
b. The principal provisions of the method by which the consolidated 
amount of current and deferred tax expense is allocated to mem­
bers of the group and the nature and effect of any changes in that 
method (and in determining related balances to or from affiliates)
during the years for which the disclosures in question 7a? ____
[SFAS 109 par. 49]
♦ 8. Are the income taxes applicable to extraordinary events disclosed on
the face of the income statement or in related notes? ____
[APB 30 par. 11]
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Note: FSP FIN 48-2, Effective Date of FASB Interpretation No. 48 for Certain 
Nonpublic Enterprises, amends paragraph 22 of FIN 48, Accounting for Uncer­
tainty in Income Taxes—an interpretation of FASB Statement No. 109, to defer 
the effective date of FIN 48 to fiscal years beginning after December 15, 
2007, for nonpublic enterprises as defined by paragraph 289 of FASB State­
ment No. 109, Accounting for Income Taxes, including nonpublic not-for- 
profit organizations. Nonpublic enterprises subject to the provisions of FIN 
48 that are consolidated with a public enterprise or that have issued a full 
set of U.S. GAAP annual financial statements prior to the issuance of this 
FSP using the recognition, measurement, and disclosure requirements of 
FIN 48 are not eligible for the deferral.
At the October 15, 2008, meeting, FASB decided to issue a proposed FSP to 
defer FIN 48 for all nonpublic entities until fiscal years beginning after 
December 15, 2008, The proposed FSP will include a request for comments 
on issues that private pass-through entities have encountered related to FIN 
48. FASB expects to issue this proposed FSP in the first quarter of 2009. 
FASB will then subsequently issue a separate proposed FSP that will pro­
vide guidance for pass-through entities and provide amendments to the 
existing disclosure requirements for nonpublic entities.
For those nonpublic entities to which the deferral provisions of FSP FIN 
48-2 apply, skip questions 9-12 that follow.
♦ 9. Does the organization disclose its policy on classification of interest
and penalties in accordance with paragraph 19 of FIN 48 in the notes 
to the financial statements?
[FIN 48 par. 20]
♦ 10. Does an enterprise disclose the following at the end of each annual
reporting period presented:
a. A tabular reconciliation of the total amounts of unrecognized tax 
benefits at the beginning and end of the period, which shall include 
at a minimum:
(1) The gross amounts of the increases and decreases in unrecog­
nized tax benefits as a result of tax positions taken during a 
prior period?
(2) The gross amounts of increases and decreases in unrecognized 
tax benefits as a result of tax positions taken during the current 
period?
(3) The amounts of decreases in the unrecognized tax benefits re­
lating to settlements with taxing authorities?
(4) Reductions to unrecognized tax benefits as a result of a lapse 
of the applicable statute of limitations?
b. The total amount of unrecognized tax benefits that, if recognized, 
would affect the effective tax rate?
c. The total amounts of interest and penalties recognized in the state­
ment of operations and the total amounts of interest and penalties 
recognized in the statement of financial position?
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d. For positions for which it is reasonably possible that the total 
amounts of unrecognized tax benefits will significantly increase or 
decrease within 12 months of the reporting date:
(1) The nature of the uncertainty? _____
(2) The nature of the event that could occur in the next 12 months
that would cause the change? _____
(3) An estimate of the range of the reasonably possible change or
a statement that an estimate of the range cannot be made? _____
e. A description of tax years that remain subject to the examination
by major tax jurisdictions? _____
[FIN 48 par. 21]
♦ 11. If a classified statement of financial position is presented, does the
organization classify a liability associated with an unrecognized tax 
benefit as a current liability (or, alternatively, reduce the amount of a 
net operating loss carryforward or amount refundable) to the extent 
the organization anticipates payment (or receipt) of cash within one 
year or the operating cycle, if longer? Furthermore, has the liability for 
unrecognized tax benefits (or reduction in amounts refundable) not
been combined with deferred tax liabilities or assets? _____
[FIN 48 par. 17]
♦ 12. Is a liability that has been recognized as a result of applying FIN 48 not
classified as a deferred tax liability unless it arises from a taxable tem­
porary difference? _____
[FIN 48 par. 18]
★13. Does the organization disclose the following information about its tax 
status:
a. Reference to the Internal Revenue Code section under which the
organization is exempt? _____
b. Whether the organization is classified as a private foundation? _____
[AAG-NPO 15.22]
★14. If the organization's tax exempt status is in question by the IRS, is the
potential impact disclosed? _____
[SFAS 5 par. 1 and 39; AAG-NPO 10.14]
★15. If the organization incurs income tax expense, do the notes to the finan­
cial statements disclose the amount of the taxes and describe the nature
of the activities that generated the taxes? _____
[AAG-NPO 13.59]
★16. If the organization incurs income tax expense, do the notes to the finan­
cial statements include the disclosures required by SFAS 109? _____
[SFAS 109 par. 43-49]
★17. If the organization incurs tax penalties and interest, has it disclosed the 
total amounts of interest and penalties recognized in the income state­
ment, the total amounts of interest and penalties recognized in the
balance sheet, and its policy on classification of interest and penalties? _____
[FIN 48 par. 20-21]
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★18. If the organization has unrecognized tax benefits, has it disclosed the
information about those benefits required by FIN 48? ------- ------- ------
[FIN 48 par. 20-21]
★19. Has the organization disclosed the tax years that remain subject to
examination by major tax jurisdictions? ------- ------- ------
[FIN 48 par. 21]
Practice Tip
In connection with the implementation of FIN 48, some taxpayers may wish to request from the Internal 
Revenue Service a greatly accelerated examination and resolution before the end of their current financial 
statement accounting year of "uncertain tax positions" taken in filed returns or expected to be taken in tax 
returns yet to be filed, or both. The Internal Revenue Service has implemented an initiative by which the 
Service will be able to greatly expedite examination and accelerate resolution of important issues within the 
framework of its normal processes and its normal rules of engagement. Certain restrictions apply. Readers 
should refer to the IRS Web site for further details, or call the Service's Office of Pre-Filing & Technical 
Guidance LMSB at (202) 283-8408.
D. Extraordinary Items
★ ♦1. Are extraordinary items segregated and shown (including applicable
income taxes) following income before extraordinary items and before 
net income?
[APB 30 par. 11]
★ ♦2. Are descriptive captions and amounts (including applicable income
taxes) presented for individual extraordinary events or transactions, 
preferably on the face of the statement of activities or income state­
ment, or both, if practicable?
[APB 30 par. 11]
★ ♦ 3. Do disclosures include descriptions of extraordinary events or trans­
actions and the principal items entering into determination of extraor­
dinary gains or losses?
[APB 30 par. 11]
★ ♦4. For an adjustment of an extraordinary item reported in a prior period
(except for correction of an error):
a. Is the adjustment classified separately as an extraordinary item in 
the current period?
b. Are the nature, year of origin, and amount of the item disclosed? 
[SFAS 16 par. 16(c)]
E. Unusual or Infrequent Items
★ ♦ 1. Are material events or transactions that are either unusual in nature or
of infrequent occurrence, but not both (and therefore not meeting cri­
teria for extraordinary items):
a. Reported as a separate component of income from continuing op­
erations?
b. Accompanied by disclosure of the nature and financial effects of 
each event?
[APB 30 par. 26]
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F. Advertising Costs
★ ♦ 1. Do disclosures for advertising costs include:
a. The accounting policy selected from the two alternatives in the
beginning of paragraph 26 of SOP 93-7, Reporting on Advertising 
Costs (AICPA, Technical Practice Aids, ACC sec. 10,590), for report­
ing advertising, indicating whether such costs are expensed as in­
curred or the first time the advertising takes place? _____
b. A description of the direct-response advertising reported as assets
(if any), the accounting policy for it, and the amortization period? _____
c. The total amount charged to advertising expense for each state­
ment of activities/income statement presented, with separate dis­
closure of amounts, if any, representing a write-down of the capi­
talized advertising costs to net realizable value? _____
d. The total amount of advertising reported as assets in each balance
sheet/statement of financial position presented? _____
[SOP 93-7 par. .49 (ACC 10,590.49)]
G. Donated or Contributed Services
★1. If the provider receives contributed services, does it disclose the fol­
lowing:
a. A description of the programs or activities for which those services 
were used, including the nature and extent of contributed services 
received for the period and the amount recognized as revenues for
the period? _____
b. The fair value of contributed services received but not recognized,
if practicable (optional)? _____
c. Nonmonetary information such as the number and trends of do­
nated hours received or service outputs provided by volunteer
efforts (optional)? _____
d. Dollar amount of contributions raised by volunteers (optional)? _____
[SFAS 116 par. 10 and 123]
H. Donated Materials and Facilities
★1. If donated materials merely pass through the organization to its chari­
table beneficiaries, and the organization is only an agent or intermedi­
ary for the donors, has that donation been excluded from contribution
revenues? _____
[SFAS 116 par. 52-53; SFAS 136 par. 8 and 11]
I. Fund Raising
★1. Do financial statement disclosures include:
a. The types of activities for which joint costs have been incurred? _____
b. A statement that such costs have been allocated? _____
c. The total amount allocated during the period and the portion allo­
cated to each functional expense category? _____
[SOP 98-2 par. .18 (ACC 10,730.18)]
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Yes No N/A
Note: SOP 98-2, Accounting for Costs of Activities of Not-for-Profit Organiza­
tions and State and Local Governmental Entities That Include Fund Raising 
(AICPA, Technical Practice Aids, ACC sec. 10,730), encourages, but does not 
require, that the amount of joint costs for each kind of joint activity be 
disclosed, if practical.
[SOP 98-2 par. .19 (ACC 10,730.19)]
★2. If the organization includes within its financial statements a ratio of 
fundraising expenses to amounts raised, has it disclosed how that ratio 
was computed?
[SFAS 136 par. 20]
J. Contributions/Pledges
★1. Does the provider distinguish between contributions received with 
permanent restrictions, those received with temporary restrictions, and 
those received without donor-imposed restrictions, so that they are 
reported as support increasing permanently restricted net assets, tem­
porarily restricted net assets, or unrestricted net assets, respectively? 
[SFAS 116 par. 14]
★2. If donor-restricted contributions whose restrictions are met in the same 
reporting period are reported as unrestricted support, is such treat­
ment consistent from period to period and is the policy disclosed? 
[SFAS 117 par. 21; SFAS 116 par. 14]
★3. Does the provider report receipt of unconditional promises to give 
with payments due in future periods as restricted support, unless ex­
plicit donor stipulations or circumstances surrounding the receipt of 
the promise make clear that the donor intended the contribution to be 
used to support activities of the current period?
[SFAS 116 par. 15]
★4. Does an entity that receives gifts of long-lived assets without donor 
stipulation about how long the donated asset must be used:
a. Disclose its accounting policy of implying or not implying a time 
restriction that expires over the useful life of the asset?
b. Report such support as restricted if it is the provider's policy to 
imply a time restriction that expires over the useful life of the do­
nated asset?
c. Report such support as unrestricted in the absence of such a pol­
icy?
[SFAS 116 par. 16]
★5. Does a provider that receives unconditional promises to give, in which 
cash promised will be received in future periods, measure the fair 
value of the contribution as the present value of estimated future cash 
flows, using a discount rate commensurate with the risks involved, and 
report subsequent accruals of the interest element as contribution in­
come increasing either the temporarily or permanently restricted class 
of net assets if the underlying promise to give is donor restricted? 
[SFAS 116 par. 20]
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★ ♦6. Are unrestricted pledges/contributions reported in the statement of
operations? ____
[AAG 10.09]
K. Expenses
★1. Does the provider provide information about expenses reported by 
their functional classification (such as major classes of program ser­
vices and supporting services) either in the statement of activities or in
notes to financial statements? ____
[SFAS 117 par. 26]
★ ♦ 2. For deferred compensation agreements, are estimated amounts to be
paid properly accrued? ____
[APB 12 par. 6-7]
★ ♦3. At a minimum, is the following information disclosed in the notes to
the financial statements in all periods affected by the September 11,
2001, attacks:
a. A description of the nature and amounts of losses and costs recog­
nized as a result of the September 11 events and the amount of 
related insurance recoveries (if any) recognized? ____
b. A description of contingencies resulting from the September 11
events that have not yet been recognized in the financial state­
ments but that are reasonably expected to impact the entity's finan­
cial statements in the near term? ____
c. Applicable disclosures pursuant to SOP 94-6, Disclosure of Certain 
Significant Risks and Uncertainties (AICPA, Technical Practice Aids,
ACC sec. 10,640)? ____
d. Applicable disclosures about environmental obligations (and re­
coveries) pursuant to SOP 96-1, Environmental Remediation Liabili­
ties (AICPA, Technical Practice Aids, ACC sec. 10,680)? ____
[EITF 01-10]
★ ♦4. Are losses and costs incurred as a result of the September 11, 2001,
attacks classified as part of income from continuing operations? ____
[EITF 01-10]
★ ♦5. If the losses and costs incurred as a result of the September 11, 2001,
attacks meet the criteria for disclosure of unusual or infrequently oc­
curring items, are they reported as a separate component of income 
from continuing operations, either on the face of the statement of op­
erations or in the notes to the financial statements? ____
[EITF 01-10]
★ ♦ 6. Is the following information disclosed in the notes to the financial state­
ments in the period(s) in which business interruption insurance recov­
eries are recognized:
a. Nature of the event resulting in business interruption losses? ____
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b. Aggregate amount of business interruption insurance recoveries 
recognized during the period and the line item(s) in the statement 
of operations in which those recoveries are classified (including 
amounts reported as extraordinary pursuant to APB 30, Reporting 
the Results of Operations Reporting the Effects of Disposal of a Segment 
of a Business, and Extraordinary, Unusual and Infrequently Occurring
Events and Transactions)? ------- ------- ------
[EITF 01-13]
★7. Does the organization report as a separate line item or items within 
changes in unrestricted net assets, apart from expenses, the gains or 
losses and the prior service costs or credits that arise during the period 
but are not recognized as components of net periodic benefit cost pur­
suant to SFAS 87 and SFAS 106, Employers' Accounting for Postretirement
Benefits Other Than Pensions? ------- ------- ------
[SFAS 87 par. 74A, as amended by SFAS 158 par. C2(s); SFAS 106 par.
103A, as amended by SFAS 158 par D2(u)]
★8. Does the organization report the contra adjustment or adjustments that 
result from the reclassification to net periodic pension cost and net 
period postretirement benefit cost (from the net gain or loss and prior 
service costs or credits previously recognized pursuant to question 11 
and from the transition asset or obligation remaining from the initial 
application of SFAS 87 and SFAS 106) in the same line item or items 
within changes in unrestricted net assets, apart from expenses, as the
initially recognized amounts? ------- ------- ------
[SFAS 87 par. 74B, as amended by SFAS 158 par. C2(s); SFAS 106 par.
103B, as amended by SFAS 158 par. D2(u)]
★9. Does the organization report net periodic pension cost and net periodic
postretirement benefit cost by functional classification? ------- ------- ------
[SFAS 87 par. 74B, as amended by SFAS 158 par. C2(s); SFAS 106 par.
103B, as amended by SFAS 158 par. D2(u)]
L. Wills
★ ♦ 1. If the entity receives a promise to give conditioned on a future uncer­
tain event that is contained in a will and the will has been declared 
valid by the probate court, has the provider disclosed the conditional
promise to give? ------- ------- ------
[SFAS 116 par. 208]
M. Endowments
★1. If the governing board determines that the relevant law requires the 
organization to retain permanently some portion of gains on invest­
ment assets of endowment funds, is that amount reported as an in­
crease in permanently restricted net assets? ------- ------- ------
[SFAS 117 par. 22]
★2. In the absence of such a law or a donor's explicit or clear implicit 
permanent restriction, is net appreciation reported as unrestricted if 
the endowment's income is unrestricted, or temporarily restricted if
the endowment's income is temporarily restricted by the donor? _____ _____ ____
[SFAS 117 par. 129]
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N. Earnings Per Share
Notes: SFAS 128, Earnings per Share, applies only to entities with publicly 
held common stock or potential common stock.
******
FASB issued SFAS 160 in March 2008 to establish accounting and reporting 
standards for the noncontrolling interests in a subsidiary and for the decon­
solidation of a subsidiary, areas for which limited guidance previously ex­
isted. In addition to the overview of this statement provided in a note 
appearing earlier in this checklist, readers should be aware that SFAS 160 
clarifies that, for purposes of computing EPS in consolidated financial state­
ments (both basic and diluted), if one or more less-than-wholly-owned sub­
sidiaries are included in the consolidated group, income from continuing 
operations and net income shall exclude the income attributable to the non­
controlling interest in subsidiaries.
SFAS 160 is effective for fiscal years, and interim periods within those fiscal 
years, beginning on or after December 15, 2008 (that is, January 1, 2009, for 
entities with calendar year-ends). Earlier adoption is prohibited. As such, 
this checklist has not been updated to include the presentation and disclo­
sure requirements of SFAS 160. Readers can refer to the full text of the 
statement on the FASB Web site at www.fasb.org.
♦ 1. Are earnings per share (EPS) data presented for all periods for which
an income statement or summary of earnings is presented?
[SFAS 128 par. 38]
♦ 2. If diluted EPS data are reported for at least one period, are they re­
ported for all periods presented, even if they are the same amounts as 
basic EPS?
[SFAS 128 par. 38]
♦ 3. For entities with only common stock outstanding, are basic EPS
amounts for income from continuing operations and for net income 
presented on the face of the income statement?
[SFAS 128 par. 36]
♦ 4. For entities with other than a simple capital structure, are basic and
diluted EPS amounts for income from continuing operations and for 
net income presented on the face of the income statement with equal 
prominence?
[SFAS 128 par. 36]
♦ 5. If discontinued operations, extraordinary items, or the cumulative ef­
fect of accounting changes are reported in a period, are the basic and 
diluted per share amounts for those line items presented on the face of 
the income statement or in the notes?
[SFAS 128 par. 37]
♦ 6. If per share amounts not required to be presented by SFAS 128 are
disclosed, are they disclosed only in the notes and do the disclosures 
indicate whether the per share amounts are pretax or net of tax?
[SFAS 128 par. 37]
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♦ 7. Are the following disclosed for each period for which an income state­
ment is presented:
a. A reconciliation of the numerators and denominators of the basic 
and diluted per share computations for income from continuing
operations? ------- ------- ------
b. The effect that has been given to preferred dividends in arriving at
income available to common stockholders in computing basic EPS? ------- ------- ------
c. Securities (including those issuable pursuant to contingent stock 
agreements) that could potentially dilute basic EPS in the future 
that were not included in the computation of diluted EPS because
to do so would have been antidilutive for the period(s) presented? _____ _____ ____
[SFAS 128 par. 40]
♦ 8. For the latest period for which an income statement is presented, do
disclosures include a description of any transaction that occurs after 
the end of the most recent period but before issuance of the financial 
statements that would have changed materially the number of com­
mon shares or potential common shares outstanding at the end of the
period if the transaction had occurred before the end of the period? _____ _____ ____
[SFAS 128 par. 41]
O. Comprehensive Income
Note: FASB issued SFAS 160 in March 2008 to establish accounting and 
reporting standards for the noncontrolling interests in a subsidiary and for 
the deconsolidation of a subsidiary, areas for which limited guidance pre­
viously existed.
In addition to the overview of this statement provided in a note appearing 
earlier in this checklist, readers should be aware that SFAS 160 clarifies that, 
if an entity has an outstanding noncontrolling interest (minority interest), 
amounts for both comprehensive income attributable to the parent and 
comprehensive income attributable to the noncontrolling interest in a less- 
than-wholly owned subsidiary are reported on the face of the financial 
statement in which comprehensive income is presented in addition to pre­
senting consolidated comprehensive income. Additionally, if an entity has 
an outstanding noncontrolling interest, the components of other compre­
hensive income attributable to the parent and noncontrolling interest in a 
less-than-wholly owned subsidiary are required to be disclosed as part of 
its equity reconciliation.
SFAS 160 is effective for fiscal years, and interim periods within those fiscal 
years, beginning on or after December 15, 2008 (that is, January 1, 2009, for 
entities with calendar year-ends). Earlier adoption is prohibited. As such, 
this checklist has not been updated to include the presentation and disclo­
sure requirements of SFAS 160. Readers can refer to the full text of the 
statement on the FASB Web site at www.fasb.org.
♦ 1. Are all components of comprehensive income reported in the financial 
statements in the period in which they are recognized?
[SFAS 130 par. 14]
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♦ 2. Is a total for comprehensive income displayed in the financial state­
ment where the components of other comprehensive income are re­
ported? _____
[SFAS 130 par. 14]
♦ 3. Is an amount for net income displayed and included as a component
of comprehensive income? _____
[SFAS 130 par. 15 and 22]
♦ 4. Are items included in other comprehensive income classified sepa­
rately into foreign currency items, gains or losses associated with pen­
sion or other postretirement benefits, prior service costs or credits as­
sociated with pension or other postretirement benefits, transition assets 
or obligations associated with pension or other postretirement benefits, 
and unrealized gains and losses on certain investments in debt and
equity securities? _____
[SFAS 130 par. 17, as amended by SFAS 158]
♦ 5. Are reclassification adjustments presented on the face of the financial
statement in which comprehensive income is reported or disclosed in
the notes? _____
[SFAS 130 par. 20]
♦ 6. Are the components of other comprehensive income and total compre­
hensive income displayed in the following the total for net income?
(Encouraged, but not required.) _____
[SFAS 130 par. 23]
♦ 7. Are comprehensive income and its components displayed either net of
related tax effects, or before related tax effects with one amount shown 
for the aggregate tax effect related to the total of other comprehensive
income items? _____
[SFAS 130 par. 24]
♦ 8. Is the amount of income tax expense or benefit allocated to each com­
ponent of other comprehensive income (including reclassification ad­
justments) disclosed either on the face of the statement in which those
components are displayed or in the notes? _____
[SFAS 130 par. 25]
♦ 9. Is the total of other comprehensive income for a period transferred to
a component of equity that is displayed separately from retained earn­
ings and additional paid-in-capital in a statement of financial position
with a descriptive title such as accumulated other comprehensive income? _____
[SFAS 130 par. 26]
♦ 10. Are accumulated balances for each classification within accumulated
other comprehensive income disclosed on the face of the statement of
financial position, in a statement of changes in equity, or in the notes? _____
[SFAS 130 par. 26]
♦ 11. Has the enterprise reported a total for comprehensive income in con­
densed financial statements of interim periods? _____
[SFAS 130 par. 27]
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♦ 12. Are unrealized holding gains and losses for available-for-sale securi­
ties, including those classified as current assets, reported in other com­
prehensive income until realized except as indicated in paragraph 13
of SFAS 115? ------- ------
[SFAS 115 par. 13, as amended by SFAS 130 and SFAS 133]
♦ 13. If an additional pension liability is required to be recognized and ex­
ceeds unrecognized prior service cost, is the excess (which would rep­
resent a net loss not yet recognized as net periodic pension cost) re­
ported in other comprehensive income net of any tax benefits that
result from considering such losses as temporary differences? ------- -----
[SFAS 87 par. 37, as amended by SFAS 130]
♦ 14. Has the entity displayed as a separate classification within other com­
prehensive income the net gain or loss on derivative instruments des­
ignated and qualifying as cash flow hedging instruments that are re­
ported in comprehensive income pursuant to paragraphs 30 and 41 of
SFAS 133? _____ ___
[SFAS 133 par. 46]
♦ 15. As part of the disclosures of accumulated other comprehensive in­
come, pursuant to paragraph 26 of SFAS 130, Reporting Comprehensive 
Income, has the entity separately disclosed the beginning and ending 
accumulated derivative gain or loss, the related net change associated 
with current period hedging transactions, and the net amount of any
reclassification into earnings? _____ ___
[SFAS 133 par. 47]
♦ 16. Does the amount for net assets on the balance sheet agree with the
amount for net assets on the statement of revenues and expenses? _____ ___
Statement of Cash Flows
★ ♦1. Is a statement of cash flows presented as a basic financial statement for
each period for which both a statement of financial position/balance
sheet and a statement of activities/income statement is presented? _____ ___
[SFAS 95 par. 3, as amended by SFAS 117 par. 30a; AAG 1.07]
★ ♦ 2. Does the statement of cash flows show the change in cash and cash
equivalents? ------- -----
[SFAS 95 par. 7]
★ ♦ 3. Is the policy for defining cash equivalents disclosed? _____ ___
[SFAS 95 par. 10]
Note: Any change in policy for determining which items are treated as cash 
equivalents is a change in accounting principle.
[SFAS 95 par. 10]
★ ♦ 4. If the direct method is used, is a separate schedule provided to recon­
cile net income of an investor-owned provider or change in net assets
of a not-for-profit provider to net cash flow from operating activities? _____
[SFAS 95 par. 30, as amended by SFAS 117 par. 30f]
★ ♦ 5. If the indirect method is used:
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a. Is the same amount for net cash flow from operating activities 
reported indirectly by adjusting net income of an investor-owned 
provider or change in net assets of a not-for-profit provider to
reconcile it to net cash flow from operating activities? ____
[SFAS 95 par. 28, as amended by SFAS 117 par. 30f]
b. Is the reconciliation of net income of an investor-owned provider
or change in net assets of a not-for-profit provider to net cash flows 
from operating activities reported, either within the statement of 
cash flows or provided in a separate schedule, with the statement 
of cash flows reporting only the net cash flow from operating activ­
ities? ____
[SFAS 95 par. 30, as amended by SFAS 117 par. 30f]
★ ♦ 6. Are cash receipts and cash payments from operating activities shown
separately on the statement of cash flows? ____
[SFAS 95 par. 27]
★ ♦7. Are cash receipts and cash payments for the following transactions
classified as cash flows from operating activities:
a. Interest received on loans? ____
b. Insurance proceeds except those directly related to investing or
financing activities? ____
c. Interest paid to creditors? ____
d. Payments to suppliers and employees? ____
e. Payments to settle lawsuits? ____
f. Contributions to charities? ____
[SFAS 95 par. 22-23]
g. If SFAS 159 is not applicable to the financial statements, cash flows
from purchases, sales, and maturities of trading securities? ____
[SFAS 115 par. 18; AAG 4.26; SFAS 95 par. 22-23]
h. Payments to governments for taxes, duties, fines, and other fees or 
penalties and the cash that would have been paid for income taxes 
if increases in the value of equity instruments issued under share- 
based payment arrangements that are not included in the cost of 
goods or services recognizable for financial reporting purposes
also had not been deductible in determining taxable income? ____
[SFAS 95 par. 23, as amended by SFAS 123(R)]
★ ♦8. Are cash receipts and cash payments for the following transactions
classified as cash flows from investing activities:
a. Receipts from collections or sales of loans? ____
b. Receipts from sales of property? ____
c. Loans to others? ____
d. Payments to acquire property? ____
e. Cash flows from purchases, sales, and maturities of available-for-
sale securities and held-to-maturity securities? ____
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f. Receipts from sales of equity instruments of other enterprises ex­
clusive of those carried in the trading account and from returns of
investment in those instruments? ------- ------- ------
g. Payments to acquire equity instruments of other enterprises, exclu­
sive of those carried in the trading account? ------- ------- ------
★ ♦ 9. Except for items described in paragraphs 12-13 of SFAS 95, Statement
of Cash Flows, are cash receipts and cash payments from investing and
financing activities shown separately on the statement of cash flows? ------- ------- ------
[SFAS 95 par. 12-13 and 31]
★ ♦10. Are cash receipts and cash payments for the following transactions
classified as cash flows from financing activities:
a. Proceeds from issuing debt? ------- ------- ------
b. Repayments for amounts borrowed? ------- ------- ------
c. Proceeds from issuing equity instruments? ------- ------- ------
d. Payment of dividends or other distributions to owners? ------- ------- ------
e. Other principal payments to creditors who have extended long­
term debt? ------- ------- ------
[SFAS 95 par. 19-20]
f. Cash payments for debt issue costs? ------- ------- ------
[EITF 95-13]
g. Proceeds received (whether at inception or over the term of the
derivative instrument) from derivative instruments that include 
financing elements (other than a financing element inherently in­
cluded in an at-the-market derivative instrument with no prepay­
ments) at inception? ------- ------- ------
h. Distributions (whether at inception or over the term of the deriva­
tive instrument) to counterparties of derivative instruments that 
include financing elements (other than a financing element inher­
ently included in an at-the-market derivative instrument with no
prepayments) at inception? _____ _____ ____
[SFAS 95 par. 19-20 (C25.117-.118), as amended by SFAS 149]
i. Cash retained as a result of the tax deductibility of increases in the
value of equity instruments issued under share-based payment ar­
rangements that are not included in the cost of goods or services 
that is recognizable for financial reporting purposes? (Note: For 
this purpose, excess tax benefits shall be determined on an individ­
ual award (or a portion thereof) basis.) _____ _____ ____
[SFAS 95 par. 19, as amended by SFAS 123(R)]
★ ♦11. Are investing and financing activities that affect recognized assets or
liabilities but that do not result in cash receipts or cash payments in the
period disclosed? _____ _____ ____
[SFAS 95 par. 32, as amended by SFAS 117 par. 30g]
★12. In its statement of cash flows, does the organization include in cash 
flows from financing activities any amounts received with donor-im­
posed stipulations that they must be used for long-term purposes? _____ _____ ____
[SFAS 117 par. 30c]
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★ ♦ 13. Are the following classes of operating cash receipts and payments for
providers using the direct method, at a minimum, separately disclosed:
a. Cash received from service recipients? ____
b. Cash received from contributors? ____
c. Interest and dividends received? ____
d. Cash collected on contributions receivable? ____
e. Other operating cash receipts, if any? ____
f Cash paid to employees and suppliers? ____
g. Interest paid? ____
h. Grants paid? ____
i. Other operating cash payments, if any? ____
[SFAS 95 par. 27, as amended by SFAS 117 par. 30e]
j. Income taxes paid and, separately, the cash that would have been 
paid for income taxes if increases in the value of equity instruments 
issued under share-based payment arrangements that are not rec­
ognizable as a cost of goods or services for accounting purposes
also had not been deductible in determining taxable income? ____
[SFAS 95 par. 27, as amended by SFAS 123(R)]
★ ♦ 14. Is the reconciliation of net income or change in net assets to net cash
flow from operating activities, including separate reporting of all major
classes of reconciling items, presented? ____
[SFAS 95 par. 29, as amended by SFAS 117 par. 30]
★ ♦ 15. If the indirect method of reporting net cash flow from operating activ­
ities is used, are amounts of interest paid (net of amounts capitalized) 
and income taxes paid during the period provided in related disclo­
sures? ____
[SFAS 95 par. 29]
★ ♦ 16. Does the statement of cash flows report net cash provided or used by
operating, investing, and financing activities and the net effect of those 
flows on cash and cash equivalents during the period in a manner that
reconciles beginning and ending cash and cash equivalents? ____
[SFAS 95 par. 26]
★ ♦ 17. Are cash receipts from contributions and investment income that by
donor stipulation are restricted for the purposes of acquiring, con­
structing, or improving property, plant, equipment, or other long-lived 
assets or establishing or increasing a permanent endowment or term
endowment classified as cash flows from financing activities? ____
[SFAS 117 par. 30(d)]
★ ♦ 18. Are cash payments made to settle an asset retirement obligation clas­
sified in the statement of cash flows as an operating activity? ____
[EITF 02-6]
★ ♦ 19. If SFAS 159 is applicable to the financial statements, are cash flows
from purchases, sales, and maturities of trading securities classified 
based on the nature and purpose for which the securities were ac­
quired? ____
[SFAS 95 par. 14; SFAS 115 par 18]
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Other Financial Statement Disclosures
A. Accounting Changes and Error Corrections
★ ♦1. For changes in accounting principle, does disclosure in the period of
the change include:
a. Nature of the change? ------- ------- ------
b. Justification for the change, including a clear explanation of why
the newly adopted principle is preferable? ------- ------- ------
c. Effect on income? ------- ------- ------
[APB 20 par. 17]
★ ♦ 2. For all changes in accounting principle except those described in para­
graphs 27-30, 34, and 35 of APB 20 regarding a change in entity:
a. Are financial statements for prior periods included for compara­
tive purposes presented as previously reported? ------- ------- ------
b. Is the cumulative effect of changing to a new accounting principle 
on the amount of retained earnings/net assets at the beginning of 
the period in which the change is made included in net income/ 
change in net assets of the period of change, between the captions
"extraordinary items" and "net income/change in net assets"? ------- ------- ------
c. Is the effect on income/change in net assets before extraordinary 
items and on net income/change in net assets (and the related per
share amounts, if applicable) of the period of change disclosed? ------- ------- ------
d. Is income/change in net assets before extraordinary items and net 
income/change in net assets computed on a pro forma basis shown 
on the face of the income statement/statement of activities for all 
periods presented as if the newly adopted accounting principle
had been applied during all periods affected? ------- ------- ------
[APB 20 par. 19]
♦ 3. For the cumulative effect of a change in accounting principle, are per- 
share amounts presented either on the face of the income statement or
in the related notes? ------- ------- ------
[APB 20 par. 20, as amended by SFAS 128 par. 163(a)]
★ ♦4. If pro forma amounts cannot be computed or reasonably estimated for
individual prior periods, although the cumulative effect on retained 
eamings/net assets at the beginning of the period of change can be 
determined, is the reason for not showing the pro forma amounts by
periods explained? ------- ------- ------
[APB 20 par. 25]
★ ♦5. If computing the effect on retained eamings/net assets at the begin­
ning of the period of change is considered impossible, are disclosures 
limited to showing the effect of the change on results of net income/ 
operations of the period of change (including per share data if appli­
cable) and explaining the reason for omitting accounting for the cu­
mulative effect and disclosure of pro forma amounts for prior years? ------- ------- ------
[APB 20 par. 26]
★ ♦ 6. For changes in accounting principle that are required to be accounted
for by restating prior period financial statements:
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a. Are all financial statements of prior periods presented restated? ____
[APB 20 par. 27]
b. Is the nature and justification for a change in accounting principle 
disclosed in the financial statements for the period the change was
adopted? ____
[APB 20 par. 28]
c. Is the effect on income/change in net assets before extraordinary 
items and net income/change in net assets (and related per share
amounts if applicable) for all prior periods presented disclosed? ____
[APB 20 par. 28]
★ ♦ 7. For accounting changes that are changes in estimates that affect several
future periods that are not ordinary course of business accounting, is 
the effect on income/change in net assets before extraordinary items, 
net income/change in net assets, and related per share amounts, if 
applicable, of the current period disclosed? (Note: Disclosure of the 
effect of a change in estimate that is in the ordinary course of business
is recommended if the effect of such changes is material.) ____
[APB 20 par. 33]
★ ♦ 8. For changes in accounting principles that are in effect changes in re­
porting entity, are the following disclosed:
a. Nature of the change? ____
b. The reason for the change? ____
c. The effect of the change on income/change in net assets before 
extraordinary items, net income/change in net assets, and related
per share amounts, if applicable, for all periods presented? ____
[APB 20 par. 35]
★ ♦ 9. Is the correction of an error in the financial statements of a prior period
discovered subsequent to their issuance reported as a prior period ad­
justment, with disclosure of the following in the period in which the 
error was discovered and corrected:
a. Nature of the error in previously issued financial statements? ____
b. Effect of its correction on revenue and gains in excess of expenses
and losses (income) before extraordinary items and net revenue 
and gains in excess of expenses and losses (net income) (and re­
lated per share amounts if applicable)? ____
[APB 20 par. 37]
Change in Accounting Principle
★ ♦10. Are changes in accounting principle reported through retrospective
application of the new principle to all prior periods unless impractica­
ble? ____
[SFAS 154 par. 7]
★ ♦ 11. Does retrospective application include any direct effects of the change
in accounting principle, including any related income tax effects? ____
[SFAS 154 par. 10]
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★ ♦ 12. In the retrospective application, are the indirect effects of a change in
accounting principle actually incurred and recognized not included in 
retrospective application but reported in the period in which the ac­
counting change is made? _____ ____
[SFAS 154 par. 10]
★ ♦ 13. If it is impracticable to determine the period-specific effects of a change
in accounting principle on all prior periods presented, but the cumu­
lative effect of applying the change to the new principle to all prior 
periods can be determined:
a. Is the cumulative effect of the change applied to the carrying 
amounts of assets and liabilities as of the beginning of the earliest
period to which the new accounting principle can be applied? _____ ____
b. Is any offsetting adjustment made to the opening balance of re­
tained earnings or other appropriate components of equity/net
assets for that period? _____ ____
[SFAS 154 par. 8]
★ ♦ 14. If it is impracticable to determine the cumulative effect of applying a
change in accounting principle to any prior period, is the new account­
ing principle applied as if the change was made prospectively as of the
earliest date practicable? _____ ____
[SFAS 154 par. 9]
♦ 15. Are changes in accounting principle made in an interim period re­
ported by retrospective application in accordance with paragraphs 
7-10 of SFAS 154? (Note: The impracticability exception in paragraph 
11 of SFAS 154 may not be applied to prechange interim periods of the
fiscal year in which the change is made.) _____ ____
[SFAS 154 par. 15]
★ ♦ 16. For changes in accounting principle, are the following disclosed in the
fiscal period in which a change in accounting principle is made:
a. The nature of and reason for the change in accounting principle, 
including an explanation of why the newly adopted accounting
principle is preferable? _____ ____
b. The method of applying the change and:
(1) A description of the prior-period information that has been
retrospectively adjusted if any? _____ ____
(2) The effect of the change on income from continuing opera­
tions, net income (or other appropriate captions of changes in 
the applicable net assets or performance indicator), any other 
affected financial statement line item, and any affected per 
share amounts for the current period and any prior periods 
retrospectively adjusted? (Note: Presentation of the effect on 
financial statement subtotals and totals other than income 
from continuing operations and net income (or other appro­
priate captions of changes in the applicable net assets or per­
formance indicator) is not required.) _____ ____
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(3) The cumulative effect of the change on retained earnings or
other components of equity or net assets in the statement of 
financial position as of the beginning of the earliest period 
presented? _____
(4) If retrospective application to all periods is impracticable, the 
reasons therefor, and a description of the alternative method
used to report the change? _____
c. If indirect effects of a change in accounting principle are recog­
nized:
(1) A description of the indirect effects including amounts recog­
nized in the current period and related per share amounts, if 
applicable? _____
(2) Unless impracticable, the amount of the total recognized indi­
rect effects of the accounting change and the related per-share 
amounts, if applicable, attributable to each prior period pre­
sented? _____
d. If a change in accounting principle has no material effect in the
period of change but is reasonably certain to have material effect 
in later periods are the disclosures in question 16a provided when­
ever the financial statements of the period of change are presented? _____
[SFAS 154 par. 17]
♦ 17. If interim financial statements are issued, are the required disclosures 
provided in the financial statements of both the interim period of the
change and the annual period of the change? _____
[SFAS 154 par. 17 fn 5]
Note: Financial statements of subsequent periods do not have to repeat the 
disclosures required in paragraph 17 of SFAS 154.
[SFAS 154 par. 17]
♦ 18. If a public company that regularly reports interim information makes 
an accounting change during the fiscal year fourth quarter and does 
not report data specified in paragraph 30 of APB 28, Interim Financial 
Reporting, in a separate fourth-quarter report or its annual report, do 
the notes to the annual financial statements in the fiscal year in which 
the change is made disclose the effects of the change on interim-period 
results as required by paragraph 17 of SFAS 154?
[SFAS 154 par. 16]
★ ♦ 19. In the fiscal year in which a new accounting principle is adopted does 
the financial information reported for interim periods after the date of 
adoption disclose the effect of the change on income from continuing 
operations, net income (or other appropriate captions of changes in 
applicable net assets or performance indicator) and related per-share 
amounts, if applicable, for those postchange interim periods?
[SFAS 154 par. 18]
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if ♦ 20. If an entity chooses to apply the consensus in EITF 06-2 as a change in 
accounting principle through a cumulative-effect adjustment to re­
tained earnings, does the entity disclose the cumulative effect of the 
change on retained earnings or other components of equity or net
assets in the statement of financial position? ------- ------
[EITF 06-2 par. 7]
★ ♦ 21. If an entity chooses to apply the consensus in EITF 06-2 as a change in
accounting principle through retrospective application to all prior per­
iods, does the entity include the recognition of:
a. The cumulative effect of the change to the new accounting princi­
ple on periods prior to those presented reflected in the carrying 
amounts of assets and liabilities as of the beginning of the first
period presented? ------- -----
b. The cumulative effect of the change on retained earnings or on
other components of equity or net assets in the statement of finan­
cial position? ------- -----
c. Adjustments to financial statements for each individual prior pe­
riod presented to reflect the period-specific effects of applying the
new accounting principle? ------- -----
[EITF 06-2 par. 8]
★ ♦ 22. If an entity chooses to apply the consensus reached in this EITF 06-2 as
a change in accounting principle through retrospective application to 
all prior periods, are the following disclosed:
a. A description of the prior-period information that has been retro­
spectively adjusted? _____ ___
b. The effect of the change on income from continuing operations, net 
income (or other appropriate captions of changes in the applicable 
net assets or performance indicator), any other affected financial 
statement line item, and any affected per-share amounts for any
prior periods retrospectively adjusted? ------- -----
c. The cumulative effect of the change on retained earnings or on
other components of equity or net assets in the statement of finan­
cial position as of the beginning of the earliest period presented? _____ ___
[EITF 06-2 par. 9]
Change in Accounting Estimate 
  ♦ 23. For changes in accounting estimate:
a. Is the effect on income from continuing operations, net income (or
other appropriate captions of changes in the applicable net assets 
or performance indicator), and any related per-share amounts of 
the current period disclosed for a change in estimate that effects 
several future periods? (Note: Not necessary for estimates made in 
ordinary course of accounting for items such as uncollectible ac­
counts, inventory obsolescence.) _____ ___
b. Are material effects of changes in estimate disclosed? _____ ___
c. If an entity effects a change in accounting estimate by changing an 
accounting principle, are the disclosures in questions 16-17 and 19
presented? _____ ___
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d. If a change in estimate does not have a material effect in the period 
of change but is reasonably certain to have material effect in later 
periods is a description of that change in estimate disclosed when­
ever the financial statements of the period of change are presented? _____
♦ e. For reporting of interim financial information, do disclosures for 
the effects of changes in accounting estimate conform with para­
graph 22 of SFAS 154? _____
[APB 28 par. 26, as amended by SFAS 154]
Change in the Reporting Entity
★ ♦ 24. For accounting changes that in effect result in financial statements of a
different reporting entity, are changes applied retrospectively to the 
financial statements of all prior periods presented, and is previously 
issued interim financial information presented on a retrospective
basis? _____
[SFAS 154 par. 23]
★ ♦ 25. For changes in reporting entity:
a. Do the financial statements of the period of change describe the
nature of the change and the reason for it? _____
b. Is the effect of the change on income before extraordinary items,
net income (or other appropriate captions of changes in the appli­
cable net assets or performance indicator), other comprehensive 
income, and any related per-share amounts disclosed for all per­
iods presented? _____
c. If a change in reporting entity does not have a material effect in the
period of change but is reasonably certain to have material effect 
in later periods is the nature of and reason for the change disclosed 
whenever the financial statements of the period of change are pre­
sented? _____
[SFAS 154 par. 24]
Correction of an Error in Previously Issued Financial Statements
★ ♦ 26. Are corrections of errors in previously issued financial statements re­
ported as prior period adjustments by restating prior-period financial
statements? _____
[SFAS 154 par. 25]
★ ♦ 27. For corrections of errors in previously issued financial statements:
a. Does the entity disclose that its previously issued financial state­
ments have been restated along with a description of the nature of
the error? _____
b. Is the effect of the correction on each financial statement line item
and any per-share amounts affected for each prior period pre­
sented disclosed? _____
c. Is the cumulative effect of the change on retained earnings or other
appropriate components of equity or net assets in the statement of 
financial position as of the beginning of the earliest period pre­
sented disclosed? _____
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Yes No N/A
d. Are disclosures of prior-period adjustments and restatements re­
quired by paragraph 26 of APB 9, Reporting the Results of Operations,
presented? _____ _____ ____
[SFAS 154 par. 26]
♦ 28. If interim financial statements are issued, are the required disclosures 
provided in the financial statements of both the interim period of the
change and the annual period of the change? _____ _____ ____
Note: Financial statements of subsequent periods do not have to repeat the 
disclosures required in paragraph 26 of SFAS 154.
[SFAS 154 par. 26]
B. Accounting Policies
★ ♦1. Is a description of all significant accounting policies of the provider
presented as an integral part of the financial statements? _____
[APB 22 par. 8-9]
★ ♦2. Does the disclosure of accounting policies identify and describe all
significant accounting principles followed by the reporting entity and 
the methods of applying those principles that materially affect the de­
termination of financial position, cash flows, and results of operations? _____
[APB 22 par. 12]
★ ♦ 3. Does disclosure of significant accounting policies encompass impor­
tant judgments as to the appropriateness of principles concerning rec­
ognition of revenue and allocation of asset costs to current and future
periods? _____
[APB 22 par. 12]
★ ♦ 4. Does the disclosure of accounting policies encompass those accounting
principles and methods that involve either:
a. A selection from existing acceptable alternatives? _____
b. Principles and methods peculiar to the industry in which the re­
porting entity operates, even if such principles and methods are 
predominantly following in that industry? _____
c. Unusual or innovative applications of GAAP? _____
[APB 22 par. 12]
★ ♦ 5. Does disclosure of significant accounting policies include appropriate
reference to details presented elsewhere (in the statements and notes
thereto) so duplication of details is avoided? _____
[APB 22 par. 14]
C. Business Combinations
Notes: Questions 4-13 in this section apply to business combinations that 
are accounted for following the provisions of SFAS 141, Business Combina­
tions. SFAS 141 does not apply to combinations between not-for-profit or­
ganizations, nor does it apply to the acquisition of a for-profit business 
entity by a not-for-profit organization. If the provisions of SFAS 141 are not 
applicable, refer to questions 1-3 in this section.
(continued) 
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Yes No N/A
EITF 97-2 provides guidance to assist PPMs in applying APB 16, Business 
Combinations, when PPMs acquire a physician practice.
***** *
In December 2007, FASB issued SFAS 141 (R) to improve the relevance, 
representational faithfulness, and comparability of the information that a 
reporting entity provides in its financial reports about a business combina­
tion and its effects. SFAS 141 (R) supersedes SFAS 141, but retains the fun­
damental requirements in SFAS 141 that the acquisition method of account­
ing (formerly called the purchase method in SFAS 141) be used for all 
business combinations and that an acquirer be identified for each business 
combination.
Among many other significant amendments to existing pronouncements 
precipitated by SFAS 141(R), this statement redefines goodwill in SFAS 142 
to mean an asset representing the future economic benefits arising from 
other assets acquired in a business combination that are not individually 
identified and separately recognized.
SFAS 141(R) applies to all transactions or other events in which an entity 
(the acquirer) obtains control of one or more businesses (the acquiree), in­
cluding those sometimes referred to as true mergers or mergers of equals and 
combinations achieved without the transfer of consideration, for example, 
by contract alone or through the lapse of minority veto rights. This state­
ment applies to all business entities, including mutual entities that previ­
ously used the pooling-of-interests method of accounting for some business 
combinations. It does not apply to
a. the formation of a joint venture.
b. the acquisition of an asset or a group of assets that does not consti­
tute a business.
c. a combination between entities or businesses under common control.
d. a combination between not-for-profit organizations or the acquisi­
tion of a for-profit business by a not-for-profit organization.
This statement applies prospectively to business combinations for which 
the acquisition date is on or after the beginning of the first annual reporting 
period beginning on or after December 15, 2008. An entity may not apply it 
before that date. As such, this checklist has not been updated to include the 
requirements of SFAS 141(R).
******
In March 2008, FASB issued SFAS 160 to establish accounting and reporting 
standards for the noncontrolling interests in a subsidiary and for the decon­
solidation of a subsidiary, areas for which limited guidance previously ex­
isted.
In addition to the overview of this statement provided in a note appearing 
earlier in this checklist, readers should be aware that SFAS 160 requires 
acquisitions of noncontrolling interests to be accounted for as equity trans­
actions. Thus, no goodwill or other intangible assets would be recognized 
on acquisitions of noncontrolling interests after the effective date of that 
statement.
(continued)
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SFAS 160 is effective for fiscal years, and interim periods within those fiscal 
years, beginning on or after December 15, 2008 (that is, January 1, 2009, for 
entities with calendar year-ends). Earlier adoption is prohibited. As such, 
this checklist has not been updated to include the presentation and disclo­
sure requirements of SFAS 160. The effective date of this statement is the 
same as that of the related FASB Statement No.l41(R).
Readers can refer to the full text of both of the aforementioned FASB state­
ments on the FASB Web site at www.fasb.org.
★1. If a business combination occurred during the period and met the spec­
ified conditions for a pooling-of-interests, do the statements and notes 
include the required disclosures?
[APB 16 par. 63-65]
Note: Not-for-profit organizations are, under certain circumstances, per­
mitted to use the pooling-of-interests method, even though they generally 
do not issue common stock. [AAG 1.50-.51]
★2. If a business combination occurred during the period and is to be ac­
counted for under the purchase method, do the statements and notes 
include the required disclosures?
[APB 16 par. 95; SFAS 38 par. 10]
★3. If, as part of a business combination accounted for as a purchase, a 
material liability is recognized by the combined company for costs 
incurred to (a) exit an activity, (b) involuntarily terminate employees of 
an acquired company, or (c) relocate employees of an acquired com­
pany:
a. Are the following disclosures made for the period in which a pur­
chase business combination occurs:
(1) If the plans to exit an activity or involuntarily terminate (relo­
cate) employees of the acquired company are not final as of the 
statement of financial position date, a description of any unre­
solved issues, the types of additional liabilities that may result 
in an adjustment to the purchase price allocation, and how any 
adjustment will be reported?
(2) A description of the type and amount of liabilities assumed in 
the purchase price allocation for costs to exit an activity or 
involuntary terminate (relocate) employees?
(3) A description of the major actions comprising the plan to exit 
an activity or involuntarily terminate (relocate) employees of 
an acquired company?
(4) A description of activities of the acquired company that will 
not be continued, including the method of disposition, and the 
anticipated date of completion and description of employee 
group(s) to be terminated (relocated)?
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b. Are the following disclosures made for all periods presented sub­
sequent to the acquisition date in which a purchase business com­
bination occurred, until a plan to exit an activity or involuntarily 
terminate or relocate employees of an acquired company is fully 
executed:
(1) A description of the type and amount of exit costs, involuntary
employee termination costs, and relocation costs paid and 
charged against the liability? _____
(2) The amount of any adjustment to the liability account and
whether the corresponding entry was an adjustment of the 
costs of the acquired company or included in the determina­
tion of net income for the period? _____
[EITF 95-3]
♦ 4. Do the notes to the financial statements of a combined entity disclose
the following information in the period in which a material business 
combination is completed:
a. The name and a brief description of the acquired entity and the
percentage of voting equity interests acquired? _____
b. The primary reasons for the acquisition, including a description of
the factors that contributed to a purchase price that results in rec­
ognition of goodwill? _____
c. The period for which the results of operations of the acquired en­
tity are included in the income statement of the combined entity? _____
d. The cost of the acquired entity and, if applicable, the number of
shares of equity interests (such as common shares, preferred 
shares, or partnership interests) issued or issuable, the value as­
signed to those interests, and the basis for determining that value? _____
e. A condensed balance sheet disclosing the amount assigned to each
major asset and liability caption of the acquired entity at the acqui­
sition date? _____
f. Contingent payments, options, or commitments specified in the
acquisition agreement and the accounting treatment that will be 
followed should any such contingency occur? _____
g. The amount of purchased research and development assets ac­
quired and written off in the period (refer to paragraph 42 of SFAS 
141) and the line item in the income statement in which the 
amounts written off are aggregated? _____
h. For any purchase price allocation that has not been finalized, that
fact and the reasons therefore? _____
i. In subsequent periods, the nature and amount of any material ad­
justments made to the initial allocation of the purchase price? _____
[SFAS 141 par. 51]
♦ 5. Is the following information disclosed in the notes to the financial state­
ments in the period in which a material business combination is com­
pleted if the amounts assigned to goodwill or to other intangible assets 
acquired are significant in relation to the total cost of the acquired 
entity:
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a. For intangible assets subject to amortization:
(1) The total amount assigned and the amount assigned to any
major intangible asset class? ------- ------- ------
(2) The amount of any significant residual value, in total and by
major intangible asset class? ------- ------- ------
(3) The weighted-average amortization period, in total and by
major intangible asset class? ------- ------- ------
b. For intangible assets not subject to amortization the total amount 
assigned and the amount assigned to any major intangible asset
class? ------- ------- ------
c. For goodwill:
(1) The total amount of goodwill and the amount that is expected
to be deductible for tax purposes? ------- ------- ------
(2) The amount of goodwill by reportable segment (if the com­
bined entity is required to disclose segment information in ac­
cordance with SFAS 131), unless not practicable? _____ _____ ____
[SFAS 141 par. 52]
♦ 6. If a series of individually immaterial business combinations completed
during the period are material in the aggregate, is the following dis­
closed:
a. The number of entities acquired and a brief description of those
entities? ------- ------- ------
b. The aggregate cost of the acquired entities, the number of equity
interests, (such as common shares, preferred shares, or partnership 
interests) issued or issuable, and the value assigned to those inter­
ests? _____ _____ ____
c. The aggregate amount of any contingent payments, options, or 
commitments and the accounting treatment that will be followed 
should any such contingency occur (if potentially significant in
relation to the aggregate cost of the acquired entities)? _____ _____ ____
d. The information described in question 5 of the preceding, if the 
aggregate amount assigned to goodwill or to other intangible as­
sets acquired is significant in relation to the aggregate cost of the
acquired entities? _____ _____ ____
[SFAS 141 par. 53]
♦ 7. If the combined entity is a public business enterprise, is the following
supplemental information on a pro forma basis for the period in which 
a material business combination occurs (or for the period in which a 
series of individually immaterial business combinations occur that are 
material in the aggregate) disclosed:
a. Results of operations for the current period as though the business 
combination or combinations had been completed at the beginning 
of the period unless the acquisition was at or near the beginning of
the period? _____ _____ ____
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b. Results of operations for the comparable prior period as though 
the business combination or combinations had been completed at 
the beginning of that period if comparative financial statements
are presented? _____
[SFAS 141 par. 54]
♦ 8. Does the supplemental pro forma information display revenue, income
before extraordinary items and the cumulative effect of accounting 
changes, net income, and earnings per share at a minimum? (Note: In 
determining the pro forma amounts, income taxes, interest expense, 
preferred share dividends, and depreciation and amortization of assets 
shall be adjusted to the accounting base recognized for each in record­
ing the combination. Pro forma information related to results of oper­
ations of periods prior to the combination shall be limited to the results
of operations for the immediately preceding period.) _____
[SFAS 141 par. 55]
♦ 9. Does the supplemental pro forma information disclose the nature and
amount of material, nonrecurring items included in the reported pro
forma results of operations, if any? _____
[SFAS 141 par. 55]
♦ 10. In the period in which an extraordinary gain is recognized related to a
business combination, do the notes to the financial statements disclose
the information required by paragraph 11 of APB 30? _____
[SFAS 141 par. 56]
♦ 11. If a material business combination is completed after the balance sheet
date but before the financial statements are issued, is the information
required by questions 4-5 of the preceding disclosed if practicable? _____
[SFAS 141 par. 57]
Interim Financial Information
♦ 12. For summarized interim financial information of a public business en­
terprise is the following information disclosed if a material business 
combination is completed during the current year up to the date of the 
most recent interim statement of financial position presented:
a. The name and a brief description of the acquired entity and the
percentage of voting equity interests acquired? _____
b. The primary reasons for the acquisition, including a brief descrip­
tion of the factors that contributed to a purchase price that results
in recognition of goodwill? _____
c. The period for which the results of operations of the acquired en­
tity are included in the income statement of the combined entity? _____
d. The cost of the acquired entity and, if applicable, the number of
shares of equity interests (such as common shares, preferred 
shares, or partnership interests) issued or issuable, the value as­
signed to those interests, and the basis for determining that value? _____
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e. Supplemental pro forma information that discloses the results of 
operations for the current interim period and the current year up 
to the date of the most recent interim statement of financial posi­
tion presented (and for the corresponding periods in the preceding 
year) as though the business combination had been completed as
of the beginning of the period reported on? _____ _____ ____
f. The nature and amount of any material, nonrecurring items in­
cluded in the reported pro forma results of operations? ------- ------- ------
g. Do the pro forma information disclosures in question 12e display 
at a minimum, revenue, income before extraordinary items and the 
cumulative effect of accounting changes (including those on an
interim basis), net income and earnings per share? _____ _____ ____
[SFAS 141 par. 58]
♦ 13. If, as part of a business combination accounted for as a purchase, a 
material liability is recognized by the combined company for costs 
incurred to (a) exit an activity, (b) involuntarily terminate employees of 
an acquired company, or (c) relocate employees of an acquired com­
pany:
a. Are the following disclosures made for the period in which a pur­
chase business combination occurs:
(1) If the plans to exit an activity or involuntarily terminate (relo­
cate) employees of the acquired company are not final as of the 
balance sheet date, a description of any unresolved issues, the 
types of additional liabilities that may result in an adjustment 
to the purchase price allocation, and how any adjustment will
be reported? ------- ------- ------
(2) A description of the type and amount of liabilities assumed in 
the purchase price allocation for costs to exit an activity or
involuntarily terminate (relocate) employees? ------- ------- ------
(3) A description of the major actions comprising the plan to exit 
an activity or involuntarily terminate (relocate) employees of
an acquired company? ------- ------- ------
(4) A description of activities of the acquired company that will 
not be continued, including the method of disposition, and the 
anticipated date of completion and description of employee
group(s) to be terminated (relocated)? ------- ------- ------
b. Are the following disclosures made for all periods presented sub­
sequent to the acquisition date in which a purchase business com­
bination occurred, until a plan to exit an activity or involuntarily 
terminate or relocate employees of an acquired company is fully 
executed:
(1) A description of the type and amount of exit costs, involuntary 
employee termination costs, and relocation costs paid and
charged against the liability? ------- ------- ------
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(2) The amount of any adjustment to the liability account and 
whether the corresponding entry was an adjustment of the 
costs of the acquired company or included in the determina­
tion of net income for the period? ____
[EITF 95-3]
♦ 14. Are the following disclosures made for business combinations between 
parties with a preexisting relationship:
a. The nature of the preexisting relationship? ____
b. The measurement of the amount of the settlement of the preexist­
ing relationship, if any, and the valuation method used to deter­
mine the settlement amount? ____
c. The amount of any settlement gain or loss recognized and its clas­
sification in the statement of operations? ____
[EITF 04-1 par. 8]
D. Commitments and Contingencies
Note: In June 2008, FASB issued Proposed Statement of Financial Account­
ing Standards Disclosure of Certain Loss Contingencies—an amendment of 
FASB Statements No. 5 and 141(R) that would replace the disclosure require­
ments in SFAS 5, Accounting for Contingencies, for loss contingencies that are 
recognized as liabilities in a statement of financial position and for unrecog­
nized loss contingencies that would be recognized as liabilities if the criteria 
for recognition in paragraph 8 of SFAS 5 were met. Loss contingencies that 
are (or would be) recognized as asset impairments would continue to be 
disclosed in accordance with SFAS 5. This proposed statement would also 
amend SFAS 141(R) to require the disclosures included in this statement for 
loss contingencies recognized in a business combination. This proposed 
statement would not change the recognition and measurement guidance 
for loss contingencies contained in SFAS 5 and in SFAS 141(R).
On September 24, 2008, FASB decided on a plan for redeliberations and 
directed the staff to prepare an alternative model that will attempt to ad­
dress the concerns that certain constituents raised about this proposed 
statement. This alternative model will be field tested along with the model 
in the exposure draft. The board also decided that any final statement on 
this topic will be effective no sooner than for fiscal years ending after De­
cember 15, 2009.
This checklist has not been updated to include the presentation and disclo­
sure requirements of this proposed statement. Readers may continue to 
check the status of this proposed statement on the FASB Web site at 
www.fasb.org.
1. Uninsured medical malpractice claims:
★ ♦ a. If a minimum amount of a probable loss (usually associated with 
litigating or settling malpractice claims) is accrued, is there disclo­
sure as to a reasonable possibility of an additional potential loss in 
excess of the amount accrued?
[AAG 8.08; SFAS 5]
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Yes No N/A
★   b. If a range of loss cannot be reasonably estimated, is a contingency
disclosed? ------- ------- ------
[AAG 8.12; SFAS 5]
★ ♦ c. Is the program of medical malpractice coverage and basis for loss
accruals disclosed? ------- ------- ------
[AAG 8.12]
★ ♦ d. If the provider discounts accrued malpractice claims, are the fol­
lowing disclosed:
(1) The carrying amount of the claims? ------- ------- ------
(2) The interest rates or other rates used to discount the claims? ------- ------- ------
[AAG 8.13]
2. Retrospectively rated premiums:
★ ♦a. If the provider cannot estimate losses from asserted or unasserted
malpractice claims, is the existing contingency disclosed? ------- ------- ------
[AAG 8.15; SFAS 5]
★ ♦ b. Does the provider disclose that it is insured under a retrospectively
rated policy? ------- ------- ------
[AAG 8.16]
★ ♦ c. Does the provider disclose that premiums are accrued based on
the ultimate cost of the experience to date of a group of entities? ------- ------- ------
[AAG 8.16]
3. Medical malpractice claims insured with captive insurance companies 
(controlled by a parent entity for the main purpose of providing insur­
ance for the parent):
★ ♦ a. Does the provider disclose that it is insured under a retrospectively
rated policy of a multiprovider captive? ------- ------- ------
[AAG 8.19]
★ ♦ b. Does the provider disclose that premiums are accrued based on
the captive's experience to date? ------- ------- ------
[AAG 8.19]
★ ♦ c. Is the provider's ownership percentage in the captive disclosed? ------- ------- ------
[AAG 8.20]
 d. Is the method of accounting for its investment in and the opera­
tions of the captive disclosed? ------- ------- ------
[AAG 8.20]
★ ♦ e. If the provider cannot make the necessary estimates of losses from
asserted or unasserted claims, does it disclose the existing contin­
gency? ------- ------- ------
[AAG 8.20; SFAS 5]
4. Trust funds:
★ ♦a. If trust funds (revocable or irrevocable) are included in the pro­
vider's financial statements:
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(1) Is a portion of the funds (the amount of assets expected to be 
liquidated to pay malpractice claims classified as current lia­
bilities) classified as a current asset in a classified balance
sheet/statement of financial position? ____
[AAG 8.21]
(2) Is the balance of the funds, if any, classified as a noncurrent
asset in a classified balance sheet/statement of financial posi­
tion? ____
[AAG 8.21]
(3) Are trust fund revenue and administrative expenses included
in the statement of activities/income statement? ____
[AAG 8.21]
(4) Are estimated losses from asserted and unasserted claims re­
ported? ____
[AAG 8.22]
(5) Is the existence of trust funds and whether they are irrevocable
disclosed? ____
[AAG 8.23]
5. Prepaid health care services:
★ ♦ a. Health care costs:
(1) Is the basis for accruing health care costs disclosed? ____
(2) Are significant business and contractual arrangements with
hospitals, physicians, and other associated entities disclosed? ____
[AAG 13.04]
★ ♦ b. Stop -loss insurance:
(1) Are receivables representing amounts recoverable from insur­
ers reported as assets net of any valuation allowance? ____
(2) Are the nature, amounts, and effects of significant stop-loss
insurance contracts disclosed? ____
[AAG 13.08]
c. Loss contracts:
(1) Are losses recognized, in accordance with SFAS 5, when it is 
probable that expected future health care costs and mainte­
nance costs under a group of existing contracts will exceed 
anticipated future premiums and stop-loss insurance on those
contracts? ____
[AAG 13.06]
d. Contract acquisition costs:
(1) Are acquisition costs of providers of prepaid health care ser­
vices, other than costs of advertising, expensed as incurred? ____
[AAG 13.11]
6. Guarantees
★ ♦ a. Are the nature and amount of guarantees disclosed (for example,
of indebtedness of others)? ____
[SFAS 5 par. 12; FIN par. 17-18]
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  b. Is the following information disclosed by a guarantor about each 
guarantee, or each group of similar guarantees, even if the likeli­
hood of the guarantor's having to make any payments under the 
guarantee is remote:
(1) The nature of the guarantee, including the approximate term, 
how the guarantee arose, and the events or circumstances that
would require the guarantor to perform under the guarantee? ------- ------- ------
(2) The maximum potential amount of future payments (undis­
counted) the guarantor could be required to make under the
guarantee? ------- ------- ------
(3) If the terms of the guarantee provide for no limitation to the 
maximum potential future payments under the guarantee, is
that fact disclosed? ------- ------- ------
(4) The reasons why the guarantor cannot estimate the maximum 
potential amount of future payments under its guarantee, if
the guarantor is unable to develop an estimate? ------- ------- ------
(5) The current carrying amount of the liability, if any, for the 
guarantor's obligations under the guarantee, including the 
amount, if any, recognized under SFAS 5 paragraph 8, regard­
less of whether the guarantee is freestanding or embedded in
another contract? ------- ------- ------
(6) The nature of
(i) Any recourse provisions that would enable the guarantor
to recover from third parties any of the amounts paid un­
der the guarantee? ------- ------- ------
(ii) Any assets held either as collateral or by third parties that, 
upon the occurrence of any triggering event or condition 
under the guarantee, the guarantor can obtain and liqui­
date to recover all or a portion of the amounts paid under
the guarantee? ------- ------- ------
(7) If estimable, the approximate extent to which the proceeds 
from liquidation of those assets would be expected to cover the 
maximum potential amount of future payments under the
guarantee? ------- ------- ------
[FIN 45 par. 13]
★ ♦ c. For product warranties and other guarantee contracts, collectively 
referred to as product warranties, is the following information dis­
closed if the guarantor is not required to disclose the maximum 
potential amount of future payments, as provided in FIN 45, Guar­
antor's Accounting and Disclosure Requirements for Guarantees, Includ­
ing Indirect Guarantees of Indebtedness of Others—an interpretation of 
FASB Statements No. 5, 57, and 107 and rescission of FASB Interpreta­
tion No. 34, paragraph 14:
(1) The guarantor's accounting policy and methodology used in
determining its liability for product warranties? _____ _____ ____
(2) A tabular reconciliation of the changes in the guarantor's ag­
gregate product warranty liability for the reporting period? _____ _____ ____
FSP §11,200.03
76 Health Care Organizations
Yes No N/A
(3) Does the tabular reconciliation present—
(i) The beginning balance of the aggregate product warranty
liability? _____ _____ ____
(ii) The aggregate reductions in that liability for payments
made in cash or in kind under the warranty? _____ _____ ____
(iii) The aggregate changes in the liability for accruals related
to product warranties issued during the reporting period, 
and the aggregate changes in the liability for accruals re­
lated to preexisting warranties, including adjustments re­
lated to changes in estimates? _____ _____ ____
(iv) The ending balance of the aggregate product warranty
liability? _____ _____ ____
[FIN 45 par. 14]
7. Other disclosures:2
2 See note in part D, "Commitments and Contingencies," for an important notice regarding the Proposed FASB Statement Disclosure of 
Certain Loss Contingencies—an amendment of FASB Statements No. 5 and 141(R) that would replace the disclosure requirements in SFAS 5. If 
finalized and issued as currently drafted, this statement would change the requirements of this question and would be effective for annual 
financial statements issued for fiscal years ending after December 15, 2008, and interim and annual periods in subsequent fiscal years. 
This checklist has not been updated to include the presentation and disclosure requirements of this proposed statement. Readers may 
continue to check the status of this proposed statement on the FASB Web site at www.fasb.org.
★ ♦ a. Is disclosure made of the nature of estimated loss contingencies
accrued when (a) information available prior to issuance of the 
financial statements indicates that it is probable that an asset has 
been impaired or liability incurred at the date of the financial state­
ments and (b) the amount of the loss can be reasonably estimated? _____ _____ ____
[SFAS 5 par. 8-9]
★ ♦ b. If necessary to keep the financial statements from being mislead­
ing, are the amounts of contingencies accrued as described in ques­
tion 7a of the preceding disclosed? _____ _____ ____
[SFAS 5 par. 8-9]
★ ♦ c. For loss contingencies not accrued because one or both of the con­
ditions in paragraph 8 of SFAS 5 are not met, or if an exposure to 
loss exists in excess of the amount accrued, when there is at least a 
reasonable possibility that a loss or an additional loss may have 
been incurred, do disclosures indicate the:
(1) Nature of the contingency? _____ _____ ____
(2) Estimate of the possible loss or range of loss (or a statement
that such an estimate cannot be made)? _____ _____ ____
[SFAS 5 par. 10]
 d. Are gain contingencies adequately disclosed with care to avoid
any misleading implications about likelihood of realization? _____ _____ ____
[SFAS 5 par. 17]
★ ♦e. Is there adequate disclosure of commitments such as those for
plant acquisition or an obligation to reduce debts, maintain work­
ing capital, or restrict dividends? _____ _____ ____
[SFAS 5 par. 18-19]
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For long-term unconditional purchase obligations that are not re­
corded in the purchaser's balance sheet/statement of financial po­
sition, are the following disclosed:
(1) Nature and term of the obligations? _____ _____ ____
(2) Amount of the fixed and determinable portion of the obliga­
tions as of the date of the latest balance sheet or statement of 
financial position, or both, presented in the aggregate and, if
determinable, for each of the next five years? _____ _____ ____
(3) Nature of any variable components of the obligation? _____ _____ ____
(4) Amounts purchased under the obligations for each period for
which an income statement/statement of operations is pre­
sented? _____ _____ ____
[SFAS 47 par. 7]
8. Postemployment benefits:
★ If an obligation for postemployment benefits (for example, salary 
continuation, supplemental unemployment benefits, severance 
benefits, disability-related benefits, job training and counseling, 
and continuation of health and insurance coverage) is not accrued 
in accordance with SFAS 5 or SFAS 43 only because the amount 
cannot reasonably be estimated, is the fact of nonaccrual disclosed
in the financial statements? ------- ------- ------
[SFAS 112 par. 7]
9. Environmental remediation liabilities:
★ ♦ a. Are environmental remediation obligations reported and disclosed
in accordance with SOP 96-1? ------- ------- ------
[SOP 96-1 par. .155-170 (ACC 10,680.115-170)]
E. Exit or Disposal Activities
Note: SFAS 146, Accounting for Costs Associated with Exit or Disposal Activi­
ties, nullifies EITF 94-3, "Liability Recognition for Certain Employee Ter­
mination Benefits and Other Costs to Exit an Activity (including Certain 
Costs Incurred in a Restructuring)" The provisions of EITF 94-3 shall con­
tinue to apply for an exit activity initiated under an exit plan that met the 
criteria of EITF 94-3 prior to SFAS 146's initial application. For the purposes 
of applying SFAS 146, an exit or disposal activity is initiated when manage­
ment, having the authority to approve the action, commits to an exit or 
disposal plan or otherwise disposes of a long-lived asset (disposal group) 
and, if the activity involves the termination of employees, the criteria for a 
plan of termination in paragraph 8 of SFAS 146 are met.
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★ ♦1. If a material liability is recognized for certain employee termination 
benefits in accordance with section A of EITF 94-3 are the following 
disclosures made in all periods until the plan of termination is com­
pleted:
a. The amount of termination benefits accrued and charged to ex­
pense and the classification of those costs in the income statement/ 
statement of activities?
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b. The number of employees to be terminated?
c. A description of the employee group(s) to be terminated?
d. The amount of actual termination benefits paid and charged 
against the liability and the number of employees actually termi­
nated as a result of the plan to terminate employees?
e. The amount of any adjustment(s) to the liability?
[EITF 94-3 sec. A]
★ ♦ 2. If management commits to an exit plan that meets the criteria in section
B of EITF 94-3, are the following reporting requirements followed:
a. Reporting the income statement effect of recognizing a liability at 
the commitment date in income from continuing operations and 
not on the face of the income statement net of taxes?
b. No disclosure made on the face of the income statement for earn­
ings per share effect?
c. Revenue and related costs and expenses of activities that will not 
be continued should not be combined and reported as a separate 
component of income?
[EITF 94-3 sec. B]
★ ♦ 3. If the activities that will not be continued are significant to the enter­
prise's revenue or operating results, or if the exit costs recognized at 
the commitment date are material, are the following disclosures made 
in all periods until the exit plan is completed:
a. A description of the major actions comprising the exit plan, activi­
ties that will not be continued, including the method of disposition, 
and the anticipated date of completion?
b. A description of the type and amount of exit costs recognized as 
liabilities and the classification of those costs in the income state­
ment/ statement of activities?
c. A description of the type and amount of exit costs paid and 
charged against the liability?
d. The amount of any adjustment(s) to the liability?
e. For all periods presented, the revenue and net operating income or 
losses from activities that will not be continued if those activities 
have separately identifiable operations?
[EITF 94-3 sec. B]
★ ♦ 4. Is the following information disclosed in notes to the financial state­
ments that include the period in which an exit or disposal activity is 
initiated and any subsequent period until the activity is completed:
a. A description of the exit or disposal activity, including the facts 
and circumstances leading to the expected activity and the ex­
pected completion date?
b. For each major type of cost associated with the activity (for exam­
ple, one-time termination benefits, contract termination costs, and 
other associated costs):
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(1) The total amount expected to be incurred in connection with
the activity, the amount incurred in the period, and the cumu­
lative amount incurred to date? ------- ------- ------
(2) A reconciliation of the beginning and ending liability balances
showing separately the changes during the period attributable 
to costs incurred and charged to expense, costs paid or other­
wise settled, and any adjustments to the liability with an expla­
nation of the reason(s) therefor? ------- ------- ------
c. The line item(s) in the income statement or the statement of activi­
ties in which the costs in question 4b are aggregated? ------- ------- ------
d. For each reportable segment:
(1) The total amount of costs expected to be incurred in connection
with the activity? ------- ------- ------
(2) The amount incurred in the period? ------- ------- ------
(3) The cumulative amount incurred to date, net of any adjust­
ments to the liability with an explanation of the reason(s)
therefor? ------- ------- ------
e. If a liability for a cost associated with the activity is not recognized 
because fair value cannot be reasonably estimated, that fact and
the reasons therefor? ------- ------- ------
[SFAS 146 par. 20]
♦ 5. Are costs associated with an exit or disposal activity that does not 
involve a discontinued operation included in income from continuing
operations before income taxes in the income statement? ------- ------- ------
[SFAS 146 par. 18]
★6. Are costs associated with an exit or disposal activity that does not 
involve a discontinued operation included in income from continuing
operations in the statement of activities? ------- ------- ------
[SFAS 146 par. 18]
★ ♦ 7. Are costs associated with an exit or disposal activity that involves a
discontinued operation included in the results of discontinued opera­
tions? _____ _____ ____
[SFAS 146 par. 18]
★ ♦8. If an event or circumstance occurs that discharges or removes an en­
tity's responsibility to settle a liability for a cost associated with an exit 
or disposal activity recognized in a prior period, is the liability re­
versed? ------- ------- ------
[SFAS 146 par. 19]
★ ♦9. Are the related costs reversed through the same line item(s) in the
income statement (statement of activities) used when those costs were
recognized initially? ------- ------- ------
[SFAS 146 par. 19]
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F. Derivative Instruments and Hedging Activities
Note: In March 2008, FASB issued SFAS 161 to enhance the current disclo­
sure framework in SFAS 133. This statement has the same scope as SFAS 
133 and, accordingly, applies to all entities.
This statement changes the disclosure requirements for derivative instru­
ments and hedging activities. Entities are required to provide enhanced 
disclosures about (a) how and why an entity uses derivative instruments, 
(b) how derivative instruments and related hedged items are accounted for 
under SFAS 133 and its related interpretations, and (c) how derivative in­
struments and related hedged items affect an entity's financial position, 
financial performance, and cash flows.
SFAS 161 is effective for financial statements issued for fiscal years and 
interim periods beginning after November 15, 2008. Early application is 
encouraged. This statement encourages but does not require disclosures for 
earlier periods presented for comparative purposes at initial adoption. In 
years after initial adoption, it requires comparative disclosures only for 
periods subsequent to initial adoption. Readers can refer to the full text of 
SFAS 161 on the FASB Web site at www.fasb.org.
★ ♦1. If an entity holds or issues derivative instruments (or nonderivative
instruments that are designated and qualify as hedging instruments 
pursuant to paragraphs 37 and 42 of SFAS 133) has disclosure been 
made of its objectives for holding or issuing those instruments, the 
context needed to understand those objectives, and its strategies for 
achieving those objectives?
[SFAS 133 par. 44]
★ ♦ 2. Does the description distinguish between derivative instruments (and
nonderivative instruments) designated as fair value hedging instru­
ments, derivative instruments designated as cash flow hedging instru­
ments, derivative instruments (and nonderivative instruments) desig­
nated as hedging instruments for hedges of the foreign currency 
exposure of a net investment in a foreign operation, and all other deriv­
atives?
[SFAS 133 par. 44]
★ ♦ 3. Does the description also indicate the entity's risk management policy
for each of those types of hedges, including a description of the items 
or transactions for which risks are hedged?
[SFAS 133 par. 44]
★ ♦4. For derivative instruments not designated as hedging instruments,
does the description indicate the purpose of the derivative activity? 
[SFAS 133 par. 44]
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★ ♦ 5. Qualitative disclosures about an entity's objectives and strategies for 
using derivative instruments may be more meaningful if such objec­
tives and strategies are described in the context of an entity's overall 
risk management profile. If appropriate, an entity is encouraged, but 
not required, to provide such additional qualitative disclosures. Have
such disclosures been made? _____ _____ ____
[SFAS 133 par. 44]
Notes: SOP 02-2 paragraph .08, requires not-for-profit health care organi­
zations to provide disclosures that are analogous to those required by par­
agraph 45 of SFAS 133 for for-profit enterprises, including the disclosure of 
anticipated reclassifications into the performance indicator of gains and 
losses that have been excluded from that measure and reported in accu­
mulated derivative gain or loss as of the reporting date. The provisions of 
SOP 02-2 are effective for fiscal years beginning after June 15, 2003. Earlier 
application is encouraged but permitted only as of the beginning of any 
fiscal quarter that begins after issuance of SOP 02-2. See paragraphs .10-.11 
of SOP 02-2 for additional effect date and transition information. If the 
provisions of SOP 02-2 are applied, see questions 8-10 for disclosures re­
quired for the transition to the provisions of SOP 02-2.
★ ♦6. For the period in which an embedded conversion option previously
accounted for as a derivative under SFAS 133 no longer meets the 
bifurcation criteria under that standard, has the organization disclosed 
the following:
a. A description of the principal changes causing the embedded con­
version option to no longer require bifurcation under SFAS 133?
b. Amount of the liability for the conversion option reclassified to 
stockholders' equity?
★ ♦ 7. Do the entity's disclosures for every reporting period for which a com­
plete set of financial statements is presented also include the following: 
Fair Value Hedges
a. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
under SFAS 52, Foreign Currency Translation, that have been desig­
nated and have qualified as fair value hedging instruments and for 
the related hedged items:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss is 
reported in the statement of income or other statement of fi­
nancial performance?
(2) The amount of net gain or loss recognized in earnings when a 
hedged firm commitment no longer qualifies as a fair value 
hedge?
[SFAS 133 par. 45a]
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Cash Flow Hedges
b. For derivative instruments that have been designated and have 
qualified as cash flow hedging instruments and for the related 
hedged transactions:
(1) The net gain or loss recognized in earnings during the report­
ing period representing (a) the amount of the hedges' ineffec­
tiveness and (b) the component of the derivative instruments' 
gain or loss, if any, excluded from the assessment of hedge 
effectiveness, and a description of where the net gain or loss is 
reported in the statement of income or other statement of fi­
nancial performance?
(2) A description of the transactions or other events that will result 
in the reclassification into earnings of gains and losses that are 
reported in accumulated other comprehensive income, and the 
estimated net amount of the existing gains or losses at the re­
porting date that is expected to be reclassified into earnings 
within the next 12 months?
(3) The maximum length of time over which the entity is hedging 
its exposure to the variability in future cash flows for fore­
casted transactions excluding those forecasted transactions re­
lated to the payment of variable interest on existing financial 
instruments?
(4) The amount of gains and losses reclassified into earnings as a 
result of the discontinuance of cash flow hedges because it is 
probable that the original forecasted transactions will not oc­
cur by the end of the originally specified time period (as doc­
umented at the inception of the hedging relationship) or 
within additional two-month period of time thereafter?
[SFAS 133 par. 45b, as amended by SFAS 138 par. 4r]
Hedges of the Net Investment in a Foreign Operation
c. For derivative instruments, as well as nonderivative instruments 
that may give rise to foreign currency transaction gains or losses 
under SFAS 52, that have been designated and have qualified as 
hedging instruments for hedges of the foreign currency exposure 
of a net investment in a foreign operation, the net amount of gains 
or losses included in the cumulative translation adjustment during 
the reporting period?
[SFAS 133 par. 45c]
★ ♦8. The quantitative disclosures about derivative instruments may be 
more useful, and less likely to be perceived to be out of context or 
otherwise misunderstood, if similar information is disclosed about 
other financial instruments or nonfinancial assets and liabilities to 
which the derivative instruments are related by activity. Accordingly, 
in such situations, has the entity presented a more complete picture of 
its activities by disclosing that information? (Encouraged, but not re­
quired.)
[SFAS 133 par. 45]
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Certain Hybrid Financial Instruments
Notes: SFAS 155 is effective for all financial instruments acquired, issued, 
or subject to a remeasurement (new basis) event occurring after the begin­
ning of an entity's first fiscal year that begins after September 15, 2006. The 
fair value election provided for in paragraph 4(c) of SFAS 155 may also be 
applied upon adoption of the statement for hybrid financial instruments 
that had been bifurcated under paragraph 12 of SFAS 133 prior to the adop­
tion of SFAS 155. At adoption, any difference between the total carrying 
amount of the individual components of the existing bifurcated hybrid fi­
nancial instrument and the fair value of the combined hybrid financial in­
strument shall be recognized as a cumulative-effect adjustment to begin­
ning retained earnings. An entity shall separately disclose the gross gains 
and losses that make up the cumulative-effect adjustment, determined on 
an instrument-by-instrument basis. Prior periods shall not be restated. 
SFAS 155 provides a fair value measurement election for certain hybrid 
financial instruments with embedded derivatives that otherwise would re­
quire bifurcation. Hybrid financial instruments that are elected to be ac­
counted for in their entirety at fair value cannot be used as a hedge instru­
ment in an SFAS 133 hedge.
In February 2007, FASB issued SFAS 159, which is effective for financial 
statements issued for fiscal years beginning after November 15, 2007. Early 
adoption is permitted as of the beginning of a fiscal year that begins on or 
before November 15, 2007, provided the organization also elects to apply 
the provisions of SFAS 157. The choice to adopt early should be made after 
issuance of this statement but within 120 days of the beginning of the fiscal 
year of adoption, provided the entity has not yet issued financial state­
ments, including required notes to those financial statements, for any in­
terim period of the fiscal year of adoption.
This statement applies to all entities, including not-for-profit organizations. 
Most of the provisions of this statement apply only to entities that elect the 
fair value option. However, the amendment to SFAS 115 applies to all en­
tities with available-for-sale and trading securities. Some requirements ap­
ply differently to entities that do not report net income.
See section V, "Fair Value Measurements," for more information. If SFAS 
159 is applicable to the financial statements, answer question 11.
★ ♦ 9. If the entity measures hybrid instruments (financial instruments con­
taining embedded derivatives) at fair value in accordance with the 
election in SFAS 155 or the practicability exception in SFAS 133, is the 
aggregate fair value of those instruments reported separately on the face 
of the statement of financial position from the aggregate carrying amounts 
of assets and liabilities measured using another measurement attrib­
ute?
[SFAS 133 par. 44A, as amended by SFAS 155 par. 4E]
★ ♦ 10. Has the entity provided information that will allow users to under­
stand the effect of changes in the fair value of hybrid financial instru­
ments measured at fair value?
[SFAS 133 par. 44B, as amended by SFAS 155 par. 4E]
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★ ♦11. For those hybrid financial instruments measured at fair value under
the election in SFAS 155 and under the practicability exception in par­
agraph 16 of SFAS 155, has the entity disclosed the information in
paragraphs 18-22 of SFAS 159? ------
[SFAS 133 par. 45A]
★ ♦ 12. Are any derivative gains and losses excluded from the performance
indicator in the financial statements issued for periods ended before 
the initial date of application of SOP 02-2 that did not meet the cash 
flow hedging criteria of SFAS 133:
a. Not reclassified and included as a component of the performance 
indicator in any period subsequent to the initial date of application
of SOP 02-2? ____
b. Not included in the disclosure of the accumulated derivative gain
or loss as described in paragraph .08 of SOP 02-2? ____
[SOP 02-2 par. .10 (ACC 10,860.10)]
★ ♦ 13. To the extent that derivative gains or losses on cash flow hedges qual­
ifying under SFAS 133 had been reported in a manner consistent with 
the provisions of SOP 02-2 in financial statements for periods prior to 
the initial date of application of SOP 02-2, are such amounts included 
in the disclosure of derivative gain or loss as described in paragraph 
.08 of SOP 02-2 and reclassified and included in the performance indi­
cator when the hedged transaction affects the performance indicator? ____
[SOP 02-2 par. .10 (ACC 10,860.10)]
★ ♦ 14. When the financial statements of the year of adoption are presented
separately or included in comparative financial statements do the notes 
to the financial statements disclose:
a. The fact that SOP 02-2 has been adopted and the effective date of
the adoption? ____
b. The nature of any differences in accounting principles or financial 
statement presentation applicable to the financial statements pre­
sented that resulted from adoption of SOP 02-2 (disclosure of pro
forma amounts is not required)? ____
[SOP 02-2 par. .10 (ACC 10,860.10)]
G. Financial Instruments
★ ♦ Disclosures About Fair Value of Financial Instruments
1. Has the entity disclosed, either in the body of the financial statements 
or in the accompanying notes, the fair value of financial instruments 
(except for those excluded in paragraphs 8 and 13 of SFAS 107) for
which it is practicable to estimate fair value? ____
[SFAS 107 par. 10, as amended by SFAS 157]
Note: If disclosed in more than a single note, one of the notes shall include 
a summary table. The summary table shall contain the fair value and related 
carrying amounts and cross-references to the location(s) of the remaining 
disclosures required by SFAS 107 as amended.
[SFAS 107 par. 10 fn*]
FSP §11,200.03
No N/A
Financial Statements and Notes Checklist 85
N/AYes No
2. Has the fair value disclosed in the notes been presented together with 
the related carrying amount in a form that makes it clear whether the 
fair value and carrying amount represent assets or liabilities and how 
the carrying amounts relate to what is reported in the statement of
financial position? _____ ____
[SFAS 107 par. 10, as amended by SFAS 157]
3. Are the methods and significant assumptions used to estimate the fair
value of financial instruments disclosed? ------- ------
[SFAS 107 par. 10, as amended by SFAS 157]
4. In disclosing the fair value of a financial instrument, has the entity 
taken care not to net that fair value with the fair value of other financial 
instruments—even if those financial instruments are of the same class 
or are otherwise considered to be related, for example, by a risk man­
agement strategy—except to the extent that the offsetting of carrying 
amounts in the statement of financial position is permitted under the 
general principle in paragraphs 5-6 of FIN 39, Offsetting of Amounts 
Related to Certain Contracts—an interpretation of APB Opinion No. 10 and 
FASB Statement No. 105, or the exceptions for master netting arrange­
ments in paragraph 10 of FIN 39 and for amounts related to certain 
repurchase and reverse repurchase agreements in paragraphs 3-4 of 
FIN 41, Offsetting of Amounts Related to Certain Repurchase and Reverse 
Repurchase Agreements—an interpretation of APB Opinion No. 10 and a
modification of FASB Interpretation No. 39? ------- ------
[SFAS 107 par. 14]
5. If it is not practicable to estimate the fair value of a financial instrument 
or a class of financial instruments, are the following disclosed:
a. Information pertinent to estimating the fair value of that financial 
instrument or class of financial instruments, such as the carrying
amount, effective interest rate, and maturity? ------- -----
b. The reasons why it is not practicable to estimate fair value? ------- ------
[SFAS 107 par. 14]
★ ♦ Disclosure About Concentrations of Credit Risk of All 
Financial Instruments
6. Except as indicated in paragraph 15B of SFAS 107, has the entity dis­
closed all significant concentrations of credit risk arising from all finan­
cial instruments (including derivative instruments accounted for under 
SFAS 133), whether from an individual counterparty or groups of 
counterparties (Group concentrations of credit risk exist if a number of 
counterparties are engaged in similar activities and have similar eco­
nomic characteristics that would cause their ability to meet contractual 
obligations to be similarly affected by changes in economic or other
conditions)? ------- -----
[SFAS 107 par. 15A]
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Note: SFAS 107 paragraph 15B provides that these disclosure requirements 
do not apply to the following financial instruments, whether written or 
held:
a. Financial instruments of a pension plan, including plan assets, when 
subject to the accounting and reporting requirements of SFAS 87, 
(financial instruments of a pension plan, other than the obligations for 
pension benefits, when subject to the accounting and reporting re­
quirements of SFAS 35, Accounting and Reporting by Defined Benefit 
Pension Plans, are subject to the reporting of paragraph 15A).
b. The financial instruments described in paragraphs 8(a), 8(c), 8(e), and 
8(f) of SFAS 107, as amended by SFAS 112 and SFAS 123, Accounting 
for Stock Based Compensation, except for reinsurance receivables and 
prepaid reinsurance premiums.
[SFAS 107 par. 15B]
7. Has the entity made the following disclosures about each significant 
concentration:
a. Information about the (shared) activity, region, or economic char­
acteristic that identifies the concentration?
Possible shared characteristics on which significant concentrations 
may be determined include, but are not limited to:
(1) Borrowers subject to significant payment increases.
(2) Loans with terms that permit negative amortization.
(3) Loans with high loan-to-value ratios.
Note: Judgment is required to determine whether loan products have terms 
that give rise to a concentration of credit risk.
b. The maximum amount of loss due to credit risk that, based on the 
gross fair value of the financial instrument, the entity would incur 
if parties to the financial instruments that make up the concentra­
tion failed completely to perform according to the terms of the 
contracts and the collateral or other security, if any, for the amount 
due proved to be of no value to the entity?
c. The entity's policy of requiring collateral or other security to sup­
port financial instruments subject to credit risk, information about 
the entity's access to that collateral or other security, and the nature 
and a brief description of the collateral or other security supporting 
those financial instruments?
d. The entity's policy of entering into master netting arrangements to 
mitigate the credit risk of financial instruments, information about 
the arrangements for which the entity is a party, and a brief de­
scription of the terms of those arrangements, including the extent 
to which they would reduce the entity's maximum amount of loss 
due to credit risk?
[SFAS 133 par. 531(d); FSP SOP 94-6-1 par. 7 (question 1)]
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8. Has the entity disclosed quantitative information about the market 
risks of financial instruments that is consistent with the way it manages
or adjusts those risks? (Encouraged, but not required.) ------ -----
[SFAS 133 par. 531(d); FSP SOP 94-6-1 par. 8 (question 1)]
Note: Appropriate ways of reporting the quantitative information encour­
aged will differ for different entities and will likely evolover time as man­
agement approaches and measurement techniques evolve. Possibilities in­
clude disclosing (a) more details about current positions and perhaps 
activity during the period, (b) the hypothetical effects on comprehensive 
income (or net assets), or annual income, of several possible changes in 
market prices, (c) a gap analysis of interest rate repricing or maturity dates, 
(d) the duration of the financial instruments, or (e) the entity's value at risk 
from derivatives and from other positions at the end of the reporting period 
and the average value at risk during the year. This list is not exhaustive, 
and an entity is encouraged to develop other ways of reporting quantitative 
information.
[SFAS 107 par. 15D]
9. Are the classification guidelines and disclosures under EITF 00-19, 
"Accounting for Derivative Financial Instruments Indexed to, and Po­
tentially Settled in, a Company's Own Stock," followed for freestand­
ing contracts that are indexed to, and potentially settled in, the com­
pany's own stock?
[EITF 00-19]
10. Is disclosure made of the primary geographic sources of patients? 
[AAG 5.24]
♦ Disclosures About Certain Financial Instruments With Characteristics of
Both Liabilities and Equity
Note: Depending upon whether an entity is a nonpublic entity, a public 
entity, or an SEC registrant, FSP FAS 150-3, Effective Date, Disclosures, and 
Transition for Mandatorily Redeemable Financial Instruments of Certain Non­
public Entities and Certain Mandatorily Redeemable Noncontrolling Interests un­
der FASB Statement No. 150, defers the effective date for applying the pro­
visions of SFAS 150, Accounting for Certain Financial Instruments with 
Characteristics of both Liabilities and Equity. Readers should read FSP FAS 
150-3 to understand the various effective dates of SFAS 150. FSP FAS 150-3 
is available on the FASB Web site at www.fasb.org.
Early adoption of the provisions of SFAS 150 for instruments within the 
scope of the indefinite deferrals established by FSP FAS 150-3 is precluded 
during the deferral period.
During the deferral period, all public entities as well as nonpublic entities 
that are SEC registrants are required to follow the disclosure requirements 
in paragraphs 26-27 of SFAS 150 (questions 14-15 in this section) as well as 
disclosures required by other applicable guidance.
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11. For items within the scope of SFAS 150, are they presented as liabilities
(or assets in some circumstances), and not between the liabilities sec­
tion and the equity section of the statement of financial position? 
[SFAS 150 par. 18]
12. If the entity has no equity instruments outstanding but has financial 
instruments in the form of shares, all of which are mandatorily redeem­
able financial instruments required to be classified as liabilities:
a. Are they described in statements of financial position as "shares 
subject to mandatory redemption"?
b. Are payments to holders of such instruments and related accruals 
presented separately from payments to and interest due to other 
creditors in statements of cash flows and income?
[SFAS 150 par. 19 and 28]
13. Do the entities referred to in question 12 of the preceding disclose the 
components of the liability that would otherwise be related to share­
holders' interest and other comprehensive income, if any, subject to the 
redemption feature? (For example, par value and other paid-in 
amounts of mandatorily redeemable instruments should be disclosed 
separately from the amount of retained earnings or accumulated defi­
cit.)
[SFAS 150 par. 28]
14. For issuers of financial instruments within the scope of SFAS 150:
a. Are the nature and terms of the financial instruments and the 
rights and obligations embodied in those instruments disclosed?
b. Does that disclosure include information about settlement alter­
natives, if any, in the contract and identify the entity that controls 
the settlement alternatives?
[SFAS 150 par. 26]
15. For all outstanding financial instruments within the scope of SFAS 150 
and for each settlement alternative, do issuers disclose:
a. The amount that would be paid, or the number of shares that 
would be issued and their fair value, determined under the condi­
tions specified in the contract if the settlement were to occur at the 
reporting date?
b. How changes in the fair value of the issuer's equity shares would 
affect those settlement amounts?
c. The maximum amount that the issuer could be required to pay to 
redeem the instrument by physical settlement, if applicable?
d. The maximum number of shares that could be required to be is­
sued, if applicable?
e. That a contract does not limit the amount that the issuer could be 
required to pay or the number of shares that the issuer could be 
required to issue, if applicable?
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f. For a forward contract or an option indexed to the issuer's equity 
shares, the forward price or option strike price, the number of is­
suer's shares to which the contract is indexed, and the settlement
date or dates of the contract, as applicable? _____ ____
[SFAS 150 par. 27]
16. Are mandatorily redeemable financial instruments classified as liabili­
ties unless the redemption is required to occur only upon the liquida­
tion or termination of the reporting entity? _____ ____
[SFAS 150 par. 9]
17. Are financial instruments, other than an outstanding share, that at in­
ception, (a) embodies an obligation to repurchase the issuer's equity 
shares or is indexed to such an obligation, and (b) requires or may 
require the issuer to settle the obligation by transferring assets, classi­
fied as liabilities (or assets in some circumstances)? _____ ____
[SFAS 150 par. 11]
18. Are financial instruments that embody an unconditional obligation, or
financial instruments other than an outstanding share that embodies a 
conditional obligation, that the issuer must or may settle by issuing a 
variable number of its equity shares, classified as liabilities (or assets 
in some circumstances) if, at inception, the monetary value of the obli­
gation is based solely or predominantly on any one of the items indi­
cated in paragraph 12 of SFAS 150? _____ ____
[SFAS 150 par. 12]
Mandatorily Redeemable Shares Requiring Redemption by Payment of an
Amount That Differs from Book Value
19. Are the cumulative transition adjustment and any subsequent adjust­
ments reported as an excess of liabilities over assets (a deficit) and 
changes thereto even though the mandatorily redeemable shares are
reported as a liability? _____ ____
[FSP FAS 150-2]
20. If the redemption price of mandatorily redeemable shares is less than 
the book value of those shares, is the excess of that book value over the 
liability reported for the mandatorily redeemable shares as an excess
of assets over liabilities (equity)? _____ ____
[FSP FAS 150-2]
SFAS 150 Effective Date Deferral
21. Although the disclosure requirements of SFAS 150 do not apply for 
those mandatorily redeemable instruments of certain nonpublic com­
panies while application of the provisions of SFAS 150 to those instru­
ments is deferred, are the capital structure disclosure requirements in 
SFAS 129 still provided, in particular:
a. Information required in paragraph 4 about the pertinent rights and 
privileges of the various securities outstanding, including manda­
tory redemption requirements? _____ ____
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b. Disclosure required in paragraph 8 of the amount of redemption 
requirements for all issues of stock that are redeemable at fixed or 
determinable prices on fixed or determinable dates in each of the
next five years? ____
[FSP FAS 150-3]
22. During the deferral period, if the entity is a public entity or a nonpublic 
entity that is an SEC registrant, are the disclosure requirements in par­
agraphs 26-27 of SFAS 150 as well as disclosures required by other
applicable guidance complied with? ____
[FSP FAS 150-3]
★ ♦ G1. Financial Instruments of Enterprises Subject to SFAS 161 
Derivative Instruments and Hedging Activities
1. Are derivative instruments that are within the scope of SFAS 133, in­
cluding certain derivative instruments embedded in other contracts, 
accounted for as assets or liabilities in the statement of financial posi­
tion and measured at their fair values? ____
[SFAS 133 par. 17]
2. Are gains and losses on derivative instruments or nonderivative finan­
cial instruments that are designated and qualifying as hedges of a for­
eign currency exposure of a net investment in a foreign operation ac­
counted for in the same manner as a translation adjustment to the 
extent they are effective as a hedge, that is, are they reported separately 
in the statement of other comprehensive income in accordance with
paragraph 13 of SFAS 52, Foreign Currency Translation? ____
[SFAS 133 par. 42^3]
3. If an entity holds or issues derivative instruments (or nonderivative 
instruments that are designated and qualify as hedging instruments 
pursuant to paragraphs 37 and 42 of SFAS 133) have the following 
disclosures been made for every annual and interim reporting period 
for which a statement of financial position and statement of financial 
performance are presented:
a. Its objectives for holding or issuing those instruments ____
b. The context needed to understand those objectives? ____
c. Its strategies for achieving those objectives? ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
4. Are the disclosures described in question 3 in the context of each in­
strument's primary underlying risk exposure (for example, interest 
rate, credit, foreign exchange rate, interest rate and foreign exchange
rate, or overall price)? ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
5. Do the disclosures described in question 3 distinguish between instru­
ments used for risk management purposes and those used for other
purposes? ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
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6. For derivative instruments designated as hedging instruments under
SFAS 161, do the disclosures described in question 3 distinguish be­
tween instruments designated as (a) fair value hedging instruments,
(b) cash flow hedging instruments, and (c) hedges of foreign currency
exposure of net investments in foreign operations? _____ ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
7. For derivative instruments not designated as hedging instruments un­
der SFAS 161, do the disclosures described in question 3 describe the
purpose of holding or issuing the derivatives? _____ ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
8. Does the entity disclose (for every annual and interim reporting period
for which a statement of financial position and statement of financial 
performance are presented) information that enables users of its finan­
cial statements to understand the volume of its derivative activity? _____ ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
9. Qualitative disclosures about an entity's objectives and strategies for
using derivative instruments may be more meaningful if such objec­
tives and strategies are described in the context of an entity's overall 
risk exposures relating to interest rate risk, foreign currency exchange 
rate risk, commodity price risk, credit risk, and equity price risk. If 
appropriate, an entity is encouraged, but not required, to provide such 
additional qualitative disclosures. Have such disclosures been made 
(for every annual and interim reporting period for which a statement 
of financial position and statement of financial performance are pre­
sented)? _____ ____
[SFAS 133 par. 44, as amended by SFAS 161 par. 3]
10. For every annual and interim reporting period for which a statement 
of financial position and statement of financial performance are pre­
sented, does the entity disclose, in a tabular format, the location and 
fair value amounts of derivative instruments (or nonderivative instru­
ments it holds or issues that are designated and qualify as hedging 
instruments pursuant to paragraphs 37 and 42 of SFAS 133) reported
in the statement of financial position? _____ ____
11. Do the disclosures described in question 10 provide the following:
a. The fair value on a gross basis (even if the derivative instruments 
qualify for net presentation in the statement of financial position
in accordance with FIN 39)? _____ ____
b. Separate asset and liability values segregated between derivatives 
that are designated and qualifying as hedging instruments under 
SFAS 161 and those that are not, and within those two broad cate­
gories, by type of derivative contract (for example, interest rate 
contracts, foreign exchange contracts, equity contracts, commodity
contracts, credit contracts, and so forth)? _____ ____
c. The line item(s) in the statement of financial position in which the
fair value amounts for the preceding categories of derivative in­
struments are included? _____ ____
[SFAS 133 par. 44Ca, as added by SFAS 161 par. 3]
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12. For every annual and interim reporting period for which a statement 
of financial position and statement of financial performance are pre­
sented, does the entity disclose the location and amounts of the gains 
and losses for derivative instruments (or nonderivative instruments it 
holds or issues that are designated and qualify as hedging instruments 
pursuant to paragraphs 37 and 42 of SFAS 133) reported in the state­
ment of financial performance (or when applicable, the statement of 
financial position; for example, gains and losses initially recognized in 
other comprehensive income [OCI])?
[SFAS 133 par. 44Cb, as added by SFAS 161 par. 3]
13. Do the disclosures described in question 12 provide separate presen­
tation of the following, in tabular format (with the exception of ques­
tion 13a for which a tabular or nontabular format is appropriate):
a. The gains and losses on derivative instruments designated and 
qualifying as hedging instruments in fair value hedges and related 
hedged items designated and qualifying in fair value hedges?
b. The effective portion of gains and losses on derivative instruments 
designated and qualifying in cash flow hedges and net investment 
hedges that was recognized in OCI during the current period?
c. The effective portion of gains and losses on derivative instruments 
designated and qualifying in cash flow hedges and net investment 
hedges recorded in accumulated other comprehensive income dur­
ing the term of the hedging relationship and reclassified into earn­
ings during the current period?
d. The portion of gains and losses on derivative instruments desig­
nated and qualifying in cash flow hedges and net investment 
hedges representing (a) the amount of the hedges' ineffectiveness 
and (b) the amount, if any, excluded from the assessment of hedge 
effectiveness?
e. The gains and losses for derivative instruments not designated or 
qualifying as hedging instruments under SFAS 161?
[SFAS 133 par. 44Cb, as added by SFAS 161 par. 3]
14. Do the disclosures described in question 12 present information sepa­
rately by type of derivative contract (for example, interest rate con­
tracts, foreign exchange contracts, equity contracts, commodity con­
tracts, credit contracts, and so forth)?
[SFAS 133 par. 44Cb, as added by SFAS 161 par. 3]
15. Do the disclosures described in question 12 identify the line item(s) in 
the statement of financial performance in which the gains and losses 
for the categories of derivative instruments are included?
[SFAS 133 par. 44Cb and SFAS 133 par. 205F, as added by SFAS 161 
par. 3]
Disclosures in Interim Financial Reports
16. If an entity's policy is to include derivative instruments that are not 
designated or qualifying as hedging instruments under SFAS 161 in its 
trading activities, and the entity elects to exclude those derivative in­
struments from the disclosures described in question 12, has the entity 
disclosed the following information:
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a. The gains and losses on its trading activities (including both deriv­
ative and nonderivative instruments) recognized in the statement 
of financial performance, separately by major types of items (such 
as fixed income/interest rates, foreign exchange, equity, commod­
ity, and credit)? _____ ____
b. The line items in the statement of financial performance in which
trading activities gains and losses are included? _____ ____
c. A description of the nature of its trading activities and related
risks, and how the entity manages those risks? _____ ____
[SFAS 133 par. 44Cc, as added by SFAS 161 par. 3]
17. For every annual and interim reporting period for which a statement 
of financial position and statement of financial performance are pre­
sented, does the entity disclose the following information about deriv­
ative instruments it holds or issues (or nonderivative instruments it 
holds or issues that are designated and qualify as hedging instruments 
pursuant to paragraphs 37 and 42 of SFAS 133) that have credit-risk- 
related contingent features and that are in a net liability position at the 
end of the reporting period:
a. The existence and nature of credit-risk-related contingent features 
and the circumstances in which the features could be triggered in 
derivative instruments that are in a net liability position at the end
of the reporting period? _____ ____
b. The aggregate fair value amounts of derivative instruments that
contain credit-risk-related contingent features that are in a net lia­
bility position at the end of the reporting period? _____ ____
c. The aggregate fair value of assets that are already posted as collat­
eral at the end of the reporting period and (1) the aggregate fair 
value of additional assets that would be required to be posted as 
collateral or (2) the aggregate fair value of assets needed to settle 
the instrument immediately, if the credit-risk-related contingent
features were triggered at the end of the reporting period? _____ ____
[SFAS 133 par. 44D, as added by SFAS 161 par. 3]
Fair Value Hedges
18. For every annual and interim reporting period for which a statement 
of financial position and statement of financial performance are pre­
sented, does the entity disclose the following for derivative instru­
ments, as well as nonderivative instruments that may give rise to for­
eign currency transaction gains or losses under SFAS 52, that have been 
designated and have qualified as fair value hedging instruments and 
for the related hedged items:
a. The net gain or loss recognized in earnings during the reporting 
period representing (a) the amount of the hedges' ineffectiveness 
and (b) the component of the derivative instruments' gain or loss,
if any, excluded from the assessment of hedge effectiveness? _____ ____
b. The amount of net gain or loss recognized in earnings when a
hedged firm commitment no longer qualifies as a fair value hedge? _____ ____
[SFAS 133 par. 45a, as amended by SFAS 161 par. 3]
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Cash Flow Hedges
19. For every annual and interim reporting period for which a statement 
of financial position and statement of financial performance are pre­
sented, does the entity disclose the following for derivative instru­
ments that have been designated and have qualified as cash flow hedg­
ing instruments and for the related hedged transactions:
a. A description of the transactions or other events that will result in 
the reclassification into earnings of gains and losses that are re­
ported in accumulated other comprehensive income, and the esti­
mated net amount of the existing gains or losses at the reporting 
date that is expected to be reclassified into earnings within the next 
12 months?
b. The maximum length of time over which the entity is hedging its 
exposure to the variability in future cash flows for forecasted trans­
actions excluding those forecasted transactions related to the pay­
ment of variable interest on existing financial instruments?
c. The amount of gains and losses reclassified into earnings as a result 
of the discontinuance of cash flow hedges because it is probable 
that the original forecasted transactions will not occur by the end 
of the originally specified time period or within the additional 
period of time discussed in paragraph 33?
[SFAS 133 par. 45b, as amended by SFAS 161 par. 3]
20. If the disclosures related to derivative instruments (or nonderivative 
instruments that are designated and qualify as hedging instruments 
pursuant to paragraphs 37 and 42) are presented in more than a single 
footnote, does each derivative note cross-reference the other notes in 
which derivative-related information is disclosed?
[SFAS 133 par. 44E, as added by SFAS 161 par. 3]
21. The quantitative disclosures about derivative instruments may be 
more useful, and less likely to be perceived to be out of context or 
otherwise misunderstood, if similar information is disclosed about 
other financial instruments or nonfinancial assets and liabilities to 
which the derivative instruments are related by activity. Accordingly, 
in such situations, an entity is encouraged, but not required, to present 
a more complete picture of its activities by disclosing that information? 
Have such disclosures been made (for every annual and interim re­
porting period for which a statement of financial position and state­
ment of financial performance are presented)?
[SFAS 133 par. 45]
H. Nonmonetary Transactions
★ ♦1. Do disclosures for nonmonetary transactions during the period in­
clude:
a. Nature of the transactions?
b. Basis of accounting for the assets transferred?
c. Gains or losses recognized on the transfers?
[APB 29 par. 28]
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♦ 2. Is the amount of gross operating revenue recognized as a result of 
nonmonetary transactions addressed by EITF 00-8, "Accounting by a 
Grantee for an Equity Instrument to Be Received in Conjunction with 
Providing Goods or Services," disclosed in each period's financial
statements? _____ _____ ____
[EITF 00-8]
I. Employers' Disclosures for Defined Benefit Pension and Other Postreti­
rement Plans for Investor-Owned Organizations Only.3
3 EITF 03-4, "Determining the Classification and Benefit Attribution Method for a 'Cash Balance' Pension Plan," states that cash balance 
plans should be considered a defined benefit plan.
Notes: In September 2006, FASB issued SFAS 158, which requires, among 
other provisions, an employer to recognize the overfunded or underfunded 
status of a defined benefit postretirement plans (other than a multiemployer 
plan) as an asset or liability in its statement of financial position and to 
recognize changes in that funded status in the year in which the changes 
occur through comprehensive income. This statement also requires an em­
ployer to measure the funded status of a plan as of the date of its year-end 
statement of financial position, with limited exceptions.
Effective Dates for Recognition and Related Disclosure Provisions
The required date of adoption of the recognition and disclosure provisions 
of SFAS 158 differs for an employer that is an issuer of publicly traded 
equity securities (as defined) and an employer that is not. Readers should 
refer to the complete FASB statement for any of the conditions that need to 
be met for an employer to be deemed to have publicly traded equity secu­
rities.
An employer with publicly traded equity securities is required to initially 
recognize the funded status of a defined benefit postretirement plan (see 
paragraph 4 of SFAS 158) and to provide the required disclosures (see par­
agraph 7 of SFAS 158) as of the end of the fiscal year ending after December 
15, 2006.
An employer without publicly traded equity securities is required to rec­
ognize the funded status of a defined benefit postretirement plan (see par­
agraphs 4 and 8 of SFAS 158) and to provide the required disclosures (see 
paragraphs 7 and 10 of SFAS 158) as of the end of the fiscal year ending 
after June 15, 2007.
However, an employer without publicly traded equity securities is re­
quired to disclose additional information in the notes to financial state­
ments for a fiscal year ending after December 15, 2006, but before June 16, 
2007, unless it has applied the recognition provisions of the statement in 
preparing those financial statements. See question 2 for those additional 
disclosure requirements.
The requirement to measure plan assets and benefit obligations as of the 
date of the employer's fiscal year-end statement of financial position (see 
paragraphs 5-6 and 9 of SFAS 158) is effective for fiscal years ending after 
December 15, 2008. If in the last quarter of the preceding fiscal year an 
employer enters into a transaction that results in a settlement or experiences
(continued)
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an event that causes a curtailment of the plan, the related gain or loss pur­
suant to SFAS 88, Employers' Accounting for Settlements and Curtailments of 
Defined Benefit Pension Plans and for Termination Benefits, or SFAS 106 is re­
quired to be recognized in earnings or changes in unrestricted net assets of 
that quarter. The requirement in paragraphs 5(k) and 8(j) of SFAS 132 (re­
vised 2003), Employers' Disclosures about Pensions and Other Postretirement 
Benefits—an amendment of FASB Statements No. 87, 88, and 106, to disclose 
the measurement date is eliminated, effective in the year the employer ini­
tially adopts the measurement date provisions of this statement.
Earlier application of the recognition or measurement date provisions is 
encouraged; however, early application must be for all of an employer's 
benefit plans. Retrospective application of the statement is not permitted. 
This checklist has been updated to include the presentation and disclosure 
requirements of SFAS 158. Readers can refer to the full text of SFAS 158 on 
the FASB Web site at www.fasb.org.
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♦ 1. Does a business entity that sponsors one or more benefit plans disclose 
the following information in the notes to its annual financial state­
ments, separately for pension plans and other postretirement benefit 
plans:
a. For each annual statement of income presented, the amounts rec­
ognized in other comprehensive income, showing separately the 
net gain or loss and net prior service cost or credit. Those amounts 
shall be separated into amounts arising during the period and re­
classification adjustments of other comprehensive income as a re­
sult of being recognized as components of net periodic benefit cost 
for the period?
b. For each annual statement of income presented, the net transition 
asset or obligation recognized as a reclassification adjustment of 
other comprehensive income as a result of being recognized as a 
component of net periodic benefit cost for the period?
c. For each annual statement of financial position presented, the 
amounts in accumulated other comprehensive income that have 
not yet been recognized as components of net periodic benefit cost, 
showing separately the net gain or loss, net prior service cost or 
credit, and net transition asset or obligation?
d. The amounts in accumulated other comprehensive income ex­
pected to be recognized as components of net periodic benefit cost 
over the fiscal year that follows the most recent annual statement 
of financial position presented, showing separately the net gain or 
loss, net prior service cost or credit, and net transition asset or 
obligation?
e. The amount and timing of any plan assets expected to be returned 
to the business entity during the 12-month period, or operating 
cycle if longer, that follows the most recent annual statement of 
financial position presented?
[SFAS 158 par. 7]
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♦ 2. Does an employer without publicly traded equity securities disclose
the following information in the notes to the financial statements for a 
fiscal year ending after December 15, 2006, but before June 16, 2007, 
unless it has applied the recognition provisions of the statement in 
preparing those financial statements:
a. A brief description of the provisions of the statement? ------- ------- -------
b. The date that adoption is required? ------- ------- -------
c. The date the employer plans to adopt the recognition provisions of
the statement, if earlier? ------- ------- -------
Disclosures Required in the Year of Application
♦ 3. In the year that the recognition provisions of SFAS 158 are initially
applied, does the employer disclose, in the notes to the annual financial 
statements, the incremental effect of applying this statement on indi­
vidual line items in the year-end statement of financial position? ------- ------- -------
[SFAS 158 par. 20]
♦ 4. In the year that the measurement date provisions of SFAS 158 are ini­
tially applied, does a business entity disclose the separate adjustments 
of retained earnings and accumulated other comprehensive income
from applying the statement? _____ _____ _____
[SFAS 158 par. 21]
Note: The disclosures specified by paragraphs 17-18 of SFAS 154 are not 
required.
[SFAS 158 par. 22]
♦ 5. If an employer sponsors one or more defined benefit pension plans or 
one or more defined benefit postretirement plans has the following 
information been provided, separately for pension plans and other 
postretirement benefit plans:
a. A reconciliation of beginning and ending balances of the benefit 
obligation4 showing separately, if applicable, the effects during the 
period attributable to each of the following: service cost, interest 
cost, contributions by plan participants, actuarial gains and losses, 
foreign currency exchange rate changes5 benefits paid, plan 
amendments, business combinations, divestitures, curtailments, 
settlements, and special termination benefits?
4 For defined benefit pension plans, the benefit obligation is the projected benefit obligation. For defined benefit postretirement plans, 
the benefit obligation is the accumulated postretirement benefit obligation.
5 The effects of foreign currency exchange rate changes that are to be disclosed are those applicable to plans of a foreign operation whose 
functional currency is not the reporting currency pursuant to SFAS 52, Foreign Currency Translation.
[SFAS 132(R) par. 5a]
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b. A reconciliation of beginning and ending balances of the fair value 
of plan assets showing separately, if applicable, the effects during 
the period attributable to each of the following: actual return on 
plan assets, foreign currency exchange rate changes,6 contributions 
by the employer, contributions by plan participants, benefits paid, 
business combinations, divestitures, and settlements?
[SFAS 132(R) par. 5b
c. The funded status of the plans and the amounts recognized in the 
statement of financial position showing separately the assets and 
current and noncurrent liabilities recognized?
[SFAS 132(R) par. 5c, as amended by SFAS 158]
d. Information about plan assets:
(1) For each major category of plan assets, which shall include, but 
is not limited to, equity securities, debt securities, real estate, 
and all other assets, the percentage of the fair value of total 
plan assets held as of the measurement date used for each 
statement of financial position presented?
(2) A narrative description of investment policies and strategies, 
including target allocation percentages or range of percentages 
for each major category of plan assets presented on a 
weighted-average basis as of the measurement date(s) of the 
latest statement of financial position presented, if applicable, 
and other factors that are pertinent to an understanding of the 
policies or strategies such as investment goals, risk manage­
ment practices, permitted and prohibited investments includ­
ing the use of derivatives, diversification, and the relationship 
between plan assets and benefit obligations?
(3) A narrative description of the basis used to determine the over­
all expected long-term rate-of-return-on-assets assumption, 
such as the general approach used, the extent to which the 
overall rate-of-return-on-assets assumption was based on his­
torical returns, the extent to which adjustments were made to 
those historical returns in order to reflect expectations of future 
returns, and how those adjustments were determined?
(4) Disclosure of additional asset categories and additional infor­
mation about specific assets within a category is encouraged if 
that information is expected to be useful in understanding the 
risks associated with each asset category and the overall ex­
pected long-term rate of return on assets?
[SFAS 132(R) par. 5d]
e. For defined benefit pension plans, the accumulated benefit obliga­
tion?
[SFAS 132(R) par. 5e]
6 Refer to footnote 5.
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f. The benefits (as of the date of the latest statement of financial po­
sition presented) expected to be paid in each of the next five fiscal 
years, and in the aggregate for the five fiscal years thereafter. The 
expected benefits should be estimated based on the same assump­
tions used to measure the company's benefit obligation at the end 
of the year and should include benefits attributable to estimated
future employee service? _____ _____ ____
[SFAS 132(R) par. 5f]
g. The employer's best estimate, as soon as it can reasonably be deter­
mined, of contributions expected to be paid to the plan during the 
next fiscal year beginning after the date of the latest statement of 
financial position presented. Estimated contributions may be pre­
sented in the aggregate combining (1) contributions required by 
funding regulations or laws, (2) discretionary contributions, and
(3) noncash contributions? _____ _____ ____
[SFAS 132(R) par. 5g]
h. The amount of net periodic benefit cost recognized, showing sep­
arately the service cost component, the interest cost component, 
the expected return on plan assets for the period, the gain or loss 
component, the prior service cost or credit component, the transi­
tion asset or obligation component, and the gain or loss recognized
due to settlements or curtailments? _____ _____ ____
[SFAS 132(R) par. 5h, as amended by SFAS 158]
i. Separately the net gain or loss and net prior service cost or credit
recognized in other comprehensive income for the period pursuant 
to paragraphs 25 and 29 of SFAS 87 and paragraphs 52 and 56 of 
SFAS 106, as amended, and reclassification adjustments of other 
comprehensive income for the period, as those amounts, including 
amortization of the net transition asset or obligation, are recog­
nized as components of net periodic benefit cost? _____ _____ ____
[SFAS 132(R) par. 5i, as amended by SFAS 158]
j. The amounts in accumulated other comprehensive income that 
have not yet been recognized as components of net periodic benefit 
cost, showing separately the net gain or loss, net prior service cost
or credit, and net transition asset or obligation? _____ _____ ____
[SFAS 132(R) par. 5ii, as amended by SFAS 158]
k. On a weighted-average basis, the following assumptions used in
the accounting for the plans: assumed discount rate, rates of com­
pensation increase (for pay-related plans), and expected long-term 
rates of return on plan assets specifying, in a tabular format, the 
assumptions used to determine the benefit obligation and the as­
sumptions used to determine net benefit cost? _____ _____ ____
[SFAS 132(R) par. 5j]
l. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to be
achieved? _____ _____ ____
[SFAS 132(R) par. 51]
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m. The effect of a one-percentage-point increase and the effect of a 
one-percentage-point decrease in the assumed health care cost 
trend rates on (1) the aggregate of the service and interest cost 
components of net periodic postretirement health care benefit cost 
and (2) the accumulated postretirement benefit obligation for 
health care benefits? (For purposes of this disclosure, all other as­
sumptions shall be held constant, and the effects shall be measured
based on the substantive plan that is the basis for the accounting.) _____
[SFAS 132(R) par. 5m]
n. If applicable, the amounts and types of securities of the employer
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period? _____
[SFAS 132(R) par. 5n]
o. If applicable, any alternative method used to amortize prior service 
amounts or net gains and losses pursuant to paragraphs 26 and 33
of SFAS 87 or paragraphs 53 and 60 of SFAS 106? _____
[SFAS 132(R) par. 5o, as amended by SFAS 158]
p. If applicable, any substantive commitment such as past practice or
a history of regular benefit increases, used as the basis for account­
ing for the benefit obligation? _____
[SFAS 132(R) par. 5p]
q. If applicable, the cost of providing special or contractual termina­
tion benefits recognized during the period and a description of the
nature of the event? _____
[SFAS 132(R) par. 5q]
r. An explanation of any significant change in the benefit obligation
or plan assets not otherwise apparent in the other disclosures re­
quired by SFAS 132? _____
[SFAS 132(R) par. 5r]
s. The amounts in accumulated other comprehensive income ex­
pected to be recognized as components of net periodic benefit cost 
over the fiscal year that follows the most recent annual statement 
of financial position presented, showing separately the net gain or 
loss, net prior service cost or credit, and net transition asset or
obligation? _____
[SFAS 132(R) par. 5s, as amended by SFAS 158]
t. The amount and timing of any plan assets expected to be returned 
to the employer during the 12-month period, or operating cycle if 
longer, that follows the most recent annual statement of financial
position presented? _____
[SFAS 132(R) par. 5t, as amended by SFAS 158]
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u. If the enterprise has not yet adopted the measurement date provi­
sions of SFAS 158, which are effective for fiscal years ending after 
December 15, 2008 (with earlier application encouraged), the meas­
urement date(s) used to determine pension and other postretire­
ment benefit measurements for the pension plans and other postre­
tirement benefit plans that make up at least the majority of plan
assets and benefit obligations? _____ _____ ____
[SFAS 132(R) par. 5k]
♦ 6. Are amounts related to the employer's results of operations disclosed
for each period for which an income statement is presented? _____ _____ ____
[SFAS 132(R) par. 5]
♦ 7. Are amounts related to the employer's statement of financial position
disclosed as of the date of each statement of financial position pre­
sented? ------- ------- ------
[SFAS 132(R) par. 5, as amended by SFAS 158]
Employers With Two or More Plans
♦ 8. Are the disclosures required by SFAS 132 aggregated for all of an em­
ployer's defined benefit pension plans and for all of an employer's 
other defined benefit postretirement plans unless disaggregating in 
groups is considered to provide useful information or is otherwise
required by paragraph 6 of SFAS 132 and paragraph 7 of SFAS 132? ------- ------- ------
[SFAS 132(R) par. 6]
♦ 9. Are disclosures as of the date of each statement of financial position
presented? ------- ------- ------
[SFAS 132(R) par. 6, as amended by SFAS 158]
Note: Disclosures about pension plans with assets in excess of the accumu­
lated benefit obligation generally may be aggregated with disclosures about 
pension plans with accumulated benefit obligations in excess of assets. The 
same aggregation is permitted for other postretirement benefit plans.
[SFAS 132(R) par. 6]
♦ 10. If aggregate disclosures are presented, does the employer disclose:
a. The aggregate benefit obligation and aggregate fair value of plan 
assets for plans with benefit obligations in excess of plan assets as 
of the measurement date of each statement of financial position 
presented?
b. The aggregate pension accumulated benefit obligation and aggre­
gate fair value of plan assets for pension plans with accumulated 
benefit obligations in excess of plan assets?
[SFAS 132(R) par. 6]
♦ 11. If a U.S. reporting entity combines disclosures about pension plans or
other postretirement benefit plans outside the United States with those 
for U.S. plans, are the benefit obligations of the plans outside the 
United States not significant relative to the total benefit obligation and 
do those plans not use significantly different assumptions?
[SFAS 132(R) par. 7]
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Yes No N/A
Note: A foreign reporting entity that prepares financial statements in con­
formity with U.S. GAAP shall apply the preceding guidance to its domestic 
and foreign plans.
Reduced Disclosure Requirements for Nonpublic Entities
Note: A nonpublic entity is not required to disclose the information re­
quired by paragraphs 5(a)-(c), 5(h), 5(m), and 5(o)-(r) of SFAS 132(R). See 
the related disclosure questions in the preceding.
♦ 12. For a nonpublic entity7 that sponsors one or more defined benefit pen­
sion plans or one or more other defined benefit postretirement plans, 
has the following information been disclosed, separately for pension 
plans and other postretirement benefit plans:
7 A nonpublic entity is any entity other than one (a) whose debt or equity securities trade in a public market either on a stock exchange 
(domestic or foreign) or in the over-the-counter market including securities quoted only locally or regionally, (b) that makes a filing with 
a regulatory agency in preparation for the sale of any class of debt or equity securities in a public market, or (c) that is controlled by an 
entity covered by (a) or (b).
a. The benefit obligation, fair value of plan assets, and funded status 
of the plan?
[SFAS 132(R) par. 8a]
b. Employer contributions, participant contributions, and benefits 
paid?
[SFAS 132(R) par. 8b]
c. Information about plan assets:
(1) For each major category of plan assets which shall include, but 
is not limited to, equity securities, debt securities, real estate, 
and all other assets, the percentage of the fair value of total 
plan assets held as of the measurement date used for each 
statement of financial position presented?
[SFAS 132(R) par. 8c(1)]
(2) A narrative description of investment policies and strategies, 
including target allocation percentages or range of percentages 
for each major category of plan assets presented on a 
weighted-average basis as of the measurement date(s) of the 
latest statement of financial position presented, if applicable, 
and other factors that are pertinent to an understanding of the 
policies or strategies such as investment goals, risk manage­
ment practices, permitted and prohibited investments includ­
ing the use of derivatives, diversification, and the relationship 
between plan assets and benefit obligations?
[SFAS 132(R) par. 8c(2)]
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(3) A narrative description of the basis used to determine the over­
all expected long-term rate-of-return-on-assets assumption, 
such as the general approach used, the extent to which the 
overall rate-of-return-on-assets assumption was based on his­
torical returns, the extent to which adjustments were made to 
those historical returns in order to reflect expectations of future
returns, and how those adjustments were determined? _____ _____ ____
[SFAS 132(R) par. 8c(3)]
Note: Disclosure of additional asset categories and additional information 
about specific assets within a category is encouraged if that information is 
expected to be useful in understanding the risks associated with each asset 
category and the overall expected long-term rate of return on assets.
[SFAS 132(R) par. 8c(4)]
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d. For defined benefit pension plans, the accumulated benefit obliga­
tion?
[SFAS 132(R) par. 8d]
e. The benefits (as of the date of the latest statement of financial po­
sition presented) expected to be paid in each of the next five fiscal 
years, and in the aggregate for the five fiscal years thereafter? (The 
expected benefits should be estimated based on the same assump­
tions used to measure the company's benefit obligation at the end 
of the year and should include benefits attributable to estimated 
future employee service.)
[SFAS 132(R) par. 8e]
f. The employer's best estimate, as soon as it can reasonably be deter­
mined, of contributions expected to be paid to the plan during the 
next fiscal year beginning after the date of the latest statement of 
financial position presented? (Estimated contributions may be pre­
sented in the aggregate combining (1) contributions required by 
funding regulations or laws, (2) discretionary contributions, and 
(3) noncash contributions.)
[SFAS 132(R) par. 8f]
g. The amounts recognized in the statements of financial position, 
showing separately the postretirement benefit assets and current 
and noncurrent postretirement benefit liabilities?
[SFAS 132(R) par. 8g, as amended by SFAS]
h. Separately, the net gain or loss and net prior service cost or credit 
recognized in other comprehensive income for the period pursuant 
to paragraphs 25 and 29 of SFAS 87 and paragraphs 52 and 56 of 
SFAS 106, as amended, and reclassification adjustments of other 
comprehensive income for the period, as those amounts, including 
amortization of the net transition asset or obligation, are recog­
nized as components of net periodic benefit cost?
[SFAS 132(R) par. 8h, as amended by SFAS 158]
i. The amounts in accumulated other comprehensive income that 
have not yet been recognized as components of net periodic benefit 
cost, showing separately the net gain or loss, net prior service cost 
or credit, and net transition asset or obligation?
[SFAS 132(R) par. 8hh, as amended by SFAS 158]
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j. On a weighted-average basis, the following assumptions used in 
the accounting for the plans: assumed discount rates, rates of com­
pensation increase (for pay-related plans), and expected long-term 
rates of return on plan assets specifying, in a tabular format, the 
assumptions used to determine the benefit obligation and the as­
sumptions used to determine net benefit cost?
[SFAS 132(R) par. 8i]
k. The assumed health care cost trend rate(s) for the next year used 
to measure the expected cost of benefits covered by the plan (gross 
eligible charges) and a general description of the direction and 
pattern of change in the assumed trend rates thereafter, together 
with the ultimate trend rate(s) and when that rate is expected to be 
achieved?
[SFAS 132(R) par. 8k]
l. If applicable, the amounts and types of securities of the employer 
and related parties included in plan assets, the approximate 
amount of future annual benefits of plan participants covered by 
insurance contracts issued by the employer or related parties, and 
any significant transactions between the employer or related par­
ties and the plan during the period?
[SFAS 132(R) par. 81]
m. The nature and effect of significant nonroutine events, such as 
amendments, combinations, divestitures, curtailments, and settle­
ments?
[SFAS 132(R) par. 8m]
n. The amounts in accumulated other comprehensive income ex­
pected to be recognized as components of net periodic benefit cost 
over the fiscal year that follows the most recent annual statement 
of financial position presented, showing separately the net gain or 
loss, net prior service cost or credit, and net transition asset or 
obligation?
[SFAS 132(R) par. 8n, as amended by SFAS 158]
o. The amount and timing of any plan assets expected to be returned 
to the employer during the 12-month period, or operating cycle if 
longer, that follows the most recent annual statement of financial 
position presented?
[SFAS 132(R) par. 8o, as amended by SFAS 158]
p. If the enterprise has not yet adopted the measurement date provi­
sions of SFAS 158 which are effective for fiscal years ending after 
December 15, 2008 (with earlier application encouraged), the meas­
urement date(s) used to determine pension and other postretire­
ment benefit measurements for the pension plans and other postre­
tirement benefit plans that make up at least the majority of plan 
assets and benefit obligations?
[SFAS 132(R) par. 8j]
♦ 13. Are amounts related to the employer's results of operations disclosed 
for each period for which a statement of income is presented?
[SFAS 132(R) par. 8]
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♦ 14. Are amounts related to the employer's statement of financial position
disclosed as of the date of each statement of financial position pre­
sented? ------- ------- ------
[SFAS 132(R) par. 8, as amended by SFAS 158]
Disclosures in Interim Financial Reports
♦ 15. If the entity is publicly traded, does it disclose the following informa­
tion in its interim financial statements that include a statement of in­
come:
a. The amount of net periodic benefit cost recognized, for each period 
for which a statement of income is presented, showing separately 
the service cost component, the interest cost component, the ex­
pected return on plan assets for the period, the gain or loss com­
ponent, the prior service cost or credit component, the transition 
asset or obligation component, and the gain or loss recognized due
to a settlement or curtailment? ------- ------- ------
b. The total amount of the employer's contributions paid, and ex­
pected to be paid, during the current fiscal year, if significantly 
different from amounts previously disclosed pursuant to para­
graph 5(g) of SFAS 132? (Estimated contributions may be pre­
sented in the aggregate combining (1) contributions required by 
funding regulations or laws, (2) discretionary contributions, and
(3) noncash contributions.) ------- ------- ------
[SFAS 132(R) par. 9, as amended by SFAS 158]
♦ 16. If the entity is nonpublic, does it disclose in interim periods, for which
a complete set of financial statements is presented, the total amount of 
the employer's contributions paid, and expected to be paid, during the 
current fiscal year, if significantly different from amounts previously 
disclosed pursuant to paragraph 8(f) of SFAS 132? (Estimated contri­
butions may be presented in the aggregate combining (a) contributions 
required by funding regulations or laws, (b) discretionary contribu­
tions, and (c) noncash contributions.) ------- ------- ------
[SFAS 132(R) par. 10]
Entities That Do Not Report Other Comprehensive Income
♦ 17. Did the entity comply with the following instructions? For employers
that do not report other comprehensive income in accordance with 
SFAS 130, the references to the net gain or loss, net prior service cost or 
credit, and net transition asset or obligation recognized in other com­
prehensive income in paragraphs 5(i) and 8(h) of SFAS 132 shall in­
stead be to such amounts recognized as changes in unrestricted net 
assets arising from a defined benefit plan but not yet included in net
periodic benefit cost. ------- ------- ------
[SFAS 132(R) par. 10A, as amended by SFAS 158]
♦ 18. Did the entity comply with the following instructions? For those em­
ployers, the references to reclassification adjustments of other compre­
hensive income in paragraphs 5(i) and 8(h) of SFAS 132 shall instead 
be to reclassifications to net periodic benefit cost of amounts previously 
recognized as changes in unrestricted net assets arising from a defined 
benefit plan but not included in net periodic benefit cost when they
arose. ------- ------- ------
[SFAS 132(R) par. 10B, as amended by SFAS 158]
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♦ 19. Did the entity comply with the following instructions? For those em­
ployers, the references to the net gain or loss, net prior service cost or 
credit, and net transition asset or obligation recognized in accumulated 
other comprehensive income in paragraphs 5(ii), 5(s), 8(hh), and 8(n) 
of SFAS 132 shall instead be to such amounts that have been recog­
nized as changes in unrestricted net assets arising from a defined ben­
efit plan but not yet reclassified as components of net periodic benefit
cost. ____
[SFAS 132(R) par. 10C, as amended by SFAS 158]
♦ 20. Did the entity comply with the following instructions? For those em­
ployers, the references to results of operations (including items of other 
comprehensive income) in paragraphs 5 and 8 of SFAS 132 shall in­
stead be to changes in unrestricted net assets and the references to a 
statement of income in those paragraphs shall instead be to a statement
of activities. ____
[SFAS 132(R) par. 10D, as amended by SFAS 158]
Defined Contribution Plans
♦ 21. Does the employer disclose the amount of cost recognized for defined
contribution pension plans and for other defined contribution postre­
tirement benefit plans for all periods presented separately from the
amount of cost recognized for defined benefit plans? ____
[SFAS 132(R) par. 11]
♦ 22. Do the disclosures include a description of the nature and effect of any
significant changes during the period affecting comparability, such as 
a change in the rate of employer contributions, a business combination,
or a divestiture? ____
[SFAS 132(R) par. 11]
Multiemployer Plans
♦ 23. Has the employer disclosed the amount of contributions to multiem­
ployer plans for each annual period for which a statement of income is
presented? ____
[SFAS 132(R) par. 12]
♦ 24. If the employer chooses to disclose total contributions to multiem­
ployer plans without disaggregating the amounts attributable to pen­
sion plans and other postretirement benefit plans, do the disclosures 
include a description of the nature and effect of any changes affecting 
comparability, such as a change in the rate of employer contributions,
a business combination, or a divestiture? ____
[SFAS 132(R) par. 12]
♦ 25. In some situations, withdrawal from a multiemployer plan may result
in an employer having an obligation to the plan for a portion of the 
unfunded benefit obligation of the pension plans and other postretire­
ment benefit plans. If withdrawal under circumstances that would give 
rise to an obligation is either probable or reasonably possible, have the
provisions of SFAS 5 been applied (SFAS 87, paragraph 70)? ____
[SFAS 132(R) par. 13]
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♦ 26. If it is either probable or reasonably possible that (a) an employer
would withdraw from the plan under circumstances that would give 
rise to an obligation or (b) an employer's contribution to the fund 
would be increased during the remainder of the contract period to 
make up a shortfall in the funds necessary to maintain the negotiated 
level of benefit coverage (a maintenance of benefits clause), has the em­
ployer applied the provisions of SFAS 5 (SFAS 106 paragraph 83)?8 ------- ------
8 See footnote 2.
[SFAS 132(R) par. 13]
Other Matters
♦ 27. If the matters addressed in EITF 03-2, "Accounting for the Transfer to
the Japanese Government of the Substitutional Portion of Employee 
Pension Fund Liabilities," apply, are the disclosure requirements of
that EITF Issue complied with? ------- ------
[EITF 03-2]
♦ 28. If the matters addressed in EITF 06-4, "Accounting for Deferred Com­
pensation and Postretirement Benefit Aspects of Endorsement Split- 
Dollar Life Insurance Arrangements," relating to benefits that extend 
into postretirement periods apply, are the disclosure requirements of
that EITF Issue complied with? ------- ------
[EITF 06-4]
♦ 29. If the matters addressed in EITF 06-10, "Accounting for Collateral As­
signment Split-Dollar Life Insurance," relating to benefits that extend 
into postretirement periods apply, are the disclosure requirements of
that EITF Issue complied with? ------- -----
[EITF 06-10]
♦ 30. Until an employer is able to determine whether benefits provided by
its plan are actuarially equivalent, does it disclose the following in 
financial statements for interim or annual periods:
a. The existence of the act? ------- -----
b. The fact that measures of the accumulated postretirement benefit 
obligation (APBO) or net periodic postretirement benefit cost do 
not reflect any amount associated with the subsidy because the 
employer is unable to conclude whether the benefits provided by 
the plan are actuarially equivalent to Medicare Part D under the
act? ------- -----
[FSP FAS 106-2]
♦ 31. In interim and annual financial statements for the first period in which
an employer includes the effects of the subsidy in measuring the APBO 
and the first period in which an employer includes the effects of the 
subsidy in measuring net periodic postretirement benefit cost, does it 
disclose the following:
a. The reduction in the APBO for the subsidy related to benefits at­
tributed to past service? ------- -----
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b. The effect of the subsidy on the measurement of net periodic pos­
tretirement benefit cost for the current period? That effect includes
(1) any amortization of the actuarial experience gain in (a) as a 
component of the net amortization called for by paragraph 59 of 
SFAS 106, (2) the reduction in current period service cost due to 
the subsidy, and (3) the resulting reduction in interest cost on the 
APBO as a result of the subsidy.
c. Any other disclosures required by paragraph 5(r) of SFAS 132(R), 
Employers' Disclosures about Pensions and Other Postretirement 
Benefits? Paragraph 5(r) of SFAS 132(R) requires disclosure of "an 
explanation of any significant change in the benefit obligation or 
plan assets not otherwise apparent in the other disclosures re­
quired by this statement."
[FSP FAS 106-2]
♦ 32. For purposes of the disclosures required by paragraphs 5(a) and 5(f) of
SFAS 132(R), does an employer disclose gross benefit payments (paid 
and expected, respectively), including prescription drug benefits, and 
separately the gross amount of the subsidy receipts (received and ex­
pected, respectively)?
[FSP FAS 106-2]
J. Related Organizations and Economic Dependency
1. Related parties and economic dependency:
★ ♦a. If the reporting entity controls a separate not-for-profit entity
through a form other than majority ownership or voting interest, 
has an economic interest in that other entity, and consolidated fi­
nancial statements are not presented, do the notes to the financial 
statements include the following disclosures:
(1) Identification of the other entity and the nature of its relation­
ship with the reporting entity that results in control?
(2) Summarized financial data of the other entity, including total 
assets, liabilities, net assets, revenue, and expenses; and re­
sources that are held for the benefit of the reporting entity or 
that are under its control?
(3) Disclosures set forth in SFAS 57, Related Party Disclosures (see 
question 1g)?
[AAG 11.12]
★ ♦b. In cases where the entity has control (other than through owner­
ship or sole corporate membership) or an economic interest in an­
other entity, but not both, has the entity made the required disclo­
sures set forth in SFAS 57 (see question 1g)?
[AAG 11.13]
★ ♦ c. If consolidated financial statements are presented and they include
a controlled not-for-profit organization, are the following dis­
closed:
(1) Restrictions made by entities outside of the reporting entity on 
distributions from the controlled not-for-profit organization to 
the reporting entity? and
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(2) Any resulting unavailability of the net assets of the controlled
not-for-profit organization for use by the reporting entity? _____ _____ ____
[AAG 11.15]
★ ♦ d. Are significant relationships and transactions not in the ordinary
course of business with directors, management, medical staff, and
so on disclosed in the financial statements? ------- ------- ------
[AAG 11.35]
★ ♦ e. If representations about transactions with related parties are made,
do they avoid the implication that the related party transactions 
were consummated at arm's length, or if such implications are
made, can they be substantiated? ------- ------- ------
[SFAS 57 par. 3]
If (a) the reporting entity and one or more other enterprises are 
under common ownership or management control and (b) the ex­
istence of the control could result in operating results or financial 
position of the reporting entity being significantly different from 
that if the enterprise were autonomous, is the nature of the con­
trolled relationships disclosed (even if there are no transactions
between the enterprises)? ------- ------- ------
[SFAS 57 par. 2 and 4]
★ ♦g. For related-party transactions, do disclosures include:
(1) The nature of the relationships involved? ------- ------- ------
(2) For each period for which an income statement/statement of 
activities is presented:
(i) A description of the transaction, including transactions to
which no amounts or nominal amounts were ascribed? _____ _____ ____
(ii) Other information deemed necessary to an understanding
of the effects of the transaction on the financial state­
ments? ------- ------- ------
(iii) The dollar amount of transactions? ------- ------- ------
(iv) The effect of any changes in the method of establishing
the terms from that used in the preceding period? _____ _____ ____
(3) Amounts due from or to related parties as of the date of each 
balance sheet/statement of financial position presented and, if
not otherwise apparent, the terms and manner of settlement? _____ _____ ____
[SFAS 57 par. 2]
(4) The information required by paragraph 49 of SFAS 109? ------- ------- ------
[SFAS 109 par. 288(s)]
K. Risks and Uncertainties
★ ♦ 1. Are the following disclosed:
a. A description of the principal services performed by the health
care provider and the revenue sources for the entity's services? _____ _____ ____
b. The fact that financial statements prepared in accordance with
GAAP require the use of management's estimates? ------- ------- ------
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c. If the reporting entity operates in more than one business, is the 
relative importance of its operations in each business and the basis 
for the determination (for example, assets, revenues, or earnings)
disclosed? _____ _____ ____
[SOP 94-6 par. .10-.11 (ACC 10,640.10)]
★ ♦ 2. If known information available before the financial statements are is­
sued indicates (1) it is at least reasonably possible that the estimate(s) 
used in preparing the financial statements will change in the near term, 
and (2) the effect(s) of the change will be material, are the following 
disclosed:
a. The nature of uncertainties inherent in estimates used to determine 
the carrying amounts of assets and liabilities, or used to disclose
gain or loss contingencies? _____ _____ ____
b. That a material change in the estimate could occur in the near
term? _____ _____ ____
[SOP 94-6, par. .12-.14 (ACC 10,640.12)]
★ ♦3. If the estimate in question 2 above involves a loss contingency covered
by SFAS 5 do disclosures include an estimate of the possible loss or
range of loss, or state that such an estimate cannot be made?9 _____ _____ ____
9 If risk reduction techniques are used to mitigate losses or the uncertainty that may result from certain events, these disclosures are 
encouraged but not required. [SOP 94-6 par. .15 (ACC 10,640.15)]
[SOP 94-6 par. .14 (ACC 10,640.14)]
★ ♦ 4. If, based on information known to management before the financial
statements are issued, (1) the concentration existed at the date of the 
financial statements, (2) the concentration made the enterprise vulner­
able to the risk of near-term severe impact, and (3) it is at least reason­
ably possible that the events that could cause the severe impact will 
occur in the near term, are the following disclosed:
a. Concentrations in the volume of the business transacted with a
particular customer (patient), supplier, lender, grantor, or contrib­
utor? _____ _____ ____
b. Concentrations in revenue from particular services provided or
fund-raising events? _____ _____ ____
c. Concentrations in the available sources of supply of labor, services,
or of applicable licenses necessary to provide services? _____ _____ ____
d. Concentrations in the market or geographical area in which an 
entity conducts its operations, including the carrying amounts of
net assets and their locations? _____ _____ ____
e. Concentrations of labor subject to collective bargaining agree­
ments, including the percentage of the labor force covered by a 
collective bargaining agreement and the percentage of the labor 
force covered by a collective bargaining agreement that will expire
within one year? _____ _____ ____
f. Information adequate to inform users of the general nature of the
risk associated with the concentration? _____ _____ ____
[SOP 94-6, par. .21-.24 (ACC 10,640.21)]
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Note: The guidance in FSP SOP 94-6-1, Terms of Load Products That May Give 
Rise to a Concentration of Credit Risk, addresses the adequacy of disclosures 
for all lending products (including both secured and unsecured loans) and 
the effect of changes in market or economic conditions on the adequacy of 
those disclosures. An entity shall provide the disclosures required by SFAS 
107 for products that are determined to represent a concentration of credit 
risk in accordance with the guidance in question 1 of the FSP for all periods 
presented.
[FSP SOP 94-6-1 par. 17]
The type and extent of information provided shall be determined by 
whether the entity is the originator, holder, investor, guarantor, or servicer 
and also by the significance of the loan product(s) to the reporting entity. 
[FSP SOP 94-6-1 par. 9 (question 2)]
♦ L. Segment Information
Note: Public business enterprises are required to provide the disclosures 
described in SFAS 131 and nonpublic business enterprises are encouraged 
to do so.
1. Are the following items disclosed for each reportable segment for each 
period for which an income statement is presented:
a. General information as described in SFAS 131 paragraph 26?
h. Information about profit or loss (including certain revenues and 
expenses included in profit or loss), segment assets, and the basis 
of measurement, as described in SFAS 131 paragraphs 27-31?
c. Reconciliations of the totals of segment revenues, reported profit 
or loss, assets, and other significant items to corresponding enter­
prise amounts as described in SFAS 131 paragraph 32?
d. Interim period information as described in SFAS 131 paragraph 
33?
[SFAS 131 par. 25-33, as amended by SFAS 135 par. 4]
Note: Reconciliations of balance sheet amounts for reportable segments to 
consolidated balance sheet amounts are required only for each year for 
which a balance sheet is presented.
[SFAS 131 par. 25, as amended by SFAS 135 par. 4(x)]
2. If an enterprise changes the structure of its internal organization in a 
manner that changes the composition of its reportable segments, has it 
disclosed whether it has restated the corresponding items of segment 
information for earlier periods?
[SFAS 131 par. 34]
3. If segment information is not restated to reflect a change in the com­
position of reportable segments, is current year segment information 
under both the old basis and the new basis of segmentation disclosed, 
unless it is impracticable to do so?
[SFAS 131 par. 35]
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4. For all enterprises subject to SFAS 131, including those that have a 
single reportable segment, are the following enterprise-wide items dis­
closed:
a. Revenues from external customers for each product and service or 
each group of similar products and services unless it is impracti­
cable to do so?
b. Geographic information as described in paragraph 38 unless it is 
impracticable to do so?
c. Information about the extent of the enterprise's reliance on its ma­
jor customers as described in paragraph 39?
[SFAS 131 par. 36-39]
5. If the information described in questions 4a-b has not been disclosed 
because it is impracticable, is that fact disclosed?
[SFAS 131 par. 37-38]
M. Subsequent Events
★1. Are subsequent events that provide evidence about conditions that did 
not exist at the date of the balance sheet, but arose subsequent to that 
date, adequately disclosed to keep the financial statements from being 
misleading?
[SFAS 5 par. 11; AU 560.05-.07 and .09; AU 561.01-.10]
♦ 2. Are subsequent events that provide evidence about conditions that did 
not exist at the date of the balance sheet, but arose subsequent to that 
date, adequately disclosed to keep the financial statements from being 
misleading?
[SFAS 5 par. 11; AU 560.05-.07 and .09; AU 561.01-.10]
Note: Consider the appropriateness of dual dating the auditor's report if a 
subsequent event is disclosed in the financial statements.
[AU 530.05]
N. Stock-Based Compensation / Share-Based Payment
♦ 1. If the entity has one or more share-based payment arrangements, does 
it disclose information that enables users of the financial statements to 
understand:
a. The nature and terms of such arrangements that existed during the 
period and the potential effects of those arrangements on share­
holders?
b. The effect of compensation cost arising from share-based payment 
arrangements on the income statement?
c. The method of estimating the fair value of the goods or services 
received, or the fair value of the equity instruments granted (or 
offered to grant), during the period?
d. The cash flow effects resulting from share-based payment arrange­
ments?
[SFAS 123(R) par. 64]
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Note: Paragraphs A240 and A241 of SFAS 123(R) indicate the minimum 
information needed to achieve those objectives and illustrate how the dis­
closure requirements might be satisfied. In some circumstances, an entity 
may need to disclose information beyond that listed in paragraph A240 to 
achieve the disclosure objectives.
On October 20, 2006, FASB issued FSP FAS 123 (R)-6, Technical Corrections 
of FASB Statement No. 123(R), which addresses certain technical corrections 
of SFAS 123 (revised 2004), Share-Based Payment. Specifically, it amends 
paragraph A240(d)(l) to exempt nonpublic entities from disclosing the ag­
gregate intrinsic value of outstanding fully vested share options (or share 
units), among other matters.
The provisions in FSP FAS 123(R)-6 are effective in the first reporting period 
beginning after October 20, 2006. If in applying SFAS 123(R) an entity did 
so in a manner consistent with the provisions of this FSP, then that entity 
should continue to apply the provisions in this FSP to prior periods. How­
ever, if an entity did not apply SFAS 123(R) in a manner consistent with the 
provisions of this FSP, then that entity should retrospectively apply the 
provisions in this FSP to prior periods when those periods' financial state­
ments are included for comparative purposes with current-period financial 
statements.
[SFAS 123(R) par. 64 and A240]
♦ 2. Does the entity disclose:
a. A description of the share-based payment arrangement(s), includ­
ing the general terms of awards under the arrangement(s)?
h. The method used for measuring compensation cost from share- 
based payment arrangements with employees?
c. For the most recent year for which an income statement is pro­
vided, the number and weighted-average exercise prices (or con­
version ratios) for each of the following groups of share options (or 
share units):
(1) Those outstanding at the beginning of the year?
(2) Those outstanding at the end of the year?
(3) Those exercisable or convertible at the end of the year?
(4) Those granted during the year?
(5) Those exercised or converted during the year?
(6) Those forfeited during the year?
(7) Those expired during the year?
d. For the most recent year for which an income statement is pro­
vided, the number and weighted-average grant-date fair value 
(calculated value for a nonpublic entity that uses that method; in­
trinsic value if a reasonable estimate of fair value is not possible) 
of equity instruments not specified in question 2c for each of the 
following groups of equity instruments:
(1) Those nonvested at the beginning of the year?
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(2) Those nonvested at the end of the year?
(3) Those granted during the year?
(4) Those vested during the year?
(5) Those forfeited during the year?
e. For each year an income statement is provided:
(1) Weighted-average grant-date fair value (calculated value for a 
nonpublic entity that uses that method; intrinsic value if rea­
sonable estimate of fair value is not possible) of equity options 
or other equity instruments granted during the year?
(2) Total intrinsic value of options exercised (or share units con­
verted), share-based liabilities paid, and total fair value of 
shares vested during the year?
f. For fully vested share options (or share units) and share options 
expected to vest at the date of the latest statement of financial 
position:
(1) Number, weighted-average exercise price (or conversion ra­
tio), aggregate intrinsic value, and weighted-average remain­
ing contractual term of options (or share units) outstanding?
(2) Number, weighted-average exercise price (or conversion ra­
tio), aggregate intrinsic value (except for nonpublic entities) 
and weighted-average remaining contractual term of options 
(or share units) currently exercisable (or convertible)?
g. For each year an income statement is presented, a description of 
the method used during the year to estimate fair value (or calcu­
lated value) of awards under share-based payment arrangements? 
(Note: Not required if intrinsic value is used pursuant to para­
graphs 24-25 of SFAS 123(R).)
h. For each year an income statement is presented, a description of 
significant assumptions used during the year to estimate fair value 
(or calculated value) of share-based compensation awards, includ­
ing, if applicable: (Note: Not required if intrinsic value is used 
pursuant to paragraphs 24-25 of SFAS 123(R).)
(1) Expected term of share options and similar instruments, in­
cluding discussion of the method used to incorporate the con­
tractual term of the instruments and employees' expected ex­
ercise and postvesting employment termination behavior into 
the fair value (or calculated value) of the instrument?
(2) Expected volatility of the entity's shares and the method used 
to estimate it?
(3) The range of expected volatilities used and weighted-average 
expected volatility if a method that employs different volatili­
ties during the contractual term is used?
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(4) For a nonpublic entity that uses the calculated value method, 
the reasons why it is not practicable to estimate expected vol­
atility of its share price, the appropriate industry sector index 
selected, reasons for selecting the particular index, and how
historical volatility was calculated using that index? _____ _____ ____
(5) Expected dividends? _____ _____ ____
(6) If a method that employs different dividend rates during the 
contractual term is used, the range of expected dividends used
and weighted-average expected dividends? _____ _____ ____
(7) Risk free rates? _____ _____ ____
(8) If a method that employs different risk-free rates is used, the
range of risk-free rates used? _____ _____ ____
(9) Discount for postvesting restrictions and method for estimat­
ing it? _____ _____ ____
Note: If an entity grants equity or liability instruments under multiple 
share-based payment arrangements with employees, the information in 
questions 2a-h is presented separately for different types of awards to the 
extent the differences in the characteristics of the awards make separate 
disclosure important to understanding the use of share-based compensa­
tion.
[SFAS 123(R) par. 65 and A240]
i. For each year an income statement is presented:
(1) Total compensation cost for share-based payment arrange­
ments (a) recognized in income as well as total recognized tax 
benefit related thereto and (b) total compensation cost capital­
ized as part of asset cost?
(2) Description of significant modifications?
j. As of the latest balance sheet date presented, total compensation 
cost related to nonvested awards not yet recognized and the 
weighted-average period over which is it expected to be recog­
nized?
k. If not separately disclosed elsewhere, amount of cash received 
from exercise of share options and similar instruments granted 
under share-based payment arrangements and the tax benefit re­
alized from stock options exercised during the annual period?
l. If not separately disclosed elsewhere, amount of cash used to settle 
equity instruments granted under share-based payment arrange­
ments?
m. Description of policy, if any, for issuing shares (including the 
source) upon share option exercise (or share unit conversion)?
n. If the entity expects to repurchase shares in the following annual 
period, an estimate of the amount (or range if more appropriate) 
of shares to be repurchased during that period?
[SFAS 123(R) par. A240]
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♦ 3. If the entity acquires goods or services other than employee services in 
share-based payment transactions, does it provide disclosures similar 
to those required by paragraph 64 of SFAS 123(R) (question 10 of the 
preceding) to the extent that those disclosures are important to an un­
derstanding of the effects of those transactions on the financial state­
ments?
[SFAS 123(R) par. 65]
Note: Entities may disclose supplemental information believed useful to 
investors and creditors, in addition to the information required by SFAS 
123(R), provided the supplemental information is reasonable and does not 
lessen the prominence and credibility of required information.
[SFAS 123(R), par. A242]
O. Accounting for Servicing of Financial Assets 
Collateral
★ ♦1. If it is not practicable to estimate the fair value of certain assets ob­
tained or liabilities incurred in transfers of financial assets during the 
period, are those items and the reasons why it is not practicable to 
estimate fair value described in the notes to the financial statements? 
[SFAS 140 par. 17d]
★ ♦ 2. Is the policy for requiring collateral or other security disclosed if the
reporting entity has entered into securities lending transactions?
[SFAS 140 par. 17a(1)]
★ ♦3. If the entity has pledged any of its assets as collateral that are not
reclassified and separately reported in the statement of financial posi­
tion pursuant to paragraph 15a of SFAS 140, is the carrying amount 
and classification of those assets as of the date of the latest statement of 
financial position presented?
[SFAS 140 par. 17a(2)]
★ ♦ 4. If the entity has accepted collateral that it is permitted by contract or
custom to sell or repledge, is the fair value, as of the date of each 
statement of financial position presented, of that collateral and of the 
portion of that collateral that it has sold or repledged disclosed?
[SFAS 140 par. 17a(3)]
★ ♦ 5. Is information about the sources and uses of that collateral, as of the
date of each statement of financial position presented, disclosed? 
[SFAS 140 par. 17a(3)]
★ ♦ 6. If debt was considered to be extinguished by in-substance defeasance
under the provisions of FASB Statement No. 76, Extinguishment of Debt, 
prior to the effective date of Statement 125, do the disclosures include 
a general description of the transaction and the amount of debt that is 
considered extinguished at the end of the period so long as that debt 
remains outstanding?
[SFAS 140 par. 17b]
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★ ♦7. If assets are set aside after the effective date of SFAS 125 solely for
satisfying scheduled payments of a specific obligation, do the disclo­
sures include a description of the nature of restrictions placed on those
assets? _____ ____
[SFAS 140 par. 17c]
Servicing Assets and Servicing Liabilities
★ ♦ 8. For all servicing assets and servicing liabilities are the following disclo­
sures made:
a. Management's basis for determining its classes of servicing assets
and servicing liabilities per SFAS 140 paragraph 13A, as amended? _____ ____
b. A description of the risks inherent in servicing assets and servicing
liabilities and, if applicable, the instruments used to mitigate the 
income statement effect of changes in fair value of the servicing 
assets and servicing liabilities? (Disclosure of quantitative infor­
mation about the instruments used to manage the risks inherent in 
servicing assets and servicing liabilities, including the fair value of 
those instruments at the beginning and end of the period, is en­
couraged but not required.) _____ ____
c. The amount of contractually specified servicing fees (as defined in
the glossary of SFAS 156), late fees, and ancillary fees earned for 
each period for which results of operations are presented, includ­
ing a description of where each amount is reported in the state­
ment of income? _____ ____
[SFAS 140 par. 17e, as amended by SFAS 156]
★ ♦ 9. For servicing assets and servicing liabilities measured at fair value, are
the following disclosures made:
a. For each class of servicing assets and servicing liabilities, the activ­
ity in the balance of servicing assets and the activity in the balance 
of servicing liabilities (including a description of where changes in 
fair value are reported in the statement of income for each period 
for which results of operations are presented), including, but not 
limited to, the following:
(1) The beginning and ending balances? _____ ____
(2) Additions (through purchases of servicing assets, assumptions 
of servicing obligations, and servicing obligations that result
from transfers of financial assets)? _____ ____
(3) Disposals? _____ ____
(4) Changes in the fair value during the period resulting from
changes in valuation inputs or assumptions used in the valua­
tion model? _____ ____
(5) Changes in the fair value during the period resulting from
other changes in fair value and a description of those changes? _____ ____
(6) Other changes that affect the balance and a description of those
changes? _____ ____
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b. A description of the valuation techniques or other methods used 
to estimate the fair value of servicing assets and servicing liabili­
ties. If a valuation model is used, the description shall include the 
methodology and model validation procedures, as well as quanti­
tative and qualitative information about the assumptions used in 
the valuation model (for example, discount rates and prepayment 
speeds)? (An entity that provides quantitative information about 
the instruments used to manage the risks inherent in the servicing 
assets and servicing liabilities, as encouraged by paragraph 
17(e)(2), is also encouraged, but not required, to disclose a descrip­
tion of the valuation techniques, as well as quantitative and quali­
tative information about the assumptions used to estimate the fair 
value of those instruments.)
[SFAS 140 par. 17f, as amended by SFAS 156]
★ ♦ 10. For servicing assets and servicing liabilities subsequently amortized in 
proportion to and over the period of estimated net servicing income or 
loss and assessed for impairment or increased obligation:
a. For each class of servicing assets and servicing liabilities, the activ­
ity in the balance of servicing assets and the activity in the balance 
of servicing liabilities (including a description of where changes in 
the carrying amount are reported in the statement of income for 
each period for which results of operations are presented), includ­
ing, but not limited to, the following:
(1) The beginning and ending balances?
(2) Additions (through purchases of servicing assets, assumption 
of servicing obligations, and servicing obligations that result 
from transfers of financial assets)?
(3) Disposals?
(4) Amortization?
(5) Application of valuation allowance to adjust carrying value of 
servicing assets?
(6) Other-than-temporary impairments?
(7) Other changes that affect the balance and a description of those 
changes?
b. For each class of servicing assets and servicing liabilities, the fair 
value of recognized servicing assets and servicing liabilities at the 
beginning and end of the period if it is practicable to estimate the 
value?
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c. A description of the valuation techniques or other methods used 
to estimate fair value of the servicing assets and servicing liabili­
ties. If a valuation model is used, the description shall include the 
methodology and model validation procedures, as well as quanti­
tative and qualitative information about the assumptions used in 
the valuation model (for example, discount rates and prepayment 
speeds)? (An entity that provides quantitative information about 
the instrument used to manage the risks inherent in the servicing 
assets and servicing liabilities, as encouraged by paragraph 
17(e)(2), is also encouraged, but not required, to disclose a descrip­
tion of the valuation techniques as well as quantitative and quali­
tative information about the assumptions used to estimate the fair
value of those instruments.) _____ _____ ____
d. The risk characteristics of the underlying financial assets used to 
stratify recognized servicing assets for purposes of measuring im­
pairment in accordance with paragraph 63 of SFAS 140, as
amended? _____ _____ ____
e. The activity by class in any valuation allowance for impairment of 
recognized servicing assets—including beginning and ending bal­
ances, aggregate additions charged and recoveries credited to op­
erations, and aggregate write-downs charged against the allow­
ance—for each period for which results of operations are
presented? _____ _____ ____
[SFAS 140 par. 17g, as amended by SFAS 156]
Securitized Financial Assets Accounted for as a Sale
★ ♦11. If the entity has securitized financial assets during any period pre­
sented and accounts for that transfer as a sale, are the following items 
disclosed for each major asset type (for example, mortgage loans, credit 
card receivables, and automobile loans):
a. Its accounting policies for initially measuring the interests that con­
tinue to be held by the transferor, if any, and servicing assets or 
servicing liabilities, if any, including the methodology (whether 
quoted market price, prices based on sales of similar assets and 
liabilities, or prices based on valuation techniques) used in deter­
mining their fair value (per paragraphs 68-70)? _____ _____ ____
b. The characteristics of securitizations (a description of the trans­
feror's continuing involvement with the transferred assets, includ­
ing, but not limited to, servicing, recourse, and restrictions on in­
terests that continue to be held by the transferor) and the gain or
loss from sale of financial assets in securitizations? _____ _____ ____
c. The key assumptions*  used in measuring the fair value of interest
that continue to be held by the transferor and servicing assets or 
servicing liabilities, if any, at the time of securitization (including, 
at a minimum, quantitative information about discount rates, ex­
pected prepayments including the expected weighted-average life 
of prepayable financial assets, and anticipated credit losses, if ap­
plicable)? _____ _____ ____
* If an entity has made multiple securitizations of the same major asset type during a period, it may disclose the range of assumptions. 
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d. Cash flows between the securitization SPE and the transferor, un­
less reported separately elsewhere in the financial statements or 
notes (including proceeds from new securitizations, proceeds from 
collections reinvested in revolving-period securitizations, pur­
chases of delinquent or foreclosed loans, servicing fees, and cash 
flows received on interests that continue to be held by the trans­
feror)? _____ _____ ____
[SFAS 140 par. 17h, as amended by SFAS 156]
Interests in Financial Assets That Continue to be Held by the Transferor
★ ♦ 12. If the entity has interest that continue to be held by the transferor in 
financial assets that it has securitized or servicing assets or servicing 
liabilities relating to assets that it has securitized, at the date of the 
latest statement of financial position presented, are the following items 
disclosed for each major asset type (for example, mortgage loans, credit 
card receivables, and automobile loans):
a. Its accounting policies for subsequently measuring those interests, 
including the methodology (whether quoted market price, prices 
based on sales of similar assets and liabilities, or prices based on
valuation techniques) used in determining their fair value? _____ _____ ____
b. The key assumptions used in subsequently measuring the fair 
value of those interests (including, at a minimum, quantitative in­
formation about discount rates, expected prepayments including 
the expected weighted-average life of prepayable financial assets, 
and anticipated credit losses, including expected static pool losses,
if applicable)? _____ _____ ____
c. A sensitivity analysis or stress test showing the hypothetical effect 
on the fair value of those interests (including any servicing assets 
or servicing liabilities) of two or more unfavorable variations from 
the expected levels for each key assumption that is reported under
b. of the preceding independently from any change in another key 
assumption, and a description of the objectives, methodology, and
limitations of the sensitivity analysis or stress test? _____ _____ ____
d. For the securitized assets and any other financial assets that it man­
ages together with them:†
(1) The total principal amount outstanding, the portion that has 
been derecognized, and the portion that continues to be rec­
ognized in each category reported in the statement of financial
position, at the end of the period? _____ _____ ____
(2) Delinquencies at the end of the period? _____ _____ ____
(3) Credit losses, net of recoveries, during the period? _____ _____ ____
Disclosure of average balances during the period is encour­
aged, but not required.
[SFAS 140 par. 17h, as amended by SFAS 156]
† Excluding securitized assets that an entity continues to service but with which it has no other continuing involvement.
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Note: Disclosure of average balances during the period is encouraged, but 
not required.
P. Long-Lived Assets and Disposal Groups to Be Disposed Of 
Reporting Discontinued Operations
★ ♦ 1. Are the results of operations of a component of an entity (as that phrase
is defined in SFAS 144) that either has been disposed of or is classified 
as held for sale reported in discontinued operations in accordance with 
paragraph 43 of SFAS 144 (questions 6-9 in this section) if both of the 
following conditions are met:
a. The operations and cash flows of the component have been (or will 
be) eliminated from the ongoing operations of the entity as a result
of the disposal transaction? _____
b. The entity will not have any significant continuing involvement in
the operations of the component after the disposal transaction? _____
[SFAS 144 par. 42]
★ ♦2. If the occurrence of a significant event or circumstance at any time
during the assessment period results in an expectation that the criteria 
in paragraph 42 of SFAS 144 will be met by the end of the assessment 
period, are the component's operations presented as discontinued op­
erations? _____
[EITF 03-13 par. 13]
★ ♦ 3. Is the following information disclosed in the notes to the financial state­
ments for each discontinued operation that generates continuing cash 
flows:
a. The nature of the activities that give rise to continuing cash flows? _____
b. The period of time continuing cash flows are expected to be gen­
erated? _____
c. The principal factors used to conclude that the expected continuing
cash flows are not direct cash flows of the disposed component? _____
[EITF 03-13 par. 17]
★ ♦ 4. For each discontinued operation in which the ongoing entity will en­
gage in a "continuation of activities" with the disposed component 
after its disposal and for which the amounts presented in continuing 
operations after the disposal transaction include a continuation of rev­
enues and expenses that were intercompany transactions (eliminated 
in consolidated financial statements) before the disposal transaction, 
are the intercompany amounts before the disposal transaction dis­
closed for all periods presented? _____
[EITF 03-13 par. 17]
★ ♦ 5. Are the types of continuing involvement, if any, that the entity will
have after the disposal transaction disclosed and is that information 
disclosed in the period in which operations are initially classified as
discontinued? _____
[EITF 03-13 par. 17]
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Note: EITF 03-13, "Applying the Conditions in Paragraph 42 of FASB State­
ment No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, 
in Determining Whether to Report Discontinued Operations," should be 
applied to a component of an enterprise that is either disposed of or classi­
fied as held for sale in fiscal periods beginning after December 15, 2004. 
Operating results related to a component that is disposed of or classified as 
held for sale within an enterprise's fiscal year that includes the date EITF 
03-13 is ratified (November 30, 2004) may be classified to reflect the consen­
sus.
[EITF 03-13 par. 18-19]
★ ♦ 6. In a period in which a component of an entity either has been disposed
of or is classified as held for sale, does the income statement of a busi­
ness enterprise or statement of activities of a not-for-profit organiza­
tion for current and prior periods report the results of operations of the 
component, including any gain or loss recognized in accordance with 
paragraph 37 of SFAS 144, in discontinued operations?
[SFAS 144 par. 43]
★ ♦ 7. Are the results of operations of a component classified as held for sale
reported in discontinued operations in the period(s) in which they oc­
cur?
[SFAS 144 par. 43]
★ ♦ 8. Are the results of discontinued operations, less applicable income taxes
(benefit), reported as a separate component of income before extraor­
dinary items and the cumulative effect of accounting changes (if appli­
cable)?
[SFAS 144 par. 43]
★ ♦ 9. Is the gain or loss recognized on the disposal disclosed either on the
face of the income statement/statement of activities or in the notes to 
the financial statements?
[SFAS 144 par. 43]
★ ♦ 10. Are adjustments to amounts previously reported in discontinued op­
erations that are directly related to the disposal of a component of an 
entity in a prior period classified separately in the current period in 
discontinued operations?
[SFAS 144 par. 44]
★ ♦ 11. Are the nature and amount of such adjustments (as discussed in ques­
tion 6 of the preceding) disclosed?
[SFAS 144 par. 44]
Reporting Disposal Gains or Losses in Continuing Operations
★ ♦ 12. Is a gain or loss, that is recognized on the sale of a long-lived asset
(disposal group) that is not a component of an entity, included in in­
come from continuing operations before income taxes in the income 
statement of a business enterprise and in income from continuing op­
erations in the statement of activities of a not-for-profit organization? 
[SFAS 144, par. 45]
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  ♦ 13. If a subtotal such as "income from operations" is presented, does it 
include the amounts of those gains or losses considered in question 8
of the preceding? _____ ____
[SFAS 144 par. 45]
Reporting a Long-Lived Asset or Disposal Group Sold or Classified 
as Held for Sale
★ ♦ 14. If the criteria of paragraph 30 of SFAS 144 are met (and thus a long-
lived asset is classified as held for sale) after the balance sheet/state­
ment of financial position date but before issuance of the financial 
statements, does the long-lived asset continue to be classified as held 
and used in those financial statements when issued and is the infor­
mation required by paragraph 47(a) of SFAS 144 (question 19 in this
section) disclosed in the notes to the financial statements? _____ ____
[SFAS 144 par. 33]
★ ♦ 15. Is a long-lived asset that is classified as held for sale presented sepa­
rately in the statement of financial position? _____ ____
[SFAS 144 par. 46]
★ ♦ 16. Are the assets and liabilities of a disposal group that is classified as
held for sale presented separately in the asset and liability sections,
respectively, of the statement of financial position? _____ ____
[SFAS 144 par. 46]
★ ♦ 17. Are those assets and liabilities considered in question 12 in this section,
not offset and presented as a single amount? _____ ____
[SFAS 144 par. 46]
★ ♦ 18. Are the major classes of assets and liabilities that are classified as held
for sale separately disclosed either on the face of the statement of finan­
cial position or in the notes to financial statements? _____ ____
[SFAS 144 par. 46]
★ ♦ 19. Is the following information disclosed in the notes to the financial state­
ments that cover the period in which a long-lived asset (disposal 
group) either has been sold or is classified as held for sale:
a. A description of the facts and circumstances leading to the ex­
pected disposal, the expected manner and timing of that disposal, 
and, if not separately presented on the face of the statement, the 
carrying amount(s) of the major classes of assets and liabilities in­
cluded as part of a disposal group? _____ ____
b. The gain or loss recognized in accordance with paragraph 37 of 
SFAS 144 and FSP FAS 144-1, Determination of Cost Basis for Fore­
closed Assets under FASB Statement No. 15, and the Measurement of 
Cumulative Losses Previously Recognized Under Paragraph 37 of FASB 
Statement No. 144, and if not separately presented on the face of the 
income statement/statement of activities, the caption in the income
statement or statement of activities that includes that gain or loss? _____ ____
c. If applicable, amounts of revenue and pretax profit or loss reported
in discontinued operations? _____ ____
N/A
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d. If applicable, the segment in which the long-lived asset (disposal
group) is reported under SFAS 131? ------
[SFAS 144 par. 47; FSP FAS 144-1]
★ ♦ 20. If either paragraph 38 or 40 of SFAS 144 applies, is a description of the
facts and circumstances leading to the decision to change the plan to 
sell the long-lived asset (disposal group) and its effect on the results of 
operations for the period and any prior periods presented disclosed in 
the notes to the financial statements that include the period of that
decision? ------
[SFAS 144 par. 48]
★ ♦21. If a long-lived asset is to be disposed of other than by sale, does it
continue to be classified as held and used until it is disposed of? ____
[SFAS 144 par. 27, as amended by SFAS 153]
Q. Asset Retirement Obligations
★ ♦ 1. Is the following information about its asset retirement obligations dis­
closed:
a. A general description of the asset retirement obligations and the
associated long-lived assets? ------
b. The fair value of assets that are legally restricted for purposes of
settling asset retirement obligations? ____
c. A reconciliation of the beginning and ending aggregate carrying 
amount of asset retirement obligations showing separately the 
changes attributable to (1) liabilities incurred in the current period,
(2) liabilities settled in the current period, (3) accretion expense, 
and (4) revisions in estimated cash flows, whenever there is a sig­
nificant change in one or more of those four components during
the reporting period? ------
[SFAS 143 par. 22]
★ ♦ 2. If the fair value of an asset retirement obligation cannot be reasonably
estimated is that fact and the reasons therefore disclosed? ------
[SFAS 143 par. 22]
★ ♦ 3. Is the liability for the asset retirement obligation computed on a pro
forma basis disclosed in the footnotes for the beginning of the earliest 
year presented and at the end of all years presented as if SFAS 143, 
Accounting for Asset Retirement Obligations, and FIN 47, Accounting for 
Conditional Asset Retirement Obligations—an interpretation of FASB State­
ment No. 143, had been applied during all periods affected? ------
[SFAS 143 par. 27; FIN 47 par. 11]
R. Impaired Loans
★ ♦1. Is the following information about loans that meet the definition of
impaired loans in SFAS 114 disclosed as of the date of each balance 
sheet/statement of financial position presented:
a. The total recorded investment in impaired loans? ------
b. The amount of that recorded investment for which there is a re­
lated allowance for credit losses determined in accordance with
SFAS 114 and the amount of that allowance? ------
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c. The amount of that recorded investment for which there is no re­
lated allowance for credit losses determined in accordance with
SFAS 114? _____ _____ ____
[SFAS 118 par. 6i]
★ ♦ 2. Is the policy for recognizing interest income on impaired loans, includ­
ing how cash receipts are handled, disclosed? _____ _____ ____
[SFAS 118 par. 6i]
★ ♦ 3. Are the following disclosures made for each period for which an in­
come statement/statement of activities is presented:
a. The average recorded investment in the impaired loans during the
period? _____ _____ ____
b. The related amount of interest income recognized during the time
within the period that the loans were considered impaired? _____ _____ ____
c. Unless not practicable, the amount of interest income recognized 
using a cash-basis method of accounting during the time within
the period that the loans were impaired? _____ _____ ____
d. Activity in the total allowance for credit losses related to loans, 
including the balance in the allowance for credit losses account at 
the beginning and end of each period, additions charged to opera­
tions, direct write-downs charged against the allowance, and re­
coveries of amounts previously charged off? (Note: The total al­
lowance for credit losses related to loans includes those amounts 
that have been determined in accordance with SFAS 5 and SFAS
114.) _____ _____ ____
[SFAS 118 par. 6i]
S. Impairment of Long-Lived Assets to Be Held and Used
★ ♦1. Is an impairment loss recognized for a long-lived asset (asset group) to
be held and used included in income from continuing operations be­
fore income taxes in the income statement of a business enterprise and 
in income from continuing operations in the statement of activities of a
not-for-profit organization? _____ _____ ____
[SFAS 144 par. 25]
★ ♦ 2. Is the following information disclosed in the notes to the financial state­
ments that include the period in which an impairment loss is recog­
nized:
a. A description of the impaired long-lived asset (asset group) and
the facts and circumstances leading to the impairment? _____ _____ ____
b. If not separately presented on the face of the statement, the amount 
of the impairment loss and the caption in the income statement or
statement of activities that includes that loss? _____ _____ ____
c. The method or methods for determining fair value (whether based
on a quoted market price, prices for similar assets, or another val­
uation technique)? _____ _____ ____
d. If applicable, the segment in which the impaired long-lived asset
(asset group) is reported under SFAS 131? _____ _____ ____
[SFAS 144 par. 26]
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Note: If SFAS 157 has been adopted, refer to section V, "Fair Value Meas­
urements," for additional disclosure requirements.
T. Lessor Leases
★ ♦ 1. For sales-type and direct financing leases, do disclosures include:
a. The components of the net investment in sales-type and direct fi­
nancing leases as of each balance-sheet date:
(1) Future minimum lease payments to be received, with separate 
deductions for (a) amounts representing executory costs, in­
cluding any profit thereon, included in minimum lease pay­
ments and (b) the accumulated allowance for uncollectible 
minimum lease payments receivable?
(2) The unguaranteed residual values accruing to the benefit of 
the lessor?
(3) For direct financing leases only, initial direct costs?
(4) Unearned income?
b. Future minimum lease payments to be received for each of the five 
succeeding fiscal years as of the latest balance sheet/statement of 
financial position presented?
c. Total contingent rentals included in income for each period for 
which an income statement/statement of activities is presented? 
[SFAS 13 par. 23a, as amended by SFAS 91 par. 25]
★ ♦ 2. For operating leases, do disclosures include:
a. Cost and carrying amount (if different) of property on lease or held 
for leasing by major classes of property according to nature or 
function and the amount of accumulated depreciation in total as of 
the date of the latest balance sheet/statement of financial position 
presented?
b. Minimum future rentals on noncancelable leases as of the date of 
the latest balance sheet/statement of financial position presented 
in the aggregate and for each of the five succeeding fiscal years?
c. Total contingent rentals included in income for each period for 
which an income statement/statement of activities is presented? 
[SFAS 13 par. 23b]
★ ♦ 3. Do disclosures include a general description of the lessor's leasing ar­
rangements?
[SFAS 13 par. 23]
★ ♦ 4. For investments in leveraged leases, do disclosures include:
a. In the balance sheet, the amount of deferred taxes presented sepa­
rately from the remainder of the net investment?
b. In the income statement or the notes thereto, separate presentation 
(from each other) of pretax income from the leveraged lease, the 
tax effect of pretax income, and the amount of investment tax 
credit recognized as income during the period?
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c. When leveraged leasing is a significant part of the lessor's business 
activities in terms of revenue, net income, or assets, the compo­
nents of the net investment balance in leveraged leases in the notes
to the financial statements? _____ ____
[SFAS 13 par. 47]
★ ♦ 5. For leasing transactions with related parties, are the nature and extent
of the transaction disclosed? _____ ____
[SFAS 13 par. 29]
★ ♦ 6. For contingent rental income:
a. Has disclosure been made of the lessor's accounting policy for con­
tingent rental income? _____ ____
b. If the lessor accrues contingent rental income prior to the lessee's 
achievement of the specified target (provided achievement of that 
target is considered probable), has disclosure been made of the 
impact on rental income as if the lessor's accounting policy was to
defer contingent rental income until the specified target is met? _____ ____
[EITF 98-9]
★ ♦ 7. Is the effect on the balance sheet and the income statement resulting
from a change in lease classification under item (b) of paragraph 6 of 
EITF 00-11, disclosed for leases that at inception would have been clas­
sified differently had the guidance in EITF 00-11 been in effect at the
inception of the original lease? _____ ____
[EITF 00-11]
U. Lessee Leases
★ ♦ 1. For capital leases do disclosures include:
a. The gross amounts of assets recorded by major classes, as of the
date of each balance sheet/statement of financial position pre­
sented? _____ ____
[SFAS 13 par. 16a.i.]
b. Future minimum lease payments, as of the date of the latest bal­
ance sheet/statement of financial position presented, in total and 
for each of the next five years, with separate deductions for execu­
tory costs, including any profit thereon, included in the minimum 
lease payments, and for the amount of the imputed interest neces­
sary to reduce net minimum lease payments to present value? _____ ____
[SFAS 13 par. 10 and 16a.ii.]
c. Total future minimum sublease rentals to be received in the future 
under noncancelable subleases as of the date of the latest balance
sheet/statement of financial position presented? _____ ____
[SFAS 13 par. 16a.iii.]
d. Total contingent rentals actually incurred for each period pre­
sented? _____ ____
[SFAS 13 par. 16a.iv.]
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e. Assets recorded under capital leases and the related accumulated 
amortization, and obligations under those leases identified sepa­
rately in the balance sheet/statement of financial position or a
note? ------
[SFAS 13 par. 13 and 16]
f. Amount of amortization of capital lease assets or the fact that the
amortization of capital lease assets is included in depreciation ex­
pense? —
[SFAS 13 par. 13]
★ ♦ 2. For operating leases that have initial or remaining noncancelable lease
terms in excess of one year, do disclosures include:
a. Future minimum rental payments required as of the latest balance 
sheet/statement of financial position presented in total and for
each of the next five years? ____
b. Total future minimum rentals under noncancelable subleases as of 
the date of the latest balance sheet/statement of financial position
presented? ____
[SFAS 13 par. 16b]
★ ♦ 3. For all operating leases, do disclosures include rental expense for each
period presented, with separate amounts for minimum rentals, contin­
gent rentals, and sublease rentals? ____
[SFAS 13 par. 16c]
★ ♦ 4. Do disclosures include a general description of the lessee's leasing ar­
rangements including, but not limited to:
a. Bases for determination of contingent rentals? ____
b. Existence and terms of any renewal or purchase options or escala­
tion clauses? ____
c. Restrictive covenants? ____
[SFAS 13 par. 16d]
★ ♦5. Is the nature and extent of leasing transactions with related parties
disclosed? ____
[SFAS 13 par. 29]
★ ♦ 6. If material, is the accounting policy used in recognizing amounts re­
lated to a modification of an operating lease (that does not change the
lease classification) disclosed? ____
[EITF 95-17]
V. Fair Value Measurements
Note: In February 2007, FASB issued SFAS 159, which is effective for finan­
cial statements issued for fiscal years beginning after November 15, 2007. 
Early adoption is permitted as of the beginning of a fiscal year that begins 
on or before November 15, 2007, provided the organization also elects to 
apply the provisions of SFAS 157. The choice to adopt early should be made 
after issuance of this statement but within 120 days of the beginning of the 
fiscal year of adoption, provided the entity has not yet issued financial 
statements, including required notes to those financial statements, for any 
interim period of the fiscal year of adoption.
(continued)
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This statement applies to all entities, including not-for-profit organizations. 
Most of the provisions of this statement apply only to entities that elect the 
fair value option. However, the amendment to SFAS 115 applies to all en­
tities with available-for-sale and trading securities. Some requirements ap­
ply differently to entities that do not report net income.
The statement permits an organization to irrevocably elect fair value as the 
initial and subsequent measurement attribute for certain financial assets 
and financial liabilities on a contract-by-contract basis, with changes in fair 
value recognized in earnings (or another performance indicator if the busi­
ness entity does not report earnings) at each subsequent reporting date. A 
not-for-profit organization shall report unrealized gains and losses in its 
statement of activities or similar statement. The provisions of this statement 
need not be applied to immaterial items. If SFAS 159 is applicable to the 
financial statements (and related notes) of the entity, questions 9-15 should 
be answered.
******
In September 2006, FASB issued SFAS 157, which is effective for financial 
statements issued for fiscal years beginning after November 15, 2007, and 
interim periods within those fiscal years. However, FSP FAS 157-2, Effective 
Date of FASB Statement No. 157, delays the effective date of FASB Statement 
No. 157 for all nonfinancial assets and nonfinancial liabilities, except those 
that are recognized or disclosed at fair value in the financial statements on 
a recurring basis (at least annually), to fiscal years beginning after Novem­
ber 15, 2008, and interim periods within those fiscal years for items within 
the scope of this FSP. This FSP does not apply to entities that have issued 
interim or annual financial statements that include the application of the 
measurement and disclosure provisions of SFAS 157. If an entity early ap­
plies SFAS 157 for nonrecurring fair value measurements made for nonfi­
nancial assets and nonfinancial liabilities, it must do so consistently for all 
items that are within the scope of this FSP.
Earlier application is encouraged, provided that the reporting entity has 
not yet issued financial statements for that fiscal year, including any finan­
cial statements for an interim period within that fiscal year. The statement 
shall be applied prospectively as of the beginning of the fiscal year in which 
this statement is initially applied. Certain exceptions apply. Readers should 
refer to the statement for those exceptions.
The statement establishes a single definition of fair value and a framework 
for measuring fair value in GAAP, and also expands disclosures about fair 
value measurements. The statement applies under other accounting pro­
nouncements that require or permit fair value measurements, FASB having 
previously concluded in those accounting pronouncements that fair value 
is the relevant measurement attribute. Accordingly, this statement does not 
require any new fair value measurements but the application of it will 
change current practice. However, FSP FAS 157-1, Application of FASB State­
ment No. 157 to FASB Statement No. 13 and Other Accounting Pronouncements 
That Address Fair Value Measurements for Purposes of Lease Classification or 
Measurement under Statement 13, establishes that SFAS 157 does not apply
(continued)
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under SFAS 13 and other accounting pronouncements that address fair 
value measurements for purposes of lease classification or measurement 
under SFAS 13. This scope exception does not apply to assets acquired and 
liabilities assumed in a business combination that are required to be meas­
ured at fair value under SFAS 141 or SFAS 141(R), regardless of whether 
those assets and liabilities are related to leases.
SFAS 157 retains the exchange price notion already established within 
GAAP but clarifies, among other matters, that fair value is the price that 
would be received to sell the asset or paid to transfer the liability (that is, 
an exit price) and not the price that would be paid to acquire the asset or 
paid to transfer the liability (that is, an entry price). Additionally, the state­
ment establishes a fair value hierarchy that prioritizes the inputs to valua­
tion techniques used to measure fair value into three broad levels.
If SFAS 157 is applicable to the financial statements (and related notes) of 
the entity and the entity is either not eligible for or has not elected to apply 
the deferral provisions of FSP FAS 157-2, questions 1-7 should be an­
swered. For those entities that are eligible to apply the provisions of FSP 
FAS 157-2 (and have elected to do so), questions 1-7 should be answered 
only in the context of assets and liabilities outside the scope of the FSP and 
question 8 should be answered also.
10 For derivative assets and liabilities, the reconciliation disclosure required by paragraph 32(c) may be presented net
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★ ♦1. For assets and liabilities that are measured at fair value on a recurring 
basis in periods subsequent to initial recognition (for example, trading 
securities), the reporting entity shall disclose information that enables 
users of its financial statements to assess the inputs used to develop 
those measurements and for recurring fair value measurements using 
significant unobservable inputs (level 3), the effect of the measure­
ments on earnings (or changes in net assets) for the period. To meet 
that objective, the reporting entity shall disclose the following infor­
mation for each interim and annual period (except as otherwise speci­
fied) separately for each major category of assets and liabilities:
a. The fair value measurements at the reporting date?
b. The level within the fair value hierarchy in which the fair value 
measurements in their entirety fall, segregating fair value measure­
ments using quoted prices in active markets for identical assets or 
liabilities (level 1), significant other observable inputs (level 2), and 
significant unobservable inputs (level 3)?
c. For fair value measurements using significant unobservable inputs 
(level 3), a reconciliation of the beginning and ending balances, 
separately presenting changes during the period attributable to the 
following:10
(1) Total gains or losses for the period (realized and unrealized), 
segregating those gains or losses included in earnings (or 
changes in net assets), and a description of where those gains 
or losses included in earnings (or changes in net assets) are 
reported in the statement of income (or activities)?
(2) Purchases, sales, issuances and settlements (net)?
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(3) Transfers in or out of level 3, or both, (for example, transfers
due to changes in the observability of significant inputs)? _____ ____
d. The amount of the total gains or losses for the period in subpara­
graph c(l) of the preceding included in earnings (or changes in net 
assets) that are attributable to the change in unrealized gains or 
losses relating to those assets and liabilities still held at the report­
ing date and a description of where those unrealized gains or
losses are reported in the statement of income (or activities)? _____ ____
e. In annual periods only, the valuation technique(s) used to measure 
fair value and a discussion of changes in valuation techniques, if
any, during the period? _____ ____
[SFAS 157 par. 32]
★ ♦ 2. For assets and liabilities that are measured at fair value on a nonrecur­
ring basis in periods subsequent to initial recognition (for example, 
impaired assets), the reporting entity shall disclose information that 
enables users of its financial statements to assess the inputs used to 
develop those measurements. To meet that objective, the reporting en­
tity shall disclose the following information for each interim and an­
nual period (except as otherwise specified) separately for each major 
category of assets and liabilities:
a. The fair value measurements recorded during the period and the
reasons for the measurements? _____ ____
b. The level within the fair value hierarchy in which the fair value 
measurements in their entirety fall, segregating fair value measure­
ments using quoted prices in active markets for identical assets or 
liabilities (level 1), significant other observable inputs (level 2), and
significant unobservable inputs (level 3)? _____ ____
c. For fair value measurements using significant unobservable inputs 
(level 3), a description of the inputs and the information used to
develop the inputs? _____ ____
d. In annual periods only, the valuation technique(s) used to measure 
fair value and a discussion of changes, if any, in the valuation 
technique(s) used to measure similar assets or liabilities, or both,
in prior periods? _____ ____
[SFAS 157 par. 33]
★ ♦ 3. Are the quantitative disclosures required by SFAS 157 presented using
a tabular format? (See appendix A of SFAS 157 for implementation
guidance and examples.) _____ ____
[SFAS 157 par. 34]
★ ♦4. Is the fair value information disclosed under SFAS 157 and the fair
value information disclosed under other accounting pronouncements 
(for example, SFAS 107) combined in the periods in which those disclo­
sures are required, if practicable? (Encouraged, but not required.) _____ ____
[SFAS 157 par. 35]
★ ♦ 5. Is information about other similar measurements (for example, inven­
tories measured at market value under ARB 43 chapter 4) disclosed, if
practicable? (Encouraged, but not required.) _____ ____
[SFAS 157 par. 35]
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★ ♦6. At the date that SFAS 157 is initially applied to the financial instru­
ments in paragraph 37(a)-(c), is the difference between the carrying 
amounts and the fair values of those instruments recognized as a cu­
mulative-effect adjustment to the opening balance of retained earnings 
(or other appropriate components of equity or net assets in the state­
ment of financial position) for that fiscal year, presented separately? 
[SFAS 157 par. 38]
Note: The disclosure requirements of SFAS 154 for a change in accounting 
principle do not apply.
★ ♦ 7. Are the disclosure requirements of SFAS 157 (paragraphs 32-35), in­
cluding those disclosures that are required in annual periods only, 
applied in the first interim period of the fiscal year in which this state­
ment is initially applied?
[SFAS 157 par. 39]
★ ♦ 8. For those entities that are eligible to apply the deferral provisions of
FSP FAS 157-2, Effective Date of FASB Statement No. 157, (and have 
elected to do so), has the entity disclosed the following:
a. The fact that the entity has only partially applied SFAS 157?
b. Each major category of assets and liabilities that are recognized 
or disclosed at fair value for which, in accordance with FSP FAS 
157-2, the entity has not applied the provisions of SFAS 157?
[FSP FAS 157-2 par. 12]
Note: The disclosure requirements of SFAS 157 need not be applied for 
financial statements for periods presented prior to initial application of this 
SFAS.
★ ♦ 9. If the organization reports assets and liabilities at fair value pursuant
to the fair value option in SFAS 159, has it either (a) presented the 
aggregate of fair value and non-fair-value amounts in the same line 
item in the statement of financial position and parenthetically dis­
closed the amount measured at fair value included in the aggregate 
amount or (b) presented two separate line items to display the fair 
value and non-fair-value carrying amounts of similar assets and liabil­
ities?
[SFAS 159 par. 15]
★ ♦ 10. As of each date for which a statement of financial position is presented,
has the organization disclosed the following information about items 
measured at fair value under the option in SFAS 159 or the option in 
paragraph 16 of SFAS 133:
a. Management's reasons for electing a fair value option for each eli­
gible item or group of similar eligible items?
b. The following information if the fair value option is elected for 
some but not all eligible items within a group of similar eligible 
items:
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(1) A description of those similar items and the reasons for partial
election? ------- ------- ------
(2) Information to enable users to understand how the group of 
similar items relates to individual line items on the statement
of financial position? ------- ------- ------
c. The following information for each line item in the statement of 
financial position that includes an item or items for which the fair 
value option has been elected:
(1) Information to enable users to understand how each line item 
in the statement of financial position relates to major categories 
of assets and liabilities presented in accordance with SFAS
157's fair value disclosure requirements? ------- ------- ------
(2) The aggregate carrying amount of items included in each line 
item in the statement of financial position that are not eligible
for the fair value option, if any? ------- ------- ------
d. The difference between the aggregate fair value and the aggregate 
unpaid principal balance of:
(1) Loans and long-term receivables (other than securities subject 
to SFAS 115) that have contractual principal amounts and for
which the fair value option has been elected? ------- ------- ------
(2) Long-term debt instruments that have contractual principal
amounts and for which the fair value option has been elected? ------- ------- ------
e. For loans held as assets for which the fair value option has been 
elected:
(1) The aggregate fair value of loans that are 90 days or more past
due? ------- ------- ------
(2) If the entity's policy is to recognize interest income separately 
from other changes in fair value, the aggregate fair value of
loans in nonaccrual status? ------- ------- ------
(3) The difference between the aggregate fair value and the aggre­
gate unpaid principal balance for loans that are 90 days or
more past due, in nonaccrual status, or both? ------- ------- ------
[SFAS 159 par. 18]
♦ 11. As of each period for which an interim or annual income statements is 
presented, has the organization disclosed the following information 
about items measured at fair value under the option in SFAS 159 or the 
option in paragraph 16 of SFAS 133:
a. For each line item in the statement of financial position, the 
amounts of gains and losses from fair value changes during the 
period included in earnings and in an intermediate measure of 
operations, if one is presented, and in which line in the income 
statement those gains and losses are reported? (An organization 
may meet this requirement by disclosing amounts of gains and 
losses that include amounts of gains and losses for other items 
measured at fair value, such as items required to be measured at
fair value.) ------- ------- ------
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b. A description of how interest and dividends are measured and 
where they are reported in the income statement?
c. For loans and other receivables held as assets:
(1) The estimated amount of gains or losses included in earnings 
during the period attributable to changes in instrument-spe­
cific credit risk?
(2) How the gains or losses attributable to changes in instrument- 
specific credit risk were determined?
d. For liabilities with fair values that have been significantly affected 
during the reporting period by changes in the instrument-specific 
credit risk:
(1) The estimated amount of gains and losses from fair value 
changes included in earnings that are attributable to changes 
in the instrument-specific credit risk?
(2) Qualitative information about the reasons for those changes?
(3) How the gains and losses attributable to changes in instru­
ment-specific credit risk were determined?
[SFAS 159 par. 19]
★12. As of each date for which a statement of activities is presented, has the 
organization disclosed the following information about items meas­
ured at fair value under the option in SFAS 159 or the option in para­
graph 16 of SFAS 133:
a. For each line item in the statement of financial position, the 
amounts of gains and losses from fair value changes during the 
period included in change in each of the net asset classes (unres­
tricted, temporarily restricted, and permanently restricted), and in 
an intermediate measure of operations, if one is presented, and in 
which line in the statement of activities those gains and losses are 
reported? (An organization may meet this requirement by disclos­
ing amounts of gains and losses that include amounts of gains and 
losses for other items measured at fair value, such as items re­
quired to be measured at fair value.)
b. A description of how interest and dividends are measured and 
where they are reported in the income statement?
[SFAS 159 par. 19]
★ ♦ 13. Has the organization disclosed the methods and significant assump­
tions used to estimate the fair value of items for which the fair value 
option has been elected?
[SFAS 159 par. 21]
★ ♦14. If an organization elects the fair value option at a remeasurement
event, has it disclosed the following for the period of the election:
a. Qualitative information about the nature of the event?
b. Quantitative information by line item in the statement of financial 
position indicating which line items in the income statement in­
clude the effect of initially electing the fair value option for an 
item?
[SFAS 159 par. 22]
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Transition Guidance
Note: Retrospective application of SFAS 159 to fiscal years preceding the 
effective date, which would involve restatement of previously issued finan­
cial statements, is not permitted because of the elective nature of the state­
ment and the benefit of hindsight. Readers should refer to paragraph 30 of 
SFAS 159 for specific requirements applicable to the early adoption of this 
statement.
★ ♦ 15. At the date that SFAS 159 is initially applied to the financial statements,
is the effect of the adoption attributable to the election of the fair value 
option for selected financial assets and financial liabilities accounted 
for as a cumulative-effect adjustment to the opening balance of re­
tained earnings (or other appropriate components of equity or net as­
sets in the statement of financial position) as of the effective date, and 
not the beginning of the earliest year presented?
[SFAS 159 par. 25]
★ ♦ 16. Has the organization electing the fair value option for items existing at
the effective date provided the following in its annual and first-in­
terim-period financial statements for the fiscal year that includes the 
effective date (or early adoption date):
a. A schedule that presents the following by line item in the statement 
of financial position:
(1) The pretax portion of the cumulative-effect adjustment to re­
tained earnings (or appropriate class or classes of net assets) 
for items on that line?
(2) The fair value at the effective date (or early adoption date) of 
eligible items for which the fair value option is elected and the 
carrying amount of those same items immediately before elect­
ing the fair value option?
b. The net effect on the entity's deferred tax assets and liabilities of 
electing the fair value option?
c. Management's reasons for electing the fair value option for each 
existing eligible item or group of similar eligible items?
d. If the fair value option is elected for some but not all eligible items 
within a group of similar eligible items:
(1) A description of those similar items and the reasons for partial 
election?
(2) Information to enable users to understand how the group of 
similar items relates to individual line items on the statement 
of financial position?
e. The amount of valuation allowances that were removed from the 
statement of financial position because they related to items for 
which the fair value option was elected?
[SFAS 159 par. 27]
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Continuing Care Retirement Communities (CCRCs)
A. Refundable Advance Fees
★ ♦ 1. Is the estimated amount of advance fees expected to be refunded to
current residents reported as a liability? ____
[AAG 14.22]
★ ♦ 2. Is the remaining amount of advance fees reported in the balance sheet/
statement of financial position as deferred revenue? ____
[AAG 14.22]
★ ♦ 3. Are the following disclosed:
a. The gross amount of contractual refund obligations under existing
contracts? ____
b. The CCRC's refund policy? ____
[AAG 14.22]
★ ♦ 4. Are amounts refunded disclosed in the statement of cash flows as a
financing transaction? ____
[AAG 14.22]
★ ♦ 5. Is the amortization method for deferred revenue disclosed? ____
[AAG 14.23]
B. Fees Refundable to Residents Only From Reoccupancy Proceeds of a 
Contract Holder's Unit
★ ♦ 1. Are the following reported as deferred revenue:
a. The portion of fees to be paid to current residents or their desig­
nees, only to the extent of a contract holder's unit reoccupancy 
proceeds, if law and management policy and practice support the 
withholding of refunds under this condition? ____
b. Similar amounts received from new residents in excess of the
amount to be paid to previous residents or their designees? ____
[AAG 14.25]
C. Nonrefundable Advance Fees
★ ♦1. Are nonrefundable advance fees reported as deferred revenue? ____
[AAG 14.26]
★ ♦ 2. Is unamortized deferred revenue reported as revenue upon a resident's
death or contract termination? ____
[AAG 14.23]
D. Obligation to Provide Future Services and Use of Facilities to Current 
Residents
★ ♦ 1. If the obligation to provide future services and use of facilities to cur­
rent residents under continuing-care contracts results in a liability, are 
the following disclosed:
a. The carrying amount of the liability that is presented at present 
value in the financial statements (if not separately disclosed in the 
balance sheet/statement of financial position)? ____
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b. The interest rate used to discount that liability? _____ _____ ____
[AAG 14.31]
E. Costs of Acquiring Initial Continuing-Care Contracts
★ ♦ 1. Are continuing-care contract acquisition costs expensed if incurred af­
ter (a) the CCRC is substantially occupied or (b) one year following
completion? _____ _____ ____
[AAG 14.33]
F. Other
★ ♦ 1. Do the notes to the financial statements of the CCRC include a descrip­
tion of the CCRC and the nature of the related continuing-care con­
tracts entered into by the CCRC? ------- ------- ------
[AAG 14.35]
★ ♦ 2. Do the notes to the financial statements of the CCRC include the stat­
utory escrow or similar requirements? ------- ------- ------
[AAG 14.35]
OMB Circular A-133 Presentation Requirements
1. Does the schedule of expenditures of federal awards disclose the basis 
of accounting and the significant accounting policies used in preparing
the schedule? ------- ------- ------
[AAG-SLA 7.05]
2. Did the auditee prepare a schedule of expenditures of federal awards 
for the period covered by the auditee's financial statements that, at a 
minimum:
a. Lists individual federal programs by federal agency? ------- ------- ------
b. Include, for federal awards received as a subrecipient, the name of 
the pass-through entity and the identifying number assigned by
the pass-through entity? ------- ------- ------
c. Provide the total federal awards expended for each individual fed­
eral program and the CFDA number or other identifying number
when the CFDA information is not available? ------- ------- ------
d. Include notes that describe the significant accounting policies used
in preparing the schedule? ------- ------- ------
e. For federal awards received as a pass-through entity, identify, to 
the extent practical, the total amount provided to subrecipients
from each federal program? ------- ------- ------
f. Include, in either the schedule or a note to the schedule, the value 
of federal awards expended in the form of noncash assistance, the 
amount of insurance in effect during the year, and loans or loan
guarantees outstanding at year end? ------- ------- ------
[AAG-SLA 7.06]
3. If nonfederal data are presented in the schedule of expenditures of 
federal awards:
a. Are the nonfederal data segregated and clearly designated as non­
federal? ------- ------- ------
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b. Is the title of the schedule modified to indicate that nonfederal
awards are included? _____
[AAG-SLA 7.09]
4. If the auditee is unable to obtain the CFDA number, does the schedule 
include:
a. A statement that the CFDA number is not available? _____
b. The program's name and, if available, other identifying numbers? _____
[AAG-SLA 7.10]
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FSP Section 11,300 
Auditors’ Reports Checklist
This section of the checklist has been developed primarily to address the requirements most 
likely to be encountered when reporting on financial statements of health care organizations in 
accordance with generally accepted auditing standards (GAAS) as issued by the Auditing Stan­
dards Board (ASB), a senior technical committee of the AICPA. Certain key differences in re­
porting requirements between audits conducted in accordance with GAAS and audits conducted 
in accordance with the rules and standards of the Public Company Accounting Oversight Board 
(PCAOB) are identified throughout this section of the checklist. However, the differences iden­
tified are not intended to be all inclusive, and readers should seek appropriate guidance for a 
comprehensive source of reporting requirements associated with audits conducted in accordance 
with the rules and standards of the PCAOB.
.01 This checklist contains the basic requirements for reporting on an audit of the financial statements in 
accordance with AICPA Professional Standards (GAAS) and PCAOB Auditing Standard No. 1, Reference in 
Auditors' Reports to the Standards of the Public Company Accounting Oversight Board (AICPA, PCAOB Standards 
and Related Rules, Rules of the Board, "Standards"). It does not contain all requirements for reports required 
to be issued in audits in accordance with Government Auditing Standards (Yellow Book), with the audit require­
ments of Office of Management and Budget Circular A-133 (Single Audits), or PCAOB professional standards.
.02 Explanation of References:
AU = Reference to section number in AICPA Professional Standards (vol. 1)
AR = Reference to section number in AICPA Professional Standards (vol. 2)
.03 Checklist Questionnaire:
Yes No N/A
1. Is each financial statement audited specifically identified in the intro­
ductory paragraph of the auditor's report? ------- ------- -------
[AU 508.06]
2. Do the titles of the financial statements referred to in the introductory
paragraph of the auditor's report match the titles of the financial state­
ment presented? _____ _____ _____
[Generally Accepted]
3. Do the dates of the financial statements referred to in the introductory
paragraph of the auditor's report match the dates of the financial state­
ments presented? ------- ------- -------
[Generally Accepted]
4. Is the report appropriately addressed? ------- ------- -------
[AU 508.09]
FSP §11,300.03
140 Health Care Organizations
Yes No N/A
Practice Tip
Interpretation No. 17, "Clarification in the Audit Report of the Extent of Testing of Internal Control Over 
Financial Reporting in Accordance With Generally Accepted Auditing Standards," of AU section 508, Reports 
on Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .85-.88), provides 
language that may be added to the auditor's standard report on the financial statements of a nonissuer to 
clarify differences between a GAAS audit and an audit conducted in accordance with the standards of the 
PCAOB. Interpretation No. 18, "References to PCAOB Standards in an Audit Report on a Nonissuer," of AU 
section 508 (AICPA, Professional Standards, vol. 1, AU sec. 9508 par. .89-.92), explains how the auditor should 
report if engaged to also follow PCAOB auditing standards in the audit of a nonissuer.
5. Does the independent auditor's report include the following elements:
a. A title that includes the word "independent"?
[AU 508.08a]
b. A statement that the financial statements identified in the report 
were audited?
[AU 508.08b]
c. A statement that the financial statements are the responsibility of 
management and that the auditor's responsibility is to express an 
opinion on the financial statements based on his or her audit?
[AU 508.08c]
d. (Audits of Nonissuers Only) For audits conducted in accordance 
with GAAS in the United States, a statement that the audit was 
conducted in accordance with GAAS and an identification of the 
United States of America as the country of origin of those stan­
dards (for example, auditing standards generally accepted in the 
United States of America or U.S. GAAS)?
[AU 508.084]
e. For audits of issuers, a statement that the audit was conducted in 
accordance with the standards of the Public Company Accounting 
Oversight Board (United States)?
[PCAOB Auditing Standard 1 par. 3]
f. A statement that those standards require that the auditor plan and 
perform the audit to obtain reasonable assurance about whether 
the financial statements are free of material misstatement?
[AU 508.08e]
g. A statement that an audit includes examining, on a test basis, evi­
dence supporting the amounts and disclosures in the financial 
statements; assessing the accounting principles used and signifi­
cant estimates made by management; and evaluating the overall 
financial statement presentation?
[AU 508.08f]
h. A statement that the auditor believes that his or her audit provides 
a reasonable basis for his or her opinion?
[AU 508.08g]
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i. When the auditor reports on financial statements presented in con­
formity with U.S. generally accepted accounting principles 
(GAAP), an opinion as to whether the financial statements present 
fairly, in all material respects, the financial position of the report­
ing entity as of the balance sheet date and the results of its opera­
tions and its cash flows for the period then ended in conformity 
with GAAP? The opinion should include an identification of the 
United States of America as the country of origin of those account­
ing principles (for example, accounting principles generally ac­
cepted in the United States of America or U.S. GAAP). ------- ------- ------
[AU 508.08h]
Note: In May 2008, the Auditing Standards Board (ASB) issued Interpreta­
tion No. 19, "Financial Statements Prepared in Conformity With Interna­
tional Financial Reporting Standards as Issued by the International Ac­
counting Standards Board," of AU section 508 (AICPA, Professional 
Standards, vol. 1, AU sec. 9508 par. .93-.97), which provides that, when the 
auditor of a nonissuer reports on financial statements prepared in conform­
ity with International Financial Reporting Standards (IFRS), the auditor 
would refer, in the auditor's report, to IFRS rather than U.S. GAAP.
When an auditor of a nonissuer reports on financial statements presented 
in conformity with both IFRS as issued by the International Accounting 
Standards Board (IASB) and a jurisdictional variation of IFRS, the auditor 
would refer, in the auditor's report, to both IFRS and IFRS as endorsed by 
[insert name of endorsing country or economic union].
When an auditor of a nonissuer reports on financial statements presented 
in conformity with a jurisdictional variation of IFRS such that the entity's 
financial statements do not contain an explicit and unreserved statement of 
compliance with IFRS as issued by the IASB, paragraphs .14-.15 of AU 
section 534, Reporting on Financial Statements Prepared for Use in Other Coun­
tries (AICPA, Professional Standards, vol. 1), and paragraphs .35-.60 of AU 
section 508 apply to financial statements prepared for more than limited 
distribution in the United States.
j. When the auditor reports on financial statements presented in con­
formity with IFRS, an opinion as to whether the financial state­
ments present fairly, in all material respects, the financial position 
of the reporting entity as of the balance sheet date and the results 
of its operations and its cash flows for the period then ended in 
conformity with IFRS as issued by the IASB?
[AU 9508.93-.97]
k. When the auditor reports on financial statements presented both 
in conformity with IFRS and a jurisdictional variant of IFRS, an 
opinion as to whether the financial statements present fairly, in all 
material respects, the financial position of the reporting entity as 
of the balance sheet date and the results of its operations and its 
cash flows for the period then ended in conformity with IFRS as 
issued by the IASB and with IFRS as endorsed by [insert name of 
endorsing country or economic union]?
[AU 9508.93-.97]
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l. When the auditor reports on financial statements presented in con­
formity with a jurisdictional variation of IFRS such that the entity's 
financial statements do not contain an explicit and unreserved 
statement of compliance with IFRS as issued by the IASB, a varia­
tion of the standard report that reflects the guidance in paragraphs 
.14-.15 of AU section 534 and paragraphs .35-60 of AU section 508 
for financial statements prepared for more than limited distribu­
tion in the United States?
[AU 9508.93-.97]
m. The manual or printed signature of the auditor's firm?
[AU 508.08i]
n. The date of the audit report?
[AU 508.08j]
o. For audits of issuers, the city and state (or city and country for non- 
U.S. auditors) from which the auditor's report is issued?
[PCAOB Auditing Standard 1 par. 3]
Notes: In May 2008, the ASB issued a revision of Interpretation No. 14, 
"Reporting on Audits Conducted in Accordance With Auditing Standards 
Generally Accepted in the United States of America and in Accordance 
With International Standards on Auditing" of AU section 508 (AICPA, Pro­
fessional Standards, vol. 1, AU sec. 9508 par. .56-.59), which provides that, 
when the audit of a nonissuer is conducted both in accordance with stan­
dards generally accepted in the United States of America and in accordance 
with the International Standards on Auditing (ISAs), the auditor may so 
indicate in the auditor's report.
To determine whether an audit was conducted in accordance with the ISA, 
it is necessary to consider the text of the ISA in their entirety, including the 
basic principles and essential procedures together with the related guidance 
included in the ISA.
6. If the audit of financial statements to be used in the United States was 
conducted in accordance with auditing standards generally accepted 
in the United States of America and ISAs as issued by the International 
Auditing and Assurance Standards Board, in their entirety, has the 
auditor considered indicating in the auditor's report, does the auditor's 
report indicate that the audit was also conducted in accordance with 
ISA as allowed? (Note: Not required - Interpretation No. 14 of AU 
section 508 provides an example report).
[AU 9508.57-.59]
Notes: On May 24, 2007, the PCAOB adopted Auditing Standard No. 5, An 
Audit of Internal Control Over Financial Reporting That Is Integrated with An 
Audit of Financial Statements (AICPA, PCAOB Standards and Related Rules, 
Rules of the Board, "Standards"), that supersedes its Auditing Standard 
No. 2. The PCAOB adopted the new Auditing Standard No. 5 with the 
primary objective of focusing the auditor on matters most important to 
internal control. Goals of this new standard are to eliminate unnecessary 
procedures, to simplify and shorten the standard by reducing detail and 
specificity, and to make the audit more scalable for smaller and less com­
plex companies.
(continued)
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Auditing Standard No. 5 is effective for audits of internal control over fi­
nancial reporting required by Section 404(b) of the Sarbanes-Oxley Act of 
2002 for fiscal years ending on or after November 15, 2007.
Among other significant guidance, Auditing Standard No. 5 states that an 
audit of internal control over financial reporting should be integrated with 
the audit of the financial statements. The auditor may choose to issue a 
combined report (that is, one report containing both an opinion on the 
financial statements and an opinion on internal control over financial re­
porting) or separate reports on the company's financial statements and on 
internal control over financial reporting. Paragraph 85 of Auditing Stan­
dard No. 5 lists the basic elements that an auditor's report on the audit of 
internal control over financial reporting must include. Readers can refer to 
the full text of the auditing standard at www.pcaob.org.
7. If a subsequent event disclosed in the financial statements occurs after 
the original date of the independent auditor's report but before the 
issuance of the related financial statements, has the auditor followed 
one of the following two methods available for dating the report:
a. Dual dating, in which the independent auditor's responsibility for 
events occurring subsequent to the original report date is limited 
to the specific event referred to in an explanatory note in the report 
(or otherwise disclosed)? or
b. Dating the report as of the later date, in which the independent 
auditor's responsibility for subsequent events extends to the date 
of the report?
[AU 530.03-.05]
8. (Audits of Issuers Only) If the auditor obtains knowledge about a sub­
sequent event that
a. materially and adversely affects the effectiveness of the company's 
internal control over financial reporting as of the date specified in 
the assessment, has the auditor either
(1) issued an adverse opinion on internal control over financial 
reporting (and followed the direction in paragraph C2 of 
PCAOB Auditing Standard No. 5 if management's assessment 
states that internal control over financial reporting is effective), 
or
(2) disclaimed an opinion if the auditor is unable to determine the 
effect of the subsequent event on the effectiveness of the com­
pany's internal control over financial reporting?
b. relates to conditions that did not exist at the date specified in the 
assessment but arose subsequent to that date and before issuance 
of the auditor's report, and the subsequent event has a material 
effect on the company's internal control over financial reporting, 
has the auditor included in his or her report an explanatory para­
graph describing the event and its effects or directed the reader's 
attention to the event and its effects as disclosed in management's 
report?
[PCAOB Auditing Standard 5 par. .96-.97]
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9. If the accountant is not independent, has he or she followed one of the 
two reporting alternatives available:
a. Disclaiming the opinion with respect to the financial statements
and specifically stating that he or she is not independent? or _____ _____ ____
b. Issuing a compilation report in accordance with Statements on 
Standards for Accounting and Review Services indicating the lack
of independence (nonpublic companies only)? _____ _____ ____
[AU 504.05 and .09-.10; AR 100A.21 and .48]
10. If the opinion is based in part on the report of another auditor:
a. Does the introductory paragraph of the standard report disclose 
the fact that the opinion is based, in part, on the report of other
auditors? _____ _____ ____
b. Does the opinion paragraph include a reference to the report of the
other auditor? _____ _____ ____
[AU 508.11a-.13]
11. If, to prevent the financial statements from being misleading because 
of unusual circumstances, the financial statements contain a departure 
from an accounting principle promulgated by a body designated by 
the AICPA Council to establish such principles, does the report in­
clude, in a separate paragraph or paragraphs, the information required 
by Rule 203, Accounting Principles, of the Code of Professional Conduct
(AICPA, Professional Standards, vol. 2, ET sec. 203)? _____ _____ ____
[AU 508.11b and .15]
12. If there is substantial doubt about the entity's ability to continue as a 
going concern for a reasonable period of time, not to exceed one year 
beyond the date of the financial statements being audited:
a. Does the report include an explanatory paragraph, following the
opinion paragraph, to reflect that conclusion? _____ _____ ____
b. Is that conclusion expressed through the use of the phrase "sub­
stantial doubt about its (the entity's) ability to continue as a going 
concern" or similar wording that includes the terms substantial
doubt and going concern? _____ _____ ____
[AU 508.11c; AU 341.12]
Practice Tips
In evaluating whether there is substantial doubt about the entity's ability to continue as a going concern, the 
auditor's evaluation is based on his or her knowledge of relevant conditions that exist at or have occurred 
prior to the date of the auditor's report. If, after considering identified conditions and events and management's 
plans, the auditor concludes that substantial doubt about the entity's ability to continue as a going concern 
for a reasonable period of time remains, the audit report should include an explanatory paragraph to reflect 
that conclusion.
In a going concern paragraph, the auditor should not use conditional language in expressing a conclusion 
concerning the existence of substantial doubt about the entity's ability to continue as a going concern. See AU 
section 341, The Auditor's Consideration of an Entity's Ability to Continue as a Going Concern (AICPA, Professional 
Standards, vol. 1), paragraph .13 for an example.
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13. For audits of issuers, is the report dated no earlier than the date on
which the auditor has obtained sufficient competent evidence to sup­
port the auditor's opinion on the financial statements? ------- ------- ------
[PCAOB Auditing Standard 5 par. 89]
14. For audits of nonissuers, is the report dated no earlier than the date on 
which the auditor has obtained sufficient appropriate audit evidence
to support the auditor's opinion on the financial statements? _____ _____ ____
[AU 530.01 and .05]
15. (Audits of Issuers Only) When performing an integrated audit of finan­
cial statements and internal control over financial reporting, are the 
auditor's reports on the company's financial statements and on internal
control over financial reporting dated the same? _____ _____ ____
[PCAOB Auditing Standard 5 par. 89]
16. (Audits of Issuers Only) Prior to the report release date, among other 
matters, has the auditor obtained sufficient evidence to support the
representations in the auditor's reports? _____ _____ ____
[PCAOB Auditing Standard 3 par. 15]
Practice Tips
Changes in Accounting Estimates
Paragraph .15 of AU section 420, Consistency of Application of Generally Accepted Accounting Principles (AICPA, 
Professional Standards, vol. 1), clarifies that the change in an accounting estimate that does not include a change 
in accounting principle does not require an explanatory paragraph in the auditor's report. However, an 
accounting change of this type having a material effect on the financial statements may require disclosure in 
a note to the financial statements.
Changes in Classification
Paragraph .17 of AU section 420 clarifies that changes in classification from the prior year's financial state­
ments are usually not of sufficient importance to necessitate disclosure; however, material changes in classi­
fication should be indicated and explained in the financial statements or notes.
Error Corrections
Paragraph .16 of AU section 420 states that the correction of an error in previously issued financial statements 
resulting from mathematical mistakes, oversight, or misuse of facts that existed at the time the financial 
statements were originally prepared does not involve the consistency standard if no element of accounting 
principles or their application is included. Accordingly, the independent auditor need not recognize the 
correction in his report. However, if the independent auditor had previously reported on the financial state­
ments containing the error, the auditor has concluded, based on the considerations in paragraph .05 of AU 
section 561, Subsequent Discovery of Facts Existing at the Date of the Auditor's Report (AICPA, Professional Stan­
dards, vol. 1), that action should be taken to prevent future reliance on his report, and the issuance of financial 
statements accompanied by the auditor's report for a subsequent period is imminent, the auditor should 
disclose the revision in such statements instead of reissuing the earlier statements.
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Notes: For audits of issuers, certain circumstances, although not affecting 
the auditor's unqualified opinion, may require that the auditor add explan­
atory language to the standard report as described in paragraphs .11-.19 of 
PCAOB AU section 508, Reports on Audited Financial Statements, (AICPA, 
PCAOB Standards and Related Rules, PCAOB Standards, As Amended).
Other circumstances may require a departure from an unqualified opinion, 
either in the form of a qualified opinion, an adverse opinion, or a disclaimed 
opinion as described in paragraphs .20-63 of PCAOB AU section 508.
For special reporting situations relating to the auditor's report on internal 
control over financial reporting, refer to appendix C, Special Reporting Situ­
ations, of Auditing Standard No. 5.
*******
In January 2008, the PCAOB adopted Auditing Standard No. 6, Evaluating 
Consistency of Financial Statements, (AICPA, PCAOB Standards and Related 
Rules, PCAOB Standards, As Amended), and an accompanying set of 
amendments to the PCAOB's interim auditing standards. Among other sig­
nificant provisions, the new standard and related amendments update the 
auditor's responsibilities to evaluate and report on the consistency of a 
company's financial statements and align the auditor's responsibilities with 
Financial Accounting Standards Board (FASB) Statement of Financial Ac­
counting Standards (SFAS) No. 154, Accounting Changes and Error Correc­
tions—a replacement of APB Opinion No. 20 and FASB Statement No. 3.
One significant difference in terminology between SFAS 154 and Auditing 
Standard No. 6 is the use of the term error in the FASB standard whereas 
the PCAOB standard uses the term misstatement and specifically states that 
the meaning is the same for purposes of the PCAOB Auditing Standards. 
Auditing Standard No. 6 also establishes that the auditor's report should 
indicate whether an adjustment to previously issued financial statements 
results from a change in accounting principle or the correction of a misstate­
ment.
Auditing Standard No. 6 contains numerous amendments to PCAOB AU 
section 508 and other interim PCAOB auditing standards. The Securities 
and Exchange Commission (SEC) approved Auditing Standard No. 6 in its 
Release No. 34-58555, dated September 16, 2008. The new standard and 
related amendments are effective November 15, 2008. If Auditing Standard 
No. 6 is applicable to issuers' financial statements, answer questions 18-19; 
otherwise, skip questions 18-19. For more information and for the full text 
of the auditing standard, refer to the PCAOB Web site at www.pcaob.org. 
Also refer to the SEC Web site at www.sec.gov.
17. (Audits of Nonissuers Only) If there has been a material change between 
periods in accounting principles or in the method of their application, 
including a change from an accounting principle that is not generally 
accepted to one that is generally accepted and a change in accounting 
principle that is inseparable from the effect of a change in estimate, that 
has a material effect on the comparability of the reporting entity's fi­
nancial statements:
a. Does the report include an explanatory paragraph, following the 
opinion paragraph, that refers to the change?
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b. Does the explanatory paragraph identify the nature of the change 
and refer the reader to the note to the financial statements that
discusses the change in detail? ------- ------- ------
[AU 508.05-.06 and .12-.13]
c. If the change in the accounting principle is a change in the report­
ing entity that did not result from a transaction or an event, is an 
explanatory paragraph included in the auditor's report? (Note: A 
change in the reporting entity resulting from a transaction or event, 
such as the creation, cessation, or complete or partial purchase or 
disposition of a subsidiary or other business unit, does not require 
that an explanatory paragraph about consistency be included in
the auditor's report.) ------- ------- ------
[AU 420.08]
18. (Audits of Nonissuers Only) If there has been a change in accounting 
principle that has a material effect on the financial statements, includ­
ing a change in the method of applying an accounting principle, a 
change in estimate effected by a change in accounting principle, and a 
change in classification that represents a change in accounting princi­
ple, and meets the four criteria established in paragraph 7 of PCAOB 
Auditing Standard No. 6:
a. Does the report include an explanatory paragraph, following the 
opinion paragraph, in the year of the change and in subsequent 
years until the new accounting principle is applied in all periods
presented? _____ _____ ____
b. Does the explanatory paragraph identify the nature of the change 
and include a reference to the note disclosure describing the
change? _____ _____ ____
c. If the change in the accounting principle is a change in reporting 
entity that did not result from a transaction or an event, is an ex­
planatory paragraph included in the auditor's report? (Note: A 
change in the reporting entity resulting from a transaction or event, 
such the creation, cessation, or complete or partial purchase or 
disposition of a subsidiary or other business unit, does not require
recognition in the auditor's report.) _____ _____ ____
[PCAOB Auditing Standard No. 6 par. 4-8 and 11]
19. (Audits of Nonissuers Only) If there has been a correction of a material 
misstatement in previously issued financial statements, including a 
change from an accounting principle that is not generally accepted to 
one that is generally accepted and a change in classification that rep­
resents the correction of a material misstatement, does the auditor's 
report contain an explanatory paragraph, following the opinion para­
graph, that includes:
a. A statement that the previously issued financial statements have 
been restated for the correction of a misstatement in the respective
period? _____ _____ ____
b. A reference to the company's disclosure of the correction of the
misstatement? _____ _____ ____
[PCAOB Auditing Standard No. 6 par. 5 and 9-11]
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20. In an updated report on the individual financial statements of one or 
more prior periods presented on a comparative basis with those of the 
current period, if the opinion is different from the opinion previously 
expressed on the financial statements of a prior period:
a. Does the report include an explanatory paragraph, preceding the 
opinion paragraph, that discloses all of the substantive reasons for 
the different opinion?
b. Does the explanatory paragraph disclose:
(1) The date of the auditor's previous report?
(2) The type of opinion previously expressed?
(3) The circumstances or events that caused the auditor to express 
a different opinion?
(4) That the auditor's updated opinion on the financial statements 
of the prior period is different from his or her previous opinion 
on those statements?
[AU 508.11e and .69]
21. If financial statements of a prior period (presented for comparative 
purposes) have been audited by a predecessor auditor whose report is 
not presented:
a. Does the introductory paragraph of the report indicate:
(1) That the financial statements of the prior period were audited 
by another auditor?
(2) The date of the predecessor auditor's report?
(3) The type of report issued by the predecessor auditor?
(4) If the report was other than a standard report, the substantive 
reasons therefore, including a description of the nature of and 
reasons for the explanatory paragraph added to the predeces­
sor's report or his or her opinion qualification?
b. If the financial statements have been restated, does the introduc­
tory paragraph indicate that the predecessor auditor reported on 
the financial statements of the prior period before restatement? 
[AU 508.11e and .74]
22. If selected quarterly financial data required by SEC Regulation S-K has 
been omitted or has not been reviewed, does the report include an 
additional paragraph stating that fact?
[AU 508.11f; AU 722.50]
23. If other information in a document containing audited financial state­
ments is materially inconsistent with information appearing in the fi­
nancial statements, has it been determined whether the financial state­
ments, the auditor's report, or both require revision?
[AU 508.11h; AU 550.04]
24. If the auditor decides to emphasize a matter regarding the financial 
statements in the report, is the matter being emphasized disclosed in 
the financial statements and is the explanatory information presented 
in a separate paragraph that avoids use of phrases such as "with the 
foregoing (following) explanation"?
[AU 508.11 and .19; AU 9410.18; AU 9342.03]
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25. If it has not been possible to conduct the audit in accordance with
GAAS or to apply all of the procedures considered necessary in the 
circumstances, has consideration been given to the need to issue a qual­
ified opinion or to disclaim an opinion? ------- ------- -------
[AU 508.22]
26. If a qualified opinion is to be expressed because of a scope limitation:
a. Are all of the substantive reasons for the qualification disclosed in
one or more explanatory paragraphs preceding the opinion para­
graph? ------- ------- -------
b. Does the qualified opinion include the word except or exception in a
phrase such as except for or with the exception of? ------- ------- -------
c. Is the situation described and referred to in both the scope and
opinion paragraphs? ------- ------- -------
d. Does the wording in the opinion paragraph indicate that the qual­
ification pertains to the possible effects on the financial statements
and not the scope limitation itself? ------- ------- -------
[AU 508.22-.32; AU 318.76]
Practice Tips
Scope limitations can be imposed by the client or by circumstances such as the timing of the auditor's work, 
the inability to obtain sufficient appropriate audit evidence, or an inadequacy in the accounting records. 
Sufficient appropriate audit evidence includes, among other things, management having asserted responsi­
bility for the final financial statements. As provided in Technical Practice Aid (TPA) Technical Question and 
Answer (TIS) section 9100.06, "The Effect of Obtaining the Management Representation Letter on Dating the 
Auditor's Report" (AICPA, Technical Practice Aids), the auditor will need to have the signed management 
representation letter in hand prior to releasing the auditor's report, because management's refusal to furnish 
written representations constitutes a limitation on the scope of the audit sufficient to preclude an unqualified 
opinion.
In circumstances in which the auditor is unable to obtain sufficient appropriate audit evidence to support 
management's assertions about the nature of a matter involving an uncertainty and its presentation or disclo­
sure in the financial statements, the auditor should consider the need to express a qualified opinion or to 
disclaim an opinion because of a scope limitation.
[AU 508.22 and .31]
In circumstances in which the auditor is unable to audit the existence or measurement of interests in invest­
ments in securities and interests in trusts, the auditor should consider whether that scope limitation requires 
the auditor to either qualify his or her opinion or to disclaim an opinion, as discussed in paragraphs .22-26 
of AU section 508; Interpretation 1, "Auditing Interests in Trusts Held by a Third-Party Trustee and Reported 
at Fair Value," of AU section 328, Auditing Fair Value Measurements and Disclosures, (AICPA, Professional 
Standards, vol. 1, AU sec. 9328.01-.04); and Interpretation No. 1, "Auditing Investments in Securities Where a 
Readily Determinable Fair Value Does Not Exist," of AU section 332, Auditing Derivative Instruments, Hedging 
Activities, and Investments in Securities (AICPA, Professional Standards, vol. 1, AU sec. 9332.01-.04).
Statement of Position (SOP) 00-1, Auditing Health Care Third-Party Revenues and Related Receivables, (AICPA, 
Technical Practice Aids, AUD sec. 14,360), discusses auditing matters to consider in testing third-party revenues 
and related receivables, and provides guidance regarding the sufficiency of evidential matter.
[SOP 00-1 par. 16-21 (AUD 14,360.16-.21)]
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27. Is a qualified opinion or disclaimer of opinion expressed if the audi­
tor's understanding of internal control raises doubts about the audita­
bility of an entity's financial statements, such as:
a. Concerns about the integrity of an entity's management cause the 
auditor to conclude that the risk of management misrepresentation 
in the financial statements is such that an audit cannot be con­
ducted?
b. Concerns about the condition and reliability of an entity's records 
cause the auditor to conclude that it is unlikely that sufficient ap­
propriate audit evidence will be available to support an unquali­
fied opinion on the financial statements?
[AU 314.109]
28. If, in the auditor's judgment, the two-way communication between the 
auditor and those charged with governance as required in AU section 
380, The Auditor's Communication With Those Charged With Governance 
(AICPA, Professional Standards, vol. 1), is not adequate, and the effect is 
material to the control environment and risks of material misstate­
ments, or has precluded the auditor from obtaining all the audit evi­
dence required to form an opinion on the financial statements, has the 
auditor considered the following:
a. Modifying the audit opinion on the basis of a scope limitation?
b. Obtaining legal advice about the consequences of different courses 
of action?
c. Communicating with an appropriate third party, (for example, a 
regulator)?
d. Withdrawing from the engagement?
[AU 380.63]
29. If, in the auditor's judgment, significant difficulties in dealing with 
management, such as those described in AU section 380, have been 
encountered, has the auditor considered modifying the audit opinion 
on the basis of a scope limitation?
[AU 380.39]
30. If an opinion is disclaimed because of a scope limitation:
a. Are all of the substantive reasons for the disclaimer stated in a 
separate paragraph or paragraphs?
b. Does the report state that the scope of the audit was not sufficient 
to warrant the expression of an opinion?
c. Does the report avoid identifying procedures that were per­
formed?
d. Is the scope paragraph omitted?
e. If there are reservations about fair presentation of the financial 
statements in conformity with GAAP, are they described in the 
report?
[AU 508.62-.63]
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Note: Consult the Topical Index to the AICPA Professional Standards under 
"Scope of Audit—Limitations" for additional references to specific types of 
scope limitations that could result in either a qualified or disclaimer of 
opinion.
31. If the financial statements are materially affected by a departure from 
GAAP (including inadequate disclosure, inappropriate accounting 
principles, and unreasonable accounting estimates), has the auditor 
issued a qualified opinion or an adverse opinion?
[AU 508.35]
Note: SOP 00-1 discusses auditing matters to consider in testing third-party 
revenues and related receivables, and provides guidance regarding the suf­
ficiency of evidential matter and reporting on financial statements of health 
care entities exposed to material uncertainties. Paragraphs 22-37 specifi­
cally address potential departures from GAAP related to estimates and 
uncertainties that fall into three categories: unreasonable accounting esti­
mates; inappropriate accounting principles; and inadequate disclosure. 
[SOP 00-1 par. 22-37 (AUD 14,360.22-.37)]
32. If a qualified opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons that have led to the conclusion 
that there is a departure from GAAP disclosed in one or more 
separate explanatory paragraphs preceding the opinion para­
graph?
b. Does the qualified opinion include the word except or exception in a 
phrase such as except for or with the exception of and a reference to 
the explanatory paragraph?
c. Does the explanatory paragraph disclose the principle effects of 
the departure on financial position, results of operations, and cash 
flows, if practicable, or state that the effects are not reasonably 
determinable?
[AU 508.21 and AU 508.37-.39]
33. If an adverse opinion is to be expressed because of a GAAP departure:
a. Are all of the substantive reasons for the adverse opinion disclosed 
in one or more separate explanatory paragraphs preceding the 
opinion paragraph?
b. Does the explanatory paragraph disclose the principle effects of 
the departure on financial position, results of operations, and cash 
flows, if practicable, or state that the effects are not reasonably 
determinable?
c. State that the financial statements do not present fairly the financial 
position, or results of operations or cash flows in conformity with 
GAAP?
[AU 508.58-.60]
FSP §11,300.03
152 Health Care Organizations
Yes No N/A
Notes: Consult the Topical Index to the AICPA Professional Standards under 
"Departures From Standard Report" for additional information.
Readers may also wish to refer to TPA TIS section 1400.31, "GAAP Depar­
ture for FIN No. 46(R)" (AICPA, Technical Practice Aids), for assistance in 
determining the implications on the auditors report if the reporting entity 
does not consolidate a variable interest entity.
Practice Tips
Reporting on financial statements prepared in conformity with an other comprehensive basis of accounting 
(OCBOA) is addressed in AU section 623, Special Reports (AICPA, Professional Standards, vol. 1). For purposes 
of that section, a comprehensive basis of accounting other than GAAP is one of the following:
a. A basis of accounting that the reporting entity uses to comply with the requirements or financial 
reporting provisions of a governmental regulatory agency to whose jurisdiction the entity is subject. 
An example is a basis of accounting insurance companies use pursuant to the rules of a state insurance 
commission.
b. A basis of accounting that the reporting entity uses or expects to use to file its income tax return for the 
period covered by the financial statements.
c. The cash receipts and disbursements basis of accounting, and modifications of the cash basis having 
substantial support, such as recording depreciation on fixed assets or accruing income taxes.
d. A definite set of criteria having substantial support that is applied to all material items appearing in 
financial statements, such as the price-level basis of accounting.
In considering whether the financial statements (including the accompanying notes) include all informative 
disclosures that are appropriate for the basis of accounting used, paragraph .09 of AU section 623 states that 
the auditor should apply essentially the same criteria to financial statements prepared on an OCBOA as he or 
she does to financial statements prepared in conformity with GAAP.
34. When reporting on financial statements prepared in conformity with a 
comprehensive basis of accounting other than GAAP, as defined in 
paragraph .04 of AU section 623, does the independent auditor's report 
include the following elements (for audits prepared in conformity with 
GAAS):
a. A title that includes the word independent? _____ _____ _____
[AU 623.05a]
b. A paragraph that states that
(1) the financial statements identified in the report were audited? _____ _____ _____
(2) the financial statements are the responsibility of the company's 
management and that the auditor is responsible for expressing
an opinion on the financial statements based on the audit? _____ _____ _____
[AU 623.05b]
c. A paragraph that states that
(1) the audit was conducted in accordance with GAAS with spe­
cific identification of the United States of America as the coun­
try of origin of those standards? _____ _____ _____
(2) those standards require that the auditor plan and perform the
audit to obtain reasonable assurance about whether the finan­
cial statements are free of material misstatement? _____ _____ _____
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(3) an audit includes examining, on a test basis, evidence support­
ing the amounts and disclosures in the financial statements; 
assessing the accounting principles used and significant esti­
mates made by management; and evaluating the overall finan­
cial statement presentation? _____ _____ ____
(4) the auditor believes that his or her audit provides a reasonable
basis for the opinion? _____ _____ ____
[AU 623.05c]
d. A paragraph that states
(1) the basis of presentation and refers to the note to the financial
statements that describes the basis? _____ _____ ____
(2) that the basis of presentation is a comprehensive basis of ac­
counting other than GAAP? _____ _____ ____
[AU 623.05d]
e. A paragraph that expresses the auditor's opinion (or disclaims an 
opinion) on whether the financial statements are presented fairly, 
in all material respects, in conformity with the basis of accounting
described? _____ _____ ____
[AU 623.05c]
f. If the financial statements are prepared in conformity with the re­
quirements or financial reporting provisions of a governmental 
regulatory agency, a separate paragraph at the end of the report 
stating that the report is intended solely for the information and 
use of those within the entity and the regulatory agencies to whose 
jurisdiction the entity is subject, and is not intended to be and
should not be used by anyone other than these specified parties? _____ _____ ____
[AU 623.05f]
g. The manual or printed signature of the auditor's firm or organiza­
tion? _____ _____ ____
[AU 623.05g]
h. The date of the audit report? _____ _____ ____
[AU 623.05h]
35. When the financial statements are prepared in conformity with the 
requirements or financial reporting provisions of a governmental reg­
ulatory agency and the financial statements and reports will be used 
by parties or distributed by the entity to parties other than the regula­
tory agencies to whose jurisdiction the entity is subject, has the stan­
dard form of report been modified as appropriate because of the de­
partures from GAAP and has an additional paragraph been added to 
express an opinion on whether the financial statements are presented 
in conformity with the regulatory basis of accounting? (Note: Interpre­
tation No. 15, "Auditor Reports on Regulatory Accounting or Presen­
tation When the Regulated Entity Distributes the Financial Statements 
to Parties Other Than the Regulatory Agency Either Voluntarily or 
Upon Specific Request," of AU section 623 [AICPA, Professional Stan­
dards, vol. 1, AU sec. 9623 par. .96-.98] provides an example report.) _____ _____ ____
[AU 544.04; AU 9623.96-.98]
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36. If certain other information, including supplementary information re­
quired by GAAP, contained in annual reports and other client-pre­
pared documents described in AU section 550, Other Information in 
Documents Containing Audited Financial Statements, paragraph .02 
(AICPA, Professional Standards, vol. 1), that contain audited financial 
statements has been subjected to auditing procedures applied in the 
audit of the basic financial statements, does the auditor express an 
opinion on whether the information is fairly stated in all material re­
spects in relation to those financial statements taken as a whole in the 
auditor's report and does the report describe clearly the character of 
the auditor's work and the degree of responsibility the auditor is tak­
ing?
[AU 550.07 and 558.09]
37. If other information contained in annual reports and other client-pre­
pared documents described in AU section 550 paragraph .02 that con­
tain audited financial statements is materially inconsistent with infor­
mation appearing in the financial statements, has it been determined 
whether the financial statements, the auditor's report, or both require 
revision?
[AU 508.11h and 550.04]
38. If other information contained in annual reports and other client-pre­
pared documents described in AU section 550 paragraph .02 that con­
tain audited financial statements is materially inconsistent with infor­
mation appearing in the financial statements, and the auditor has 
determined that neither the financial statements nor the auditor's re­
port require revision, has the auditor either:
a. Requested that the client revise the other information to eliminate 
the material consistency? or
b. Considered other actions such as revising the audit report to in­
clude an explanatory paragraph describing the material inconsis­
tency, withholding the use of the audit report in the document, 
and withdrawing from the engagement?
[AU 550.04]
39. If information accompanies the basic financial statements and auditor's 
report in an auditor-submitted document, is it accompanied by a report 
that
a. states that the audit was performed for the purpose of forming an 
opinion on the basic financial statements taken as a whole?
b. specifically identifies the accompanying information?
c. states that the accompanying information is presented for pur­
poses of additional analysis and is not a required part of the basic 
financial statements?
d. includes either an opinion on whether the accompanying infor­
mation is fairly stated in all material respects in relation to the basic 
financial statements taken as a whole or a disclaimer of opinion 
(depending on whether the information was subjected to the au­
diting procedures applied in the audit of the basic financial state­
ments)?
[AU 551.05-.06]
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40. If information accompanying the basic financial statements and audi­
tor's report in an auditor-submitted document is materially misstated 
in relation to the basic financial statements taken as a whole, has the 
auditor either:
a. Requested that the client revise the accompanying information to
eliminate the material misstatement? or _____ _____ ____
b. Considered other actions such as modifying the audit report to 
describe the misstatement or refusing to include the accompanying
information in the auditor-submitted document? _____ _____ ____
[AU 551.09]
41. When the basic financial statements are accompanied by supplemen­
tary information required by GAAP and such supplementary infor­
mation has not been audited as part of the basic financial statements, 
does the auditor's report exclude any language that refers to the sup­
plementary information or the limited procedures applied (except in 
the circumstances described in AU section 558, Required Supplementary
Information, paragraph .08 [AICPA, Professional Standards, vol. 1])? _____ _____ ____
[AU 558.08]
42. When the basic financial statements are accompanied by supplemen­
tary information required by GAAP and such supplementary infor­
mation has been audited as part of the basic financial statements, has 
the audit report been expanded in accordance with AU section 550
paragraph .07? _____ _____ ____
[AU 558.09]
43. If supplementary information required by GAAP has been omitted, the 
presentation of such information departs materially from prescribed 
guidelines, the auditor is unable to complete prescribed procedures 
with respect to such information, or the auditor is unable to remove 
substantial doubt about whether the supplementary information con­
forms to prescribed guidelines, does the report include an additional
paragraph stating that fact? ------- ------- -------
[AU 558.08]
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Auditors' Reports Checklist for Audits
Performed in Accordance With
Government Auditing Standards and
OMB Circular A-133
.01 Government Auditing Standards (also referred to as the Yellow Book), issued by the Comptroller Gen­
eral of the United States of the U.S. Government Accountability Office (GAO), applies to the audits of govern­
mental entities, programs, activities, and functions, and of governmental assistance administered by contrac­
tors, not-for-profit organizations (NPOs), and other nongovernmental entities, when required by statute or 
other mandates or when auditors hold themselves out as following those standards.1 The Single Audit Act 
Amendments of 1996 (the Single Audit Act) and Office of Management and Budget (OMB) Circular A-133, 
Audits of States, Local Governments, and Non-Profit Organizations (Circular A-133), require a single or program- 
specific audit for entities that expend $500,000 or more of federal awards in a fiscal year. The Single Audit Act 
requires single audits and program-specific audits of federal awards to be performed in accordance with 
Government Auditing Standards. Similarly, Government Auditing Standards requires the use of its standards when 
auditing compliance with regulations relating to federal award expenditures and other governmental finan­
cial assistance in conjunction with or as a byproduct of a financial statement audit.
1 As discussed in paragraph 4.26 of the AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits, paragraph 5.06 
of Government Auditing Standards acknowledges that an auditee may need a financial statement audit for purposes other than to comply 
with a requirement calling for an audit in accordance with Government Auditing Standards. For example, the auditee may need a financial 
statement audit to issue bonds. In that case, Government Auditing Standards permits auditors to issue a separate report on the financial 
statements conforming only to the requirements of generally accepted auditing standards (GAAS). The AICPA Audit and Accounting 
Guide State and Local Governments discusses auditor association with municipal securities filings and the use of Government Auditing 
Standards reports and references in the official statement. That guide states that the official statement should not include the reports 
required by Government Auditing Standards and that guide states that it generally is advisable for the official statements to use an auditor's 
report on the financial statements that does not refer to the Government Auditing Standards audit or to those reports. (The information 
contained in this checklist is based on the 2007 revision of Government Auditing Standards, which is effective for audits of periods beginning 
on or after January 1, 2008.)
.02 This checklist has two parts: part I is for auditor's reports on financial statement audits performed in 
accordance with Government Auditing Standards. (This checklist does not address the performance auditing or 
attestation standards of Government Auditing Standards. It also does not address types of financial audits other 
than financial statement audits, except for Circular A-133 audits.) Part II contains the additional requirements 
for auditor's reports on audits performed in accordance with the Single Audit Act and Circular A-133. For 
audits performed in accordance with Circular A-133, both parts I and II of this checklist must be completed. 
Illustrative auditor's reports on financial statement audits performed in accordance with Government Auditing 
Standards and illustrative auditor's reports and an illustrative schedule of findings and questioned costs for 
Circular A-133 audits are in the AICPA Audit Guide Government Auditing Standards and Circular A-133 
Audits.
.03 The OMB issues an annual Circular A-133 compliance supplement for conducting single audits. That 
supplement is available from the Government Printing Office by calling (202) 512-1800 and on the OMB's 
Web site at www.whitehouse.gov/omb/grants/grants_circulars.html. The AICPA issues the annual Audit 
Risk Alert Government Auditing Standards and Circular A-133 Audits as a complement to the Audit Guide 
Government Auditing Standards and Circular A-133 Audits. The AICPA has also issued a related practice aid,
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Auditing Recipients of Federal Awards: Practical Guidance for Applying OMB Circular A-133, Third Edition (product 
no. 006621).
.04 The Public Company Accounting Oversight Board (PCAOB) establishes standards for audits of issuers, 
as that term is defined by the Sarbanes-Oxley Act of 2002 (the act) or whose audit is prescribed by the rules of 
the Securities and Exchange Commission (SEC). Other entities are referred to as nonissuers. Because health 
care organizations generally are nonissuers, this section of this checklist does not address PCAOB standards. 
However, the auditee may be an issuer or the auditor may be engaged to audit and report on the effectiveness 
of a nonissuer's internal control over financial reporting in accordance with PCAOB auditing standards. In 
those cases, the auditor should modify this checklist considering the guidance in PCAOB standards, the GAO 
Internet notice at www.gao.gov/govaud/ybk01.htm titled Guidance on Complying with Government Auditing 
Standards Reporting Requirements for the Report on Internal Control for Audits of Certain Entities Subject to the 
Requirements of the Sarbanes-Oxley Act of 2002 and Government Auditing Standards, and Auditing Interpreta­
tion No. 18, "Reference to PCAOB Standards in an Audit Report on a Nonissuer," of AU section 508, Reports 
on Audited Financial Statements (AICPA, Professional Standards, vol. 1, AU sec. 9508.89-.92), as well as the 
discussion in the notice to readers and appendix A to chapter 4 of the AICPA Audit Guide Government 
Auditing Standards and Circular A-133 Audits.
.05 As explained in chapter 14 of AICPA Audit and Accounting Guide State and Local Governments, and 
the first practice tip in FSP section 13,200, the auditor generally expresses or disclaims an opinion on a 
government's basic financial statements by providing an opinion or disclaimer of opinion on each opinion 
unit required to be presented in those financial statements. This checklist sometimes uses the singular terms 
opinion and disclaimer of opinion to encompass the multiple opinions and disclaimers of opinions that generally 
will be provided on a government's financial statements.
.06 This checklist has been updated for the revisions to OMB Circular A-133 published in the Federal 
Register on June 26, 2007, which changes the reporting requirements on internal control deficiencies over 
compliance to be consistent with the control deficiency definitions of AU section 325A, Communicating Internal 
Control Related Matters Identified in an Audit (AICPA, Professional Standards, vol. 1). Interpretation No. 1, "Com­
municating Deficiencies in Internal Control Over Compliance in an Office of Management and Budget (OMB) 
Circular A-133 Audit," of AU section 325A (AICPA, Professional Standards, vol. 1, AU sec. 9325A par. .01-.04), 
provides guidance on implementing these reporting requirements.
.07 Explanation of References:
A-133 = Office of Management and Budget (OMB) Circular A-133, Audits of States, Local
Governments, and Non-Profit Organizations (June 2007 revision)
GAS = Government Accountability Office (GAO) 2007 revision to Government Auditing
Standards
SAS = AICPA Statement on Auditing Standards
AU = Reference to section number in AICPA Professional Standards (vol. 1)
AAG-SLA = AICPA Audit Guide Government Auditing Standards and Circular A-133 Audits
(with conforming changes as of May 1, 2007)
.08 Checklist Questionnaire:
Yes No N/A
Part I—Reports on Audits Performed in Accordance With
Government Auditing Standards
1. In a financial statement audit performed in accordance with Govern­
ment Auditing Standards, has the auditor issued the following reports:
a. A report on the entity's financial statements that provides an opin­
ion or disclaimer of opinion on the financial statements? _____ _____ _____
[GAS 5.03; AAG-SLA 4.04 and 4.22]
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b. A report on internal control over financial reporting and on com­
pliance and with laws, regulations, and provisions of contracts or 
grant agreements based on an audit of financial statements per­
formed in accordance with Government Auditing Standards? _____ _____ _____
[GAS 5.07; AAG-SLA 4.04, 4.08, and 4.27]
Report on the Financial Statements
2. In addition to the elements listed in the checklist for the auditor's re­
port on the financial statements at FSP section 11,300, does the audi­
tor's report on the financial statements contain:2
2 There is no provision in Government Auditing Standards that requires the auditee to prepare financial statements in accordance with 
accounting principles generally accepted in the United States of America (GAAP). If an auditee prepares financial statements in conformity 
with comprehensive bases of accounting other than GAAP, known as other comprehensive bases of accounting, or OCBOA, the auditor 
still is required to express or disclaim an opinion and should follow the reporting guidance in AU section 623, Special Reports. (AICPA, 
Professional Standards, vol. 1). [GAS 5.03 fn 62; AAG-SLA 4.22b]
3 When personal, external, and organizational impairments to independence exist, a government auditor who cannot decline to perform 
the work because of a legislative requirement or for other reasons should report the impairment in the scope section of the auditor's 
report. [GAS 3.04 and 4.22d]
4 If the reporting on internal control over financial reporting and on compliance and other matters is included in the report on the
financial statements, the reference to the separate report is not required. The Audit Guide Government Auditing Standards and Circular 
A-133 Audits recommends separate reporting. [AAG-SLA 4.05b and 4.22i]
a. A statement that the audit was conducted in accordance with the 
standards applicable to financial audits contained in Government 
Auditing Standards, issued by the Comptroller General of the
United States?3 _____ _____ _____
[GAS 5.05; AAG-SLA 4.05a, 4.22d, and 4.24]
b. A statement or a reference to a separate report on internal control 
over financial reporting and on compliance with certain provisions 
of laws, regulations, contracts, and grant agreements and other 
matters prepared in accordance with Government Auditing Stan­
dards,4 which includes
(1) a description of the scope of testing of internal control over 
financial reporting and compliance with laws, regulations and 
provisions of contracts or grant agreements and the results of 
that testing, and a statement as to whether the tests performed 
provided sufficient appropriate evidence to support an opin­
ion on the internal control over financial reporting or on com­
pliance with laws, regulations and provisions of contracts or
grant agreements?5 _____ _____ _____
(2) If a separate report is issued, a reference to the separate report 
is included in the report on the financial statements and a state­
ment that the separate report is an integral part of an audit 
performed in accordance with Government Auditing Standards
and should be considered in assessing the results of the audit? _____ _____ _____
[GAS 5.08-.09; AAG-SLA 4.05b and 4.22i]
5 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial reporting
or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion on internal
control over financial reporting or on compliance in the Government Auditing Standards report. [AAG-SLA 4.05b and 4.22i]
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3. If the auditor does not follow an applicable standard of Government
Auditing Standards, does the scope section of the report disclose the 
standard that was not followed, the reasons therefore, and how not 
following the standard affected, or could have affected, the results of
the audit? ------- ------- -------
[GAS 1.12b; AAG-SLA 4.25]
4. If a material organizational unit is not required to have an audit in 
accordance with Government Auditing Standards, has the scope para­
graph of the report on the financial statements been modified to indi­
cate the portion of the entity that was not audited in accordance with
Government Auditing Standards? _____ _____ _____
[AAG-SLA 4.39-.40]
Report on Internal Control Over Financial Reporting and on Compliance
and Other Matters Based on an Audit Performed in Accordance With
Government Auditing Standards
5. Does the auditor's report on internal control over financial reporting 
and on compliance and other matters conform to the standard report
language illustrated in AAG-SLA? _____ _____ _____
[AAG-SLA examples 4-4 and 4-6 in app. A (par. 4.51)]
6. Does the auditor's report on internal control over financial reporting 
and on compliance and other matters contain:
a. A statement that the auditor has audited the financial statements 
of the auditee and a reference to the auditor's report on the finan­
cial statements, including a description of any departure from the 
standard report (for example, a qualified opinion, a modification 
as to consistency because of a change in accounting principle, or a
reference to the report of other auditors)? _____ _____ _____
[AAG-SLA 4.28a and examples 4-4 and 4-6 in app. A (par. 4.51)]
b. A statement that the audit was conducted in accordance with 
GAAS (with an identification of the United States of America as 
the country of origin of those standards) and with the standards 
applicable to financial audits contained in Government Auditing
Standards, issued by the Comptroller General of the United States?6 _____ _____ _____
6 See footnote 3. [GAS 3.06; AAG-SLA 4.28b]
7 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial reporting 
or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion on internal 
control over financial reporting. [AAG-SLA 4.28c]
c. A statement that in planning and performing the audit, the auditor 
considered the auditee's internal control over financial reporting 
in order to determine the auditing procedures for the purpose of 
expressing an opinion on the financial statements and not to pro­
vide an opinion on the internal control over financial reporting; 
and accordingly, does not express an opinion on the effectiveness
of the auditee's internal control over financial reporting?7 _____ _____ _____
d. The definition of control deficiency and significant deficiency? If 
applicable, a statement that deficiencies were identified that are 
considered to be significant deficiencies in internal control over
financial reporting? _____ _____ _____
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e. A statement that the auditor's consideration of internal control
over financial reporting would not necessarily identify all deficien­
cies in internal control that might be significant deficiencies or ma­
terial weaknesses. If significant deficiencies are identified, a state­
ment that certain deficiencies in internal control over financial 
reporting were identified that the auditor considers to be signifi­
cant deficiencies? _____ _____ _____
f. If applicable, a description of the significant deficiencies identified 
(including the views of responsible officials and their planned cor­
rective action) or a reference to a separate schedule in which the 
significant deficiencies, views of responsible officials, and their
planned corrective action are described?8 _____ _____ _____
8 For an audit in accordance with Circular A-133, all findings, including those required to be reported under Government Auditing 
Standards, should be included in the schedule of findings and questioned costs. Therefore, for such audits, this report should refer to the 
schedule of findings and questioned costs. See the questions about that schedule in part II of this checklist. [AAG-SLA 4.28f and 12.17]
9 In reporting reportable conditions, the auditor should identify those that are individually or in the aggregate material weaknesses.
[GAS 5.13; AAG-SLA 4.09]
g. The definition of a material weakness? _____ _____ _____
h. If no significant deficiencies are identified, a statement that no ma­
terial weaknesses were identified. If significant deficiencies are 
identified, a statement that the auditor's consideration of internal 
control over financial reporting would not necessarily identify all 
deficiencies in the internal control that might be significant defi­
ciencies, and a statement about whether the auditor believes any 
of the significant deficiencies identified are material weaknesses 
and, if they are, that identifies which significant deficiencies are
considered material weaknesses?9 _____ _____ _____
i. A statement that as part of obtaining reasonable assurance about 
whether the auditee's financial statements are free of material mis­
statement, the auditor performed tests of the auditee's compliance 
with certain provisions of laws, regulations, contracts, and grant 
agreements, noncompliance with which could have a direct and 
material effect on the determination of financial statement
amounts? _____ _____ _____
j. A statement that providing an opinion on compliance with those 
provisions was not an objective of the audit and that, accordingly,
the auditor does not express such an opinion?10 _____ _____ _____
10 Paragraph 5.08 of Government Auditing Standards permits, but does not require, an opinion on internal control over financial reporting
or on compliance if sufficient work was performed. This statement should be modified if the auditor is providing an opinion on compliance.
[AAG-SLA 4.28j]
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k. A statement that notes whether the results of tests disclosed in­
stances of noncompliance or other matters (certain fraud and 
abuse) that are required to be reported under Government Auditing 
Standards and, if they are, describes the instances of noncompliance 
and other matters (including the views of responsible officials and 
their planned corrective action) or refers to the separate schedule 
in which the noncompliance and other matters, views of responsi­
ble officials, and their planned corrective action are described?11 If 
applicable, a statement that the auditor did not audit the auditee's
11 See footnote 8. [AAG-SLA 4.28k]
12 For an audit in accordance with Circular A-133, this reference should include federal awarding agencies and, if applicable, pass­
through entities. [AAG-SLA 4.28m and 12.17]
13 This paragraph conforms to AU section 532, Restricting the Use of an Auditor's Report (AICPA, Professional Standards, vol. 1). See AU 
section 532 for additional guidance on restricted-use reports. [AAG-SLA 4.28m]
response and, accordingly, expresses no opinion on it? ------- ------- -------
[AAG-SLA 4.26]
l. If applicable, a statement that the auditor did not audit the audi­
tee's response and, accordingly, expresses no opinion on it? _____ _____ _____
[AAG-SLA 4.28]
m. If applicable, a statement that additional matters were communi­
cated to the auditee in a management letter? _____ _____ _____
[AAG-SLA 4.28l, 4.37 and examples 4-4 and 4-6 in app. A (par.
4.51)]
n. A separate paragraph at the end of the report stating that the report 
is intended solely for the information and use of management 
[identify the body or individuals charged with governance] and others 
within the entity [identify any specified legislative or regulatory body],12 
and is not intended to be and should not be used by anyone other
than these specified parties?13 _____ _____ _____
o. The manual or printed signature of the auditor's firm or organiza­
tion? _____ _____ _____
p. The date of the auditor's report? _____ _____ _____
[AAG-SLA 4.28o]
7. Does the report carry the same date as the report on the financial state­
ments? _____ _____ _____
[AAG-SLA 4.26o]
8. If a component unit or fund that is material to an opinion unit is not 
required to have an audit in accordance with Government Auditing Stan­
dards, has the scope paragraph of the report been modified to indicate 
the portion of the entity that was not audited in accordance with Gov­
ernment Auditing Standards? (If it is not evident from the financial state­
ments to which opinion unit the component unit or fund relates, the 
auditor should consider identifying the opinion unit in addition to the
name of the component unit or fund.) _____ _____ _____
[AAG-SLA 4.39-.40]
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9. If certain pertinent information is prohibited from public disclosure or 
is excluded from a report due to the confidential or sensitive nature of 
the information (as it may be by federal, state, or local laws or regula­
tions), does the auditor's report state that certain information has been 
omitted and the reason or other circumstance that makes the omission
necessary? _____ _____ _____
[GAS 5.39; AAG-SLA 4.05g]
10. Does the language in the compliance and other matters section of the 
report refer to findings that do or may include fraud and abuse? (That 
language should appear in all reports, even if the report does not de­
scribe or refer to findings of fraud or abuse or even if the only findings 
of fraud or abuse are described in or referred to from the section on
internal control over financial reporting.) _____ _____ _____
[AAG-SLA 4.31]
11. Are findings that relate to both internal control over financial reporting 
and to compliance reported in or referred to from both the section of 
the report concerning internal control over financial reporting and in 
the section of the report concerning compliance and other matters?
(The reporting in one section of the report or schedule may be in sum­
mary form with a reference to a detailed reporting in the other section.) _____ _____ _____
[AAG-SLA 4.30]
12. Are findings of fraud and abuse reported in or referred to from the 
compliance and other matters section of the report, unless the primary 
nature of the finding is a significant deficiency in internal control?
(Auditors should present or refer to findings of fraud and abuse that 
represent significant deficiencies in internal control in the internal con­
trol section.) _____ _____ _____
[AAG-SLA 4.31]
13. Do the reported findings include all identified deficiencies in internal
control over financial reporting considered to be significant deficien­
cies (identifying those considered material weaknesses), all fraud and 
illegal acts (unless inconsequential),14 and material violations of provi­
sions of contracts or grant agreements and material abuse that has _____ _____ _____
14 In an audit conducted in accordance with Circular A-133, the auditor should apply a financial statement materiality consideration in 
reporting in the Government Auditing Standards report fraud and illegal acts involving federal awards that are subject to Circular A-133 
reporting. That is because those findings already are reported in the Circular A-133 report and reporting findings that are not material to 
the financial statements again in the Government Auditing Standards report would be unnecessarily duplicative. [AAG-SLA 4.16, 12.16, and 
12.33]
occurred or is likely to have occurred?
[GAS 5.10; AAG-SLA 4.05c, 4.09, 4.16-.17, 4.29, and 12.33]
14. Does each finding include a reference number? (For example, findings
identified and reported in the audit of fiscal year 20X1 could be as­
signed reference numbers 20X1-1, 20X1-2, and so forth.) _____ _____ _____
[AAG-SLA 4.34]
15. Do the reported findings place the findings in proper perspective (or 
context) by describing the nature and extent of the issues reported and 
the work performed that resulted in the finding? (The identified in­
stances should be related to the population or the number of cases 
examined and be quantified in terms of dollar value or other measures,
if appropriate.) _____ _____ _____
[GAS 5.22; AAG-SLA 4.32]
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a. When reporting instances of fraud, illegal acts, violations of pro­
visions of contracts or grant agreements, or abuse, are the results 
projected? (If the results cannot be projected, auditors should limit
their conclusions appropriately.) ------- ------- -------
[GAS 5.22; AAG-SLA 4.32]
16. To the extent possible and to achieve audit objectives, do the reported 
findings present criteria, condition, cause, effect or potential effect, and
recommendation? ------- ------- -------
[GAS 4.14-.18 and 5.21; AAG-SLA 4.33]
17. Does the auditor's report include the views of responsible officials con­
cerning the findings, conclusions, and recommendations, as well as
planned corrective actions?15,16 ------- ------- -------
15 In an audit in accordance with Circular A-133, the auditee is required to submit a corrective action plan. For those audits, depending 
on the status of the development of the corrective action plan at the time the auditor's reports are released, the auditor may be able to 
refer to the corrective action plan to satisfy as the required presentation of the auditee's views and planned corrective actions. See the 
questions about the reporting of auditee views and the corrective action plan in part II of this checklist. [AAG-SLA, par. 4.35]
16 The auditor is required to extend a reasonable effort to obtain and report auditee views and planned corrective actions. Government 
Auditing Standards does not require the auditor to delay or withhold the release of the report if the auditee does not provide the necessary 
information on a timely basis. If, however, the auditee does not provide the necessary information by the time the report is released, the 
report should indicate the status of the auditee's response. [AAG-SLA 4.36]
17 When the responsible officials provide oral comments only, auditors should prepare a summary of the oral comments and provide a 
copy of the summary to the responsible officials to verify that the comments are accurately stated.
18 Generally, Government Auditing Standards requires the auditor to evaluate findings for the purpose of communication in the manage­
ment letter based on their consequence to the financial statements or other financial data significant to the audit objectives. In an audit in 
accordance with Circular A-133, however, the auditor should evaluate findings involving federal awards for the purpose of that com­
munication based only on their consequence to the financial statements. Further, the auditor should not communicate such findings in 
the management letter if they are otherwise reported as audit findings in accordance with Circular A-133. [AAG-SLA 4.37 and 12.25]
[GAS 5.32; AAG-SLA 4.05f and 4.35]
a. If the auditor receives, in writing, the views of responsible officials, 
is a copy of the officials' written comments or a summary of the
comments received included in the auditor's report?17 _____ _____ _____
b. Does the auditor's report include an evaluation of the comments,
as appropriate? ------- ------- -------
c. If the auditee's views are inconsistent or in conflict with the re­
port's findings, conclusions, or recommendations, and are not, in 
the auditor's opinion, valid—or if the planned corrective actions 
do not adequately address the auditor's recommendations—does
the report state reasons for disagreeing with the comments or _____ _____ _____
planned corrective actions?
d. If the auditee refused to provide comments or is unable to provide 
comments within a reasonable period of time, does the auditor's
report state that the audited entity did not provide comments? _____ _____ _____
[GAS 5.34-.38; AAG-SLA 4.35]
Other Reporting and Communication Considerations
18. Does the management letter communicate the following unless clearly 
inconsequential—deficiencies in internal control that are not signifi­
cant deficiencies, immaterial violations of provisions of contracts or
grant agreements, and immaterial abuse?18 _____ _____ _____
[GAS 5.16; AAG-SLA 4.19 and 4.37]
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a. Are the management letter discussions worded so that readers can
distinguish those matters that are required to be included by 
GAAS or Government Auditing Standards from matters that are rec­
ommendations for improvements or information about "best prac­
tices"? _____ _____ _____
[AAG-SLA 4.38]
b. Does the management letter not include personal identification or
other potentially sensitive matters? _____ _____ _____
[AAG-SLA 4.49]
19. Has the auditor used professional judgment to determine whether and
how to communicate to auditee officials deficiencies in internal control, 
fraud, illegal acts, violations of provisions of contracts or grant agree­
ments, and abuse that are less than material but more than inconse­
quential?19 _____ _____ _____
19 GAAS require that whenever the auditor has determined that there is evidence that fraud may exist, the auditor should bring that 
matter to the attention of an appropriate level of management, even if the matter might be considered inconsequential. [AU 316.79; AAG- 
SLA 4.12 and 4.37]
[GAS 5.16; AAG-SLA 4.37]
20. Has the auditor reported known or likely fraud, illegal acts, violations 
of provisions of contracts or grant agreements, and abuse directly to 
parties outside of the auditee in the situations required by Government 
Auditing Standards, even if the auditor has resigned or been dismissed
from the audit? _____ _____ _____
[GAS 5.18-5.20; AAG-SLA 4.20]
21. In addition to the communications required by GAAS, has the auditor 
communicated the following information regarding his or her planned 
work and reporting related to testing internal control over financial 
reporting and compliance with laws, regulations and provisions of 
contracts or grant agreements, preferably in a writing such as the en­
gagement letter, to those charged with governance of the audited entity 
and to the individuals contracting for or requesting the audit during 
the planning stages of the audit:
a. The auditor's responsibilities for testing and reporting on internal
control over financial reporting and on compliance with laws, reg­
ulations, and provisions of contracts or grant agreements? _____ _____ _____
b. The nature of any additional testing of internal control and com­
pliance required by laws, regulations, and provisions of contracts 
or grant agreements or otherwise requested, and whether the au­
ditor is planning on providing an opinion on internal control over 
financial reporting or on compliance with laws, regulations, and
provisions of contracts or grant agreements? _____ _____ _____
c. A contrasting of the responsibilities in questions a and b in the
preceding with other audits of internal control and compliance? _____ _____ _____
d. Potential restrictions on the auditor's reports? _____ _____ _____
e. Additional relevant topics, such as the auditor's fieldwork and re­
porting responsibilities for fraud and abuse? _____ _____ _____
[GAS 4.06-.07]
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Yes
22. If an audit is terminated before it is complete, is the reason for termi­
nating the audit communicated to auditee management, the entity re­
questing the audit, and other appropriate officials, preferably in writ­
ing? —
[GAS 4.08; AAG-SLA 2.30]
23. If the auditor is:
a. A government auditor, does the auditor submit the auditor's re­
ports to the appropriate officials of the audited entity, appropriate 
officials of the organizations requiring or arranging for the audits 
(unless legal restrictions prevent it), and other officials who have 
legal oversight authority or who may be responsible for acting on 
audit findings and recommendations and to others authorized to 
receive such reports? -------
b. A nongovernment auditor, does the auditor clarify report distri­
bution responsibilities with the party contracting for the audit and
follow the agreements reached? -------
[GAS 5.44; AAG-SLA 4.05g]
24. Unless the report is restricted by law or regulation, or contains privi­
leged and confidential information, does the auditor clarify that copies 
are made available for public inspection? (That clarification should be 
made in the engagement letter and may also be made in correspon­
dence that transmits the reports to the auditee and other recipients.) _____
[GAS 5.44; AAG-SLA 4.05h]
25. If the auditor is reporting on restated financial statements, did the au­
ditor's report include an explanatory paragraph in the reissued or up­
dated auditor's report that included:
a. A statement disclosing that the previously-issued financial state­
ments have been restated? _____
b. A statement that the previously-issued report (referred to by report
date) is not to be relied upon (because previously issued financial 
statements were materially misstated) and is being replaced by the 
auditor's report on the restated financial statements? _____
c. A reference to the notes to the restated financial statements that
discusses the restatement? _____
d. If applicable, a reference to the report on internal control contain­
ing a discussion of any significant deficiency identified related to 
the failure to prevent or detect the misstatement and any manage­
ment corrective action taken? _____
[GAS 5.29]
26. If the auditor is reporting on restated financial statements and if man­
agement fails to include the appropriate disclosures related to the re­
statement, are the omitted disclosures included in the auditor's report? _____
[GAS 5.28c and 5.30]
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27. Has the auditor notified those charged with governance if the entity's 
management (a) does not act in an appropriate time frame after new 
information was available to determine the financial statement effects 
of the new information and take the necessary steps to timely inform 
those who are likely to rely on the financial statements and the related 
auditor's reports of the situation or (b) does not restate with reasonable 
timeliness the financial statements under circumstances in which au­
ditors believe they need to be restated? _____ _____ _____
[GAS 5.31]
Part II—Reports on Audits Performed in Accordance
With Circular A-133
1. In an audit performed in accordance with Circular A-133, has the au­
ditor issued the following reports in addition to those in part I of this 
checklist:20
20 Because of the requirements of Government Auditing Standards, the auditor also has other reporting and communication responsibilities 
in a Circular A-133 audit. See the questions in the section titled "Other Reporting and Communication Considerations" in part I of this 
checklist.
a. A report on the supplementary schedule of expenditures of federal 
awards that provides an opinion (or disclaimer of opinion) as to 
whether the schedule is presented fairly in all material respects in
relation to the financial statements taken as a whole? ------- ------- -------
b. A report on compliance with requirements applicable to each ma­
jor program and on internal control over compliance in accordance 
with Circular A-133 that provides an opinion (or disclaimer of 
opinion) as to whether the auditee complied with laws, regula­
tions, and the provisions of contracts or grant agreements which 
could have a direct and material effect on each major program, 
and, where applicable, a reference to the separate schedule of find­
ings and questioned costs? ------- ------- -------
c. A schedule of findings and questioned costs? ------- ------- -------
[A-133 Sec. 505; AAG-SLA 12.07]
Report on the Supplementary Schedule of Expenditures of 
Federal Awards
2. Is the report on the schedule (a) included in the auditor's report on the 
financial statements, (b) included in the report on compliance with 
requirements applicable to each major program and on internal control 
over compliance in accordance with Circular A-133, or (c) issued as a
stand-alone report? ------- ------- -------
[AAG-SLA 12.12, 12.15, 12.24, and 12.28]
3. If the report on the financial statements refers to the work of other
auditors, has the auditor considered the need to refer to the major 
federal programs audited by other auditors in the report on the sched­
ule? ------- ------- -------
[AAG-SLA 12.29]
4. If the report on the schedule is included in the auditor's report on the 
financial statements or in the Circular A-133 report on compliance and 
on internal control over compliance, does it:
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a. Conform to the standard report language illustrated in AAG-SLA? _____
[AAG-SLA 12.14 and example 12-1 in app. A (12.54)]
b. Identify the schedule of expenditures of federal awards as accom­
panying supplementary information by descriptive title or by page 
number of the document? _____
c. Contain a statement that the audit was conducted for the purpose
of forming an opinion on the basic financial statements taken as a 
whole and that the schedule is presented for purposes of addi­
tional analysis and is not a required part of the financial state­
ments? _____
[AAG-SLA 12.12 and example 12-1 in app. A (12.54)]
d. Contain an opinion or a disclaimer of opinion as to whether the 
Schedule is fairly stated, in all material respects, in relation to the
financial statements taken as a whole? _____
[AAG-SLA 12.10, 12.12, and example 12-1 in app. A (12.54)]
e. Carry the same date as the report on the financial statements, even
if that requires a dual date on the Circular A-133 report on compli­
ance and on internal control over compliance? _____
[AAG-SLA 12.26-.28]
f. Consider the effect of any modifications to this report? _____
[AAG-SLA 12.14]
5. If the report on the schedule is issued as a stand-alone report, is the
guidance of AU section 508 followed in issuing that report? _____
a. Does the report carry the same date as the Circular A-133 report
on compliance and on internal control over compliance? _____
[AAG-SLA 12.28]
Report on Compliance With Requirements Applicable to Each Major
Program and on Internal Control Over Compliance in Accordance With
Circular A-133
6. Does the report conform to the standard report language illustrated in
AAG-SLA? _____
[AAG-SLA examples 12-1-12-5 in app. A (par. 12.54)]
7. Does the report contain the following elements:
a. A statement that the auditor has audited the compliance of the 
auditee with the types of compliance requirements described in 
the OMB Circular A-133 Compliance Supplement that are applicable
to each of its major programs? _____
b. A statement that the auditee's major programs are identified in the
summary of the auditor's results section of the accompanying 
schedule of findings and questioned costs? _____
c. A statement that compliance with the requirements of laws, regu­
lations, contracts, and grants applicable to each of the auditee's 
major federal programs is the responsibility of the auditee's man­
agement, and that the auditor's responsibility is to express an opin­
ion on the auditee's compliance based on the audit? _____
FSP §11,400.08
Yes No N/A
169
N/A
Auditors' Reports Checklist for Audits Performed in Accordance With GAS & OMB Circular A-133
Yes No
d. A statement that the audit of compliance was conducted in accor­
dance with GAAS (with an identification of the United States of 
America as the country of origin of those standards), the standards 
applicable to financial audits contained in Government Auditing 
Standards issued by the Comptroller General of the United States,
and Circular A-133? _____ ____
e. A statement that those standards and Circular A-133 require that
the auditor plan and perform the audit to obtain reasonable assur­
ance about whether noncompliance with the types of compliance 
requirements that could have a direct and material effect on a ma­
jor federal program occurred? _____ ____
f. A statement that an audit includes examining, on a test basis, evi­
dence about the auditee's compliance with those requirements and 
performing such other procedures as the auditor considered nec­
essary in the circumstances? ------- ------
g. A statement that the auditor believes that the audit provides a
reasonable basis for the auditor's opinion? ------- ------
h. A statement that the audit does not provide a legal determination
of the auditee's compliance with those requirements? ------- ------
i. If instances of noncompliance are noted that result in an opinion 
modification, a reference to a description in the accompanying 
schedule of findings and questioned costs, including:
(1) The reference number(s) of the finding(s)? ------- ------
(2) An identification of the type(s) of compliance requirements
and related major program(s)? ------- ------
(3) A statement that compliance with such requirements is neces­
sary, in the auditor's opinion, for the auditee to comply with
the requirements applicable to the program(s)? ------- ------
j. An opinion on whether the auditee complied, in all material re­
spects, with the types of compliance requirements that are appli­
cable to each of its major federal programs? ------- ------
k. If applicable, a statement that the results of the auditing procedu­
res disclosed instances of noncompliance that are required to be 
reported in accordance with Circular A-133 and a reference to the 
schedule of findings and questioned costs in which they are de­
scribed? ------- ------
l. A statement that the auditee's management is responsible for es­
tablishing and maintaining effective internal control over compli­
ance with the requirements of laws, regulations, contracts, and
grants applicable to federal programs? ------- ------
m. A statement that in planning and performing the audit, the auditor
considered the auditee's internal control over compliance with re­
quirements that could have a direct and material effect on a major 
federal program, to determine the auditing procedures for the pur­
pose of expressing an opinion on compliance but not for the pur­
pose of expressing an opinion on the effectiveness of internal con­
trol over compliance? ------- -----
FSP §11,400.08
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n. The definition of control deficiency and significant deficiency. If
applicable, a statement that deficiencies were identified that are 
considered to be significant deficiencies in internal control over 
compliance? ____
o. If applicable, a reference to a description of the significant deficien­
cies identified in the accompanying schedule of findings and ques­
tioned costs, including the reference number of the finding(s)? ____
p. If no significant deficiencies are identified, a statement that the
auditor's consideration of internal control over compliance would 
not necessarily disclose all matters in internal control that might 
be significant deficiencies or material weaknesses; if significant de­
ficiencies are identified, a statement that the auditor's considera­
tion of internal control over compliance would not necessarily dis­
close all matters in the internal control that might be significant 
deficiencies or material weaknesses and a statement that certain 
deficiencies were identified that are considered to be significant 
deficiencies (and, if applicable, material weaknesses)? ____
q. The definition of a material weakness? ____
r. If applicable, a statement about whether the auditor believes any
of the significant deficiencies identified are material weaknesses 
and, if they are, a reference to a description of the material weak­
nesses in the schedule of findings and questioned costs, including 
the reference number of the finding(s)? (If there are no significant 
deficiencies identified, a statement should be made that no mate­
rial weaknesses were identified.) ____
s. If applicable, a statement that the auditee's response to findings 
identified in the audit are described in the accompanying schedule 
of findings and questioned costs, and that the auditor did not audit 
the auditee's response and, accordingly, expresses no opinion on
it? ____
t. A separate paragraph at the end of the report stating that the report
is intended solely for the information and use of [identify the body 
or individuals charged with governance], others within the entity [iden­
tify the specified legislative or regulatory body], federal awarding agen­
cies, and (if applicable) pass-through entities and is not intended 
to be and should not be used by anyone other than these specified 
parties?21 ____
21 See footnote 13. [AAG-SLA 12.23t]
u. The manual or printed signature of the auditor's firm or organiza­
tion? ____
v. The date of the auditor's report? ____
[AAG-SLA 12.23]
8. If the audit of the auditee's compliance with requirements applicable 
to a major program detects material instances of noncompliance with 
those requirements, does the auditor's report express a qualified or
adverse opinion? ____
[AAG-SLA 12.19]
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9. Have scope limitations on the auditor's testing of the auditee's compli­
ance with laws, regulations, and the provisions of contracts or grant 
agreements been considered in the opinion on compliance with re­
quirements applicable to each major program? _____ ____
[AAG-SLA 12.20-.22]
10. Have the cumulative effects of all instances of noncompliance with 
federal programs and scope limitations been considered in the opinion
on the financial statements? _____ ____
[AAG-SLA 12.19-.20]
11. If there are abuse findings reported in the federal awards section of the 
schedule of findings and questioned costs that do not otherwise meet 
the Circular A-133 requirements for reporting as findings, has the au­
ditor considered the need to modify the report on compliance and on
internal control over compliance? ------- ------
[AAG-SLA 12.36]
12. Is the report dated the same as or later than the date of the auditor's
report on the financial statements? ------- ------
a. If the report is dated later than the date of the auditor's report on 
the financial statements, have appropriate subsequent events pro­
cedures been performed? ------- ------
[AAG-SLA 12.27]
13. If the audit of federal awards does not encompass the entirety of the 
auditee's operations expending federal awards, are the operations that 
are not included identified in a separate paragraph following the first
paragraph of the report? ------- ------
[AAG-SLA 12.30]
14. If the report on the financial statements refers to the work of other
auditors, has the auditor considered the need to refer to the major 
federal programs audited by other auditors in the report on compli­
ance and on internal control over compliance? ------- -----
[AAG-SLA 12.29]
Schedule of Findings and Questioned Costs
15. Does the report conform to the standard report language illustrated in
AAG-SLA? _____ ___
[AAG-SLA example 12-6 in app. A (par.12.54)]
16. Is the report presented even if there are no findings to report? (In a 
situation in which there are no findings or questioned costs, the auditor 
should prepare the summary of auditor's results section of the sched­
ule and either omit the other sections or include them, indicating that
no matters were reported.) ------- -----
[AAG-SLA 12.40]
17. Does the report contain the following three sections:
a. A summary of the auditor's results? ------- -----
b. Findings related to the financial statements that are required to be 
reported in accordance with Government Auditing Standards? (See
the questions about those findings in part I of this checklist.) _____ ___
c. Findings and questioned costs for federal awards? ------- -----
[AAG-SLA 12.31]
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18. Does the summary of auditor's results include:
a. The type of report the auditor issued on the financial statements of 
the auditee (that is, unqualified opinion, qualified opinion, adverse 
opinion, or disclaimer of opinion)?
[AAG-SLA 12.32a]
b. Where applicable, a statement that significant deficiencies in inter­
nal control were disclosed by the audit of the financial statements 
and whether any such deficiencies were material weaknesses?
c. A statement on whether the audit disclosed any noncompliance 
that is material to the financial statements?
d. Where applicable, a statement that significant deficiencies in the 
internal control over major programs were disclosed by the audit 
and whether any such deficiencies were material weaknesses? 
[AAG-SLA 12.32a]
e. The type of report the auditor issued on compliance for major pro­
grams (that is, unqualified opinion, qualified opinion, adverse 
opinion, or disclaimer of opinion)? (If the audit report for one or 
more major programs is other than unqualified, indicate the type 
of report issued for each program.)
[AAG-SLA 12.32a and example 12-6 in app. A (12.54)]
f. A statement on whether the audit disclosed any audit findings that 
the auditor is required to report under Circular A-133? (See ques­
tion 20 of the following.)
g. An identification of major programs?
h. The dollar threshold used to distinguish between type A and type 
B programs?
i. A statement on whether the auditee qualified as a low-risk audi­
tee?
[AAG-SLA 12.32a]
19. If there are abuse findings reported in the federal awards section of the 
schedule of findings and questioned costs that do not otherwise meet 
the Circular A-133 requirements for reporting as findings, has the au­
ditor considered the need to modify the summary of the auditor's re­
sults?
[AAG-SLA 12.36]
20. Are the following reported as audit findings related to federal awards:
a. Significant deficiencies and material weaknesses in internal control 
over major programs? (The auditor should identify significant de­
ficiencies that are individually or cumulatively material weak­
nesses.)
b. Material noncompliance with the provisions of laws, regulations, 
contracts, or grant agreements related to a major program?
c. Known questioned costs that are greater than $10,000 for a type of 
compliance requirement for a major program?
d. Known questioned costs when likely questioned costs are greater 
than $10,000 for a type of compliance requirement for a major pro­
gram?
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e. Known questioned costs that are greater than $10,000 for programs
that are not audited as major? _____ _____ _____
f. The circumstances concerning why the auditor's report on compli­
ance for major programs is other than an unqualified opinion, if
not otherwise reported as an audit finding? _____ _____ _____
g. Known fraud affecting a federal award, if not otherwise reported 
as an audit finding? (An audit finding is not required if the fraud
was reported outside the entity as required by GAS.) _____ _____ _____
[A-133 Sec. 510(a); AAG-SLA 12.35]
h. Instances of material misrepresentation by the auditee of the status
of any prior audit findings? _____ _____ _____
[A-133 Sec. 510(a); AAG-SLA 12.35 and 12.42]
i. Abuse involving federal awards that is material to a major pro­
gram? _____ _____ _____
[AAG-SLA 12.36]
21. Does the audit finding detail include:
a. A reference number? (For example, findings identified and re­
ported in the audit of fiscal year 20X1 would be assigned reference
numbers 20X1-1, 20X1-2, and so forth.) _____ _____ _____
[A-133 Sec. 510(c); AAG-SLA 12.39]
b. Identification of the federal program and specific federal award, 
including Catalog of Federal Domestic Assistance title and num­
ber, federal award number and year, name of the federal agency,
and name of the applicable pass-through entity?22 _____ _____ _____
22 When information such as the Catalog of Federal Domestic Assistance (CFDA) title and number or the federal award number is not 
available, the auditor should provide the best information available to describe the federal award. (Chapter 7 of AAG-SLA discusses an 
alternative for presentation if a CFDA number is not available.) [A-133 Sec. 510(b)(1); AAG-SLA 12.37a]
23 Where appropriate, the instances identified should be related to the universe and the number of cases examined and be quantified in 
terms of the dollar value. [A-133 Sec. 510(b)(5); AAG-SLA 12.37e]
c. The criteria or specific requirement upon which the audit finding
is based, including the statutory, regulatory, or other citation? _____ _____ _____
d. The condition found, including facts that support the deficiency
identified in the audit finding? _____ _____ _____
e. Identification of questioned costs and how they were computed? _____ _____ _____
f. Information to provide a proper perspective for judging the prev­
alence and consequences of the audit findings?23 _____ _____ _____
g. The possible asserted effect to provide sufficient information to the 
auditee and federal agency, or pass-through entity in the case of a 
subrecipient, to permit them to determine the cause and effect, to
facilitate prompt and proper corrective action? _____ _____ _____
h. Recommendations to prevent future occurrences of the deficiency? _____ _____ _____
[A-133 Sec. 510(b); AAG-SLA 12.37]
22. Do the audit findings related to federal awards also meet the presen­
tation requirements of Government Auditing Standards? (See the ques­
tions about those presentation requirements in part I of this checklist.) _____ _____ _____
[AAG-SLA 12.38]
23. Are audit findings that relate to federal awards:
FSP §11,400.08
174 Health Care Organizations
Yes No N/A
a. And that relate to the same issue presented as one finding? ------- ------- -------
b. Organized by federal agency or pass-through entity, where prac­
tical? ------- —----- -------
[A-133 Sec. 505(d)(3)(i); AAG-SLA 12.32c]
24. Are audit findings that relate to both the financial statements and the 
federal awards reported in both sections of the schedule? A alternative 
is to report the finding in one section of the schedule in summary form, 
with a reference to a detailed reporting in the other section of the
schedule. ------- ------- -------
[A-133 Sec. 505(d)(3)(ii); AAG-SLA 12.32c]
25. Are findings of abuse involving federal awards presented in the com­
pliance section of the schedule, unless the primary nature of the finding 
is a significant deficiency in internal control? (Auditors should present 
findings of abuse that represent significant deficiencies in internal con­
trol in the internal control section.) ------- ------- -------
[AAG-SLA 12.36]
26. Do the findings report the views of responsible officials concerning the 
findings, conclusions, and recommendations, as well as planned cor­
rective actions, as required by Government Auditing Standards, or refer 
to the corrective action plan, depending on the status of the develop­
ment of the corrective action plan at the time the auditor's reports are
released?24 _____ _____ _____
24 See footnote 16.
25 The data collection form and related instructions are available from the Federal Audit Clearinghouse's (FAC's) Web site at http:// 
harvester.census.gov/sac or by calling the FAC at (888) 222-9907. The form number is SF-SAC. The FAC prefers to receive the data 
collection form via an online Internet Data Entry System. The Office of Management and Budget periodically revises the data collection 
form and its accompanying instructions. Auditors should exercise caution to make sure they use the version of the form and instructions 
that applies to the fiscal year audited. [AAG-SLA 12.46]
[AAG-SLA 12.34 and 12.38]
a. If the auditee's comments oppose the report's findings, conclu­
sions, or recommendations, and are not, in the auditors' opinion, 
valid—or if the planned corrective actions do not adequately ad­
dress the auditors' recommendations—does the federal awards 
section of the schedule of findings and questioned costs state the 
auditor's reasons for disagreeing with the comments or planned
corrective actions? _____ _____ _____
[A-133 Sec. 510(b)(8); AAG-SLA 12.38]
27. Do the audit report and any attached or referenced schedules not in­
clude names, Social Security numbers, other personal identification, or
other potentially sensitive matters? _____ _____ _____
[AAG-SLA 12.53]
Data Collection Form25
28. Has the auditor completed the appropriate parts of the data collection
form? _____ _____ _____
29. Has the auditor signed the form and dated it as of the date on which
the auditor completes and signs the form? _____ _____ _____
[AAG-SLA 12.45]
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Yes No N/A
30. Does the information on the data collection form agree to the informa­
tion in the auditor's reports and the summary of auditor's results in
the schedule of findings and questioned costs? _____ _____ _____
[Federal Audit Clearinghouse Data Collection Form No. SF-SAC]
Program-Specific Audits
Practice Tip
When an auditee expends federal awards under only one federal program (excluding research and develop­
ment) and the federal program's laws, regulations, or grant agreements do not require a financial statement 
audit of the auditee, the auditee may elect to have a program-specific audit. A program-specific audit may 
not be elected for research and development unless all federal awards expended were received from the same 
federal agency (or the same federal agency and the same pass-through entity) and that federal agency (or 
pass-through entity, in the case of a subrecipient) approves a program-specific audit in advance.
[A-133 Sec. 200(c); AAG-SLA 13.02]
31. If a program-specific audit guide is available and current with regard 
to the program's compliance requirements, has the auditor issued the 
reports required by the guide?
[A-133 Sec. 235(a); AAG-SLA 13.04]
32. If a program-specific audit guide is not available or not current with 
regard to the program's compliance requirements, has the auditor is­
sued the following reports:26,27
26 If the financial statement(s) of the program present only the activity of the federal program, the auditor is not required to issue a 
separate report to meet the reporting requirements of GAS. However, if the financial statement(s) of the federal program present more 
than the program's activity the auditor should issue a separate GAS report and modify it so that it refers only to the financial statement(s) 
of the federal program. [AAG-SLA 13.10]
27 See footnote 20.
a. A report on the federal program's financial statements that pro­
vides an opinion or disclaimer of opinion on the financial state­
ments?
b. A report on compliance with requirements applicable to the fed­
eral program and on the internal control over compliance in accor­
dance with the program-specific audit option under Circular 
A-133?
c. A schedule of findings and questioned costs for the program? 
[A-133 Sec. 235(b)(4); AAG-SLA 13.07 and 13.09]
33. Do the reports conform to the standard report language illustrated in
AAG-SLA?
[AAG-SLA examples 12-1-12-6 in app. A (par. 12.54) and examples 
13-1-13-2 in app. A (par. 13.16)]
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FSP Section 11,500 
Illustrative Financial Statements
.01 The following illustrative financial statements demonstrate the practical applications of the reporting 
practices discussed in the June 1996 AICPA Audit and Accounting Guide Health Care Organizations with 
conforming changes as of May 1, 2008 (the guide). The checklists and illustrative financial statements do not 
include all disclosures and presentation items promulgated. Pronouncements deemed remote for audits of 
health care providers are not included in this document. Specific types of health care organizations have been 
selected to illustrate a wide diversity of reporting practices; it is not intended that these illustrations represent 
either the only types of disclosure or the only statement formats that would be appropriate. Health care 
providers are urged to develop financial statement formats that are appropriate for their individual circum­
stances while being consistent with the accounting and reporting practices discussed in the guide. Further­
more, the illustrative financial statements do not include all disclosures and presentation items promulgated.
This section contains illustrative financial statements, prepared using the illustrative financial statements in 
the AICPA Audit and Accounting Guide Health Care Organizations (with conforming changes as of May 1, 
2008), for the following types of health care organizations:
1. Not-for-Profit Hospital
2. For-Profit Nursing Home
3. Not-for-Profit Continuing Care Retirement Community
4. Not-for-Profit Home Health Agency
5. Not-for-Profit Health Maintenance Organization
6. Not-for-Profit Ambulatory Care Organization
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.02
Sample Not-for-Profit Hospital 
Balance Sheets*
* In February 2007, the Financial Accounting Standards Board (FASB) issued Statement No. 159, The Fair Value Option for Financial Assets 
and Financial Liabilities—Including an amendment of FASB Statement No. 115, that permits all entities, including not-for-profit organizations, 
to choose to measure eligible items at fair value at specified election dates. Notable eligible items include recognized financial assets and 
financial liabilities (except for those specifically prohibited), written loan commitments, and rights and obligations under a warranty that 
is not a financial instrument (because it requires or permits the insurer to provide goods or services rather than a cash payment) but whose 
terms permit the insurer to settle by paying a third party to provide those goods or services. Prohibited recognized financial assets and 
liabilities include:
a. An investment in a subsidiary that the entity is required to consolidate
b. An interest in a variable interest entity that the entity is required to consolidate
c. Employers' and plans' obligations (or assets representing net overfunded positions) for pension benefits, other postretirement 
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase 
plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements
d. Financial assets and financial liabilities recognized under leases as defined in FASB Statement No. 13, Accounting for Leases, 
excluding guarantees of a third-party lease obligation or a contingent obligation arising from a cancelled lease
e. Deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository 
institutions
f. Financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder's equity (including 
"temporary equity"). An example is a convertible debt security with a noncontingent beneficial conversion feature.
Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a 
manner that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another 
measurement attribute. To accomplish that, an entity shall either:
a. Present the aggregate of fair value and nonfair-value amounts in the same line item in the statement of financial position and 
parenthetically disclose the amount measured at fair value included in the aggregate amount, or
b. Present two separate line items to display the fair value and nonfair-value carrying amounts.
This statement shall be effective as of the beginning of each reporting entity's first fiscal year that begins after November 15, 2007. 
This statement should not be applied retrospectively to fiscal years beginning prior to the effective date, except as permitted in paragraph 
30 for early adoption. At the effective date, an entity may elect the fair value option for eligible items that exist at that date. The entity 
shall report the effect of the first remeasurement to fair value as a cumulative-effect adjustment to the opening balance of retained earnings. 
Readers can find more information pertaining to election dates, disclosure requirements, early adoption limitations, and the full text of 
this statement on the FASB Web site at www.fasb.org.
In February 2006, FASB issued Statement No. 155, Accounting for Certain Hybrid Financial Instruments—an amendment of FASB Statements 
No. 133 and 140. Among other matters, FASB Statement No. 155 paragraph 4(c), amends paragraph 16 of FASB Statement No. 133, 
Accounting for Derivative Instruments and Hedging Activities. An entity that initially recognizes a hybrid financial instrument that under 
FASB Statement No. 133 paragraph 12, would be required to be separated into a host contract and a derivative instrument may irrevocably 
elect to initially and subsequently measure that hybrid financial instrument in its entirety at fair value (with changes in fair value recognized 
in earnings). FASB Statement No. 155 is effective for all financial instruments acquired or issued after the beginning of an entity's first 
fiscal year that begins after September 15, 2006. The fair value election in paragraph 4(c) may also be applied upon adoption of FASB 
Statement No. 155 for hybrid financial instruments that had been bifurcated under FASB Statement No. 133, paragraph 12, prior to the 
adoption of FASB Statement No. 155. Earlier adoption is permitted as of the beginning of an entity's fiscal year, provided the entity has 
not yet issued financial statements for any period for that fiscal year.
December 31, 20X7 and 20X6 
(in thousands)
(continued)
20X7 20X6
Assets
Current assets:
Cash and cash equivalents $ 4,758 $ 5,877
Short-term investments 15,836 10,740
Assets limited as to use 970 1,300
Patient accounts receivable, net of allowance for doubtful
accounts of $2,500 in 20X7 and $2,400 in 20X6 15,100 14,194
Other current assets 2,670 2,856
Total current assets 39,334 34,967
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20X7 20X6
Interest in net assets of Sample Hospital Foundation† 510 462
Assets limited as to use:
Internally designated for capital acquisition 12,000 12,500
Held by trustee 6,949
18,949
7,341
19,841
Less amount required to meet current obligations (970)
17,979
(1,300)
18,541
Long-term investments 4,680 4,680
Long-term investments restricted for capital acquisition 320 520
Property and equipment, net 51,038 50,492
Other assets 1,185 908
Total assets $115,046 $110,570
Liabilities and Net Assets
Current liabilities:
Current portion of long-term debt $ 1,470 $ 1,750
Accounts payable and accrued expenses 5,818 5,382
Estimated third-party payor settlements 2,143 1,942
Other current liabilities 1,969 2,114
Total current liabilities 11,400 11,188
Long-term debt, net of current portion 23,144 24,014
Other liabilities 3,953 3,166
Total liabilities 38,497 38,368
Net assets:
Unrestricted 70,846 66,199
Temporarily restricted 2,115 2,470
Permanently restricted 3,588 3,533
Total net assets 76,549 72,202
Total liabilities and net assets $115,046 $110,570
See accompanying notes to financial statements.
FSP §11,500.02
† These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this 
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in paragraph
10.20 of the guide for contributions restricted to property acquisitions. Readers should be aware that FASB Statement No. 136, Transfers 
of Assets to a Not-for-Profit Organization or Charitable Trust That Raises or Holds Contributions for Others, is silent on this classification. The 
AICPA has released a group of Technical Practice Aids (TPAs) (Technical Questions and Answers [TIS] sections 6400.36-6400.42 [AICPA, 
Technical Practice Aids]) that address recognition of the interests in the net assets of financially interrelated organizations and the classifi­
cation of the changes in those interests. TPAs are nonauthoritative and are not sources of established accounting principles as described 
in AU section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles (AICPA, Professional 
Standards, vol. 1). See footnote * to paragraph 1.01 of the guide for information about a proposed FASB statement that would move 
responsibility for the generally accepted accounting principles (GAAP) hierarchy for nongovernmental entities from AU section 411 to 
FASB literature, and a proposed AICPA Statement on Auditing Standards (SAS) that would delete the GAAP hierarchy for nongovern­
mental entities from AU section 411.
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FORMAT A
Sample Not-for-Profit Hospital 
Statements of Operations 
Years Ended December 31, 20X7 and 20X6 
(in thousands)
20X7 20X6
Unrestricted revenues, gains and other support:
Net patient service revenue $85,156 $78,942
Premium revenue 11,150 10,950
Other revenue 2,601 5,212
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 99,207 95,104
Expenses:
Operating expenses 88,521 80,585
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Provision for bad debts 1,000 1,300
Other 2,000 1,300
Total expenses 98,055 89,290
Operating income 1,152 5,814
Other income:
Investment income 3,900 3,025
(continued)
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20X7 20X6
Other expense:
Loss from extinguishment of debt (500)
Excess of revenues over expenses 4,552 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Change in interest in net assets of Sample Hospital
Foundation† 283 536
Transfers to parent (688) (3,051)
Increase in unrestricted net assets $ 4,647 $ 6,699
See accompanying notes to financial statements.
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† These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this 
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in paragraph
10.20 of the guide for contributions restricted to property acquisitions. Readers should be aware that FASB Statement No. 136, Transfers 
of Assets to a Not-for-Profit Organization or Charitable Trust That Raises or Holds Contributions for Others, is silent on this classification. The 
AICPA has released a group of Technical Practice Aids (TPAs) (Technical Questions and Answers [TIS] sections 6400.36-6400.42 [AICPA, 
Technical Practice Aids]) that address recognition of the interests in the net assets of financially interrelated organizations and the classifi­
cation of the changes in those interests. TPAs are nonauthoritative and are not sources of established accounting principles as described 
in AU section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles (AICPA, Professional 
Standards, vol. 1). See footnote * * to paragraph 1.01 of the guide for information about a proposed FASB statement that would move 
responsibility for the generally accepted accounting principles (GAAP) hierarchy for nongovernmental entities from AU section 411 to 
FASB literature, and a proposed AICPA Statement on Auditing Standards (SAS) that would delete the GAAP hierarchy for nongovern­
mental entities from AU section 411.
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FORMAT B
Sample Not-for-Profit Hospital 
Statements of Operations
Years Ended December 31, 20X7 and 20X6 
(in thousands)
20X7 20X6
Unrestricted revenues, gains and other support:
Net patient service revenue $ 85,156 $78,942
Premium revenue 11,150 10,950
Other, primarily investment income 6,501 8,237
Net assets released from restrictions used for operations 300
Total revenues, gains and other support 103,107 98,129
Expenses:
Salaries and benefits 53,900 49,938
Medical supplies and drugs 26,532 22,121
Insurance 8,089 8,526
Depreciation and amortization 4,782 4,280
Interest 1,752 1,825
Allowance for bad debts 1,000 1,300
Loss from extinguishment of debt 500
Other 2,000 1,300
Total expenses 98,555 89,290
Excess of revenues, gains, and other support over expenses 4,552 8,839
Change in net unrealized gains and losses on other than
trading securities 300 375
Net assets released from restrictions used for purchase of
property and equipment 200
Change in interest in net assets of Sample Hospital
Foundation† 283 536
Transfers to parent (688) (3,051)
Increase in unrestricted net assets $ 4,647 $ 6,699
See accompanying notes to financial statements.
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† These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this 
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in paragraph
10.20 of the guide for contributions restricted to property acquisitions. Readers should be aware that FASB Statement No. 136, Transfers 
of Assets to a Not-for-Profit Organization or Charitable Trust That Raises or Holds Contributions for Others, is silent on this classification. The 
AICPA has released a group of Technical Practice Aids (TPAs) (Technical Questions and Answers [TIS] sections 6400.36-6400.42 [AICPA, 
Technical Practice Aids]) that address recognition of the interests in the net assets of financially interrelated organizations and the classifi­
cation of the changes in those interests. TPAs are nonauthoritative and are not sources of established accounting principles as described 
in AU section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles (AICPA, Professional 
Standards, vol. 1). See footnote * to paragraph 1.01 of the guide for information about a proposed FASB statement that would move 
responsibility for the generally accepted accounting principles (GAAP) hierarchy for nongovernmental entities from AU section 411 to 
FASB literature, and a proposed AICPA Statement on Auditing Standards (SAS) that would delete the GAAP hierarchy for nongovern­
mental entities from AU section 411.
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Sample Not-for-Profit Hospital 
Statements of Changes in Net Assets 
Years Ended December 31, 20X7 and 20X6 
(in thousands)
20X7 20X6
Unrestricted net assets:
Excess of revenues over expenses $4,552 $8,839
Net unrealized gains on investments, other than trading 
securities 300 375
Change in interest in net assets of Sample Hospital 
Foundation† 283 536
Transfer to parent (688) (3,051)
Net assets released from restrictions used for purchase 
of property and equipment 200
Increase in unrestricted net assets 4,647 6,699
Temporarily restricted net assets:
Contributions for charity care 140 996
Net realized and unrealized gains on investments 5 8
Net assets released from restrictions (500)
Increase (decrease) in temporarily restricted net assets (355) 1,004
Permanently restricted net assets:
Contributions for endowment funds 50 411
Net realized and unrealized gains on investments 5 2
Increase in permanently restricted net assets 55 413
Increase in net assets 4,347 8,116
Net assets, beginning of year 72,202 64,086
Net assets, end of year $76,549 $72,202
See accompanying notes to financial statements.
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† These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this 
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in paragraph
10.20 of the guide for contributions restricted to property acquisitions. Readers should be aware that FASB Statement No. 136, Transfers 
of Assets to a Not-for-Profit Organization or Charitable Trust That Raises or Holds Contributions for Others, is silent on this classification. The 
AICPA has released a group of Technical Practice Aids (TPAs) (Technical Questions and Answers [TIS] sections 6400.36-6400.42 [AICPA, 
Technical Practice Aids]) that address recognition of the interests in the net assets of financially interrelated organizations and the classifi­
cation of the changes in those interests. TPAs are nonauthoritative and are not sources of established accounting principles as described 
in AU section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles (AICPA, Professional 
Standards, vol. 1). See footnote * to paragraph 1.01 of the guide for information about a proposed FASB statement that would move 
responsibility for the generally accepted accounting principles (GAAP) hierarchy for nongovernmental entities from AU section 411 to 
FASB literature, and a proposed AICPA Statement on Auditing Standards (SAS) that would delete the GAAP hierarchy for nongovern­
mental entities from AU section 411.
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Sample Not-for-Profit Hospital 
Statements of Cash Flows (Indirect Method)
Years Ended December 31, 20X7 and 20X6 
(in thousands)
20X7 20X6
Cash flows from operating activities:
Change in net assets $ 4,347 $8,116
Adjustments to reconcile change in net assets to net
cash provided by operating activities:
Loss from extinguishment of debt 500
Depreciation and amortization 4,78 4,280
Net realized and unrealized gains on investments,
other than trading (450) (575)
Undistributed portion of change in interest in net
assets of Sample Hospital Foundation (48) (51)
Transfers to parent 688 3,051
Allowance for bad debts 1,000 1,300
Restricted contributions and investment income
received (290) (413)
(Increase) decrease in:
Patient accounts receivable (1,906) (2,036)
Trading securities 215
Other current assets 186 (2,481)
Other assets (277) (190)
Increase (decrease) in:
Accounts payable and accrued expenses 436 679
Estimated third-party payor settlements 201 305
Other current liabilities (145) (257)
Other liabilities 787 (128)
Net cash provided by operating activities 10,026 11,600
Cash flows from investing activities:
Proceeds from sale of investments 45,100 50,650
Purchase of investments (48,869) (52,800)
Capital expenditures (4,728) (5,860)
Net cash used in investing activities (8,497) (8,010)
Cash flows from financing activities:
Transfer to parent (688) (3,051)
Proceeds from restricted contributions and restricted
investment income 290 413
Payments on long-term debt (24,700) (804)
Payments on capital lease obligations (150) (100)
Proceeds from issuance of long-term debt 22,600 500
Net cash used in financing activities (2,648) (3,042)
Net (decrease) increase in cash and cash equivalents (1,119) 548
Cash and cash equivalents, beginning of year 5,877 5,329
Cash and cash equivalents, end of year $ 4,758 $ 5,877
Supplemental Disclosures of Cash Flow Information:
The Hospital entered into capital lease obligations in the amount of $600,000 for new 
equipment in 20X7.
Cash paid for interest (net of amount capitalized) in 20X7 and 20X6 was $1,780,000 
and $1,856,000, respectively.
See accompanying notes to financial statements.
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.07
Sample Not-For-Profit Hospital 
Notes to Financial Statements‡ 
December 31, 20X7 and 20X6
1. Description of Organization and Summary of Significant Accounting Policies1
‡ In September 2006, FASB issued FASB Statement No. 157, Fair Value Measurements, which defines fair value, establishes a framework 
for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. 
This statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having 
previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this 
statement does not require any new fair value measurements but the application of it will change current practice.
The statement retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value is 
the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would 
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, the statement establishes a fair value 
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted 
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement 
date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than quoted prices 
included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for example, quoted 
prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs 
shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is 
little, if any, market activity. Unobservable inputs shall be developed based on the best information available in the circumstances, which 
might include the reporting entity's own data.
The guidance in this statement expands disclosures about the use of fair value to measure assets and liabilities in interim and annual 
periods subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings 
(or changes in net assets) for the period. This statement encourages entities to combine the fair value information disclosed under this 
statement with the fair value information disclosed under other accounting pronouncements, including FASB Statement No. 107, Disclo­
sures about Fair Value of Financial Instruments, where practicable.
This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within 
those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that 
fiscal year, including financial statements for an interim period within that fiscal year. The provisions of this statement should be applied 
prospectively as of the beginning of the fiscal year in which this statement is initially applied, except in limited circumstances as discussed 
in the statement. Readers should refer to the FASB Web site at www.fasb.org for more information.
1 Paragraph 13 of SOP 01-6, Accounting by Certain Entities (Including Entities With Trade Receivables) That Lend to or Finance the Activities 
of Others, (AICPA, Technical Practice Aids, ACC sec. 10,850), provides guidance on disclosures that should be included in the summary of 
significant accounting policies, including accounting policies for loans, trade receivables, and doubtful accounts.
Organization. The Sample Not-for-Profit Hospital (the Hospital), located in Tulsa, Oklahoma, is a 
not-for-profit acute care hospital. The Hospital provides inpatient, outpatient and emergency care 
services for residents of northeastern Oklahoma. Admitting physicians are primarily practitioners 
in the local area. The Hospital was incorporated in Oklahoma in 20X1 and is affiliated with the 
Sample Health System.
Use of estimates. The preparation of financial statements in conformity with generally accepted 
accounting principles (GAAP) requires management to make estimates and assumptions that affect 
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at 
the date of the financial statements and the reported amounts of revenues and expenses during the 
reporting period. Actual results could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include certain investments in highly liquid 
debt instruments with original maturities of three months or less.
The Hospital routinely invests its surplus operating funds in money market mutual funds. These 
funds generally invest in highly liquid U.S. government and agency obligations.
Investments. Investments in equity securities with readily determinable fair values and all in­
vestments in debt securities are measured at fair value in the balance sheet. Investment income or 
loss (including realized gains and losses on investments, interest and dividends) is included in the 
excess of revenues over expenses unless the income or loss is restricted by donor or law. Unrealized 
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gains and losses on investments are excluded from the excess of revenues over expenses unless the 
investments are trading securities.
Assets limited as to use. Assets limited as to use primarily include assets held by trustees under 
indenture agreements and designated assets set aside by the Board of Trustees for future capital 
improvements, over which the Board retains control and may at its discretion subsequently use for 
other purposes. Amounts required to meet current liabilities of the Hospital have been reclassified 
in the balance sheet at December 31, 20X7 and 20X6.
Property and equipment. Property and equipment acquisitions are recorded at cost. Depreciation 
is provided over the estimated useful life of each class of depreciable asset and is computed using 
the straight-line method. Equipment under capital lease obligations is amortized on the straight- 
line method over the shorter period of the lease term or the estimated useful life of the equipment. 
Such amortization is included in depreciation and amortization in the financial statements. Interest 
cost incurred on borrowed funds during the period of construction of capital assets is capitalized 
as a component of the cost of acquiring those assets.
Gifts of long-lived assets such as land, buildings, or equipment are reported as unrestricted 
support, and are excluded from the excess of revenues over expenses, unless explicit donor stipu­
lations specify how the donated assets must be used. Gifts of long-lived assets with explicit restric­
tions that specify how the assets are to be used and gifts of cash or other assets that must be used 
to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations 
about how long those long-lived assets must be maintained, expirations of donor restrictions are 
reported when the donated or acquired long-lived assets are placed in service.
Temporarily and permanently restricted net assets. Temporarily restricted net assets are those whose 
use by the Hospital has been limited by donors to a specific time period or purpose. Permanently 
restricted net assets have been restricted by donors to be maintained by the Hospital in perpetuity.
Excess of revenues over expenses. The statement of operations includes excess of revenues over 
expenses. Changes in unrestricted net assets which are excluded from excess of revenues over 
expenses, consistent with industry practice, include unrealized gains and losses on investments 
other than trading securities, permanent transfers of assets to and from affiliates for other than 
goods and services, and contributions of long-lived assets (including assets acquired using contri­
butions which by donor restriction were to be used for the purposes of acquiring such assets).
Net patient service revenue. The Hospital has agreements with third-party payors that provide for 
payments to the Hospital at amounts different from its established rates. Payment arrangements 
include prospectively determined rates per discharge, reimbursed costs, discounted charges, and 
per diem payments. Net patient service revenue is reported at the estimated net realizable amounts 
from patients, third-party payors, and others for services rendered, including estimated retroactive 
adjustments under reimbursement agreements with third-party payors. Retroactive adjustments 
are accrued on an estimated basis in the period the related services are rendered and adjusted in 
future periods as final settlements are determined.
Premium revenue. The Hospital has agreements with various Health Maintenance Organizations 
(HMOs) to provide medical services to subscribing participants. Under these agreements, the Hos­
pital receives monthly capitation payments based on the number of each HMO's participants, 
regardless of services actually performed by the Hospital. In addition, the HMOs make fee-for- 
service payments to the Hospital for certain covered services based upon discounted fee schedules.
Charity care. The Hospital provides care to patients who meet certain criteria under its charity 
care policy without charge or at amounts less than its established rates. Because the Hospital does 
not pursue collection of amounts determined to qualify as charity care, they are not reported as 
revenue.
Donor-restricted gifts. Unconditional promises to give cash and other assets to the Hospital are 
reported at fair value at the date the promise is received. Conditional promises to give and indica­
tions of intentions to give are reported at fair value at the date the gift is received. The gifts are
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reported as either temporarily or permanently restricted support if they are received with donor 
stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when 
a stipulated time restriction ends or purpose restriction is accomplished, temporarily restricted net 
assets are reclassified as unrestricted net assets and reported in the statement of operations as net 
assets released from restrictions. Donor-restricted contributions whose restrictions are met within 
the same year as received are reported as unrestricted contributions in the accompanying financial 
statements.
Estimated malpractice costs. The provision for estimated medical malpractice claims includes es­
timates of the ultimate costs for both reported claims and claims incurred but not reported.
Income taxes. The Hospital is a not-for-profit corporation and has been recognized as tax-exempt 
pursuant to Section 501(c)(3) of the Internal Revenue Code.
2. Net Patient Service Revenue
The Hospital has agreements with third-party payors that provide for payments to the Hospital 
at amounts different from its established rates. A summary of the payment arrangements with 
major third-party payors follows:
• Medicare. Inpatient acute care services and outpatient services rendered to Medicare program 
beneficiaries are paid at prospectively determined rates. These rates vary according to a 
patient classification system that is based on clinical, diagnostic, and other factors. Inpatient 
nonacute services and defined capital and medical education costs related to Medicare bene­
ficiaries are paid based on a cost reimbursement methodology. The Hospital is reimbursed 
for cost reimbursable items at a tentative rate with final settlement determined after submis­
sion of annual cost reports by the Hospital and audits thereof by the Medicare fiscal interme­
diary. Beginning in 20X3, the Hospital claimed Medicare payments based on an interpretation 
of certain "disproportionate share" rules. The intermediary disagreed and declined to pay the 
excess reimbursement claimed under that interpretation. Through 1996, the Hospital has not 
included the claimed excess in net patient revenues pending resolution of the matter. In 20X7, 
the intermediary accepted the claims and paid the outstanding claims, including $950,000 
applicable to 20X6 and $300,000 applicable to 20X5 and prior, which has been included in 
20X7 net revenues.
• Medicaid. Inpatient and outpatient services rendered to Medicaid program beneficiaries are 
reimbursed under a cost reimbursement methodology. The Hospital is reimbursed at a ten­
tative rate with final settlement determined after submission of annual cost reports by the 
Hospital and audits thereof by the Medicaid fiscal intermediary.
Revenue from the Medicare and Medicaid programs accounted for approximately XX percent 
and XX percent, respectively, of the Hospital's net patient revenue for the year ended 20X7, and 
XX percent and XX percent, respectively, of the Hospital's net patient revenue, for the year ended 
20X6. Laws and regulations governing the Medicare and Medicaid programs are extremely com­
plex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded 
estimates will change by a material amount in the near term. The 20X6 net patient service revenue 
increased approximately $XXX due to removal of allowances previously estimated that are no 
longer necessary as a result of final settlements and years that are no longer subject to audits, 
reviews, and investigations. The 20X7 net patient service revenue decreased approximately $XXX 
due to prior-year retroactive adjustments in excess of amounts previously estimated.
The Hospital also has entered into payment agreements with certain commercial insurance 
carriers, health maintenance organizations, and preferred provider organizations. The basis for 
payment to the Hospital under these agreements includes prospectively determined rates per 
discharge, discounts from established charges, and prospectively determined daily rates.
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3. Investments
Assets Limited as to Use
The composition of assets limited as to use at December 31, 20X7 and 20X6, is set forth in the 
following table. Investments are stated at fair value.
6,949,000 7,341,000
$18,949,000 $19,841,000
20X7 20X6
Internally designated for capital acquisition:
Cash $ 545,000 $ 350,000
U.S. Treasury obligations 11,435,000 12,115,000
Interest receivable 20,000 35,000
12,000,000 12,500,000
Held by trustee under indenture agreement:
Cash and short-term investments 352,000 260,000
U.S. Treasury obligation 6,505,000 7,007,000
Interest receivable 92,000 74,000
Other Investments
Other investments, stated at fair value, at December 31, 20X7 and 20X6, include:
20X7 20X6
Trading:
U.S. Corporate Bonds $ 1,260,000 $ 1,475,000
Other
U.S. Treasury obligations $19,266,000 $14,233,000
Interest receivable 310,000 232,000
20,836,000 15,940,000
Less:
Long-term investments 4,680,000 4,680,000
Long-term investments restricted for capital acquisitions 320,000 520,000
Short-term investments $15,836,000 $10,740,000
Investment income and gains for assets limited as to use, cash equivalents, and other invest­
ments are comprised of the following for the years ending December 31, 20X7 and 20X6:
20X7 20X6
Income:
Interest income $3,585,000 $2,725,000
Realized gains on sales of securities 150,000 200,000
Unrealized gains on trading securities 165,000 100,000
$3,900,000 $3,025,000
Other Changes in Unrestricted Net Assets:
Unrealized gains on other than trading securities $ 300,000 $ 375,000
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4. Property and Equipment
A summary of property and equipment at December 31, 20X7 and 20X6, follows:
20X7 20X6
Land $ 3,000,000 $ 3,000,000
Land improvements 472,000 472,000
Buildings and improvements 46,852,000 46,636,000
Equipment 29,190,000 26,260,000
Equipment under capital lease obligations 2,851,000 2,752,000
82,365,000 79,120,000
Less accumulated depreciation and amortization 34,928,000 30,661,000
47,437,000 48,459,000
Construction in progress 3,601,000 2,033,000
Property and equipment, net $51,038,000 $50,492,000
Depreciation expense for the years ended December 31, 20X7 and 20X6 amounted to approxi­
mately $4,782,000 and $4,280,000. Accumulated amortization for equipment under capital lease 
obligations was $689,000 and $453,000 at December 31,20X7 and 20X6, respectively. Construction 
contracts of approximately $7,885,000 exist for the remodeling of Hospital facilities. At December 
31, 20X7, the remaining commitment on these contracts approximated $4,625,000.
5. Long-Term Debt
A summary of long-term debt and capital lease obligations at December 31, 20X7 and 20X6, fol­
lows:
20X7 20X6
7.25 percent 20X7 Tax-Exempt Revenue Bonds, principal 
maturing in varying annual amounts, due November 1,
20XX, collateralized by a pledge of the Hospital's gross 
receipts $21,479,000
8.50 percent 20X2 Tax-Exempt Revenue Bonds, principal 
maturing in varying annual amounts, due June 1, 20XX $22,016,000
7.75 percent mortgage loan, principal maturing in varying 
annual amounts, due January 20XX, collateralized by a 
mortgage on certain property and equipment 2,010,000 2,127,000
7.75 percent note payable, payable in monthly installments of 
$12,000, including interest, due March 20XX, unsecured 125,000 671,000
Capital lease obligations, at varying rates of imputed interest 
from 6.8 percent to 9.3 percent collateralized by leased 
equipment 1,000,000 950,000
24,614,000 25,764,000
Less current portion 1,470,000 1,750,000
$23,144,000 $24,014,000
Under the terms of the 20X7 and 20X2 revenue bond indentures, the Hospital is required to 
maintain certain deposits with a trustee. Such deposits are included with assets limited as to use. 
The revenue note indenture also places limits on the incurrence of additional borrowings and 
requires that the Hospital satisfy certain measures of financial performance as long as the notes are 
outstanding.
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Scheduled principal repayments on long-term debt and payments on capital lease obligations 
are as follows:
Year Ending 
December 31,
Long-Term Capital Leases 
Debt Obligations
20X8
20X9
20Y0
20Y1
20Y2
Thereafter
Less amount representing interest under 
capital leases obligations
$ 970,000
912,000 
983,000 
1,060,000 
1,143,000 
18,546,000
$23,614,000
$ 550,000 
260,000 
260,000 
45,000
1,115,000
115,000
$1,000,000
A summary of interest cost and investment income on borrowed funds held by the trustee under 
the 20X7 and 20X2 revenue bond indentures during the years ended December 31, 20X7 and 20X6, 
follows:
20X7 20X6
Interest cost:
Capitalized $ 740,000 $ 700,000
Charged to operations 1,752,000 1,825,000
Total $2,492,000 $2,525,000
Investment income:
Capitalized $ 505,000 $ 663,000
Credited to other revenue 330,000 386,000
Total $ 835,000 $1,049,000
6. Temporarily and Permanently Restricted Net Assets
Temporarily restricted net assets are available for the following purposes or periods at Decem­
ber 31, 20X7 and 20X6:
$2,115,000 $2,470,000
20X7 20X6
Health care services
Purchase of equipment $ 320,000 $ 520,000
Indigent care 840,000 950,000
Health education 350,000 400,000
For periods after December 31, 20X9 605,000 600,000
Permanently restricted net assets at December 31, 20X7 and 20X6, are restricted to:
20X7 20X6
Investments to be held in perpetuity, the income 
from which is expendable to support health care 
services (reported as operating income) $2,973,000 $2,923,000
Endowment requiring income to be added to 
original gift until fund value is $1,500,000 615,000 610,000
$3,588,000 $3,533,000
During 20X7, net assets were released from donor restrictions by incurring expenses satisfying the 
restricted purposes of indigent care and health care education in the amounts of $250,000 and 
$50,000, respectively.
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7. Medical Malpractice Claims
The Hospital purchases professional and general liability insurance to cover medical malprac­
tice claims. There are known claims and incidents that may result in the assertion of additional 
claims, as well as claims from unknown incidents that may be asserted arising from services 
provided to patients. The Hospital has employed independent actuaries to estimate the ultimate 
costs, if any, of the settlement of such claims. Accrued malpractice losses have been discounted at 
7 percent and in management's opinion provide an adequate reserve for loss contingencies.
On March 15, 20X7, a patient filed a suit against the Hospital for malpractice during care re­
ceived as an inpatient. The Hospital believes it has meritorious defenses against the suit; however, 
the ultimate resolution of the matter could result in a loss. The patient has claimed $16 million in 
actual damages. Under state law, punitive damages are determined at trial. The Hospital maintains 
insurance coverage for malpractice claims. The coverage does not include punitive damages 
awards. Trial is scheduled to occur within the next year.
8. Pension Plan and Other Postretirement Benefit Plans2, 3
2 The disclosures for pensions and other postretirement benefits in this note to the illustrative financial statements have been modified 
to reflect the requirements of FASB Statement No. 132 (revised 2003), Employers' Disclosures about Pensions and Other Postretirement Benefits. 
This note to the financial statements illustrates the financial statement disclosures about pension and postretirement benefit plans for a 
public entity. Readers should refer to FASB Statement No. 132 (revised), when considering disclosure requirements for nonpublic entities.
In September 2006, FASB issued Statement No. 158, Employers' Accounting for Defined Benefit Pension and Other Postretirement Plans—an 
amendment of FASB Statements No. 87, 88, 106, and 132(R). An employer with publicly traded equity securities shall initially apply the 
requirement to recognize the funded status of a benefit plan and the disclosure requirements as of the end of the fiscal year ending after 
December 15, 2006. An employer without publicly traded equity securities shall initially apply the requirement to recognize the funded 
status of a benefit plan and the disclosure requirements as of the end of the fiscal year ending after June 15, 2007. An employer without 
publicly traded equity securities shall provide the disclosures in paragraph 14 in the notes to the financial statements for a fiscal year 
ending after December 15, 2006, but before June 16, 2007 unless it has applied the recognition provisions of this statement in preparing 
those financial statements; the requirement to measure plan assets and benefit obligations as of the date of the employer's fiscal year-end 
statement of financial position shall be effective for fiscal years ending after December 15, 2008.
3 Readers may also need to consider the accounting and disclosure requirements of FASB Staff Position No. 106-2, Accounting and 
Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, when an employer provides 
postretirement prescription drug coverage.
[The following two paragraphs are encouraged hut not required.]
The Hospital has a defined benefit pension plan covering substantially all of its employees. The 
plan benefits are based on years of service and the employees' compensation during the last five 
years of covered employment. Contributions are intended to provide not only for benefits attrib­
uted to service to date but also for those expected to be earned in the future.
The Hospital also sponsors two defined benefit postretirement plans that cover both salaried 
and nonsalaried employees. One plan provides medical and dental benefits, and the other provides 
for the payment of life insurance premiums. The postretirement health care plan is contributory, 
with retiree contributions adjusted annually; the life insurance plan is noncontributory. The ac­
counting for the health care plan anticipates future cost-sharing changes to the written plan that 
are consistent with the Hospital's expressed intent to increase retiree contributions each year to 50 
percent of the excess of the expected general inflation rate over 6 percent. Beginning in 20X7, the 
Hospital adopted a funding policy for its postretirement health care plan similar to its funding 
policy for its life insurance plan—an amount equal to a level percentage of the employees' salaries 
is contributed to the plan annually. For 20X7, that percentage was 4.25, and the aggregate contri­
bution for both plans was $34,000. The Hospital uses a December 31 measurement date for its 
plans.
The following table sets forth the changes in benefit obligations, changes in plan assets and 
components of net periodic benefit cost for both the pension plan and the other postretirement 
benefit plans:
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Pension Benefits Other Benefits
20X7 20X6 20X7 20X6
Change in benefit obligation:
Benefit obligation at beginning of year $ 9,710 $ 9,700 $ 585 $ 500
Service cost 905 770 14 15
Interest cost 700 650 50 44
Plan participants' contributions
Actuarial gain
Benefits paid
(20)
(375) (1,410)
34
(7)
(66)
34
Benefit obligation at end of year 10,920 9,710 610 585
Change in plan assets:
Fair value of plan assets at beginning of year 9,800 9,610 89 40
Actual return on plan assets 759 810 4 4
Employer contribution 866 790 39 19
Plan participants' contributions
Benefits paid (375)
34
(1,410)
34
(66)
Fair value of plan assets at end of year 11,050 9,800 100 89
Funded status 130 90 (510) (496)
Unrecognized net actuarial gain (30) (40) (30) (40)
Unrecognized prior service cost 50 55 16 19
Unrecognized transition obligation
Unrecognized transition asset (15) (20)
445 470
Prepaid (accrued) benefit cost $ 135 $ 85 ($79) ($47)
The accumulated benefit obligation for the defined benefit pension plan was $XXX and $XXX at 
December 31, 20X7, and 20X6, respectively.
Pension Benefits Other Benefits 
20X7 20X6 20X7 20X6
Components of net periodic benefit cost:
Service cost $905 $770 $14 $15
Interest cost 700 650 50 44
Expected return on plan assets (784) (769) (6) (3)
Amortization of prior service cost 5 7 3 2
Recognized net actuarial (gain) (5) (2) (15) (1)
Amortization of transition obligation 25 25
Amortization of transition asset (5) (1) — —
Net periodic benefit cost $816 $655 $71 $82
Additional Information
Assumptions
Weighted-average assumptions used to determine 
benefit obligations at December 31
Discount rate
Rate of compensation increase
7.00% 7.00% 7.00% 7.00%
6.00% 6.00%
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Weighted-average assumptions used to determine net 
periodic benefit cost for years ended December 31
Discount rate
Expected long-term return on plan assets
Rate of compensation increase
7.00%
8.00%
6.00%
7.00%
8.00%
6.00%
7.00%
6.60%
7.00%
6.60%
(Entity specific narrative description of the basis used to determine the overall expected long-term 
rate of return on assets, as described in paragraph 5(d)(3) of FASB Statement No. 132 (revised 
2003), Employers' Disclosures about Pensions and Other Postretirement Benefits—an amendment of FASB
Statements No. 87, 88, and 106, would be included here.)
20X7 20X6
Assumed health care cost trend rates at December 31
Health care cost trend rate assumed for next year
Rate to which the cost trend rate is assumed to decline
7% 7%
(the ultimate trend rate) 5% 5%
Year that the rate reaches the ultimate trend rate 20Y2 20Y2
Assumed health care cost trend rates have a significant effect on the amounts reported for the 
health care plans. A one-percentage-point change in assumed health care cost trend rates would 
have the following effects:
1-Percentage- 1-Percentage- 
Point Increase Point Decrease
Effect on total of service and interest cost $13 $(11)
Effect on postretirement benefit obligation 73 (67)
Plan Assets
The composition of plan assets at December 31, 20X7, and 20X6, is as follows:
Pension Benefits Other Benefits
Asset Category
20X7 20X6 20X7 20X6
Equity securities XX% XX% XX% xx%
Debt securities XX XX XX XX
Real estate XX XX XX XX
Other XX XX XX XX
Total 100% 100% 100% 100%
(Entity specific narrative description of investment policies and strategies for plan assets, including 
weighted-average target asset allocations [if used as part of those policies and strategies] as de­
scribed in paragraph 5(d)(2) of FASB Statement No. 132 (revised), would be included here.)
Cash Flows
Contributions
The Hospital expects to contribute $XXX to its pension plan and $XXX to its other postretirement 
benefit plan in 20X8.
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Estimated Future Benefit Payments
The following benefit payments, which reflect expected future service, as appropriate, are expected 
to be paid:
Pension
Benefits
Other
Benefits
20X8 $xxx $xxx
20X9 XXX XXX
20Y0 XXX XXX
20Y1 XXX XXX
20Y2 XXX XXX
Years 20Y3-20Y7 XXX XXX
9. Concentrations of Credit Risk
The Hospital grants credit without collateral to its patients, most of whom are local residents 
and are insured under third-party payor agreements. The mix of receivables from patients and 
third-party payors at December 31, 20X7 and 20X6, was as follows:
20X7 20X6
Medicare 51% 53%
Medicaid 17 14
Blue Cross 18 17
Other third-party payors 7 9
Patients 7
100%
7
100%
10. Commitments and Contingencies
Operating leases. The Hospital leases various equipment and facilities under operating leases 
expiring at various dates through April 20Y2. Total rental expense in 20X7 and 20X6 for all oper­
ating leases was approximately $859,000 and $770,000, respectively.
The following is a schedule by year of future minimum lease payments under operating leases 
as of December 31, 20X7, that have initial or remaining lease terms in excess of one year.
Year Ending 
December 31,
20X8
20X9
20Y0
20Y1
20Y2
Amount
$517,000
506,000
459,000
375,000
343,000
Litigation. The Hospital is involved in litigation and regulatory investigations arising in the 
course of business. After consultation with legal counsel, management estimates that these matters 
will be resolved without material adverse effect on the Hospital's future financial position or 
results from operations.
Allowance for doubtful accounts. Beginning in 20X5, the Hospital has provided care under an 
agreement with Associated HMO. The HMO currently owes the Hospital $950,000, substantially 
all of which is overdue. The Hospital has notified the HMO that further services under the contract 
cannot be provided without payment on the outstanding balance. The HMO has assured the 
Hospital that additional funds are being obtained in order to pay the overdue balance and continue 
service under the agreement, however, if the HMO is unable to make payments, additional allow­
ances for bad debts would need to be accrued.
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11. Related Party Transactions
During the years ended December 31, 20X7 and 20X6, the Hospital contributed capital to Sample 
Health System, an affiliate with some board members in common with the Hospital, in the amounts 
of $688,000 and $3,051,000, respectively.
The Sample Hospital Foundation (the Foundation), which is controlled by Sample Health Sys­
tem, was established to solicit contributions from the general public solely for the funding of capital 
acquisitions by the Hospital. Funds are distributed to the Hospital as determined by the Founda­
tion's Board of Directors. A summary of the foundation's assets, liabilities, net assets, results of 
operations, and changes in net assets follows. The Hospital's interest in the net assets of the Foun­
dation is reported as a noncurrent asset in the balance sheets.
At December 31,
Assets principally cash and cash equivalents
20X7
$521,000
20X6
$472,000
Liabilities 11,000 10,000
Unrestricted net assets 510,000 462,000
Total liabilities and net assets $521,000 $472,000
Support and revenue $269,000 $535,000
Expenses
Distributions to Sample Hospital for property acquisitions 235,000 485,000
Other 13,000 16,000
Total expenses 248,000 501,000
Excess of support and revenue over expenses 21,000 34,000
Other changes in net assets 27,000 17,000
Unrestricted net assets, beginning of year 462,000 411,000
Unrestricted net assets, end of year $510,000 $462,000
Liabilities include $10,000 payable at the end of each year to Sample Hospital. These amounts were 
paid after the end of each year.
12. Functional Expenses
The Hospital provides general health care services to residents within its geographic location. 
Expenses related to providing these services are as follows (in thousands):
At December 31,
20X7 20X6
Health care services $86,000 $78,647
General and administrative 12,055
$98,055
10,643
$89,290
13. Fair Value of Financial Instruments
The following methods and assumptions were used by the Hospital in estimating the fair value 
of its financial instruments:
Cash and cash equivalents: The carrying amount reported in the balance sheet for cash and cash 
equivalents approximates its fair value.
Investments: Fair values, which are the amounts reported in the balance sheet, are based on 
quoted market prices, if available, or estimated using quoted market prices for similar securities. 
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Assets limited as to use: These assets consist primarily of cash and short-term investments and 
interest receivable. The carrying amount reported in the balance sheet is fair value.
Accounts payable and accrued expenses: The carrying amount reported in the balance sheet for 
accounts payable and accrued expenses approximates its fair value.
Estimated third-party payor settlements: The carrying amount reported in the balance sheet for 
estimated third-party payor settlements approximates its fair value.
Long-term debt: Fair values of the Hospital's revenue notes are based on current traded value. 
The fair value of the Hospital's remaining long-term debt is estimated using discounted cash 
flow analyses, based on the Hospital's current incremental borrowing rates for similar types of 
borrowing arrangements.
The carrying amounts and fair values of the Hospital's financial instruments at December 31, 20X7 
and 20X6, are as follows (In thousands):
20X7 20X6
Carrying Carrying
Amount Fair Value Amount Fair Value
Cash and cash equivalents $ 4,758 $ 4,758 $ 5,877 $ 5,877
Short-term investments 15,836 15,836 10,740 10,740
Assets limited as to use 18,949 18,949 19,841 19,841
Long-term investments 4,680 4,680 4,680 4,680
Long-term investments restricted
for capital acquisition 320 320 520 520
Accounts payable and
accrued expenses 5,818 5,818 5,382 5,382
Estimated third-party
payor settlements 2,143 2,143 1,942 1,942
Long-term debt 24,614 23,980 25,764 24,918
14. Promises to Contribute
At December 31, 20X7, the Hospital had received $1,500,000 of conditional promises to contrib­
ute to the building of a new facility for outpatient services. These contributions will be recorded as 
temporarily restricted support when received. The Hospital had no material outstanding uncon­
ditional promises of support at December 31, 20X7.
15. Charity Care
The amount of charges foregone for services and supplies furnished under the Hospital's charity 
care policy aggregated approximately $4,500,000 and $4,100,000 in 20X7 and 20X6, respectively.
16. Subsequent Event
On February 9, 20X8, the Hospital signed a contract in the amount of $1,050,000 for the purchase 
of certain real estate.
FSP §11,500.07
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Sample For-Profit Nursing Home, Inc. 
Balance Sheets†
December 31, 20X7 and 20X6
20X7 20X6
Assets
Current assets:
Cash and cash equivalents 
Investments
Assets limited as to use
Patient accounts receivable, net of allowance
for doubtful accounts of $6,700 in 20X7 and 
$5,300 in 20X6
Estimated third-party payor settlements
Interest receivable
Supplies
Prepaid expenses 
Deferred tax asset
Total current assets
Assets limited as to use, net of amount required 
for current liabilities
Property and equipment:
Land
Land improvements 
Buildings
Furniture, fixtures, and equipment
Less accumulated depreciation 
Property and equipment, net
$ 95,000 $ 129,000
150,000
50,000 50,000
162,000 152,000
71,000 62,000
7,000
47,000 43,000
3,000 2,000
12,000 14,000
597,000 452,000
173,000 150,000
205,000 205,000
37,000 32,000
1,399,000 1,399,000
228,000 189,000
1,869,000 1,825,000
210,000 141,000
1,659,000 1,684,000
(continued)
FSP §11,500.08
† These illustrative financial statements include a presentation of an interest in the net assets of a financially interrelated foundation 
that is based on the particular fact pattern described in note 11 to the illustrative financial statements and the following additional facts:
• Sample Not-for-Profit Hospital can influence the financial decisions of Sample Hospital Foundation to such an extent that it can 
determine the timing and amount of distributions from the Foundation. Thus, it is inappropriate for the Hospital to imply a time 
restriction on amounts held by the Foundation.
• Contributions to Foundation are restricted by donors for property acquisitions. Those restrictions have been met by the Hospital 
even though the net assets remain at the Foundation. Thus, the net assets related to the interest in the Foundation are classified 
as unrestricted in the Hospital's financial statements.
• The Hospital's policy is to report restricted revenues as unrestricted if the restriction is met in the same period as the revenues 
are recognized.
Because the change in the interest in net assets of the foundation results from contributions restricted to property acquisitions, this 
presentation shows the change in that interest reported separately from the performance indicator, in the spirit of the guidance in paragraph 
10.20 of the guide for contributions restricted to property acquisitions. Readers should be aware that FASB Statement No. 136, Transfers 
of Assets to a Not-for-Profit Organization or Charitable Trust That Raises or Holds Contributions for Others, is silent on this classification. The 
AICPA has released a group of Technical Practice Aids (TPAs) (Technical Questions and Answers [TIS] sections 6400.36-6400.42 [AICPA, 
Technical Practice Aids]) that address recognition of the interests in the net assets of financially interrelated organizations and the classifi­
cation of the changes in those interests. TPAs are nonauthoritative and are not sources of established accounting principles as described 
in AU section 411, The Meaning of Present Fairly in Conformity With Generally Accepted Accounting Principles (AICPA, Professional 
Standards, vol. 1). See footnote * to paragraph 1.01 of the guide for information about a proposed FASB statement that would move 
responsibility for the generally accepted accounting principles (GAAP) hierarchy for nongovernmental entities from AU section 411 to 
FASB literature, and a proposed AICPA Statement on Auditing Standards (SAS) that would delete the GAAP hierarchy for nongovern­
mental entities from AU section 411.
198 Health Care Organizations
See accompanying notes to financial statements.
20X7 20X6
Other assets 150,000 127,000
Total assets $2,579,000 $2,413,000
Liabilities and Shareholders' Equity
Current liabilities:
Current maturities of long-term debt $ 50,000 $ 50,000
Accounts payable 78,000 52,000
Accrued expenses 175,000 188,000
Deposits from patients 50,000 45,000
Other current liabilities 74,000 15,000
Total current liabilities 427,000 350,000
Deferred tax liability 6,000 14,000
Long-term debt, net of current maturities 1,700,000 1,750,000
Shareholders' equity:
Common stock $20 par value; authorized
5,000 shares; issued and outstanding
3,500 shares 70,000 70,000
Retained earnings 376,000 229,000
Total shareholders' equity 446,000 299,000
Total liabilities and shareholders' equity $2,579,000 $2,413,000
FSP §11,500.08
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Sample For-Profit Nursing Home, Inc. 
Statements of Income and Retained Earnings 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Revenue:
Net patient service revenue $2,163,000 $1,949,000
Other revenue 67,000 22,000
Interest on investments held by trustee 13,000 7,000
Total revenue 2,243,000 1,978,000
Expenses:
Salaries and benefits 969,000 919,000
Medical supplies and drugs 511,000 499,000
Insurance and other 216,000 176,000
Provision for bad debts 92,000 83,000
Depreciation 69,000 57,000
Interest 164,000 172,000
Total expenses 2,021,000 1,906,000
Operating income 222,000 72,000
Nonoperating income:
Other interest income 5,000
Income before provision for income taxes 227,000 72,000
Provision for income taxes 80,000 29,000
Net income 147,000 43,000
Retained earnings, beginning of year 229,000 186,000
Retained earnings, end of year $ 376,000 $ 229,000
FSP §11,500.09
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Sample For-Profit Nursing Home, Inc. 
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
20X7 20X6
Cash flows from operating activities:
Cash received from residents and third party payors $2,019,000 $1,796,000
Cash received from others 67,000 22,000
Cash paid to employees and suppliers (1,679,000) (1,495,000)
Interest and dividends received 10,000 10,000
Interest paid (160,000) (170,000)
Taxes paid (29,000) (30,000)
Deposits received from patients 35,000 15,000
Deposits refunded to patients (30,000) (20,000)
Net cash provided by operating activities 233,000 128,000
Cash flows from investing activities:
Purchase of investments (150,000)
Proceeds from sale of property 2,000
Capital expenditures (44,000) (79,000)
Purchase of assets limited as to use (23,000)
Net cash used in investing activities (217,000) (77,000)
Cash flows from financing activities:
Repayment of long-term debt (50,000) (50,000)
Net cash used in financing activities (50,000) (50,000)
Net increase (decrease) in cash and cash equivalents (34,000) 1,000
Cash and cash equivalents, beginning of year 129,000 128,000
Cash and cash equivalents, end of year $ 95,000 $ 129,000
Reconciliation of net income to net cash 
provided by operating activities:
Net income $ 147,000 $ 43,000
Adjustments to reconcile net income to net cash 
provided by operating activities:
Depreciation 69,000 57,000
Provision for bad debts 92,000 83,000
Loss on sale of property — 11,000
Change in deferred income taxes (6,000) (14,000)
(Increase) decrease in:
Patient accounts receivable (102,000) (41,000)
Other current assets (21,000) (15,000)
Estimated third-party payor settlements (9,000) (10,000)
Interest receivable (7,000) (3,000)
Other assets (7,000) (10,000)
Increase (decrease) in:
Accounts payable and accrued expenses 13,000 43,000
Deposits from patients 5,000 (5,000)
Other current liabilities 59,000 (11,000)
Net cash provided by operating activities $ 233,000 $ 128,000
See accompanying notes to financial statements.
FSP §11,500.10
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Sample For-Profit Nursing Home, Inc. 
Notes to Financial Statements‡  
December 31, 20X7 and 20X6
1. Description of Organization and Summary of Significant Accounting Policies4
‡ In September 2006, FASB issued FASB Statement No. 157, Fair Value Measurements, which defines fair value, establishes a framework 
for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. 
This statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having 
previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this 
statement does not require any new fair value measurements but the application of it will change current practice.
The statement retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value is 
the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would 
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, the statement establishes a fair value 
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted 
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement 
date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than quoted prices 
included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for example, quoted 
prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs 
shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is 
little, if any, market activity. Unobservable inputs shall be developed based on the best information available in the circumstances, which 
might include the reporting entity's own data.
The guidance in this statement expands disclosures about the use of fair value to measure assets and liabilities in interim and annual 
periods subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings 
(or changes in net assets) for the period. This statement encourages entities to combine the fair value information disclosed under this 
statement with the fair value information disclosed under other accounting pronouncements, including FASB Statement No. 107, Disclo­
sures about Fair Value of Financial Instruments, where practicable.
This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within 
those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that 
fiscal year, including financial statements for an interim period within that fiscal year. The provisions of this statement should be applied 
prospectively as of the beginning of the fiscal year in which this statement is initially applied, except in limited circumstances as discussed 
in the statement. Readers should refer to the FASB Web site at www.fasb.org for more information.
4 Paragraph 13 of SOP 01-6 provides guidance on disclosures that should be included in the summary of significant accounting policies, 
including accounting policies for loans, trade receivables, and doubtful accounts.
Organization. The Sample Nursing Home, Inc. (the Company) was incorporated in New State in 
20X1 and operates a 128-bed nursing home in Abacus, New State. A summary of the Company's 
significant accounting policies follows:
Use of estimates. The preparation of financial statements in conformity with GAAP requires 
management to make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements 
and the reported amounts of revenues and expenses during the reporting period. Actual results 
could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less, excluding amounts whose use is 
limited by note indenture.
Investments. Investments in debt instruments, including assets limited as to use, are classified as 
held-to-maturity because the Company has the positive intent and ability to hold the securities 
until maturity. Held-to-maturity securities are carried at cost adjusted for amortization of premi­
ums and accretion of discounts.
FSP §11,500.11
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Assets limited as to use. Assets deposited with a trustee under terms of the note indenture and 
assets set aside by the Board of Directors for capital improvements are classified as assets limited 
as to use. Amounts required to meet current liabilities have been reclassified in the balance sheet.
Property and equipment. Property and equipment are recorded at cost. Depreciation is calculated 
on the straight-line method over the estimated useful lives of depreciable assets.
Bond issuance costs. Costs incurred in issuing the Series 20X1 bonds are being amortized based 
on the effective interest method.
Net patient service revenue. Net patient service revenue is reported at the estimated net realizable 
amounts from residents, third-party payors, and others for service rendered.
Revenue under third-party payor agreements is subject to audit and retroactive adjustment. 
Provisions for estimated third-party payor settlements are provided in the period the related ser­
vices are rendered. Differences between the estimated amounts accrued and interim and final 
settlements are reported in operations in the year of settlement.
Income taxes. The provisions for income taxes are based on amounts estimated to be currently 
payable and those deferred because of temporary differences between the financial statement and 
tax bases of assets and liabilities. These differences consist principally of bad debts and deprecia­
tion.
2. Assets Limited as to Use
Assets limited as to use include:
Assets held by trustee under the Series 20X1 note indenture agreement 
at December 31, 20X7 and 20X6.
20X7 20X6
U.S. Government obligations $150,000 $130,000
Cash 24,000 21,000
Accrued interest income 2,000 2,000
Internally designated by the Board of
Directors for capital improvements
176,000 153,000
Certificate of deposit $ 45,000 $ 45,000
Accrued interest 2,000 2,000
47,000 47,000
$223,000 $200,000
3. Investments||
4. Long-Term Debt
Long-term debt at December 31, 20X7 and 20X6, was as follows:
FSP §11,500.11
|| In reporting disclosures about investments in securities, entities should comply primarily with the requirements of paragraphs 6,17, 
and 19-22 of FASB Statement No. 115, Accounting for Certain Investments in Debt and Equity Securities, as amended. Other disclosure 
requirements may also be applicable.
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20X7 20X6
9.5 percent bonds payable to the City of 
Abacus, maturing $50,000 annually 
through November 1, 20YY, with a 
final maturity of $1 million on
November 1, 20YY $1,750,000 $1,800,000
Less current maturities 50,000 50,000
$1,700,000 $1,750,000
The notes are collateralized by a first mortgage lien on all property and equipment of the 
Company and a security interest in all of its receipts. The note indenture requires the maintenance 
of certain deposits with a trustee, which are included in assets limited as to use.
Future maturities of long-term debt as of December 31, 20X7, follow:
Year Ending December 31, Amount
20X8 $ 50,000
20X9 50,000
20Y0 50,000
20Y1 50,000
20Y2 50,000
Thereafter 1,500,000
Total $1,750,000
5. Income Taxes
The provisions for income taxes are as follows:#
20X7 20X6
Current:
Federal $72,000 $15,000
State 2,000
Total current 74,000 15,000
Deferred:
Federal 6,000 13,000
State 1,000
Total deferred 6,000 14,000
Total provision for income taxes $80,000 $29,000
Deferred income taxes are provided for the temporary differences between the financial report­
ing basis and the tax basis of the Company's assets and liabilities.
For the years ended December 31, 20X7 and 20X6, the effective tax rate approximated the statu­
tory rate of 34 percent and 40 percent, respectively.
The net current and noncurrent components of deferred income taxes recognized in the balance 
sheet at December 31, 20X7 and 20X6, follows:
FSP §11,500.11
# In June 2006, FASB issued Interpretation No. 48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No. 109. 
This interpretation is effective for fiscal years beginning after December 15, 2006. The interpretation clarifies the accounting for uncertainty 
in income taxes recognized in an organization's financial statements in accordance with FASB Statement No. 109, Accounting for Income 
Taxes. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition, measure­
ment and disclosures of a tax position taken or expected to be taken in a tax return. This interpretation also provides guidance on 
derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.
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20X7 20X6
Net current assets $12,000 $14,000
Net noncurrent liabilities 6,000 14,000
$ 6,000 $ 0
Management has determined that no valuation allowance related to deferred tax assets is nec­
essary at December 31, 20X7 and 20X6, respectively.
6. Concentration in State Medicaid Program
The Company has 100 of its 128 beds designated for care of patients under the state's Medicaid 
program. The current funding of that program is 90 days behind filed claims. The current state 
budget has no provision for reducing that lag and, while the proposed budget for 20X8 includes 
additional funding, there is no assurance that the final budget will include the needed additional 
funds.
7. Third Party Rate Adjustments and Revenue
Revenue from the Medicaid program accounted for approximately XX percent for the year 
ended 20X7, and XX percent for the year ended 20X6, of the Company's net patient revenue. Laws 
and regulations governing the Medicaid program are extremely complex and subject to interpre­
tation. As a result, there is at least a reasonable possibility that recorded estimates will change by a 
material amount in the near term. The 20X7 net patient service revenue increased approximately 
$XXX due to removal of allowances previously estimated that are no longer necessary as a result 
of final settlements and years that are no longer subject to audits, reviews, and investigations. The 
20X6 net patient service revenue decreased approximately $XXX due to prior-year retroactive 
adjustments in excess of amounts previously estimated.
8. Risks and Uncertainties Disclosures**
9. Pension Plan**
10. Postretirement Benefits**
11. Fair Values of Financial Instruments**
12. Concentrations of Credit Risk**
** The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the 
not-for-profit hospital and, therefore, are not repeated here.
FSP §11,500.11
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Sample Not-for-Profit Continuing Care Retirement Community 
Balance Sheets*
* In February 2007, the Financial Accounting Standards Board (FASB) issued Statement No. 159, The Fair Value Option for Financial Assets 
and Financial Liabilities—Including an amendment of FASB Statement No. 115, that permits all entities, including not-for-profit organizations, 
to choose to measure eligible items at fair value at specified election dates. Notable eligible items include recognized financial assets and 
financial liabilities (except for those specifically prohibited), written loan commitments, and rights and obligations under a warranty that 
is not a financial instrument (because it requires or permits the insurer to provide goods or services rather than a cash payment) but whose 
terms permit the insurer to settle by paying a third party to provide those goods or services. Prohibited recognized financial assets and 
liabilities include:
a. An investment in a subsidiary that the entity is required to consolidate
b. An interest in a variable interest entity that the entity is required to consolidate
c. Employers' and plans' obligations (or assets representing net overfunded positions) for pension benefits, other postretirement 
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase 
plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements
d. Financial assets and financial liabilities recognized under leases as defined in FASB Statement No. 13, Accounting for Leases, 
excluding guarantees of a third-party lease obligation or a contingent obligation arising from a cancelled lease
e. Deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository 
institutions
f. Financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder's equity (including 
"temporary equity"). An example is a convertible debt security with a noncontingent beneficial conversion feature.
Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a 
manner that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another 
measurement attribute. To accomplish that, an entity shall either:
a. Present the aggregate of fair value and nonfair-value amounts in the same line item in the statement of financial position and 
parenthetically disclose the amount measured at fair value included in the aggregate amount, or
b. Present two separate line items to display the fair value and nonfair-value carrying amounts.
This statement shall be effective as of the beginning of each reporting entity's first fiscal year that begins after November 15, 2007. 
This statement should not be applied retrospectively to fiscal years beginning prior to the effective date, except as permitted in paragraph 
30 for early adoption. At the effective date, an entity may elect the fair value option for eligible items that exist at that date. The entity 
shall report the effect of the first remeasurement to fair value as a cumulative-effect adjustment to the opening balance of retained earnings. 
Readers can find more information pertaining to election dates, disclosure requirements, early adoption limitations, and the full text of 
this statement on the FASB Web site at www.fasb.org.
In February 2006, FASB issued Statement No. 155, Accounting for Certain Hybrid Financial Instruments—an amendment of FASB Statements 
No. 133 and 140. Among other matters, FASB Statement No. 155 paragraph 4(c), amends paragraph 16 of FASB Statement No. 133, 
Accounting for Derivative Instruments and Hedging Activities. An entity that initially recognizes a hybrid financial instrument that under 
FASB Statement No. 133 paragraph 12, would be required to be separated into a host contract and a derivative instrument may irrevocably 
elect to initially and subsequently measure that hybrid financial instrument in its entirety at fair value (with changes in fair value recognized 
in earnings). FASB Statement No. 155 is effective for all financial instruments acquired or issued after the beginning of an entity's first 
fiscal year that begins after September 15, 2006. The fair value election in paragraph 4(c) may also be applied upon adoption of FASB 
Statement No. 155 for hybrid financial instruments that had been bifurcated under FASB Statement No. 133 paragraph 12, prior to the 
adoption of FASB Statement No. 155. Earlier adoption is permitted as of the beginning of an entity's fiscal year, provided the entity has 
not yet issued financial statements for any period for that fiscal year.
December 31, 20X7 and 20X6
20X7 20X6
Assets
Current assets:
Cash $ 375,000 $ 330,000
Assets limited as to use 265,000 170,000
Accounts receivable, net of allowance for
doubtful accounts of $4,000 in 20X7 and
$5,000 in 20X6 187,000 197,000
Supplies 40,000 21,000
Prepaid expenses 115,000 73,000
(continued)
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20X7 20X6
Total current assets 982,000 791,000
Assets limited as to use, net of amount required
for current liabilities 1,865,000 1,583,000
Property and equipment, net 14,893,000 15,280,000
Deferred financing costs, net of accumulated am­
ortization of $28,000 in 20X7 and $21,000 in
20X6 83,000 90,000
Total assets $17,823,000 $17,744,000
Liabilities and Net Assets
Liabilities:
Current maturities of long-term debt $ 90,000 $ 77,000
Accounts payable 180,000 174,000
Accrued expenses 161,000 178,000
Deposits on unoccupied units 22,000 40,000
Total current liabilities 453,000 469,000
Long-term debt, less current maturities 8,871,000 8,935,000
Refundable fees 59,000 144,000
Estimated obligation to provide future services,
in excess of amounts received or to be received 88,000 100,000
Deferred revenue from advance fees 6,304,000 6,585,000
Total liabilities 15,775,000 16,233,000
Net assets:
Unrestricted 1,286,000 833,000
Temporarily restricted 311,000 294,000
Permanently restricted 451,000 384,000
Total net assets 2,048,000 1,511,000
Total liabilities and net assets $17,823,000 $17,744,000
See accompanying notes to financial statements.
FSP §11,500.12
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Sample Not-for-Profit Continuing Care Retirement Community 
Statements of Operations 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Revenue, gains, and other support:
Resident services, including amortization
of advance fees of $935,000 in 20X7 and 
$915,000 in 20X6 $3,946,000 $3,152,000
Patient revenue from nonresidents 249,000 275,000
Change in obligation to provide future services 12,000 (82,000)
Contributions 54,000 39,000
Net assets released from restrictions used for 
operations 24,000 50,000
Investment income 29,000 30,000
Other 75,000 68,000
Total revenue, gains, and other support 4,389,000 3,532,000
Expenses:
Salaries and benefits 1,708,000 1,250,000
Medical supplies and drugs 543,000 742,000
Insurance 291,000 311,000
Depreciation 452,000 447,000
Interest 967,000 955,000
Total expenses 3,961,000 3,705,000
Operating income (loss) 428,000 (173,000)
Net assets released from restriction— 
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets $ 453,000 $ (128,000)
FSP §11,500.13
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Sample Not-for-Profit Continuing Care Retirement Community 
Statements of Changes in Net Assets 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Unrestricted net assets:
Operating income (loss) $ 428,000 $ (173,000)
Net assets released from restriction—
purchase of equipment 25,000 45,000
Increase (decrease) in unrestricted net assets 453,000 (128,000)
Temporarily restricted net assets:
Contributions 40,000 15,000
Net assets released from restrictions used
for operations (24,000) (50,000)
Net assets released from restriction—
purchase of equipment (25,000) (45,000)
Investment income 26,000 15,000
Increase (decrease) in temporarily restricted
net assets 17,000 (65,000)
Permanently restricted net assets:
Contributions 67,000 52,000
Increase in permanently restricted net assets 67,000 52,000
Increase (decrease) in net assets 537,000 (141,000)
Net assets, beginning of year 1,511,000 1,652,000
Net assets, end of year $2,048,000 $1,511,000
FSP §11,500.14
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Sample Not-for-Profit Continuing Care Retirement Community 
Statements of Cash Flows
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Cash flows from operating activities:
Cash received from residents and
third party payors $3,252,000 $2,341,000
Advance fees received 654,000 857,000
Other receipts from operations 75,000 68,000
Investment income received 68,000 53,000
Contributions received 51,000 44,000
Cash paid to employees and suppliers (2,576,000) (2,040,000)
Interest paid (950,000) (945,000)
Net cash provided by operating activities 574,000 378,000
Cash flows from investing activities:
Purchase of property and equipment (65,000) (250,000)
Purchase of assets limited as to use (377,000) 229,000
Net cash used in investing activities (442,000) (21,000)
Cash flows from financing activities:
Permanently restricted funds received 67,000 52,000
Refunds of deposits and refundable fees (103,000) (52,000)
Proceeds from issuance of long-term debt 26,000
Principal payments of long-term debt (77,000) (307,000)
Net cash used in financing activities (87,000) (307,000)
Net increase in cash 45,000 50,000
Cash, beginning of year 330,000 280,000
Cash, end of year $ 375,000 $ 330,000
Reconciliation of change in net assets to 
net cash provided by operating activities:
Change in net assets $ 537,000 $ (141,000)
Adjustments to reconcile change in net assets to 
net cash provided by operating activities:
Advance fees received 654,000 857,000
Restricted net assets received (67,000) (52,000)
Amortization of advance fees (935,000) (915,000)
Loss (gain) on obligation to provide 
future services (12,000) 82,000
Depreciation 452,000 447,000
Amortization of deferred financing costs 7,000 34,000
Provision for bad debts 3,000 3,000
(Increase) decrease in:
Accounts receivable 7,000 (33,000)
Other assets (61,000) (4,000)
Increase (decrease) in:
Accounts payable and accrued expenses (11,000) 100,000
Net cash provided by operating activities $ 574,000 $ 378,000
FSP §11,500.15
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Sample Not-for-Profit Continuing Care Retirement Community 
Notes to Financial Statements5,‡
5 SOP 00-1, Auditing Health Care Third-Party Revenues and Related Receivables (AICPA, Technical Practice Aids, AUD 14,360), provides 
auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample disclosure in paragraph 37 of 
the SOP for material differences between an original estimate and subsequent revisions regarding third-party payments. SOP 00-1 is 
included in appendix E of Health Care Organizations guide.
† In September 2006, FASB issued FASB Statement No. 157, Fair Value Measurements, which defines fair value, establishes a framework 
for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. 
This statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having 
previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this 
statement does not require any new fair value measurements but the application of it will change current practice.
The statement retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value is 
the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would 
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, the statement establishes a fair value 
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted 
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement 
date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than quoted prices 
included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for example, quoted 
prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs 
shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is 
little, if any, market activity. Unobservable inputs shall be developed based on the best information available in the circumstances, which 
might include the reporting entity's own data.
The guidance in this statement expands disclosures about the use of fair value to measure assets and liabilities in interim and annual 
periods subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings 
(or changes in net assets) for the period. This statement encourages entities to combine the fair value information disclosed under this 
statement with the fair value information disclosed under other accounting pronouncements, including FASB Statement No. 107, Disclo­
sures about Fair Value of Financial Instruments, where practicable.
This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within 
those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that 
fiscal year, including financial statements for an interim period within that fiscal year. The provisions of this statement should be applied 
prospectively as of the beginning of the fiscal year in which this statement is initially applied, except in limited circumstances as discussed 
in the statement. Readers should refer to the FASB Web site at www.fasb.org for more information.
†† Does not include all disclosures common to all health care entities.
6 Paragraph 13 of SOP 01-6 provides guidance on disclosures that should be included in the summary of significant accounting policies, 
including accounting policies for loans, trade receivables, and doubtful accounts.
December 31, 20X7 and 20X6
1. Description of Organization and Summary of Significant Accounting Policies††, 6
Organization. The Sample Continuing Care Retirement Community (the CCRC) is a nonprofit 
organization that principally provides housing, health care, and other related services to residents 
through the operation of a retirement facility containing 249 apartments and a 78-bed health care 
facility located in Evergreen Park, Illinois. The CCRC was incorporated in Illinois in 20X1. A 
summary of significant accounting policies follows.
Use of estimates. The preparation of financial statements in conformity with GAAP requires 
management to make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements 
and the reported amounts of revenues and expenses during the reporting period. Actual results 
could differ from those estimates.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, inter­
est, and dividends) is included in operating income (loss) unless restricted by donor or law. Un­
realized gains and losses on investments, if any, are excluded from operating income (loss).
Deferred financing costs. Deferred financing costs are amortized using the effective interest 
method over the term of the related financing agreement.
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Advance fees. Fees paid by a resident upon entering into a continuing care contract, net of the 
portion thereof that is refundable to the resident, are recorded as deferred revenue and are amor­
tized to income using the straight-line method over the estimated remaining life expectancy of the 
resident.
Obligation to provide future services. The CCRC annually calculates the present value of the net 
cost of future services and the use of facilities to be provided to current residents and compares 
that amount with the balance of deferred revenue from advance fees. If the present value of the net 
cost of future services and the use of facilities exceeds the deferred revenue from advance fees, a 
liability is recorded (obligation to provide future services and use of facilities) with the correspond­
ing charge to income. The obligation is discounted at 9 percent, based on the expected long-term 
rate of return on government obligations.
Donor restrictions. The CCRC reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor restric­
tion expires (that is, when a stipulated time restriction ends or a purpose restriction is accom­
plished), temporarily restricted net assets are reclassified as unrestricted net assets and reported in 
the statement of operations as net assets released from restrictions. Donor-restricted contributions 
whose restrictions are met within the same year as received are reflected as unrestricted contribu­
tions in the accompanying financial statements.
The CCRC reports gifts of property and equipment (or other long-lived assets) as unrestricted 
support unless explicit donor stipulations specify how the donated assets must be used. Gifts of 
long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of 
cash or other assets that must be used to acquire long-lived assets are reported as restricted sup­
port. Absent explicit donor stipulations about how long those long-lived assets must be main­
tained, the CCRC reports expirations of donor restrictions when the donated or acquired long- 
lived assets are placed in service.
Income taxes. The CCRC has been recognized by the IRS as a not-for-profit corporation as de­
scribed in Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal income 
taxes pursuant to Section 501(a) of the IRC.
Property and equipment. Property and equipment are stated at cost. Donated property is recorded 
at its estimated fair value at the date of receipt. Depreciation is computed on the straight-line 
method based on the following estimated useful lives:
Land improvements 
Buildings and improvements 
Furniture and equipment
20 years 
40 years
5-15 years
Operating income (loss). The statement of operations includes operating income (loss). Changes in 
unrestricted net assets which are excluded from operating income (loss), consistent with industry 
practice, include unrealized gains and losses on investments other than trading securities, perma­
nent transfers of assets to and from affiliates for other than goods and services, and contributions 
of long-lived assets (including assets acquired using contributions which by donor restriction were 
to be used for the purposes of acquiring such assets).
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2. Property and Equipment
A summary of property and equipment at December 31, 20X7 and 20X6, follows:
$14,893,000 $15,280,000
20X7 20X6
Land $ 557,000 557,000
Land improvements 205,000 203,000
Buildings and improvements 14,573,000 14,564,000
Furniture and equipment 752,000 698,000
16,087,000 16,022,000
Less accumulated depreciation (1,194,000) (742,000)
3. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
20X7 20X6
Purchase of equipment $169,000 $152,000
Charity care 142,000 142,000
$311,000 $294,000
Net assets were released from donor restrictions by incurring expenses satisfying the restricted
purposes or by occurrence of other events specified by donors:
20X7 20X6
Charity care $24,000 $50,000
Purchase of equipment $25,000 $45,000
4. Permanently Restricted Net Assets
Permanently restricted net assets are restricted to investment in perpetuity, the income from
which is expendable to support:
20X7 20X6
Charity care $168,000 $168,000
Community activities 283,000 216,000
$451,000 $384,000
5. Long-Term Debt
Long-term debt at December 31, 20X7 and 20X6, is as follows:
20X7 20X6
10.75 percent mortgage note payable $8,901,000 $8,965,000
Notes payable to bank—unsecured 34,000 14,000
Other 26,000 33,000
8,961,000 9,012,000
Less current maturities 90,000 77,000
$8,871,000 $8,935,000
The mortgage note is payable in consecutive monthly installments of principal and interest of 
$85,425 to May 20XX. The note is collateralized by a first mortgage on property and equipment 
with a depreciated cost at December 31, 20X7, of $14,893,000 and by a pledge of all operating 
revenue.
As required by the mortgage note agreement, the CCRC established an initial debt service 
reserve fund of $1,000,000 at April 15, 20X5. All resident fees received thereafter, net of resident fee 
refunds and debt service payments not to exceed $300,000 annually in the first four years and 
$200,000 annually thereafter, are to be added to the debt service reserve fund until the total sum of 
$2,050,000 is accumulated. Since June 1, 20X6, the CCRC has been required to deliver to the trustee
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$5,500 per month to establish maintenance reserves until the aggregate of such payments equals a 
residential unit reserve and a health care center reserve of $240,000 and $90,000, respectively. At 
December 31, 20X7 and 20X6, the trustee held investments aggregating $2,130,000 and $1,753,000, 
respectively. Such amount has been classified as assets limited as to use.
Scheduled annual principal maturities of long-term debt for the next five years are as follows:
Year Ending December 31, Amount
20X8 $ 90,000
20X9 90,000
20Y0 95,000
20Y1 105,000
20Y2 105,000
6. Classification of Expenses
20X7 20X6
Program activities 3,368,000 3,135,000
General and administrative 593,000 570,000
$3,961,000 $3,705,000
7. Assets Limited as to Use"
8. Risks and Uncertainties Disclosures**
9. Pension Plan**
10. Postretirement Benefits**
11. Fair Values of Financial Instruments**
12. Concentrations of Credit Risk**
13. Investments**
** The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the 
not-for-profit hospital and, therefore, are not repeated here.
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ILLUSTRATIVE FINANCIAL STATEMENTS FOR A HOME HEALTH AGENCY
.17
Sample Not-for-Profit Home Health Agency 
Balance Sheets*
* In February 2007, the Financial Accounting Standards Board (FASB) issued Statement No. 159, The Fair Value Option for Financial Assets 
and Financial Liabilities—Including an amendment of FASB Statement No. 115, that permits all entities, including not-for-profit organizations, 
to choose to measure eligible items at fair value at specified election dates. Notable eligible items include recognized financial assets and 
financial liabilities (except for those specifically prohibited), written loan commitments, and rights and obligations under a warranty that 
is not a financial instrument (because it requires or permits the insurer to provide goods or services rather than a cash payment) but whose 
terms permit the insurer to settle by paying a third party to provide those goods or services. Prohibited recognized financial assets and 
liabilities include:
a. An investment in a subsidiary that the entity is required to consolidate
b. An interest in a variable interest entity that the entity is required to consolidate
c. Employers' and plans' obligations (or assets representing net overfunded positions) for pension benefits, other postretirement 
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase 
plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements
d. Financial assets and financial liabilities recognized under leases as defined in FASB Statement No. 13, Accounting for Leases, 
excluding guarantees of a third-party lease obligation or a contingent obligation arising from a cancelled lease
e. Deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository 
institutions
f. Financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder's equity (including 
"temporary equity"). An example is a convertible debt security with a noncontingent beneficial conversion feature.
Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a 
manner that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another 
measurement attribute. To accomplish that, an entity shall either:
a. Present the aggregate of fair value and nonfair-value amounts in the same line item in the statement of financial position and 
parenthetically disclose the amount measured at fair value included in the aggregate amount, or
b. Present two separate line items to display the fair value and nonfair-value carrying amounts.
This statement shall be effective as of the beginning of each reporting entity's first fiscal year that begins after November 15, 2007. 
This statement should not be applied retrospectively to fiscal years beginning prior to the effective date, except as permitted in paragraph 
30 for early adoption. At the effective date, an entity may elect the fair value option for eligible items that exist at that date. The entity 
shall report the effect of the first remeasurement to fair value as a cumulative-effect adjustment to the opening balance of retained earnings. 
Readers can find more information pertaining to election dates, disclosure requirements, early adoption limitations, and the full text of 
this statement on the FASB Web site at www.fasb.org.
In February 2006, FASB issued Statement No. 155, Accounting for Certain Hybrid Financial Instruments—an amendment of FASB Statements 
No. 133 and 140. Among other matters, FASB Statement No. 155 paragraph 4(c), amends paragraph 16 of FASB Statement No. 133, 
Accounting for Derivative Instruments and Hedging Activities. An entity that initially recognizes a hybrid financial instrument that under 
FASB Statement No. 133 paragraph 12, would be required to be separated into a host contract and a derivative instrument may irrevocably 
elect to initially and subsequently measure that hybrid financial instrument in its entirety at fair value (with changes in fair value recognized 
in earnings). FASB Statement No. 155 is effective for all financial instruments acquired or issued after the beginning of an entity's first 
fiscal year that begins after September 15, 2006. The fair value election in paragraph 4(c) may also be applied upon adoption of FASB 
Statement No. 155 for hybrid financial instruments that had been bifurcated under FASB Statement No. 133, paragraph 12, prior to the 
adoption of FASB Statement No. 155. Earlier adoption is permitted as of the beginning of an entity's fiscal year, provided the entity has 
not yet issued financial statements for any period for that fiscal year.
December 31, 20X7 and 20X6
20X7 20X6
Assets
Current assets:
Cash and cash equivalents $ 74,000 $ 41,000
Investments 147,000 137,000
Accounts receivable, net of allowance for doubtful 
accounts of $61,000 in 20X7 and $30,000 in 20X6 752,000 476,000
Other receivables 27,000 22,000
Total current assets 1,000,000 676,000
(continued)
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See accompanying notes to financial statements.
20X7 20X6
Investments 100,000 100,000
Equipment:
Medical and office equipment 56,000 39,000
Vehicles 50,000 37,000
Less accumulated depreciation
106,000
(45,000)
76,000
(24,000)
Equipment, net 61,000 52,000
Deferred finance charges, net of accumulated amor-
tization of $15,000 in 20X7 and $10,000 in 20X6
Total assets $1,181,000
25,000
$853,000
Liabilities and Net Assets
Current liabilities:
Current maturities of long-term debt $ 13,000 $ 13,000
Accounts payable 40,000 21,000
Accrued payroll and vacation costs 496,000 352,000
Estimated third-party payor settlements 28,000 31,000
Advances from third-party payors 70,000 66,000
Total current liabilities 647,000 483,000
Long-term debt, less current maturities 105,000 118,000
Total liabilities 752,000 601,000
Net assets:
Unrestricted 330,000 167,000
Temporarily restricted 9,000 5,000
Permanently restricted 90,000 80,000
Total net assets 429,000 252,000
Total liabilities and net assets $1,181,000 $853,000
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FORMAT A
Sample Not-for-Profit Home Health Agency 
Statements of Operations 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Revenue, gains, and other support:
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Investment income 13,000 6,000
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,092,000 2,747,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Excess of revenue over expenses and
change in unrestricted net assets $ 163,000 $ 99,000
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FORMAT B
Sample Not-for-Profit Home Health Agency 
Statements of Operations 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Revenue, gains, and other support:
Net patient service revenue $4,042,000 $2,687,000
Contributions 5,000 22,000
Net assets released from restrictions 5,000 —
Other revenue 27,000 32,000
Total revenue, gains, and other support 4,079,000 2,741,000
Expenses:
Salaries and benefits 2,714,000 1,835,000
Medical supplies and drugs 1,042,000 675,000
Insurance and other 90,000 83,000
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Interest 16,000 19,000
Total expenses 3,929,000 2,648,000
Operating income 150,000 93,000
Other income:
Investment income 13,000 6,000
Excess of revenue over expenses and
change in unrestricted net assets $ 163,000 $ 99,000
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Sample Not-for-Profit Home Health Agency 
Statements of Changes in Net Assets 
Years Ended December 31, 20X7 and 20X6
20X7 20X6
Unrestricted net assets:
Excess of revenue over expenses 
Increase in unrestricted net assets
Temporarily restricted net assets:
Contributions
Net assets released from restrictions 
Increase in temporarily restricted net assets
Permanently restricted net assets:
Contributions
Increase in permanently restricted net assets 
Increase in net assets
Net assets, beginning of year
Net assets, end of year
See accompanying notes to financial statements.
$163,000
163,000
9,000
(5,000)
4,000
10,000
10,000
177,000
252,000
$429,000
$ 99,000
99,000
5,000
5,000
6,000
6,000
110,000
142,000
$252,000
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Sample Not-for-Profit Home Health Agency 
Statements of Cash Flows 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Cash flows from operating activities:
Cash received from patients and
third party payors $3,721,000 $2,542,000
Other receipts from operations 22,000 32,000
Cash paid to employees and suppliers (3,679,000) (2,541,000)
Interest paid (11,000) (14,000)
Nonoperating revenue 23,000 22,000
Net cash provided by operating activities 76,000 41,000
Cash flows from investing activities:
Purchase of equipment (30,000) (19,000)
Purchase of investments (10,000) (15,000)
Net cash used in investing activities (40,000) (34,000)
Cash flows from financing activities:
Proceeds from contributions restricted for:
Endowment 10,000 6,000
Other financing activities:
Payment of long-term debt (13,000) —
Net cash provided by (used in) financing activities (3,000) 6,000
Net increase in cash and cash equivalents 33,000 13,000
Cash and cash equivalents, beginning of year 41,000 28,000
Cash and cash equivalents, end of year $ 74,000 $ 41,000
Reconciliation of change in net assets to net 
cash provided by operating activities:
Change in net assets $ 177,000 $ 110,000
Adjustments to reconcile change in net assets 
to net cash provided by operating activities:
Increase in permanently restricted net assets (10,000) (6,000)
Provision for bad debts 46,000 21,000
Depreciation 21,000 15,000
Amortization of deferred financing charges 5,000 5,000
(Increase) decrease in:
Accounts receivable (322,000) (150,000)
Other receivables (5,000) 4,000
Increase (decrease) in:
Accounts payable, accrued payroll, and
vacation costs 163,000 38,000
Estimated third-party payor settlements 1,000 4,000
Net cash provided by operating activities $ 76,000 $ 41,000
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Sample Not-for-Profit Home Health Agency 
Notes to Financial Statements‡
Years Ended December 31, 20X7 and 20X6
1. Description of Organization and Summary of Significant Accounting Policies7
‡ In September 2006, FASB issued FASB Statement No. 157, Fair Value Measurements, which defines fair value, establishes a framework 
for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. 
This statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having 
previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this 
statement does not require any new fair value measurements but the application of it will change current practice.
The statement retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value is 
the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would 
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, the statement establishes a fair value 
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted 
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement 
date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than quoted prices 
included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for example, quoted 
prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs 
shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is 
little, if any, market activity. Unobservable inputs shall be developed based on the best information available in the circumstances, which 
might include the reporting entity's own data.
The guidance in this statement expands disclosures about the use of fair value to measure assets and liabilities in interim and annual 
periods subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings 
(or changes in net assets) for the period. This statement encourages entities to combine the fair value information disclosed under this 
statement with the fair value information disclosed under other accounting pronouncements, including FASB Statement No. 107, Disclo­
sures about Fair Value of Financial Instruments, where practicable.
This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within 
those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that 
fiscal year, including financial statements for an interim period within that fiscal year. The provisions of this statement should be applied 
prospectively as of the beginning of the fiscal year in which this statement is initially applied, except in limited circumstances as discussed 
in the statement. Readers should refer to the FASB Web site at www.fasb.org for more information.
7 Paragraph 13 of SOP 01-6 provides guidance on disclosures that should be included in the summary of significant accounting policies, 
including accounting policies for loans, trade receivables, and doubtful accounts.
Organization. The Sample Home Health Agency (the Agency) was incorporated in 20X0 in New 
State as a not-for-profit corporation. The Agency provides health and supportive services to indi­
viduals at their homes, primarily in the New State area.
Use of estimates. The preparation of financial statements in conformity with GAAP requires 
management to make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements 
and the reported amounts of revenues and expenses during the reporting period. Actual results 
could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Investments. Investments, which consist of U.S. Treasury obligations, are measured at fair value 
in the balance sheet. Investment income (including realized gains and losses on investments, inter­
est and dividends) is included in excess of revenues over expenses unless restricted by donor or 
law. Unrealized gains and losses on investments, if any, are excluded from excess of revenues over 
expenses.
Equipment. Equipment is recorded at cost. Depreciation is computed using the straight-line 
method over the estimated useful lives of the assets.
Deferred financing costs. Deferred financing costs are being amortized using the effective interest 
method over the term of the related financing agreement.
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Donor restrictions. The Agency reports gifts of cash and other assets as restricted support if they 
are received with donor stipulations that limit the use of the donated assets. When a donor restric­
tion expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, 
temporarily restricted net assets are reclassified as unrestricted net assets and reported in the 
statement of operations as net assets released from restrictions. When long-lived assets are placed 
in service, thus satisfying purpose restrictions, the amount is included as a change in net assets, 
restricted and unrestricted. Donor-restricted contributions whose restrictions are met within the 
same year as received are reflected as unrestricted contributions in the accompanying financial 
statements.
The Agency reports gifts of equipment (or other long-lived assets) as unrestricted support unless 
explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets 
with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets 
that must be used to acquire long-lived assets are reported as restricted support. Absent explicit 
donor stipulations about how long those long-lived assets must be maintained, the Agency reports 
expirations of donor restrictions when the donated or acquired long-lived assets are placed in 
service.
Net patient service revenue. Net patient service revenue represents the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. The Agency has a policy of providing charity care to patients who are unable to 
pay. Such patients are identified based on financial information obtained from the patient and 
subsequent analysis. Since the Agency does not expect payment, estimated charges for charity care 
are not included in revenue.
Income taxes. The Agency has been recognized by the IRS as a not-for-profit corporation as 
described in Section 501(c)(3) of the Internal Revenue Code (IRC) and is exempt from federal 
income taxes on related income pursuant to Section 501(a) of the IRC.
Excess of revenue over expenses. The statement of operations includes excess of revenue over ex­
penses. Changes in unrestricted net assets which are excluded from excess of revenue over expenses, 
consistent with industry practice, include unrealized gains and losses on investments other than 
trading securities, permanent transfers of assets to and from affiliates for other than goods and 
services, and contributions of long-lived assets (including assets acquired using contributions 
which by donor restriction were to be used for the purposes of acquiring such assets).
2. Temporarily Restricted Net Assets
Temporarily restricted net assets are available for the following purposes:
20X7 20X6
Charity care $ — $5,000
Purchase of equipment 9,000 —
$9,000 $5,999
Net assets were released from donor restrictions by incurring expenses satisfying the
purposes or by occurrence of other events specified by donors:
20X7 20X6
Charity care expenditures $5,000 $ —
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3. Permanently Restricted Net Assets
Permanently restricted net assets are restricted in perpetuity, the income from which is expend­
able to support:
20X7 20X6
Program A activities $10,000 $ —
Any activities of the Agency 80,000 80,000
$90,000 $80,000
4. Third-Party Rate Adjustments and Revenue
Approximately 38 percent in 20X7 and 37 percent in 20X6 of net patient service revenue was 
derived under federal and state third-party reimbursement programs. These revenues are based, 
in part, on cost reimbursement principles and are subject to audit and retroactive adjustment by 
the respective third-party fiscal intermediaries. Laws and regulations governing these programs 
are extremely complex and subject to interpretation. As a result, there is at least a reasonable 
possibility that recorded estimates will change by a material amount in the near term. The 20X7 
net patient service revenue increased approximately $XXX due to removal of allowances previ­
ously estimated that are no longer necessary as a result of final settlements and years that are no 
longer subject to audits, reviews, and investigations. The 20X6 net patient service revenue de­
creased approximately $XXX due to prior-year retroactive adjustments in excess of amounts pre­
viously estimated.
5. Internally-Designated Assets
The Board of Directors has designated investments aggregating $100,000 to be used for future 
major capital improvements. Those assets are classified in the balance sheet as long-term invest­
ments.
6. Long-Term Debt
Long-term debt at December 31, 20X7 and 20X6, is as follows:
20X7 20X6
Note payable to bank, interest at 15 percent, 
payable in monthly installments of $2,200 per 
month, including interest, collateralized by 
equipment with a depreciated cost of $42,000 $118,000 $131,000
Less current maturities 13,000 13,000
$105,000 $118,000
Scheduled maturities of long-term debt at December 31, 20X7, are as follows:
Year Ending December 31, Amount
20X8 $ 13,000
20X9 13,000
20Y0 13,000
20Y1 13,000
20Y2 13,000
Thereafter 53,000
Total $118,000
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7. Classification of Expenses
____________ Program____________ General and
Total A B C Administrative
Expenses incurred for the year 
ended December 31, 20X7, 
were for:
Salaries and benefits $2,714,000 $1,363,000 $699,000 $363,000 $289,000
Medical supplies and drugs 1,042,000 511,000 246,000 285,000
Insurance and other 90,000 58,000 32,000
Provision for bad debts 46,000 16,000 30,000
Depreciation 21,000 5,000 16,000
Interest 16,000 10,000 3,000 — 3,000
Total expenses $3,929,000 $1,963,000 $978,000 $648,000 $340,000
Program____________ General and
Total A B C Administrative
Expenses incurred for the year
ended December 31, 20X6,
were for:
Salaries and benefits $1,835,000 $ 915,000 $463,000 $216,000 $241,000
Medical supplies and drugs 675,000 335,000 211,000 129,000
Insurance and other 83,000 64,000 19,000
Provision for bad debts 21,000 21,000
Depreciation 15,000 6,000 9,000
Interest 19,000 12,000 5,000 — 2,000
Total expenses $2,648,000 $1,353,000 $679,000 $345,000 $271,000
(The preparer of the financial statements may wish to include a brief description of the types of programs.)
8. Charity Care
Charity care represented approximately 3 percent and 4 percent of visits in 20X7 and 20X6, respec­
tively.
9. Risks and Uncertainties Disclosures**
10. Pension Plan”
11. Postretirement Benefits**
12. Fair Value of Financial Statements**
13. Concentrations of Credit Risk**
14. Investments**
** The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the 
not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Health Maintenance Organization 
Balance Sheets*
* In February 2007, the Financial Accounting Standards Board (FASB) issued Statement No. 159, The Fair Value Option for Financial Assets 
and Financial Liabilities—Including an amendment of FASB Statement No. 115, that permits all entities, including not-for-profit organizations, 
to choose to measure eligible items at fair value at specified election dates. Notable eligible items include recognized financial assets and 
financial liabilities (except for those specifically prohibited), written loan commitments, and rights and obligations under a warranty that 
is not a financial instrument (because it requires or permits the insurer to provide goods or services rather than a cash payment) but whose 
terms permit the insurer to settle by paying a third party to provide those goods or services. Prohibited recognized financial assets and 
liabilities include:
a. An investment in a subsidiary that the entity is required to consolidate
b. An interest in a variable interest entity that the entity is required to consolidate
c. Employers' and plans' obligations (or assets representing net overfunded positions) for pension benefits, other postretirement 
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase 
plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements
d. Financial assets and financial liabilities recognized under leases as defined in FASB Statement No. 13, Accounting for Leases, 
excluding guarantees of a third-party lease obligation or a contingent obligation arising from a cancelled lease
e. Deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository 
institutions
f. Financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder's equity (including 
"temporary equity"). An example is a convertible debt security with a noncontingent beneficial conversion feature.
Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a 
manner that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another 
measurement attribute. To accomplish that, an entity shall either:
a. Present the aggregate of fair value and nonfair-value amounts in the same line item in the statement of financial position and 
parenthetically disclose the amount measured at fair value included in the aggregate amount, or
b. Present two separate line items to display the fair value and nonfair-value carrying amounts.
This statement shall be effective as of the beginning of each reporting entity's first fiscal year that begins after November 15, 2007. 
This statement should not be applied retrospectively to fiscal years beginning prior to the effective date, except as permitted in paragraph 
30 for early adoption. At the effective date, an entity may elect the fair value option for eligible items that exist at that date. The entity 
shall report the effect of the first remeasurement to fair value as a cumulative-effect adjustment to the opening balance of retained earnings. 
Readers can find more information pertaining to election dates, disclosure requirements, early adoption limitations, and the full text of 
this statement on the FASB Web site at www.fasb.org.
In February 2006, FASB issued Statement No. 155, Accounting for Certain Hybrid Financial Instruments—an amendment of FASB Statements 
No. 133 and 140. Among other matters, FASB Statement No. 155 paragraph 4(c), amends paragraph 16 of FASB Statement No. 133, 
Accounting for Derivative Instruments and Hedging Activities. An entity that initially recognizes a hybrid financial instrument that under 
FASB Statement No. 133 paragraph 12, would be required to be separated into a host contract and a derivative instrument may irrevocably 
elect to initially and subsequently measure that hybrid financial instrument in its entirety at fair value (with changes in fair value recognized 
in earnings). FASB Statement No. 155 is effective for all financial instruments acquired or issued after the beginning of an entity's first 
fiscal year that begins after September 15, 2006. The fair value election in paragraph 4(c) may also be applied upon adoption of FASB 
Statement No. 155 for hybrid financial instruments that had been bifurcated under FASB Statement No. 133, paragraph 12, prior to the 
adoption of FASB Statement No. 155. Earlier adoption is permitted as of the beginning of an entity's fiscal year, provided the entity has 
not yet issued financial statements for any period for that fiscal year.
June 30, 20X7 and 20X6
Assets
Current assets:
Cash and cash equivalents
Premiums receivable, net of allowance for
doubtful accounts of $36,000 in 20X7 
and $42,000 in 20X6
Other receivables 
Supplies
Prepaid expenses
20X7 20X6
$2,937,000 $1,021,000
358,000 407,000
263,000 261,000
190,000 184,000
197,000 99,000
(continued)
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See accompanying notes to financial statements.
20X7 20X6
Total current assets 3,945,000 1,972,000
Property and equipment, net 5,756,000 5,626,000
State guaranty fund deposit 150,000 150,000
Debt issuance costs, net of accumulated 
amortization of $42,000 in 20X7 and 
$39,000 in 20X6 18,000 21,000
Total assets $9,869,000 $7,769,000
Liabilities and Net Assets
Current liabilities:
Unsecured 12 percent note payable to a bank $ — $ 44,000
Current maturities of long-term debt 241,000 109,000
Accounts payable—medical services 2,245,000 1,471,000
Other accounts payable and accrued expenses 829,000 661,000
Unearned premium revenue 141,000 202,000
Total current liabilities 3,456,000 2,487,000
Long-term debt, less current maturities 4,295,000 2,382,000
Total liabilities 7,751,000 4,869,000
Net assets—unrestricted 2,118,000 2,900,000
Total liabilities and net assets $9,869,000 $7,769,000
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Sample Not-for-Profit Health Maintenance Organization 
Statements of Operations and Changes in Net Assets
Years Ended June 30, 20X7 and 20X6
20X7 20X6
Revenue:
Premiums earned 
Coinsurance
Interest and other income 
Total revenue
Expenses:
Salaries and benefits 
Medical supplies and drugs 
Insurance
Provision for bad debts
Depreciation
Interest
Total expenses 
Operating income (loss)
Net assets, beginning of year
Net assets, end of year
See accompanying notes to financial statements.
$27,682,000
689,000
242,000
28,613,000
16,154,000
8,507,000
3,963,000
19,000
367,000
385,000
29,395,000
(782,000)
2,900,000
$ 2,118,000
$22,500,000
500,000
100,000
23,100,000
13,328,000
5,988,000
2,463,000
20,000
336,000
375,000
22,510,000
590,000
2,310,000
$ 2,900,000
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Sample Not-for-Profit Health Maintenance Organization 
Statements of Cash Flows 
Years Ended June 30, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Cash flows from operating activities:
Cash received from premiums, stop-loss
insurance recoveries, and coinsurance $28,969,000 $24,410,000
Cash paid to employees and to providers 
of health care services (28,405,000) (22,818,000)
Interest and other income received 230,000 90,000
Interest paid (382,000) (372,000)
Net cash provided by operating activities 412,000 1,310,000
Cash flows from investing activities:
Capital expenditures (497,000) (121,000)
Net cash used in investing activities (497,000) (121,000)
Cash flows from financing activities:
Proceeds from long-term debt 2,300,000
Principal payments on long-term debt (255,000) (1,000,000)
Principal payments on note payable (44,000) —
Net cash provided by (used in) 
financing activities 2,001,000 (1,000,000)
Net increase in cash and cash equivalents 1,916,000 189,000
Cash and cash equivalents, beginning of year 1,021,000 832,000
Cash and cash equivalents, end of year $ 2,937,000 $ 1,021,000
Reconciliation of change in net assets to net cash 
provided by operating activities:
Change in net assets $ (782,000) $ 590,000
Adjustments to reconcile change in net assets to 
net cash provided by operating activities: 
Depreciation and amortization 370,000 339,000
Provision for bad debts 19,000 20,000
(Increase) decrease in:
Premiums receivables 30,000 64,000
Other current assets 230,000 (93,000)
Increase (decrease) in:
Accounts payable—medical services 774,000 335,000
Other accounts payable and accrued expenses (168,000) (60,000)
Unearned premium revenue (61,000) 115,000
Net cash provided by operating activities $ 412,000 $ 1,310,000
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Sample Not-for-Profit Health Maintenance Organization 
Notes to Financial Statements8,‡ 
8 SOP 00-1 provides auditors with guidance regarding uncertainties in health care revenue recognition and includes a sample disclosure 
in paragraph 37 of the SOP for material differences between an original estimate and subsequent revisions regarding third-party payments. 
SOP 00-1 is included in appendix E to the Health Care Organizations guide.
‡ In September 2006, FASB issued FASB Statement No. 157, Fair Value Measurements, which defines fair value, establishes a framework 
for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. 
This statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having 
previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this 
statement does not require any new fair value measurements but the application of it will change current practice.
The statement retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value is 
the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would 
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, the statement establishes a fair value 
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted 
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement 
date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than quoted prices 
included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for example, quoted 
prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs 
shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is 
little, if any, market activity. Unobservable inputs shall be developed based on the best information available in the circumstances, which 
might include the reporting entity's own data.
The guidance in this statement expands disclosures about the use of fair value to measure assets and liabilities in interim and annual 
periods subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings 
(or changes in net assets) for the period. This statement encourages entities to combine the fair value information disclosed under this 
statement with the fair value information disclosed under other accounting pronouncements, including FASB Statement No. 107, Disclo­
sures about Fair Value of Financial Instruments, where practicable.
This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within 
those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that 
fiscal year, including financial statements for an interim period within that fiscal year. The provisions of this statement should be applied 
prospectively as of the beginning of the fiscal year in which this statement is initially applied, except in limited circumstances as discussed 
in the statement. Readers should refer to the FASB Web site at www.fasb.org for more information.
9 Paragraph 13 of SOP 01-6 provides guidance on disclosures that should be included in the summary of significant accounting policies, 
including accounting policies for loans, trade receivables, and doubtful accounts.
June 30, 20X7 and 20X6
1. Organization
The Sample Health Maintenance Organization (the HMO) was incorporated in 20X0 in New 
State as a not-for-profit corporation for the purpose of providing comprehensive health care ser­
vices on a prepaid basis and for the purpose of establishing and operating organized health main­
tenance and health care delivery systems.
The HMO has been determined to be a qualified health maintenance organization under Title 
XIII of the Public Health Service Act.
2. Summary of Significant Accounting Policies9
Use of estimates. The preparation of financial statements in conformity with GAAP requires 
management to make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements 
and the reported amounts of revenues and expenses during the reporting period. Actual results 
could differ from those estimates.
Cash and cash equivalents. Cash and cash equivalents include investments in highly liquid debt 
instruments with an original maturity of three months or less.
Supplies. Inventories of drugs and other supplies are stated at the lower of cost (first-in, first-out) 
or market.
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Property and equipment. Property and equipment are recorded at cost. Maintenance and repairs 
are charged to expense, and betterments are capitalized. Property and equipment costing approx­
imately $700,000 was financed by health maintenance organization initial development grants 
received in 20X1 and 20X2 from the U.S. Department of Health and Human Services (HHS). This 
property will be owned by the HMO as long as the equipment and facilities are used for projects 
related to the objectives of the Public Health Service Act.
Depreciation is computed using the straight-line method over the estimated useful lives of the
related assets as follows:
Building 40 years
Improvements 20-25 years
Data processing and laboratory 3-7 years
equipment and automobiles
Medical equipment 10 years
Office equipment 5-10 years
Amortization of debt issuance costs. Debt issuance costs are deferred and amortized using the 
effective interest method over the term of the related debt.
Health care service cost recognition. The HMO contracts with various health care providers for the 
provision of certain medical care services to its members. The HMO compensates these providers 
on a capitation basis. As part of a cost control incentive program, the HMO retains up to 20 percent 
of the capitation as a risk-sharing fund. In the event of hospital utilization in excess of budget, 
those providers bear the risk to the extent of 15 percent of the capitation fee. Operating expenses 
include all amounts incurred by the HMO under the aforementioned contracts.
The cost of other health care services provided or contracted for is accrued in the period in 
which it is provided to a member based in part on estimates, including an accrual for medical 
services provided but not reported to the HMO.
Premiums revenue. Membership contracts are on a yearly basis subject to cancellation by the 
employer group or the HMO upon 30 days written notice. Premiums are due monthly and are 
recognized as revenue during the period in which the HMO is obligated to provide services to 
members.
Reinsurance (stop-loss insurance). Reinsurance premiums are reported as health care costs, and 
reinsurance recoveries are reported as a reduction of related health care costs.
Federal income tax. The HMO is exempt from federal income taxes under Sec. 501(c)(4) of the 
Internal Revenue Code; accordingly, no provision for federal income taxes has been made in the 
accompanying financial statements.
3. Property and Equipment
Property and equipment at June 30, 20X7 and 20X6, consists of the following:
20X7 20X6
Land $ 300,000 $ 300,000
Buildings and improvements 5,473,000 5,459,000
Furniture and equipment 1,786,000
7,559,000
1,303,000
7,062,000
Less accumulated depreciation (1,803,000)
$5,756,000
(1,436,000)
$5,626,000
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4. Long-Term Debt
Long-term debt is collateralized by assets with a depreciated cost of $4,943,000. A summary of 
long-term debt at June 30, 20X7 and 20X6, follows.
20X7 20X6
HHS loan, interest at 7.5 percent,
payable in monthly installments of 
$50,000, including interest $2,020,000 $ 111,000
HHS loan, interest at 9.25 percent, 
payable in monthly installments of 
$10,000, including interest 1,658,000 1,694,000
Secured equipment loans, payable 
in monthly installments of $15,000, 
including interest 858,000 686,000
Less current maturities
4,536,000
241,000
2,491,000
109,000
$4,295,000 $2,382,000
Scheduled principal payments on long-term debt are as follows:
$4,536,000
Year Ending December 31, Amount
20X8 $ 241,000
20X9 259,000
20Y0 280,000
20Y1 800,000
20Y2 2,956,000
5. State Guarantee Fund Deposit
In August 20X4 the state in which the HMO is domiciled enacted legislation specifically govern­
ing HMOs. Under this legislation, the corporation is required to maintain a deposit of $150,000 
with the director of the division of insurance of the state.
6. Employee Retirement Plan
The HMO has a contributory defined contribution retirement plan covering substantially all 
employees. Expense determined in accordance with the plan formula (4 percent to 10 percent of 
eligible covered compensation) was $354,000 and $275,000 for the years ended June 30, 20X5 and 
20X4, respectively.
7. Stop-Loss Insurance
The HMO entered into a stop-loss insurance agreement with an insurance company to limit its 
losses on individual claims. Under the terms of this agreement, the insurance company will reim­
burse the HMO approximately 25 percent of the cost of each member's annual hospital services, in 
excess of a $1,000 deductible, up to a lifetime limitation of $500,000 per member. In the event the 
HMO ceases operations, (a) plan benefits will continue for members who are confined in an acute 
care hospital on the date of insolvency until their discharge, and (b) plan benefits will continue for 
any other member until the end of the contract period for which premiums have been paid.
Stop-loss insurance premiums of approximately $700,000 and $500,000 are included in insurance 
expense (note 9) in 20X7 and 20X6 respectively. Approximately $600,000 and $400,000 in stop-loss 
insurance recoveries are deducted from insurance expense in 20X7 and 20X6, respectively.
Included in other receivables is approximately $50,000 recoverable from insurers.
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8. Malpractice Claims
Malpractice claims have been asserted against the HMO by various claimants. The claims are in 
various stages of processing, and some may ultimately be brought to trial. In the opinion of coun­
sel, the outcome of these actions will not have a significant effect on the financial position or the 
operating income of the HMO. Incidents occurring through June 30, 20X7, may result in the asser­
tion of additional claims. Other claims may be asserted arising from past services provided. Man­
agement believes that these claims, if asserted, would be settled within the limits of insurance 
coverage.
9. Classification of Expenses
20X7 20X6
Program activities 26,921,000 20,909,000
General and administrative 2,474,000
$29,395,000
1,601,000
$22,510,000
10. Risks and Uncertainties Disclosures**
11. Pension Plan**
12. Postretirement Benefits**
13. Fair Value of Financial Instruments**
14. Concentrations of Credit Risk**
** The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the 
not-for-profit hospital and, therefore, are not repeated here.
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Sample Not-for-Profit Ambulatory Care, Inc. 
Balance Sheets*
* In February 2007, the Financial Accounting Standards Board (FASB) issued Statement No. 159, The Fair Value Option for Financial Assets 
and Financial Liabilities—Including an amendment of FASB Statement No. 115, that permits all entities, including not-for-profit organizations, 
to choose to measure eligible items at fair value at specified election dates. Notable eligible items include recognized financial assets and 
financial liabilities (except for those specifically prohibited), written loan commitments, and rights and obligations under a warranty that 
is not a financial instrument (because it requires or permits the insurer to provide goods or services rather than a cash payment) but whose 
terms permit the insurer to settle by paying a third party to provide those goods or services. Prohibited recognized financial assets and 
liabilities include:
a. An investment in a subsidiary that the entity is required to consolidate
b. An interest in a variable interest entity that the entity is required to consolidate
c. Employers' and plans' obligations (or assets representing net overfunded positions) for pension benefits, other postretirement 
benefits (including health care and life insurance benefits), postemployment benefits, employee stock option and stock purchase 
plans, and certain other forms of deferred compensation arrangements, as defined by the applicable FASB pronouncements
d. Financial assets and financial liabilities recognized under leases as defined in FASB Statement No. 13, Accounting for Leases, 
excluding guarantees of a third-party lease obligation or a contingent obligation arising from a cancelled lease
e. Deposit liabilities, withdrawable on demand, of banks, savings and loan associations, credit unions, and other similar depository 
institutions
f. Financial instruments that are, in whole or in part, classified by the issuer as a component of shareholder's equity (including 
"temporary equity"). An example is a convertible debt security with a noncontingent beneficial conversion feature.
Entities shall report assets and liabilities that are measured at fair value pursuant to the fair value option in this statement in a 
manner that separates those reported fair values from the carrying amounts of similar assets and liabilities measured using another 
measurement attribute. To accomplish that, an entity shall either:
a. Present the aggregate of fair value and nonfair-value amounts in the same line item in the statement of financial position and 
parenthetically disclose the amount measured at fair value included in the aggregate amount, or
b. Present two separate line items to display the fair value and nonfair-value carrying amounts.
This statement shall be effective as of the beginning of each reporting entity's first fiscal year that begins after November 15, 2007. 
This statement should not be applied retrospectively to fiscal years beginning prior to the effective date, except as permitted in paragraph 
30 for early adoption. At the effective date, an entity may elect the fair value option for eligible items that exist at that date. The entity 
shall report the effect of the first remeasurement to fair value as a cumulative-effect adjustment to the opening balance of retained earnings. 
Readers can find more information pertaining to election dates, disclosure requirements, early adoption limitations, and the full text of 
this statement on the FASB Web site at www.fasb.org.
In February 2006, FASB issued Statement No. 155, Accounting for Certain Hybrid Financial Instruments—an amendment of FASB Statements 
No. 133 and 140. Among other matters, FASB Statement No. 155 paragraph 4(c), amends paragraph 16 of FASB Statement No. 133, 
Accounting for Derivative Instruments and Hedging Activities. An entity that initially recognizes a hybrid financial instrument that under 
FASB Statement No. 133 paragraph 12, would be required to be separated into a host contract and a derivative instrument may irrevocably 
elect to initially and subsequently measure that hybrid financial instrument in its entirety at fair value (with changes in fair value recognized 
in earnings). FASB Statement No. 155 is effective for all financial instruments acquired or issued after the beginning of an entity's first 
fiscal year that begins after September 15, 2006. The fair value election in paragraph 4(c) may also be applied upon adoption of FASB 
Statement No. 155 for hybrid financial instruments that had been bifurcated under FASB Statement No. 133, paragraph 12, prior to the 
adoption of FASB Statement No. 155. Earlier adoption is permitted as of the beginning of an entity's fiscal year, provided the entity has 
not yet issued financial statements for any period for that fiscal year.
December 31, 20X7 and 20X6
Assets
Current assets:
Cash
Patient accounts receivable, net of allowance for 
doubtful accounts of $15,000 in 20X7 and 
$5,000 in 20X6
Estimated retroactive adjustments—third-party payors
Accounts receivable—other
Supplies
20X7 20X6
65,000 $ 76,000
290,000 278,000
19,000 32,000
13,000 8,000
21,000 18,000
(continued)
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See accompanying notes to financial statements.
20X7 20X6
Prepaid expenses and deposits 5,000 9,000
Total current assets 413,000 421,000
Property and equipment, at cost:
Land 100,000 100,000
Land improvements 322,000 322,000
Buildings 682,000 682,000
Equipment 1,390,000 1,389,000
Less accumulated depreciation
2,494,000
217,000
2,493,000
100,000
Property and equipment, net 2,277,000 2,393,000
Other assets:
Advances receivable 14,000 5,000
Total assets $2,704,000 $2,819,000
Liabilities and Net Assets
Current liabilities:
Notes payable $ 138,000 $ 144,000
Accounts payable 42,000 77,000
Accrued payroll, benefits, and taxes 33,000 22,000
Estimated retroactive adjustments—
third-party payors 30,000 24,000
Financing advance from third-party payors — 1,000
Total current liabilities 243,000 268,000
Guarantee liability 10,000 10,000
Total liabilities 253,000 278,000
Net assets—unrestricted 2,451,000 2,541,000
Total liabilities and net assets $2,704,000 $2,819,000
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Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Operations and Changes in Net Assets
Years Ended December 31, 20X7 and 20X6
20X7
Revenue and gains:
Net patient service revenue $ 860,000
Other 29,000
Total revenue and gains 889,000
Expenses:
Salaries and benefits 485,000
Medical supplies and drugs 189,000
Insurance 154,000
Provision for bad debts 14,000
Depreciation 117,000
Interest 20,000
Total expenses 979,000
Operating loss (90,000)
Net assets, beginning of year 2,541,000
Net assets, end of year $2,451,000
20X6
$ 357,000 
15,000
372,000
243,000
66,000
98,000
4,000
100,000
18,000
529,000
(157,000)
2,698,000
$2,541,000
See accompanying notes to financial statements.
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Sample Not-for-Profit Ambulatory Care, Inc. 
Statements of Cash Flows 
Years Ended December 31, 20X7 and 20X6
See accompanying notes to financial statements.
20X7 20X6
Cash flows from operating activities:
Cash received from patients and third-party payors $866,000 $ 368,000
Cash received from others 21,000 6,000
Interest received 3,000 11,000
Interest paid (15,000) (16,000)
Cash paid to employees and suppliers (870,000) (432,000)
Net cash provided by (used in) operating activities 5,000 (63,000)
Cash flows from investing activities:
Purchase of equipment (1,000) (4,000)
Advances made to XYZ Affiliate (9,000) (5,000)
Net cash used in investing activities (10,000) (9,000)
Cash flows from financing activities:
Proceeds from notes payable — 144,000
Payments on notes payable (6,000) —
Net cash provided by (used in) financing activities (6,000) 144,000
Net increase (decrease) in cash (11,000) 72,000
Cash, beginning of year 76,000 4,000
Cash, end of year $ 65,000 $ 76,000
Reconciliation of change in net assets 
to net cash provided by (used in) 
operating activities:
Change in net assets $ (90,000) $(157,000)
Adjustments to reconcile change in net 
assets to net cash provided by (used in) 
operating activities:
Depreciation 117,000 100,000
Provision for bad debts 14,000 4,000
(Increase) decrease in:
Patient accounts receivable (12,000) (19,000)
Other current assets 1,000 (2,000)
Increase (decrease) in:
Accounts payable and accrued payroll,
benefits, and taxes (24,000) 10,000
Other current liabilities (1,000) 1,000
Net cash provided by (used in)
operating activities $ 5,000 $ (63,000)
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Sample Not-for-Profit Ambulatory Care, Inc.
Notes to Financial Statements‡ 
December 31, 20X7 and 20X6
1. Description of Organization and Summary of Significant Accounting Policies10
‡ In September 2006, FASB issued FASB Statement No. 157, Fair Value Measurements, which defines fair value, establishes a framework 
for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. 
This statement applies under other accounting pronouncements that require or permit fair value measurements, the FASB having 
previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this 
statement does not require any new fair value measurements but the application of it will change current practice.
The statement retains the exchange price notion already established within GAAP but clarifies, among other matters, that fair value is 
the price that would be received to sell the asset or paid to transfer the liability (for example, an exit price) and not the price that would 
be paid to acquire the asset or paid to transfer the liability (for example, an entry price). Additionally, the statement establishes a fair value 
hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. Level 1 inputs are quoted 
prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement 
date and shall be used to measure fair value when available, with limited exceptions. Level 2 inputs are inputs other than quoted prices 
included within level 1 that are observable for the asset or liability, either directly or indirectly, and may include, for example, quoted 
prices for similar assets or liabilities in active markets. Level 3 inputs are unobservable inputs for the asset or liability. Unobservable inputs 
shall be used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is 
little, if any, market activity. Unobservable inputs shall be developed based on the best information available in the circumstances, which 
might include the reporting entity's own data.
The guidance in this statement expands disclosures about the use of fair value to measure assets and liabilities in interim and annual 
periods subsequent to initial recognition. The disclosures focus on the fair value hierarchy and the effect of the measurements on earnings 
(or changes in net assets) for the period. This statement encourages entities to combine the fair value information disclosed under this 
statement with the fair value information disclosed under other accounting pronouncements, including FASB Statement No. 107, Disclo­
sures about Fair Value of Financial Instruments, where practicable.
This statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 and interim periods within 
those fiscal years. Earlier application is encouraged, provided that the reporting entity has not yet issued financial statements for that 
fiscal year, including financial statements for an interim period within that fiscal year. The provisions of this statement should be applied 
prospectively as of the beginning of the fiscal year in which this statement is initially applied, except in limited circumstances as discussed 
in the statement. Readers should refer to the FASB Web site at www.fasb.org for more information.
10 Paragraph 13 of SOP 01-6 provides guidance on disclosures that should be included in the summary of significant accounting policies, 
including accounting policies for loans, trade receivables, and doubtful accounts.
Organization. Ambulatory Care, Inc. was incorporated on September 7, 20X3, in New State, to 
operate an ambulatory care health facility to treat or prevent injury and disease, to provide funds 
or to expend funds to further the treatment or prevention of injury or disease, and to develop and 
participate in activities designed to promote the general health of the community.
Three area hospitals—ABC Hospital and Health Center, DEF Hospital, and GHI Hospi­
tal—entered into a members' agreement to develop this ambulatory care center. In accordance 
with this agreement, each hospital contributed capital of $947,000 to Ambulatory Care, Inc. Am­
bulatory Care, Inc. began operations in October 20X3.
Use of estimates. The preparation of financial statements in conformity with GAAP requires 
management to make estimates and assumptions that affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of the financial statements 
and the reported amounts of revenues and expenses during the reporting period. Actual results 
could differ from those estimates.
Supplies. Supplies are stated at the lower of cost (first-in, first-out) or net realizable value.
Depreciation. Depreciation of property and equipment is computed on the straight-line method 
over the estimated lives of depreciable assets.
Third-party contractual adjustments. Retroactively calculated third-party contractual adjustments 
are accrued on an estimated basis in the period the related services are rendered. Net patient 
service revenue is adjusted as required in subsequent periods based on final settlements.
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Net patient service revenue. Patient service revenue is reported at the estimated net realizable 
amounts from patients, third-party payors, and others for services rendered.
Charity care. Ambulatory Care, Inc. has a policy of providing charity care to patients who are 
unable to pay. Such patients are identified and related charges are estimated, based on financial 
information obtained from the patient and subsequent analysis. Since management does not expect 
payment for charity care, the estimated charges are excluded from revenue.
Income taxes. Ambulatory Care, Inc. has been recognized by the Internal Revenue Service as a 
not-for-profit corporation as described in Section 501(c)(3) of the Internal Revenue Code (IRC) and 
is exempt from federal income taxes on related income pursuant to Section 501(a) of the IRC.
2. Advances Receivable
In May 20X4, Ambulatory Care, Inc. entered into a five-year agreement with XYZ Affiliates 
(XYZ). Under this agreement, XYZ is to provide emergency medical services as well as charge and 
bill each patient treated at Ambulatory Care, Inc. Ambulatory Care, Inc. has guaranteed that XYZ 
will collect at least $18,000 per month during the term of this agreement. In any month in which 
XYZ does not collect the minimum guarantee, Ambulatory Care, Inc. advances funds to XYZ to 
cover the deficiency. Such advances are to be repaid to the extent XYZ's net cash collections exceed 
the minimum guarantee amount. Management estimates that the advances will be fully recovered 
in 20X8.
3. Related-Party Transactions
During 20X3, Ambulatory Care, Inc. entered into a contract with one of the member hospitals 
(the managing hospital) for the management of the business and affairs of Ambulatory Care, Inc. 
Under this agreement, Ambulatory Care, Inc. pays $4,000 per month to the managing hospital. The 
agreement with the managing hospital was to remain in effect through December 31, 20X5, but has 
been extended on a month-to-month basis.
In addition, during 20X4 each hospital loaned $48,000 to Ambulatory Care, Inc. in the form of 
promissory notes at an interest rate of prime rate plus 1 percent (effective rates of 10 percent and 9 
percent in 20X7 and 20X6, respectively). Of the total $144,000 liability, $48,000 is payable on de­
mand after November 28, 20X7, to one member hospital, with the remaining portion ($96,000) 
payable on demand after December 8, 20X6, to the other two member hospitals. During 20X7, 
Ambulatory Care, Inc. paid $2,000 to each member hospital, thereby reducing the obligation to 
$138,000.
4. Revenue From Contracting Agencies
Ambulatory Care, Inc. participates as a provider of health care services to Blue Cross, Medicare, 
and County Indigent Plan patients. Reimbursement for covered services is based on tentative 
payment rates. Final reimbursement is determined after submission of annual cost reports and 
audits thereof by the fiscal intermediaries. Provisions for estimated reimbursement adjustments 
are reported in the financial statements in the period that the services are rendered.
Revenue from the Medicare program accounted for approximately XX percent for the year 
ended 20X7, and XX percent for the year ended 20X6, of Ambulatory Care, Inc.'s net patient 
revenue. Laws and regulations governing the Medicare program are extremely complex and sub­
ject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates 
will change by a material amount in the near term. The 20X7 net patient service revenue increased 
approximately $XXX due to removal of allowances previously estimated that are no longer neces­
sary as a result of final settlements and years that are no longer subject to audits, reviews, and 
investigations. The 20X6 net patient service revenue decreased approximately $XXX due to prior- 
year retroactive adjustments in excess of amounts previously estimated.
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5. Charity Care
Ambulatory Care, Inc. has a policy of providing charity care to indigent patients in emergency 
situations. These services, which are excluded from revenues, amounted to $27,000 and $13,000 in 
20X7 and 20X6, respectively, when measured at Ambulatory Care, Inc.'s established rates.
6. Classification of Expenses
Program      --------------------- ---------------------- General and
Total A B C Administrative
Expenses incurred for the 
year ended December 31,
20X7, were for:
Salaries and benefits $485,000 $216,000 $102,000 $121,000 $46,000
Medical supplies and drugs 189,000 98,000 43,000 48,000
Insurance 154,000 79,000 45,000 14,000 16,000
Provision for bad debts 14,000 9,000 — 5,000 —
Depreciation 117,000 100,000 — 17,000 —
Interest 20,000 9,000 — — $11,000
Total expenses $979,000 $511,000 $190,000 $205,000 $73,000
Expenses incurred for the
year ended December
31, 20X6, were for:
Salaries and benefits $243,000 $111,000 $46,000 $ 57,000 $29,000
Medical supplies and drugs 66,000 31,000 15,000 20,000 —
Insurance and other 98,000 45,000 19,000 26,000 8,000
Provision for bad debts 4,000 — 4,000 — —
Depreciation 100,000 56,000 — 44,000 —
Interest 18,000 7,000 — — 11,000
Total expenses $529,000 $250,000 $84,000 $147,000 $48,000
(The preparer of the financial statements may wish to include a brief description of the types of 
programs.)
7. Risks and Uncertainties Disclosures**
8. Pension Plan**
9. Postretirement Benefits**
10. Fair Value of Financial Instruments**
11. Concentrations of Credit Risk**
** The disclosures contained in these notes would be similar to the disclosures contained in the notes to the financial statements for the 
not-for-profit hospital and, therefore, are not repeated here.
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Your Opinion Matters
Thank you for selecting this publication for your accounting or auditing needs.
At the AICPA, we strive to provide the most useful publications available to the profession, which have been 
produced with the highest quality. Responsiveness to our members and the profession as a whole is our 
hallmark. We rely on feedback from our users to continually hone and improve our products.
Please take a few moments to let us know what you think of this edition. Does it meet your needs? Is it written 
clearly? Is it comprehensive in its coverage? Is it easy to use? If not, how can we improve it?
Send your feedback by e-mail to A&APublications@aicpa.org.
Please note the name and edition of the publication, answers to the preceding questions, and anything else 
you would like to share with us. Your feedback will help us improve subsequent editions and better serve 
you.
Do you want to help even more?
Consider participating in a focus or advisory group related to this subject matter. If you are interested in, and 
available for, participating in such a group, please be sure to include that information in your e-mail.
Thank you in advance for taking the time to write. We appreciate your feedback!
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The AICPA has created a unique online research tool by combining the power 
and speed of the Web with comprehensive accounting and auditing standards. 
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